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Multi-component crystallisation is investigated as a route to controlling crystalline forms 
of selected materials that possess pharmaceutical properties. This includes investigating 
the use of co-crystallisation methodology to selectively crystallise metastable polymorphs 
and solvated forms of these materials. This differs from the conventional use of co-
crystallisation, as the aim of this aspect of the investigation is not to obtain a molecular 
complex of the two components, but instead for them to crystallise independently, while 
one component perturbs the solution environment to direct the crystallisation of the 
second component towards a different, often metastable, polymorph (or solvate). This 
co-crystallisation methodology is used as a route to crystallising new or elusive 
polymorphs (or solvates) of the active pharmaceutical ingredients paracetamol, 
piroxicam, gallic acid monohydrate and piracetam. It is also demonstrated that the use of 
this method can lead to crystal forms with otherwise unobtainable structural features.  
 
Co-crystallisation is also investigated as a route to controlling the ionisation state of 
piroxicam in the formation of molecular complexes. Molecular complexes were formed 
with a number of mono-substituted benzoic acids as well as with nitrogen-heterocycles 
and strong acids. In the molecular complexes formed, piroxicam was found to adopt the 
non-ionised, zwitterionic, anionic or cationic form, depending on the co-former used. 
Attempts are made to rationalise the occurrence of each ionisation state by consideration 
of the relative pKa values of piroxicam and the co-formers. The hydrogen bonded 
supramolecular synthons in these molecular complexes are also investigated.  
 
Co-crystallisation is also used as a route to obtaining molecular complexes of paracetamol 
and its derivative, 4-acetamidobenzoic acid, with nitrogen-heterocycles as co-formers. 
Molecular complexes of the two, with similar co-formers, are compared in terms of their 
hydrogen bonded supramolecular synthons. Despite having otherwise similar structural 
features, the phenolic hydroxyl group in paracetamol and carboxylic acid group in 4-
acetamidobenzoic acid result in the formation of very different synthons and in some 
cases different component ratios. The susceptibility of 4-acetamidobenzoic acid to 
deprotonation is found to play a major role in the differences observed.  
 
 4
Molecular complexes of paracetamol with co-formers containing multiple carboxylic acid 
groups are also investigated, with a view towards further crystal engineering approaches 
for molecular complexes of paracetamol. Piracetam complexes with carboxylic acids are 
investigated in a similar manner.  
 
The potential for transfer of a range of these multi-component crystallisations into a non-
evaporative environment, with a view to implementing continuous crystallisation 
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1.1 Co-crystallisation  
 
Co-crystallisation is described as a deliberate attempt to bring together different 
molecular species within one periodic crystalline lattice without making or breaking 
covalent bonds1. The intent is to obtain a hetero-molecular crystal product with discrete 
molecules held together by intermolecular interactions, distinguishing it from 
recrystallisation, where a homo-molecular product is obtained1. Although the meaning of 
co-crystallisation is generally agreed upon, the exact definition of the term “co-crystal” is 
cause for much debate2-6 as the term could be interpreted to imply a relationship is 
present between the crystal structure of the co-crystal and those of its components. The 
one broad commonality in this debate is that a co-crystal comprises at least two different 
components, although further ambiguity arises as to whether or not both components 
are required to be solid at room temperature4 and whether a distinction should be made 
between multi-component ionic solids (salts) and multi-component solids containing 
neutral molecules (neutral molecular complexes)1, 4, 5.  
The use of the term co-crystal will therefore be avoided in this work and the term 
“multi-component molecular complex” will be used in the broadest sense to describe 
crystals comprising two or more components, i.e. with neutral molecular complexes, 
molecular complexes where hydrogen transfer has taken place (generating charged 
molecular species), and solvates being subsets. For the purpose of this section, 
discrimination will be made between pharmaceutical salts produced using traditional 
counter-ions and molecular complexes between two (or more) neutral starting 
components where hydrogen transfer has taken place (although both are generally 
considered as salts).  
 
1.2 Molecular Complexes as Functional Materials  
 
The consensus is that co-crystallisation, like crystallisation in general, is not a well 
understood process in that it is not currently possible to predict with any reasonable level 
of confidence the crystal structure of an organic material7. However, molecular 
complexes from co-crystallisation are considered to have a lot to offer the pharmaceutical 
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industry, as not only can they be patented as new compounds8, 9 but they can also have 
very different properties from their component materials9-11 (Table 1.1). They offer 
multiple opportunities to modify the chemical and/or physical properties of active 
pharmaceutical ingredients (APIs) without making or breaking covalent bonds10 and 
pharmaceutical companies routinely screen for and patent such complexes12. This 
derivatisation of APIs (or indeed materials in general) through non-covalent interactions is 
considered a greener approach than making and breaking covalent bonds as it minimises 
the formation of by products13. In addition, the potential number of molecular complexes 
for a given API far exceeds that of traditional pharmaceutical salts due to the relatively 
low number of acceptable counter-ions when compared with the large number of 
counter-molecules that would be acceptable in a molecular complex8. Molecular complex 
formation also provides a potential route to optimising the properties of APIs which are 
not acidic or basic enough to form a salt10. Given that in the chemical industry “few 
compounds reach development and even fewer are marketed”14, the potential benefits of 
such a flexible approach are obvious. It is somewhat surprising, therefore, that salt-
formation is one of the most common methods of altering the solid state properties of a 
drug and that over half of medicines on the market are administered as salts, whereas 
there are no drugs on the market which are molecular complexes9.  
The practical use of molecular complexes to optimise properties of APIs has been 
demonstrated in several recent studies. These have shown that complexes of APIs can 
have favourable properties such as: resistance to relative humidity stress15, 16, improved 
compaction properties (for tabletting)17, 18, improved solubility15, 19, 20, improved 
dissolution rate15, 21 22 and improved bioavailability15, 23. In addition to patent space 
expansion and property optimisation, another potential application is that of combination 
drugs, where two APIs are included in a single molecular complex6, 24, 25. Molecular 
complex formation also offers a method of preferentially crystallising a particular 
tautomer of a material depending on the co-former used. This has previously been carried 
out by exploiting the preferential hydrogen bond interactions of the different functional 
groups present in different tautomers26. Other studies have shown that varying the co-
former used to co-crystallise the APIs piroxicam27, sulfamethazine28 and norfloxacin29 will 
result in a different tautomer in the molecular complex formed - although in these cases 
this outcome has to date been serendipitous rather than the result of rational design. 
Molecular complexes of APIs therefore represent a broad patent space and have 
broad scope for non-covalent derivatisation13 through the formation of freely reversible 
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interactions that do not compromise the structural integrity of the API, thus allowing it to 
retain its bioactivity.  
 Although a large portion of the literature is devoted to the co-crystallisation of 
APIs, the applications of multi-component molecular complexes are much further 
reaching. Molecular complex formation has previously been investigated as a means of 
altering the properties of other functional materials such as agrochemicals30 and coloured 
materials31, 32. It has also been shown to be useful in generating non-centrosymmetric 
complexes with non-linear optical (NLO) properties33-35 as well as porous materials with 
gas or small molecule storage applications36, 37.    
 
Table 1.138 Examples of physical and chemical properties that can differ among different 




Density and refractive index, thermal and electrical 
conductivity, hygroscopicity, free energy and chemical 
potential, melting points, heat capacity, vapour pressure, 
solubility, thermal stability 
Spectroscopic 
properties 
Electronic, vibrational and rotational properties, nuclear 
magnetic resonance spectral features 
Kinetic 
properties 








Hardness, compression, thermal expansion 
Chemical 
properties 
Chemical and photochemical reactivity 
 
 
1.3 Polymorphism  
 
Another crucial aspect with regards to the properties of materials such as APIs during 
their development for application is polymorphism, as different polymorphs of a material 
can also possess very different properties (Table 1.1), effectively behaving as different 
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materials in terms of their physical properties38. Polymorphism is defined as “the ability of 
a substance to exist as two or more crystalline phases that have different arrangements 
and/or conformations of the molecules in the crystal lattice”39. Like multi-component 
complexes, different polymorphs of a drug can also be patented as discrete materials40 
and it is commonplace to search for polymorphs in solid-state pharmaceutics9. 
Polymorphism has long been known to be a very common occurrence41 and it has been 
suggested that “every compound has different polymorphic forms and that, in general, 
the number of forms known for a given compound is proportional to the time and money 
spent in research on that compound”42. Although caution should be exercised with 
regards to the accuracy of this statement43, it is clear that polymorphism further 
broadens the range of non-covalent derivatives that can be generated for a given material 
(Figure 1.1). Combining the potential of the two types of materials discussed to date, 
polymorphs of molecular complexes could offer even further opportunities to modify the 
properties of organic materials. Several examples of polymorphic molecular complexes of 
APIs, including carbamazepine44, piroxicam27 and chlorzoxazone45, have been published in 
recent years.    
 
 
Figure 1.19 An illustration of some of the possible crystal forms that can result from non-
covalent derivatisation of materials such as APIs. 
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1.3.1 Polymorphism in Functional Materials 
 
Polymorph screening is a routine part of solid form selection of functional materials such 
as APIs. In the vast majority of cases, the most stable polymorph is selected for 
processing, scale-up, formulation and storage as it minimises the chance of conversion to 
another form46. However, the most stable form of a material generally has the lowest 
solubility at any given temperature and a metastable form of an API may be selected if it 
offers a significant improvement in solubility or indeed other properties such as 
dissolution rate or bioavailability46. A prominent example of a metastable polymorph of 
an API with potentially improved properties over the commercial form is paracetamol 
form II47. Studies of the properties of paracetamol form II have concluded it has both 
improved dissolution rate48 and compaction properties49 compared with those of form I. 
Its potential for large scale use has been limited, however, by the inability to produce this 
metastable solid form in large quantities and its poor stability over time50.  
The importance of solid form selection and properties has perhaps been most 
dramatically illustrated by the case of the anti-HIV drug ritonavir51, 52, where the sudden 
appearance and subsequent prevalence of an unknown, more stable polymorph, 
prevented formulation of the marketed product. It became clear that the marketed 
product utilised a metastable polymorph of ritonavir and the significantly altered 
dissolution rate of the new form precluded formulation. This illustrates the need to 
identify the most stable form prior to taking a product to market in order to be aware of 
the potential for such difficulties arising and to take steps to mitigate this. It also 
highlights the importance of being able to selectively crystallise and maintain a 
metastable form if it has favourable properties.  
The case of ritonavir also raises the subject of “disappearing polymorphs”, where 
the (often serendipitous) crystallisation of a more stable polymorph is believed to 
subsequently nucleate the crystallisation of that polymorph through undetectable seeds - 
precluding crystallisation of the less stable form thereafter53. Several other examples of 
this have been reported54-56. The general consensus is that re-obtaining the metastable 
forms is always possible by manipulating the crystallisation conditions - although 
identifying the conditions required may not be a trivial task54, 57.  
 As is the case for molecular complexes, polymorphism can also be exploited for 
functional materials other than APIs. Polymorphic porous materials have been shown to 
have gas absorption properties and have also been shown to have the potential to turn 
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the porosity “on and off” by converting between porous and non-porous polymorphs58. 
Different polymorphs of materials can also exhibit different NLO properties35, 59, affect the 
colour of pigments43, 60 and affect the properties of high energy materials43.  
 
1.3.2 Tautomeric Polymorphism 
 
Tautomeric polymorphism - more strictly termed desmotropy, although arguments have 
been made for use of both terms61-63 - is the existence of two or more crystal structures 
of the same chemical composition, but with different tautomers in each. In some cases, 
polymorphs are also known to have both tautomers co-existing in the same crystal 
structure12, 64. A recent study62 of the Cambridge Structural Database (CSD)65 showed that 
tautomeric polymorphism is a very rare phenomenon; only 16 pairs of tautomers were 
found in the CSD, representing just 0.5% of molecules that are known to have different 
tautomeric forms. A handful of materials exhibiting tautomeric polymorphism have been 
found since, including triclabendazole12 and 2-(p-tolylamino)nicotinic acid66.   
 Cases of tautomeric polymorphism have been reported with one polymorph 
comprising a neutral form and another comprising a zwitterionic form27, 64, 66, as well as 
cases where both polymorphs comprise only neutral tautomers12, 67. In addition to pure 
compounds, tautomeric polymorphism has also been reported to occur in a molecular 
complex27.    
 
 
1.4 Controlling and Predicting Crystal Forms 
 
1.4.1 Crystal Engineering  
 
As stated above, co-crystallisation is not a well understood process and there is no 
guaranteed method of predicting the interactions that will occur in a molecular complex 
or whether or not a co-crystallisation experiment will even be successful in producing a 
molecular complex9. A commonly used method of increasing the probability of forming a 
molecular complex, however, is using the “supramolecular synthon68” approach. A 
supramolecular synthon describes recognition events when molecules assemble into 
supermolecules1. These transferrable connectors can be identified by empirical 
methods69, such as systematic co-crystallisation experiments and/or analysis of the CSD, 
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to map out the common molecular associations in which functional groups engage. These 
molecular recognition events can be with other identical functional groups 
(homosynthons) or with different but complementary functional groups 
(heterosynthons)70 (Figure 1.2). Although recent studies have suggested that π···π 
interactions71, 72, CH···π interactions73, 74 and halogen bonds75-78 may have the potential 
for use in crystal engineering, the majority of organic molecular complexes are assembled 
via conventional (stronger) hydrogen bonds, with other intermolecular interactions 
having not been found to be as robust1. Accordingly, crystal engineering of molecular 
complexes usually involves identifying hydrogen bonding synthons and using them to 
determine suitable co-formers for a material based on the complementarities of the 
functional groups. This approach, in theory, should lead to heteromeric interactions being 
favoured over homomeric interactions. The nature of APIs means that they inherently 
contain functional groups that engage in molecular recognition, making co-crystallisation 
much more probable79 although still impossible to guarantee.  
 
 
Figure 1.2 Examples of hydrogen bonded homosynthons and heterosynthons that can be 
formed by a carboxylic acid group. (a) carboxylic acid dimer homosynthon; (b) carboxylic 
acid catemer homosynthon; (c) carboxylic acid : amide dimer heterosynthon; (d) carboxylic 
acid : amide catemer heterosynthon. 
 
To aid in the identification of common hydrogen bonding motifs, they are commonly 
classified using graph set notation80. Graph set notation is written in the form XD
A(Y). X is 
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a letter describing the hydrogen bonding in a motif (C = chains, D = dimers, R = rings, S = 
intramolecular hydrogen bonds). A and D are numbers denoting the number of hydrogen 
bond donors (subscript D) and acceptors (superscript A). A third number in parentheses 




Figure 1.380 Examples of graph set assignments for some hydrogen bonding motifs. 
 
Various studies of known crystal structures have been carried out investigating the 
hierarchy of hydrogen bonds and statistical probabilities of certain supramolecular 
synthons occurring69, 79, 81-85. These studies can be used to increase the probability that a 
co-crystallisation experiment will be successful. Early empirical studies of the hierarchy of 
hydrogen bonds resulted in a general set of guidelines being devised for the design of 
molecular solids80. These guidelines are as follows: 
 
 1. All good proton donors and acceptors are involved in hydrogen bonding; 
2. Six-membered ring intramolecular hydrogen bonds form in preference to 
intermolecular hydrogen bonds; 
3. The best proton donor and acceptor remaining after intramolecular hydrogen 
bond formation will form intermolecular hydrogen bonds.  
 
The empirical method of determining transferrable synthons has proved to be highly 
useful in some cases. For example, the carboxylic acid - pyridine OH···N hydrogen bonding 
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motif has been demonstrated to be a highly robust synthon in co-crystallisation 
experiments. A recent CSD study showed it is present in 98% of complexes with no other 
competing functional groups present and 77% of complexes where competing functional 
groups are present86.  
Another transferrable synthon commonly used in the crystal engineering of 
molecular complexes is the carboxylic acid - primary amide heterodimer (illustrated in 
Figure 1.2c) 40, 87-91. However, this synthon is far less predictable, with a 2004 CSD study85 
showing that only 47% of molecular complexes containing both functional groups exhibit 
this heteromeric hydrogen bonding motif. Of these, 28% also exhibited either homomeric 
acid-acid synthons or amide-amide synthons. It has also been shown that in the presence 
of other competing functional groups, the occurrence of this hydrogen bonding motif 
becomes even less likely88, 91, 92. This example illustrates the difficulty in using non-
covalent interactions as synthetic tools with an incomplete understanding of the forces 
involved. Further complications in the design of molecular complexes arise with the 
possibility of solvated or hydrated molecular complexes, as they interfere with the 
formation of hydrogen bonded synthons and their formation is generally not considered 
predictable in a co-crystallisation experiment93. Even in cases where the predicted 
primary hydrogen bonding synthon is consistently observed, progression from this to 
prediction of the structure as a whole is not possible - even for molecular complexes 
comprising structurally similar components94.  
In order to achieve the ultimate goal of crystal engineering - the design of 
molecular solids with specific interactions to obtain specific properties - a complete 
understanding of the interrelated strong and weak interactions, close packing effects and 
nucleation kinetics is required. The need for a complete understanding of these factors 
has long been stressed by various authors95-100. Progress in crystal structure prediction of 
molecular complexes is being made using computational methods, although these too 
require a fuller understanding of the kinetic aspects of crystallisation100-104.  
 Despite the relative success of the supramolecular synthon approach, it is not yet 
possible to predict if a co-crystallisation experiment will be successful. Knowledge of the 
common synthons is not always enough, as compounds with the same functional groups 
can exhibit different reactivity towards molecular complex formation and molecules may 
form molecular complexes without any obvious synthons connecting them84. For this 
reason a high-throughput (trial and error) screening strategy can be used to maximise the 
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potential number of hits, from which a more designed synthon based strategy may evolve 
based specifically on the target molecule19, 105, 106.  
 It has been suggested that a more careful consideration of the component 
solubilities is required to predict if a co-crystallisation experiment will be successful; 
ternary phases diagrams can be used in this respect to determine the mole fraction of 
each component that is required at a given temperature to crystallise the molecular 
complex 107, 108. The mole fraction of each component required will be dependent on the 
solubility curve of the two components and of the molecular complex in that particular 
solvent. Using solvents which result in similar solubilities of the two components is more 
likely to result in crystallisation of the 1:1 stoichiometric complex. Where there is a large 
difference in the solubility of the component materials, different solution stoichiometries 
may be required for successful co-crystallisation. Recent work has also suggested that it 
may be possible to predict the successful formation of molecular complexes by 
theoretical prediction of the solid state miscibility of the components109 or by comparison 
of the global lattice energies of the component crystal structures with that of the 
molecular complex using computational methods110.  
  
1.4.2 Intermolecular and Intramolecular Hydrogen Transfer in Molecular Complexes 
 
An important consideration when co-crystallising two (or more) materials is whether or 
not intermolecular hydrogen transfer will take place between them. When intermolecular 
hydrogen transfer is complete the complex is a salt and when no hydrogen transfer 
occurs it is a neutral molecular complex. Predicting the occurrence of hydrogen transfer 
for a particular system is generally done using the “pKa rule”, which states the 
approximation that ∆pKa = pKa[protonated base] – pKa[acid] ≥ 3 for salt formation111. In 
general, when ∆pKa is less than 0, no intermolecular hydrogen transfer will take place112. 
When ∆pKa lies between 0 and 3, however, hydrogen transfer may or may not occur 
depending on the particular system113. Predicting if hydrogen transfer will occur can be 
critical when using the supramolecular synthon approach as it can have consequences for 
the primary interactions between the molecules, as well as the stoichiometry of the 
complex114, 115. The pKa rule has been shown to be a useful tool for successfully predicting 
hydrogen transfer in various molecular complex systems111, 116, 117. Its utility has, however, 
been shown to be system-dependent and the ∆pKa boundaries for hydrogen transfer may 
need to be adjusted depending on the system being investigated112, 118. The lack of 
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ubiquity in transferring the pKa rule between systems comes as little surprise. pKa values 
describe solution processes and thus a rule based on pKa values to describe solid state 
processes cannot be expected to be a hard and fast one. The pKa “rule” can therefore be 
seen as more of a guideline when predicting the possible occurrence of intermolecular 
hydrogen transfer for a molecular complex system.   
 Classifying a molecular complex as a salt or neutral molecular complex is not 
always a trivial procedure5, 6, 119. Issues arise in the identification of the exact position of 
the proton, as illustrated by examples where the proton position is temperature 
dependent120, 121. The 4-methylpyridine : pentachlorophenol complex120, for example, 
exhibits a short strong intermolecular O···H···N hydrogen bond where the proton lies on 
the oxygen at room temperature, on the nitrogen at low temperature and is exactly 
centred at 90K (Figure 1.4).  Hydrogen bonds in molecular complexes are therefore said 
to lie on a continuum113, with complete hydrogen transfer at one extreme and no 
hydrogen transfer at the other. Further ambiguity may arise in 2:1 molecular complexes 
where hydrogen transfer occurs, for example, in the anilinium fumarate-fumaric acid 
complex122. This complex features a deprotonated fumaric acid molecule, a protonated 
aniline molecule and a neutral fumaric acid molecule in the asymmetric unit making the 
term “salt” an inadequate descriptor.  
 
Figure 1.4 Thermally induced proton migration in the O···H···N hydrogen bond in the 4-






The pKa rule can be used for predicting intermolecular hydrogen transfer in molecular 
complexes; however, no such guidelines exist for predicting intramolecular hydrogen 
transfer in a co-crystallisation experiment. Tautomeric materials have been observed to 
form molecular complexes with the tautomer present in the complex dependent on the 
co-former used12, 27, 28. Only one study has been carried out investigating the influence of 
the co-former on the tautomeric preference of a material12. Another study also suggested 
that using crystal engineering principles, certain zwitterionic materials can be induced 
into crystallising as the zwitterion by exploiting the preferential hydrogen bonding 
synthon of the zwitterionic tautomer with weakly acidic co-formers26. As yet, no attempt 
has been made to rationalise intramolecular hydrogen transfer, in terms of the properties 
of the co-formers, to facilitate the prediction of which tautomer will be present in a given 
molecular complex system.  
 
1.4.3 Crystallisation Methods for Controlling Polymorph and Molecular Complex 
Formation 
 
1.4.3.1  The Rule of Stages 
 
Crystallisation follows the Rule of Stages as postulated by Ostwald123. The rule states that 
crystallisation follows the quickest path to the lowest free energy state through a number 
of metastable states, with minimal changes in free energy between each step124. In 
practical terms this means that in a given crystallisation, the least stable polymorph will 
form first, followed by sequential recrystallisations to thermodynamically more stable 
polymorphs. The free energy barrier for this change dictates how rapid this 
transformation is and it is accelerated when the system is in contact with solution, which 
can make obtaining metastable polymorphs difficult125. When the free energy barrier is 
low enough, polymorphs of materials can be obtained through solid-solid transformations 
of single crystals which can occur over time125-127. Solid-solid transformations can also be 
induced to higher or lower energy states by altering the environment of the crystal, for 




1.4.3.2  Common Crystallisation Techniques for Isolation of Polymorphs and 
Molecular Complexes 
 
Screening of polymorphs and molecular complexes is frequently carried out via 
crystallisation from solution, often in an evaporative environment. Polymorph selectivity 
can be achieved through varying the solvent used131, 132 and the success of a co-
crystallisation experiment is also often dependent on the solvent used107, 133. The rate of 
solvent extraction can also affect the solid phase obtained, with rapid evaporation 
generally resulting in metastable forms and slow evaporation producing 
thermodynamically stable forms134. Similarly, cooling crystallisation can be used to obtain 
different crystal forms by varying the solvent used135 or by varying the cooling rate136.  
 Crystallisation / co-crystallisation at high pressure has recently emerged as a route 
to novel and otherwise unobtainable polymorphs and molecular complexes. This 
technique has been used to produce a new dihydrate of piracetam130 as well as a 
dihydrate137, a trihydrate138 and a methanol solvate of paracetamol139. In recent years 
there has also been an increase in research focused on “solvent free” co-crystallisation140-
142. This is viewed as an environmentally friendly process compared with other methods, 
as it involves the co-grinding of two components in little or no solvent to induce 
molecular complex formation. It has proved of great interest in co-crystallisation as it has 
been shown to facilitate synthesis of new multi-component complexes32, 140 and can also 
be used to obtain different polymorphs of materials40, 142.    
 
1.4.3.3 Seeding, Additives and Co-Crystallisation in Controlling Polymorph Selection 
 
A common method of promoting the growth of a particular polymorph of a material is to 
seed a saturated solution with crystals of the desired polymorph143, 144. Under cooling or 
evaporation to supersaturation, nucleation should occur preferentially at the surface of 
the seed, promoting crystallisation of that form. As well as homonucleation it has also 
been observed that heteronucleation is possible, where seeds of one polymorph can 
cross-nucleate the crystallisation of another145.  
 Additives have been widely used to direct and control the formation of metastable 
polymorphs; these are normally used in trace quantities146, 147 or are engineered so that a 
structural relationship is present between the additive and the desired polymorph, thus 
facilitating epitaxial growth on the substrate surface148-150 or inhibiting the growth of the 
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more stable form151. Co-crystallisation from multi-component environments, however, is 
relatively rare as a route to polymorph selection. This method differs from the 
conventional co-crystallisation method, as the two components do not form a complex, 
instead crystallising independently, whilst one component perturbs the solution 
environment to direct crystallisation of the second component towards a particular, often 
metastable, polymorph. In contrast to the use of additives, co-crystallisation utilises 
molar quantities of the two components. Although rare, discovery of new and elusive 
polymorphs resulting from co-crystallisation experiments has been known to occur, 
mainly as the serendipitous outcome from experiments aimed at molecular complex 
formation.56, 66, 132, 152, 153 
 
1.4.3.4 Continuous Crystallisation  
 
In industry, large scale crystallisation of materials is generally performed in stirred-tank 
batch crystallisers. Stirred tank reactors have operated on the same basic principles for 
hundreds of years however, and are seen as being inefficient due to the large vessels 
required and limited control over temperature and mixing when scaled up. This can result 
in inconsistent products being obtained and a greater amount of wastage and cost154.  
 In recent years there has been an increase in research focused on large scale 
continuous flow crystallisation with a view to improving the efficiency of crystallisation 
processes154. Of particular interest is the continuous oscillatory baffled crystalliser 
(COBC)155-158. The COBC consists of a continuous cylindrical tube or column with baffles 
periodically spaced along the inside walls, with the sharp edges of these baffles 
positioned transverse to the flow (Figure 1.5). The solution is oscillated axially by means 
of a diaphragm, bellows or pistons at one or both ends of the column. The oscillating flow 
forces the liquid through the baffles on the upstroke, generating vortex rings, which are 
then unravelled on the downstroke (also Figure 1.5).  
The generation of these vortex rings in the cell means that mixing is uniform 
throughout the column, which facilitates uniform control over the temperature. Plug flow 
of the solution through the column can be achieved in the COBC even at low flow rates, 
i.e. radial mixing is uniform and axial dispersion is at a minimum. This also allows for very 
precise cooling profiles along the length of the reactor. Being able to exercise such precise 
control over crystal growth conditions therefore allows for the development of processes 




Figure 1.5 Schematic of an OBC. The typical set up of an OBC155 (LHS) and the mixing 




In a study of the crystallisation of L-glutamic acid in a COBC, it has been demonstrated 
that selective polymorph formation can be achieved by altering the solution 
concentration and the crystal size can also be varied by altering the cooling rate157. A 
study of this technology using paracetamol showed that the product recrystallised from 
an OBC is of much better consistency in terms of particle size and surface characteristics 
than from conventional methods156. These studies emphasise the value of the technology 
in developing processes for precise control of the crystallisation of materials such as APIs.   
 
 
1.5 Intermolecular Interactions 
 
1.5.1 The Hydrogen Bond 
 
The hydrogen bond is considered the most important of all directional intermolecular 
interactions160. It is the main force responsible for molecular recognition and it can be 
strong enough and directional enough so that this recognition is orientationally 
specific161. Hydrogen bonds are responsible for biological processes such as protein 
folding and enzyme-substrate recognition and they are the primary influence in the 
crystal packing of solids, causing deviations from the principles of close packing as defined 
by Kitajgorodskij162. The importance of the hydrogen bond in crystal engineering is 
highlighted in Section 1.4.1.  
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 The IUPAC recommends that a hydrogen bond is defined as “an attractive 
interaction between a hydrogen atom from a molecule or a molecular fragment X–H in 
which X is more electronegative than H, and an atom or a group of atoms in the same or a 
different molecule, in which there is evidence of bond formation”163 (X will from here 
forward be referred to as the donor atom (D)). Hydrogen bonds, Dδ--Hδ+···Aδ- (where A is 
the acceptor), could be viewed as an extreme case of a dipole-dipole interaction, 
however, the unique characteristics of hydrogen bonds indicate that this is an over-
simplification. The distance between D and A atoms is often less than the sum of the van 
der Waals (vdW) radii and the DHA angle is typically very linear (although a significant 
degree of variation in the DHA angle can occur in weaker hydrogen bonds). Hydrogen 
bond energies range from 2-170 kJ mol-1; the strongest hydrogen bonds are stronger than 
the weakest covalent bonds and the weakest hydrogen bonds are weaker than vdW 
interactions. The characteristics outlined above distinguish hydrogen bonds from both 
vdW interactions and covalent bonds161.  
 Classification of hydrogen bonds can be generally broken down into three 
categories as defined by Jeffrey164: strong, moderate and weak (Table 1.2). Strong 
hydrogen bonds generally occur when there is an electron deficiency in the donor atom, 
which deshields the proton and thus induces a greater electropositive charge upon it. 
They also occur when there is an excess in electron density on the acceptor atom, which 
increases the dipole-dipole interaction potential between the proton and the acceptor 
atom. These types of hydrogen bonds are usually referred to as ionic or charge assisted 
hydrogen bonds. Strong hydrogen bonds can also occur when the conformation of a 
molecule forces the hydrogen bond donors and acceptors into being closer than would 
normally be expected.  
 Moderately strong hydrogen bonds (also Table 1.2) are the most commonly 
occurring and generally involve an electronegative donor atom and an acceptor atom 
which has lone-pair unshared electrons. The term “conventional hydrogen bonds” 
normally comprises both moderate and strong hydrogen bonds. The supramolecular 
synthon approach to crystal engineering normally utilises these conventional hydrogen 
bonds, as they are the most robust and transferrable intermolecular interactions.  
 Weak hydrogen bonds typically involve a carbon as the donor atom, which is 
relatively electroneutral - reducing the electropositive charge on the hydrogen. Acceptor 
groups are typically those with polarisable π electrons such as double bonds, triple bonds 
or aromatic rings. Halogen atoms are also common acceptors in weak hydrogen bonds. 
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These three classifications of hydrogen bond are mainly for convenience and there can be 
significant overlap between the characteristics and the functional groups involved. 
 
Table 1.2 Classification of hydrogen bonds into strong, moderate and weak164. 
 Strong Moderate Weak 
D-H···A interaction 
Bond lengths 
    H···A (Å) 
    D···A (Å) 
Bond angles (°) 
Bond energy (kJ mol-1) 
mostly covalent 


















Hydrogen bonds can involve two hydrogen atoms (and hence two donors) or two 
acceptors, and hydrogen bonds of this type are referred to as bifurcated hydrogen bonds 
(Figure 1.6). Bifurcated hydrogen bonds, where two acceptors are present also have 
constraints, in that the hydrogen atom should lie approximately in the plane of the donor 
atom and the two acceptor atoms. Where two donor hydrogen atoms are present the 
interaction is usually asymmetric, with one component forming a stronger interaction 
than the other.   
 
Figure 1.6 An illustration of a bifurcated hydrogen bond with two acceptor atoms (LHS) 




1.5.2 Other Intermolecular Interactions 
 
1.5.2.1  π···π Interactions 
 
Although hydrogen bonds are considered the dominant interactions in the relative 
arrangement of molecules in the solid state, other weaker interactions such as π 
interactions also play an important role. π···π interactions typically involve the interaction 
of aromatic rings. Aromatic ring systems are composed of a σ-framework sandwiched 
between two π-electron clouds. In π···π interactions, aromatic rings align themselves to 
maximise the attractive electrostatic interaction of the orbitals and to minimise 
electrostatic repulsion71 (Figure 1.7). The relative orientation of the aromatic rings is 
therefore important in determining how attractive or repulsive the interaction is, as are 
the electron donating/withdrawing characteristics of any substituents, as these influence 
how electron rich/poor the π system is. π systems can also form interactions with anions 
or cations, depending on how electron deficient or rich the system is.   
 
 
Figure 1.7 π···π interactions between electron rich and electron deficient aromatic rings, 
showing how the orbitals align relative to each other. (a) Face to face stacking (b) Offset 
stacking (c) edge to face interactions/CH···π interactions.   
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1.5.2.2  Halogen Bonds 
 
Halogen bonding is an interaction of the form D···X-Y, where a halogen atom (X) acts as an 
electron density acceptor from an electron rich donor (D) such as oxygen, nitrogen, sulfur 
or π systems (Y = C, N, X etc that is covalently bonded to X). All halogens are capable of 
forming halogen bonds, with their tendency to form these interactions and the strength 
of the interactions generally increasing with decreasing electronegativity. The strength of 
the halogen interaction is also dependent on the donor; nitrogen as an electron donor 
generally forms stronger halogen bonds than oxygen and sulfur, with π systems generally 
being weaker halogen bond acceptors than electron rich atoms77. Accordingly, N···I 
interactions have been shown to be particularly useful in the design of molecular 
complexes36, 78, 165, 166. The donor atom can also be another halogen atom and these 
halogen-halogen bonds have also been used in crystal engineering75. There are two 
classifications of halogen-halogen bonds based on the geometry of the interaction (Figure 
1.8). Geometries which fall outwith the ranges set in these classifications are 
electrostatically repulsive in nature, although can still be attractive due to dispersion 
forces75. An analogy is often made between halogen bonds and hydrogen bonds77, as 
both have an electron density donor/acceptor relationship, both are generally highly 
directional and both are hierarchical - giving rise to robust reproducible supramolecular 
synthons that can be used in crystal engineering. The energy of halogen bonds also spans 
a wide range (5-180 kJ mol-1) and strong halogen bonds have been known to be effective 
in breaking the tendency for hydrogen bond formation by the preferential formation of 
halogen bonds77.  
 
Figure 1.8 The geometry of the two types of halogen-halogen bonds. In type I, 140° < θ1 ≈ 
θ2 < 160°. In type II, θ1 ≈ 90° and θ2 ≈ 180°.  
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2. Characterisation of Materials 
 
2.1  X-Ray Diffraction 
 
Perfect crystalline solids are composed of many molecules, atoms or ions, arranged in a 
regular way, repeating in three dimensions to give a highly ordered structure167. 
Diffraction from such regular arrays allows access to objects that are of similar dimension 
to the wavelength of the incident radiation; the wavelength of X-rays is of comparable 
magnitude to interatomic distances in crystalline solids and this property of X-rays is 
exploited in X-ray diffraction. When a beam of monochromatic X-rays is passed through a 
single crystal, the beam is scattered by the electrons of the atoms in definite directions 
with varying intensities. This process is called diffraction and the scattered rays can be 
recorded with a detector giving a pattern consisting of a regular array of spots with a 
definite geometry and a degree of symmetry in the positions and intensities of the spots. 
It is from this pattern that crystal structures can be determined, as the symmetry of the 
pattern is related to the symmetry of the solid state arrangement of the molecules, while 
the intensities are related to the positions of atoms of different scattering powers in the 
crystal structure168. 
 
2.1.1  The Crystal Lattice and Unit Cell 
 
All crystalline solids contain translational symmetry, regardless of whether other types of 
symmetry are present. The complete crystal structure can be described by the contents of 
the unit cell and translations of this in all three dimensions. To define the symmetry of a 
crystal structure, the lattice is initially obtained by taking a point in the structure and all 
other points identical to this (i.e. identical surroundings and same orientation). What is 
left is a regular pattern of equivalent points all related to each other by translational 
symmetry – this is called the crystal lattice. The lattice defines the repeating nature of the 
structure but not the contents of the unit cell. The vectors between lattice points define 
the unit cell, which is represented by three vector lengths (a, b and c) and three angles (α, 
β and γ), such that α lies between b and c, β between a and c, and γ between a and b 
(Figure 2.1). These six values are the unit cell (or lattice) parameters.  
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Figure 2.1 Illustration of a 3-D unit cell167. 
 
There are many choices of unit cell, however in the absence of any internal symmetry, 
convention states that the three sides should be as short as possible and the three angles 
as close to 90° as possible. The presence of internal symmetry in the unit cell imposes 
restrictions on values that can be taken by the unit cell parameters. These restrictions 
divide the crystal symmetry into seven different types called the seven crystal systems. 
Table 2.1 shows the unit cell restrictions on each of these crystal systems. Unit cells with 
only one lattice point are referred to as primitive (P). For some structures it is convenient 
to select a unit cell that contains more than one lattice point for the purpose of adding 
symmetry to the cell. Different kinds of centering are possible involving unit cells with 
lattice points at the centre of opposite pairs of faces (A, B or C depending on which faces 
are centred), at the centre of all faces (F), or body centred (I). The combination of crystal 
systems with cell centring choices (Table 2.1) gives fourteen possible lattices – the Bravais 
lattices (Figure 2.2).  
 In the solid state, there are symmetry elements such as rotation axes, mirror 
planes and inversion centres, together with combinations of these with internal 
translations, creating screw axes and glide planes; the total number of possible 
arrangements of these symmetry elements within the lattices is 230. These are the 230 
so-called space groups to which every crystal structure belongs.  
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Table 2.1 Unit cell restrictions on each of the seven crystal systems 
Crystal System Unit Cell Restrictions Cell Types 
Triclinic None P 
Monoclinic α = γ = 90° P, C 
Orthorhombic α = β = γ = 90° P, C, I, F 
Tetragonal a = b; α = β = γ = 90° P, I 
Trigonal / Rhombohedral a = b; α = β = 90°, γ = 120° P  
Hexagonal a = b; α = β = 90°, γ = 120° P 





Figure 2.2 The fourteen Bravais Lattices169
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2.1.2  Bragg’s Law and the Ewald Construction 
 
When an X-ray beam passes through a crystal, each atom scatters the incident beam in all 
directions and these scattered rays interact via constructive and destructive interference. 
For a set of lattice planes, the path differences of the radiation scattered by a lattice 
plane and that of the lattice plane(s) below must be a whole number of wavelengths for 
interference to be completely constructive. The directions in which this interference is 
completely constructive are defined by Bragg’s law (Equation 2.1). Bragg’s law is derived 
from the construction that every diffracted beam that can be produced by the crystal in 
an appropriate orientation can be treated as if it were a reflection from a set of parallel 
planes within the crystal168. Figure 2.3 shows a two-dimensional illustration of Bragg’s 
law. The three Miller indices, h, k and l, are used to define the orientation of the plane 
within the crystal with respect to the unit cell edges, such that the plane intercepts the 
cell axes at a/h, b/k and c/l.  
 
Equation 2.1  Braggs Law:  λ = 2 dhkl sin θ   ∴  sin θ = (λ/2) x (1/dhkl) 
where λ = wavelength of incident beam 
dhkl =  spacing between planes with Miller indices hkl  









Every reflection therefore represents a set of lattice planes. This allows construction of a 
reciprocal lattice that is used in the interpretation of a diffraction experiment; the 
reciprocal lattice point associated with each plane is defined with both a direction 
(perpendicular to the plane) and a magnitude (1/dhkl). This construction can be used to 
predict the orientation that the reciprocal lattice (and therefore the direct crystal lattice) 
must lie in relative to the incident X-ray beam for a particular reflection to be observed. 
The Ewald sphere is one construction used to derive the relative lattice orientation 




Figure 2.4168 A 2D representation of the Ewald construction showing (top) the geometry of 
the Ewald sphere and (bottom) a visualisation of the reciprocal lattice placed on the 
sphere (with the origin placed at point O). With the lattice in this orientation only one 
reflection is observed (point B) as only one reciprocal lattice point intersects the sphere. 
Rotation of the lattice about the origin brings other reciprocal lattice points into contact 
with the sphere.  
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The Ewald construction consists of a sphere of radius 1/λ, centred on the crystal position, 
A. The reciprocal lattice is placed with its origin lying on the edge of the sphere (O) and a 
reflection is observed when the reciprocal lattice point for reflecting planes hkl intersects 
the surface of the sphere (B). The vector AB gives the direction of this diffracted beam. If 
a lattice point does not lie on the sphere then Bragg’s law is not satisfied. Rotation of the 
reciprocal lattice around the origin brings other lattice points into contact with the sphere 
allowing the conditions to be specified under which Bragg’s law will be satisfied for those 
reflections. Reflections which cannot be brought into contact with the sphere cannot be 
observed, limiting the maximum number of reflections that can be accessed for a given 
incident wavelength (which defines the radius of the Ewald sphere).  
 
2.1.3  The Fourier Transform and the Phase Problem 
 
From the diffraction pattern an image of electron density must be obtained, where areas 
of concentrated electron density generally represent individual atoms. The intensities of 
the diffraction pattern and the arrangement of atoms in the unit cell are related to each 
other by Fourier transformation. The diffraction pattern is the Fourier transform of the 
crystal structure (Eq. 2.2a), and is defined in terms of the structure factor Fhkl, which 
represents the diffraction pattern measured at the reciprocal lattice point hkl.  The crystal 
structure expressed in terms of the electron density is thus the inverse Fourier transform 
of the diffraction pattern (Eq. 2.2b).  
The structure factor associated with each reflection is a complex number that 
describes both the phase (Φhkl) and the amplitude (│Fhkl│) of the diffracted wave. The 
intensity of the beam reflected from the lattice planes can be measured and from this the 
wave amplitude │Fhkl│ can be calculated (Eq. 2.3). The phase information is lost, 
however, and this is known as “the phase problem”; evaluating the Fourier transform 
requires the phases of the different reflections to be known to allow the calculation of 
the electron density (Eq. 2.2b). The task of solving a crystal structure involves recovery of 
these lost phases, at least as approximate values so that the inverse Fourier 
transformation can be carried out.  
 
Equation 2.2  (a) The Structure Factor as Fourier Transform of the electron density: 
Fhkl = ∫cellρ(xyz) . exp [2πi(hx + ky + lz)]dV 
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Equation 2.2  (b) The electron density as inverse Fourier Transform of the structure 
factors: 
ρ(xyz) = 1/V 
, ,h k l
∑ Fhkl . exp[-2πi(hx + ky + lz)], or 
ρ(xyz) = 1/V 
, ,h k l
∑ │Fhkl│.exp[iΦhkl].exp[-2πi(hx + ky + lz)] 
 
where Fhkl =│Fhkl│.exp[iΦhkl] is the Structure Factor 
ρ(xyz) = the electron density  
│Fhkl│ = magnitude of reflection hkl 
Φhkl = phase of reflection hkl 
V = Volume of unit cell  
x, y, z = coordinates of the position within the unit cell 
 
Equation 2.3:   │Fohkl│ = c Ihkl1/2  
 
│Fohkl│= observed structural amplitude 
Ihkl = Intensity of reflection hkl 
c = experimental constant 
 
Eq. 2.2a can be used at any point during structure determination to calculate the 
diffraction pattern for a known structure even if it is incomplete. This results in the 
calculated structure factor, Fchkl. The experiment only gives us the amplitudes and not the 
phases so the observed structure factors are the structure factor amplitudes │Fohkl│.  
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2.1.4  Structure Solution 
 
As previously stated, structure solution involves the regeneration of the phase 
information lost during the diffraction experiment. The two most common methods of 
doing this are outlined in the following.  
 
2.1.4.1 Patterson Methods 
 
In Patterson methods the intensities are used as the Fourier coefficients in Eq. 2.2b rather 
than the structure factors. As the intensity is the product of the structure factor and its 
complex conjugate, this effectively results in the observed amplitudes (│Fohkl│) in Eq. 2.2b 
being replaced by their squares (│Fohkl│2) and the phases being set to 0 (Eq. 2.4). The 
result of this equation is a Patterson map which is no longer a map of electron density but 
instead represents vectors between individual atoms; every pair of atoms in a structure 
will have a vector represented in the Patterson map. This shows where atoms lie relative 
to each other but not where they lie relative to the unit cell origin. The peak magnitudes 
are proportional to the product of the atomic numbers of the two atoms concerned and 
therefore their number of electrons. If the structure consists of a small number of heavy 
atoms with a majority of lighter atoms then the heavy atom – heavy atom vectors will be 
the largest peaks on the map. This allows a set of positions to be deduced for the heavy 
atoms from which approximate phases can be calculated and the reverse Fourier 
synthesis carried out, as the electron density of these heavy atoms will dominate the 
overall electron density. The map of electron density produced will allow more atomic 
positions to be determined and a better estimate of the phases can be used to repeat the 
reverse Fourier transform calculation. 
 
Equation 2.4  The Patterson Function: 
 
I = │Fhkl│exp (iΦhkl) . │Fhkl│exp (-iΦhkl) = │Fhkl│2   
(since: exp (iΦhkl). exp (-iΦhkl) = exp(0) = 1) 
 
Therefore: P(uvw) = 1/V 
, ,h k l
∑ │Fhkl│2 . exp[-2πi(hu + kv + lw)] 
u, v, w = coordinates of vectors between pairs of atoms in the structure 
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2.1.4.2  Direct Methods 
 
Direct methods are methods which attempt to derive the structure factor phases, and 
hence the electron density and atomic coordinates by mathematical means from a single 
set of X-ray intensities with no other information of the crystal structure, i.e. it is a direct 
solution to the phase problem. They are statistical methods and do not depend on the 
presence of heavy atoms meaning it is possible to solve most structures by direct 
methods. The discrete atomic nature of matter and its implications for diffraction allows 
constraints and probability relationships to be set up to generate the phases. Constraints, 
such as atoms being discrete and the impossibility of negative electron density, put 
restrictions on the possible values for phases and probability relationships are set up 
between the phases of the most important reflections (those which contribute most to 
the Fourier transform).  
The probability relationships used in direct methods make use of the Sayre 
equation which is based on the above constraints that electron density must be positive 
and that atoms are discrete, i.e. the electron density is concentrated in well-defined 
maxima. The Sayre equation states that the structure factor of a reflection can be 
calculated as the sum of the products of all pairs of reflections whose indices sum to it170. 
For centrosymmetric structures, where the solution to the phase problem is a case of 
assigning positive or negative values, reflections that are weak have little contribution to 
the magnitude of the structure factor and are ignored initially which allows triplet 
relationships to be set up (Eq. 2.5 illustrates a triplet relationship for reflection (3,2,1)). 
Triplet relationships allow the calculation of structure factors using three strong 
reflections. The structure factors are normalised to an expectation value, Ehkl, to allow for 
intensity fall off (and therefore fall off in the magnitude of the structure factor) with 
increasing scattering angle.  
 
Equation 2.5
170 E321 ≈ E100 · E221  
 
Ehkl  = normalised structure factor 
 
The phase of E321 in Eq. 2.5 is now assumed to be approximately the product of the 
phases of E100 and E221. Therefore, if E100 and E221 have the same sign, then E321 is probably 
positive and if they have different signs then E321 is probably negative. A number of similar 
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relationships are set up and starting with random phases, different possible phases are 
tried in order to see which will satisfy the probability relationships best. The stronger the 
reflections used in these relationships, the more likely the relationships are to be 
accurate. Fourier transforms are then calculated for the best set of phases and observed 
amplitudes and an electron density map is generated which can then be analysed for 
recognisable molecular fragments167.  
 For the case of non-centrosymmetric structures, the same principle applies, 
except that the values of the phase can now assume all values not just positive and 
negative. In practice a multi-solution approach is usually adopted in the application of 
direct methods, in which sets of reflections are assigned a range of potential initial 
phases, which are permuted until a plausible set can be obtained. 
 
2.1.5 Structure Completion and Refinement 
 
When all non-hydrogen atoms have been found, the model has to be refined to reach the 
best agreement between the calculated diffraction data of the model structure and the 
diffraction data from the experiment. A measure of the agreement is usually obtained 
using the residual factor or R-factor. Using the Fourier transform, the diffraction data 
resulting from the current model can be constructed, and a set of calculated structure 
factors is determined. The calculated structure factors contain values for both amplitudes 
and phases, but since the observed structure factors only have a value for amplitude, the 
calculated structural amplitudes are compared to the observed amplitudes to give the R-
factor (Eq. 2.6a). The closer this value is to zero, the better the model. There are 
variations on this equation using F2 values instead of │F│and weighted R-factors can also 
be calculated (Eq. 2.6b) where the structure factors of the reflections are multiplied by 
factors depending on the reliability of the measurement167.  
 




The calculated phases, Φc (from the model structure), and the observed amplitudes, 
│Fo│, are used to calculate a new electron density map for the structure which will show 
the molecular fragments already found as well as regions of electron density that may 
represent atoms yet to be assigned. When only a partial structure model is obtained from 
initial structure determination, this process is repeated until all non-hydrogen atoms are 
found. Each time a new set of improved structure factors (and therefore Φc) are 
determined until the difference in Fc and Fo give as low an R-factor as possible. During this 
process, least squares optimisation of atom positions and thermal parameters are carried 
out to further improve the R-factor. Fourier difference maps can also be used to find 
atoms not yet found and can indicate incorrect atom assignments. Fourier difference 
maps are generated via replacing │Fo│ in Eq. 2.2b with │Fo│-│Fc│. 
 With all non hydrogen atoms found and assigned, the difference in Fc and Fo must 
be minimised by further least-squares refinement of the atomic coordinates and the 
vibrational parameters of the atoms. The vibration of the atoms is initially represented by 
a single value as the atoms are represented as spheres vibrating by the same amount in 
all directions. This value is the isotropic thermal parameter. A more realistic 
representation is given by refining the atoms anisotropically, where the atoms vibrate by 
different amounts in different directions. This then becomes six values, representing the 
magnitude and directions of the vibrations, known as the anisotropic thermal 
displacement parameters. Hydrogen atoms identified from the electron density map or 
difference map should not be refined anisotropically against X-ray data as they contribute 
relatively little to the scattering due to only having one electron. The fact hydrogen has 
only one electron also means that covalent bonds involving hydrogen will be observed as 
being shortened due to displacement of the bonding electron towards the heavier atom 
to which the hydrogen is bonded. This has the effect of producing systematic errors in 
hydrogen bond lengths. As it may not be possible to locate hydrogen atoms accurately, in 
some cases they should be constrained to have fixed bond lengths and their vibrations 
tied to the atoms to which they are bonded. As a consequence of these factors, hydrogen 
bond lengths from X-ray data are often expressed in terms of the distance from the donor 
atom to the acceptor atom.  
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2.1.6 Powder X-ray Diffraction 
 
As well as using single crystal X-ray diffraction for structure determination, powder X-ray 
diffraction (PXRD) is also used in this work. PXRD is primarily used for identification and 
quantification of new co-crystals and/or phases although structure determination is 
possible in some cases using, where appropriate, structure determination from powder 
diffraction (SDPD) methods, and Rietveld refinement techniques171. In PXRD, instead of 
using a single crystal, the sample is extracted or ground to a polycrystalline powder and 
packed into a capillary for data collection; one advantage of this technique is that it 
negates the need to find good quality single crystals as required for single-crystal XRD.  
The capillary is placed in an X-ray beam and rotated to minimise preferred orientation 
effects. Instead of a pattern of spots, as is produced with a single crystal, a pattern of 
concentric rings is produced. As the powder contains randomly orientated 
polycrystallites, each individual crystal generates a limited set of Bragg reflections 
depending on its orientation. The resultant pattern from all of the many randomly 
oriented crystallites generates the full set of Bragg reflections, characterised only by the 
Bragg angle 2θ.  A detector measures the diffracted beams and intensity is recorded as a 
function of angle for each reflection i.e. a cross section through the diffraction rings. As 
with single crystal XRD, the peak positions are related to the unit cell geometry and 
intensities are related to atom positions within the cell.  Different crystal structures thus 
produce their own unique diffraction pattern. Figure 2.5 shows how the powder 
diffraction pattern is built up from a large number of crystallites.  
 Where a heterogeneous sample is being analysed, the technique can be used to 
probe the bulk, resulting in a pattern showing a superposition of the PXRD patterns of all 
components of the mixture. This allows for fairly high-throughput analysis of whole 
samples to identify the composition of multi-phase samples and determine if a new phase 
has been produced in co-crystallisation experiments. Tentative quantitative analysis of 
the mixture can also be carried out by comparing relative peak heights. The relative peak 
heights are affected by the scattering strength of the material and therefore factors such 
as different chemical composition can prevent accurate phase quantification using this 
method. Quantitative analysis is further complicated by preferred orientation effects as 
well as peak overlap in some cases, although these issues can be taken into account using 
Rietveld refinement172. As previously stated, structure solution from powder data can be 
carried out for samples containing a single phase but is made difficult as the three-
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dimensional information from the diffraction pattern is compressed into a one-
dimensional pattern.  This method will thus only be used in this work for identification of 
new phases (both new molecular complexes and new polymorphs) and quantitative 
analysis of mixtures of polymorphs.  
 
 
Figure 2.5168 Illustration of how a diffraction pattern is built up showing: (a) spots from a 
single crystal; (b) spots from 4 single crystals in different orientations; (c) rings from 
polycrystalline powder; (d) diffraction pattern of intensity vs. 2theta. 
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2.1.7 Single Crystal Neutron Diffraction 
 
As mentioned previously, locating hydrogen atoms via X-ray diffraction is difficult and 
results in inaccuracies due to hydrogen atoms possessing only one electron that is 
inherently involved in a covalent bond. To this end, neutron diffraction can be used as an 
alternative to X-ray diffraction as a means of locating and modelling the parameters of 
hydrogen atoms more accurately. Neutrons are scattered by atomic nuclei rather than 
the electrons and thus all atoms in a crystal structure are measured at a similar level of 
precision173 with scattering lengths varying irregularly with Z across a smaller range of 
values (Figure 2.6). Hydrogen has a relatively large negative neutron scattering length 
allowing hydrogen atom coordinates and amplitudes of vibration to be measured to a 
precision that is similar to that obtained for heavier (C, N, O) atoms in X-ray experiments, 
in which hydrogen atoms can only be measured to an order of magnitude less in 
precision173. This makes neutron diffraction an ideal technique in cases where accurate 
modelling of hydrogen atoms is required. Another advantage of neutron diffraction is that 
the intensity fall-off with increasing scattering angle is far less pronounced than in X-ray 
diffraction (Figure 2.7), allowing access to high-resolution and therefore more precise 
data. A less pronounced fall-off does occur due to thermal vibration of the atoms about 
their equilibrium position which is described, as in the case of X-rays, by the Debye-Waller 
factor173.   
 Due to the limited access to neutron diffraction sources, materials suitable for 
study are usually characterised by X-ray diffraction initially. Materials where hydrogen 
atoms exhibit interesting behaviour may then be selected for study via neutron 
diffraction, for example, materials where hydrogen atoms appear to be disordered (to 
verify/quantify the disorder) or involved in very short strong hydrogen bonds (to identify 
the accurate position of the hydrogen). X-ray diffraction data also provides initial heavy 
atom coordinates to simplify the process of refining the structure against the neutron 
data. Variable temperature neutron diffraction studies are frequently carried out in 
examining those structures where the neutron data can provide key information, allowing 
the study of the evolution of hydrogen parameters with increasing temperature. This has 
previously been used to study phenomena such as proton migration174 or libration of 
functional groups175.  
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Figure 2.7 Powder diffraction patterns emphasising the fall-off in X-ray intensity with 





2.2 Thermal Analysis 
 
2.2.1  Differential Scanning Calorimetry (DSC) 
 
Differential scanning calorimetry is a thermoanalytical technique which is routinely used 
in the identification and characterisation of co-crystals and polymorphs of materials. The 
method is based on the principle that a change in the physical state of a material is 
accompanied by the liberation or absorption of heat177. In practice it is used to measure 
the heat energy necessary to establish a near zero temperature difference between a 
substance and a reference material, as the two specimens are subjected to identical 
temperature regimes in an environment where they are heated or cooled at a controlled 
rate178.  
In the analyses carried out as part of this work, the DSC method used is heat flux 
DSC. In heat flux DSC the sample and reference are enclosed in a single furnace and 
connected by a low-resistance heat-flow path (Figure 2.8) with a purge gas flow for 
efficient heat transfer and removal of volatiles.  
 
 
Figure 2.8 Schematic of Heat Flux DSC Set-up179. 
 
As the temperature is changed in a linear manner, any heat changes in the sample will 
result in a difference in the energy needed to maintain the sample and reference at the 
same temperature. As they are in good thermal contact any excess heat energy will flow 
into the metallic disc and this heat flow is measured as it is directly proportional to the 
small temperature difference between the sample and the reference. This technique can 
therefore be used to observe phase transitions in materials as they undergo heating or 
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cooling, as endothermic processes such as melting will result in a negative heat flow, 
whereas exothermic processes such as crystallisation will result in a positive heat flow 
(Figure 2.9). Glass transitions, where a change in heat capacity occurs in the sample, can 
also be observed using DSC (also Figure 2.9). 
 
 
Figure 2.9 Example of a DSC trace exhibiting endothermic (melting) and exothermic 





This technique will be used in the initial analysis of the products of the attempted co-
crystallisations to ascertain which, if any, have formed new phases. Comparing the 
melting point of the product to that of a reference of the starting materials gives an 
indication of whether they are the same or not. A co-crystal would be expected to have a 
unique melting point, different from that of its components, while a new polymorph of 
one (or both) of the components would also be expected to have a unique melting point. 
Should the results indicate the presence of a potentially new phase, this preliminary 
analysis would have to be followed up by X-ray diffraction techniques to ascertain the 
exact nature of the new phase. In cases where polymorphic materials are discovered in 
this work, DSC will be used to ascertain the relative thermal stability of the polymorphs, 
as the more stable polymorphs should have higher melting points.  
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2.2.2 Thermogravimetric Analysis 
 
Thermogravimetric analysis (TGA) is a technique used to measure the change in weight of 
a sample as a function of temperature, providing information on the composition of the 
sample. The sample is loaded in an inert pan (normally platinum) which is placed on a 
balance and the sample weight recorded accurately. The pan is then heated until 
vaporisation of one of the sample components occurs causing it to leave the pan with the 
weight being recorded throughout. A plot of % weight versus temperature is produced 
(Figure 2.10), where the % weight loss can be used to infer information on the process 
that has taken place. A derivative weight loss curve can also be produced to aid 
interpretation, emphasising areas where weight loss is more pronounced (also Figure 
2.10). TGA is often used to assess sample purity as well as investigate the 
decomposition/stability of samples. It is also used in studies of porous materials to 
investigate the evolution of gases stored in the pores181.  
 
 
Figure 2.10 Example of typical weight loss TGA plot (green) and the corresponding 
derivative weight loss TGA plot (blue). The drop in weight between 375°C and 450°C 




3. Techniques and Instrumentation 
 
This chapter will outline the general experimental techniques used to gather data for this 
work and will detail the instrumentation used for analysis. Where appropriate, more 
specific details will be given throughout the chapters describing the materials studied, or 
in the relevant appendices.  
 
3.1  Crystallisation Techniques 
 
3.1.1 General Evaporative Method for Co-Crystallisation Screening 
 
Obtaining good quality crystalline samples of the molecular complexes or polymorphs 
under investigation is the first step of the studies presented herein. As discussed in 
Chapter 1, various crystallisation methods can be used to screen for co-crystals. In this 
work, a medium-to-high throughput evaporation method was selected. The simplicity of 
the evaporation method offers the opportunity to set up numerous experiments 
simultaneously under various conditions to maximise the chances of obtaining good 
quality crystals of the desired molecular complex.  
 
The general evaporative co-crystallisation screening method used in this work is outlined 
below: 
 
1. Target molecule and co-former were dissolved in a 1:1 molar ratio (between 10-
100 mg) in an excess quantity of an appropriate solvent (generally 2-6 ml). 
Samples were sometimes heated gently to facilitate dissolution of the materials. 
The vials used were made of glass and had a maximum volume of 7 ml.  
 
2. The plastic lid of the vial was perforated to allow the solvent to evaporate slowly 
over time. The solvent was allowed to evaporate completely at a fixed 
temperature (or at ambient temperature) and crystallisation occurs at the point 
where the solution becomes supersaturated.  
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3. Iterations of each co-crystallisation were set up under various conditions to 
maximise the chances of obtaining the desired molecular complex and good 
quality crystals thereof. The use of different crystallisation conditions may also 
result in different polymorphs of the complex. The main variables altered in this 
screen were the solvent used and the temperature of evaporation. The solvents 
generally used were methanol, ethanol, acetone, isopropanol and acetonitrile. The 
poor solubility of piroxicam in most solvents meant that acetonitrile was used 
initially (see Chapters 4, 5 and 6). If this failed to yield a molecular complex, 
methanol or acetonitrile/methanol mixtures were used as solvent. The 
temperature of evaporation was controlled using an Asynt hot-plate with jacketed 
vessels (Figure 3.1).  
 
4. If varying the solvent and/or the evaporation temperature failed to yield a 




Figure 3.1 A temperature controlled hot-plate with jacketed vessels used for controlling 
the temperature of evaporation of the co-crystallisation experiments. The glass vials were 
kept in the jacketed vessels during the evaporation process to maintain a constant 
temperature during crystallisation.  
 75
3.1.2 Scale-up for Co-Crystallisation in an Oscillating Baffled Crystalliser (OBC) 
 
3.1.2.1  General Viability Screening Method for Co-Crystallisation in an OBC 
 
After full structural characterisation, certain phases that have potential pharmaceutical 
relevance were selected to be trialled for scaled-up crystallisation in an OBC. This 
required conversion from an evaporation co-crystallisation technique to a cooling or anti-
solvent addition technique, as evaporation crystallisation is not possible in an OBC. 
 Small scale trials were carried out to assess the viability for scale-up to a cooling 
co-crystallisation method. These initially involved dissolving the two components in the 
same solvent and molar ratio used in the corresponding successful evaporation co-
crystallisation. The components were dissolved at high temperature (60-75°C) to 
generate a saturated solution and the solution was allowed to cool to induce 
crystallisation. The crystalline product was then isolated by filtration and the sample 
analysed by PXRD. Several co-crystallisations were set up at varying degrees of 
supersaturation and cooled to different temperatures (either room temperature or 0°C). 
If these initial trials failed to produce the desired crystalline phase, different conditions 
were trialled, i.e. using different solvents or different component ratios. If the PXRD 
indicated that one component precipitated preferentially (“crashed”) out of solution 
while the second component remained in solution, the relative molar quantity of the 
second component could be increased in an attempt to encourage molecular complex 
formation upon crystallisation. Anti-solvent crystallisation could also be trialled, with the 
anti-solvent used dependent on the solubilities of the component materials. 
 
3.1.2.2  The Batch OBC (BOBC) and Continuous OBC (COBC) 
 
When a viable co-crystallisation system had been identified for scale-up, initial scaled-up 
trials were to be carried out in a BOBC (Figure 3.2). The BOBC is a round bottom jacketed 
vessel (typically of volume 250 ml – 500 ml), in which the baffles are oscillated through 
the solution by a linear motor - as opposed to oscillation of the solution through the 
baffles by bellows, as is the case in the COBC. A programmable temperature controlled oil 
circulator unit is attached to the jacket to control the cooling profile and a thermocouple 
inserted from the top to monitor the solution temperature. Probes can also be attached 
to the side of the vessel to monitor particle size of the product. The BOBC is used to 
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determine an initial set of parameters for crystallisation in the COBC, such as optimal 
cooling rate, optimal oscillation amplitude and optimal oscillation frequency. Solution 
concentration may have to be significantly altered at this stage as solubility does not 
scale-up linearly.  
 
 
Figure 3.2 Photograph of the 250 ml batch oscillatory baffled crystalliser (BOBC) in the 
laboratory, with a linear motor and control box attached (LHS) and a schematic of a 
BOBC
155
 (RHS). The probe indicated on the schematic is optional.  
 
When initial parameters have been determined from the BOBC, scale-up trials move to 
the COBC (Figure 3.3). Although the set-up in the COBC is based on the parameters from 
the BOBC trials, the solution concentration must again be optimised due to the larger 
volume used. Differences in the parameters should also be anticipated due to the 
different oscillation mechanism and the fact that the solution is flowing through the 
column. In the COBC at the University of Bath, the column is constructed from twenty 
125 ml jacketed glass tubes. The temperature in each tube can be controlled individually 
by attaching separate temperature controlled oil circulator units. A 5 L – 20 L solution is 
initially dissolved in a stirred tank and fed into the COBC, where it is oscillated with a 
positive net flow. As the temperature decreases along the length of the column, 
crystallisation occurs. The slurry is collected at the end of the column and filtered. For 
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anti-solvent crystallisation, inlets can be introduced along the length of the column to add 
the anti-solvent.    
 
 
Figure 3.3 Photograph of the continuous oscillatory baffled reactor (COBC) installed in the 
laboratory (LHS), with a coloured sample solution being pumped through – this has 
reached around halfway up the COBC in this picture.  A schematic of the COBC
155




3.2  Single-crystal X-ray Diffraction 
 
3.2.1  Sample Selection 
 
When performing a single crystal X-ray diffraction experiment, selection of a suitable 
sample is critical to the success of the experiment and the quality of the data obtained. A 
number of crystals are selected from the crystallisation vessel and placed under the 
microscope for initial inspection. The difficulty in selecting a single crystal can vary 
immensely depending on the sample under investigation. Generally a single crystal will 
have clear, well defined faces and edges with few or no fault lines visible.  Visual analysis 
using plane polarised light is a key method in identifying if crystals are single or not. A 
single crystal should extinguish uniformly when rotated 90° under plane-polarised light. 
Two or more extinctions would suggest the crystal is not single. Ideally the crystal should 
be approximately 0.2 mm - 0.5 mm in at least two dimensions, although smaller crystals 
can be used. Significantly larger crystals may be cut down to a more suitable size.  
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3.2.2 Laboratory Source Diffractometers  
 
Three different laboratory diffractometers were used during the course of this work. The 
Bruker Apex II and Bruker-Nonius Kappa diffractometers were equipped with charge-
coupled-device (CCD) detectors and the Rigaku R-axis/RAPID diffractometer was 
equipped with an image-plate detector (Figure 3.4). All three diffractometers were 
equipped with graphite monochromated Mo-Kα radiation (λ = 0.71073 Å). Data for all 
samples were collected at 100 K. Samples on the Kappa and RAPID diffractometers were 
cooled by Oxford Cryosystems cryostream low temperature devices, while the Apex used 
an Oxford Cryosystems Helix, all of which which direct gaseous nitrogen onto the sample 
from above (Figure 3.4). The cryostream is fed by a liquid nitrogen cylinder, while the 
Helix uses a nitrogen recovery unit.  
 
 
Figure 3.4 The setup of the Rigaku R-axis RAPID diffractometer. The sample is kept at low 





3.2.3 General Procedure of a Diffraction Experiment 
 
Although there are slight differences between the three diffractometers, the general 
procedure of the diffraction experiment is the same. The sample is mounted on a glass 
fibre on a goniometer and centred in the X-ray beam to ensure it remains in the beam in 
all orientations. A preliminary set of X-ray images is taken from different regions of 
reciprocal space. The number of images is dependent on the diffractometer and the 
detector type. The Rigaku diffractometer generally requires only four images in this initial 
scan as the image plate measures a much a larger area of reciprocal space in a single 
image whereas the Apex II and Kappa diffractometers require more images (between ten 
and thirty) as the CCD detector measures a relatively small area of reciprocal space in a 
single image. Exposure time for each image is dependent on the X-ray intensity from the 
diffractometer as well as the sample size and composition. A tentative unit cell is 
determined from the spot positions in this set of initial images and this unit cell is 
compared to the unit cell parameters of the starting materials. If a different unit cell from 
those of the the starting materials is determined, this is likely to indicate that a molecular 
complex has been formed, or possibly a new polymorph of one of the starting materials. 
This unit cell screening procedure can also be useful when identifying phases in complex 
mixtures, which can be difficult to interpret using PXRD. During the unit cell screening 
stage a better assessment of the crystal quality can be made, as when a single crystal 
diffracts it should produce a pattern of well defined peaks. Split peaks or streaks on the 
diffraction pattern indicate that the crystal may be twinned or have poor mosaicity or 
have intergrown crystallites. 
 When a possible new material is identified, a data collection strategy is 
determined by the diffractometer software based on the Bravais lattice of the unit cell. 
The data collection should ideally have a d-spacing resolution of approximately 0.75 Å - 
0.80 Å with a minimum redundancy of three or four. After all images are collected, the 
data have to be integrated to obtain a set of peak intensities. At this point background 
intensity is accounted for in each individual peak. In this work absorption corrections are 
applied using the multi-scan correction method182. The multi-scan correction method also 
corrects for any other systematic errors such as poor crystal centring. After integration, a 
reflection data file (.hkl file) is generated comprising the Miller indices of the reflections 
and their corresponding intensities. This file is then used in the structure solution 
programme. In this work, all structures were solved by direct methods using SHELXS-
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97183, SHELXS-86183, or SIR-92184. Full-matrix least-squares refinement on F2 was carried 
out using SHELXL-97183 within the WinGX program suite185. The data processing software 
used for each diffractometer is summarised in Table 3.1. 
 
 
Table 3.1 The data processing software used for each diffractometer. 
Diffractometer Data Processing Software Absorption Correction 




HKL Denzo and Scalepack189 
SADABS187 
Rigaku R-Axis RAPID CrystalClear v1.4.0 190 ABSCOR191 
 
 
3.2.4 Synchrotron X-ray Source (Diamond Light Source) 
 
Crystals that were too small for X-ray diffraction studies using a lab source were analysed 
at Beamline I19 (experimental hutch 1) at the Diamond Light Source synchrotron facility 
(Figure 3.5). The synchrotron exploits the relativistic effects of moving charged electrons 
at close to the speed of light to produce a high flux and high brilliance X-ray beam with 
tuneable wavelengths. Electrons are initially produced by an electron gun, in which a 
cathode is heated to incandescence resulting in the ejection of electrons from the 
surface. These electrons are accelerated by the high voltage into the linear accelerator 
(Linac), which further accelerates the electrons through a series of potential differences 
into the booster ring. In the booster ring, electrons are accelerated to approximately 
99.9% of the speed of light before being injected into the storage ring. Bending magnets 
in the rings control the path of the electrons. When the electrons travel in a straight line 
no radiation is emitted; when the path of the electron is changed (i.e. they are 
accelerated), high intensity radiation is emitted tangentially to the storage ring. The X-
rays produced from this process can be used for diffraction experiments. Greater 
intensity can be achieved by the use of insertion devices called wigglers and undulators, 
positioned in the straight sections of the storage ring. These induce oscillations in the 
path of the electrons, with each oscillation resulting in more radiation being emitted. 
 81
Focusing magnets are also used to keep the electron beam narrow and well defined 
which results in higher intensity X-rays being produced.  
 The experiments using synchrotron radiation in this work utilised silicon (111) 
monochromated radiation (λ = 0.6889 A°) with a Rigaku Saturn CCD detector. Data were 
processed using CrystalClear-SM Expert 2.0 r5192 and absorption corrections were carried 
out using ABSCOR191. 
 
 
Figure 3.5 A 3D schematic of the synchrotron at the Diamond Light Source193. 
 
 
3.3 Single Crystal Neutron Diffraction  
 
Single crystal neutron diffraction for this work was carried out at the Institut Laue 
Langevin (ILL) facility in Grenoble, France. The ILL facility is a steady state neutron source 
where neutrons are produced by nuclear fission, similar to a nuclear power station. It 
provides the most intense continuous neutron source in the world, providing neutrons 
with tuneable wavelengths for more than forty instruments.  
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3.3.1 VIVALDI at ILL 
 
The instrument used for the neutron diffraction experiments was VIVALDI (very intense 
vertical axis Laue diffractometer)194. VIVALDI is a Laue diffractometer that utilises a high 
intensity (quasi-) white beam, with a wavelength range of 0.8 Å - 5.2 Å used for the 
diffraction studies presented in this work. The use of white beam radiation allows faster 
data collection and also facilitates the use of smaller sample sizes (< 1 mm3) than are 
typically required for neutron diffraction (although still requiring larger crystals than are 
typically used in X-ray diffraction). Data collection time is also reduced as the instrument 
is equipped with large image plates which cover a large area of reciprocal space. A helium 
cryostat allows data collection to be carried out at temperatures as low as 30 K. As the 
experiments use white beam radiation and VIVALDI is one of only two instruments of its 
type in the world, the data are difficult to process and processing was therefore carried 
out by the beamline scientists at ILL, subsequent to the experiments being carried out at 
the ILL by the author. Reflection data files containing processed structure factor data 
suitable for structural refinement in a program such as SHELXL-97 were provided to the 
author by the beamline scientists.  
 
3.4 Powder X-ray diffraction (PXRD) 
 
3.4.1 Sample preparation 
 
Samples for PXRD were prepared by gently grinding the sample in a mortar and pestle to 
obtain a larger number of small crystallites which will reduce preferred orientation 
effects. The ground sample is then packed into a capillary. Unlike single crystal diffraction, 
PXRD is used to probe the crystalline properties of the bulk product and so a sample 
representative of the entire contents of the crystallisation vessel is taken. Capillaries of 
0.5 mm - 1.0 mm diameter were used in this work depending on the sample quantity and 
ease of filling the capillary. Samples were mounted on the diffractometer and centred to 
ensure they remained in the beam when rotated. Samples were rotated in the beam to 
minimise preferred orientation effects.  
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3.4.2 X-ray Powder Diffractometers  
 
The X-ray powder diffractometers used in this work were a Bruker D8 Advance and a 
PANalytical X’pert Pro. Both machines were equipped with graphite monchromated Cu-
Kα radiation and a capillary holder using transmission geometry (Figure 3.6). In this 
configuration the incident X-ray beam is kept stationary. The sample holder is kept 
stationary relative to the path of the incident beam while the centred capillary is rotated 
around an axis perpendicular to the incident beam path - such that the capillary remains 
in the beam at all times. The detector is attached to an arm and moved through a user-
defined 2θ range throughout the experiment. Measurements in this work were carried 
out between a 2θ range of 5° and 50°. Scan speeds were typically 1° per minute, although 
slower speeds were used for weakly scattering samples and to obtain patterns with lower 
background relative to the peaks, for quantitative analysis.   
 
 




3.4.3 PolySNAP - Phase Identification and Quantitative Analysis  
 
The PolySNAP software package195 was used to assist in the interpretation of the PXRD 
results. This software can be used to match powder patterns in terms of similarity and for 
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quantitative analysis of mixtures. PolySNAP performs cluster analysis and uses full profile 
powder pattern matching as opposed to some older methods which only use the 2θ and 
intensity values of the strongest peaks196. Background can also be removed and the data 
smoothed before peak finding, although this is optional processing. The PXRD patterns 
can be imported in various formats; the Bruker raw data format is used in this work. Once 
the powder patterns are imported, various statistical correlation calculations (full pattern 
and optional individual peak methods) are carried out and a weighted mean of the 
correlation coefficients is used as an overall measure of the correlation between patterns. 
Each pattern imported is matched against every other imported pattern and each 
correlation value for a pair of patterns is used to give a numerical value of similarity 
between the two patterns. The patterns are then partitioned into related clusters or sets 
and this partitioning can be presented numerically or in various graphical forms.  
 A database of pure phases can also be imported by the user to carry out pattern 
matching relative to an individual input pattern. In this case the input sample is checked 
against the database for similarity to any of the known phases. Quantitative analysis of 
mixtures can also be carried out for an individual pattern, using the database to 
determine a percentage composition of known phases.  
 In this work, the basic pattern-matching operation was used to compare the 
products of the co-crystallisations to the starting materials (and known polymorphs 
thereof) and assist in identifying any interesting or new phases. As mixtures of phases 
may be difficult to interpret, the quantitative analysis function was used in conjunction 
with pattern matching to determine if the co-crystallisation had resulted in a new phase 
or if the sample contained a mixture of the starting materials. Using this method enabled 
rapid identification of samples which required further analysis. In cases where more than 
one polymorph of a material had been produced, quantitative analysis allowed quick and 
easy deduction of the relative ratios of the polymorphs.   
  
 
3.5  Thermal Analysis 
 
3.5.1  DSC – differential scanning calorimetry 
 
Heat flux DSC measurements were carried out using a TA Instruments Q100 DSC system. 
Crystals were gently ground and 1–3 mg of sample placed in a hermetically sealed 
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aluminum pan. Where molecular complexes were analysed, the sample was heated from 
ambient temperature to typically 10°C or 20°C above the melting point of the highest 
melting component of the molecular complex. DSC measurements on new polymorphs of 
materials were carried out to 10°C or 20°C above the melting point of the most stable 
known polymorph. Samples were heated at either 5°C min-1or 10°C min-1.  Melting points 
were derived from the onset point of the peak using the TA Universal Analysis software 
from TA instruments. 
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4. Multi-Component Crystallisation Routes to New and Elusive 
Polymorphs 
 
This chapter will focus on the use of the co-crystallisation approach to direct the assembly 
of rare or new metastable polymorphs of one of the components (as discussed in Chapter 
1, Section 1.4.3.3). The co-crystallisation experiments discussed herein do not result in 
molecular complex formation between the API and the co-molecule; they instead 
crystallise independently, with the co-molecule perturbing the crystallisation 
environment in such a way as to direct the formation of a metastable polymorph of the 
API (or in some cases, a solvate). This technique is investigated as an alternative method 
of polymorph control for four different materials with pharmaceutical properties: 
paracetamol, piroxicam, piracetam and gallic acid.  
 
4.1 Introduction to Paracetamol Crystal Forms 
 
Paracetamol (acetaminophen, p-hydroxyacetanilide; Scheme 4-1) is an important 
bioactive compound and active pharmaceutical ingredient (API), previously studied 
intensively in the crystalline state47-50, 175, 197-199. There are currently three known 
polymorphs of paracetamol (PA); the crystal structures of all three have been determined 
previously, although the structure of form III has only been determined relatively recently 
from powder X-ray diffraction data200. The metastable orthorhombic form II polymorph 
(PA II) has been shown to be more soluble48 and more readily compressible into tablets 
than the commercially available form I49,50, due to the layered nature of its packing in the 
solid state. PA molecules in form I (PA I) are arranged in a herringbone fashion resulting in 
an interlocked structure with poor compression properties50 (Figure 4.1). The layered 
arrangement of the molecules in form II results in slip layers which facilitate direct 
compression for tabletting without the need for binding agents49,50. These physical 
characteristics make form II far more attractive in formulation. However, existing routes 
to selective crystallisation of this phase are complex, and solid form II products from 
these tend to convert into form I over time50; form II is a metastable polymorph. Previous 
crystallisation routes to this polymorph include carefully controlled heating, cooling and 
filtering cycles over periods of days201, rapid removal and drying of crystals grown by 
seeding using crystals from the melt50, heteronucleation involving heating and cooling 
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cycles202, high pressure crystallisation197 and using porous membrane crystallisers203. The 
favourable physical properties of form II make it desirable to find a facile route to 
selective crystallisation of this polymorph that would lend itself to production on an 
industrial scale but as yet no straightforward, reliable method is known. 
 
Scheme 4-1 Molecular structure of paracetamol 
 
 
Figure 4.1 The crystal packing in paracetamol form I (LHS) and form II (RHS). The 
molecules in paracetamol form I are packed in a herringbone arrangement whereas the 
molecules in form II are arranged in layers. 
 
 
4.2 Multi-Component Crystallisation Routes to Paracetamol Form II: Co-
crystallisation with Carboxylic Acids 
 
A medium to high throughput co-crystallisation screen of paracetamol was initially carried 
out with a view to molecular complex formation. The discovery that co-crystallisation 
with certain mono-substituted benzoic acids resulted in the concomitant recrystallisation 
of the mono-substituted benzoic acid with metastable PA II - as opposed to the stable PA I 





4.2.1 Crystallisation Conditions 
 
4.2.1.1  Evaporation Co-crystallisations 
 
Co-crystallisations were carried out according to the procedure outlined in Chapter 3 
unless otherwise stated. Systematic 1:1 evaporative co-crystallisations of paracetamol 
were carried out with a range of mono-substituted benzoic acids in a range of different 
solvents at room temperature. In some cases other temperatures were used for the 
crystallisation in attempts to induce molecular complex formation. Co-crystallisations of 
4-bromobenzoic acid and 4-chlorobenzoic acid were also carried out in 2:1 molar ratios 
(PA:BA) and in the case of 4-bromobenzoic acid, 4:1 ratios were also used, to assess the 
affects of altering the component ratios.  Other molecules containing carboxylic acid 
groups were also used as co-molecules in crystallisation attempts. Relevant results from 
co-crystallisations with co-molecules that do not possess carboxylic acid groups are also 
presented in this chapter. Table 4.1 shows a summary of all the relevant co-molecules 













Table 4.1 Summary of the relevant co-molecules and the main solvents used in the co-
crystallisation experiments with paracetamol. Only one co-molecule from either column A 
or B was used with one solvent from column C.   
Note: In the case of taurine, water was used as the solvent as it is poorly soluble in most 
solvents. 
(A) Carboxylic Acid Co-molecules (B) Other Co-molecules  (C) Solvents 
Benzoic acid (BA) 
2-, 3-, and 4-fluorobenzoic acid (FBA) 
2-, 3-, and 4-chlorobenzoic acid (CLBA) 


























4.2.1.2  Recrystallisations of Paracetamol Using Acetic Acid 
Recrystallisation of paracetamol was carried out by dissolving paracetamol (approx. 80 
mg) in excess acetic acid (5-7 ml) and allowing the solvent to evaporate at room 
temperature. Further evaporative experiments were carried out using supersaturated 
solutions generated through heating, which were then allowed to evaporate at room 
temperature.  
Recrystallisations were also carried out using acetic acid as an additive in varying 
molar quantities. Acetic acid was added to paracetamol (between 40 mg and 80 mg) in 
20:1, 10:1 and 1:1 (acetic acid: paracetamol) molar ratios with excess solvent (methanol, 
ethanol, acetone, acetonitrile or IPA). The solvent was then allowed to evaporate at room 
temperature.  
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4.2.1.3  Co-Grinding  
 
Co-grinding experiments were carried out by grinding the two components in a 1:1 molar 
ratio using a mortar and pestle for approximately ten minutes. Experiments were carried 
out both in the absence of solvent and with 4-5 drops of methanol from a pipette.   
 
4.2.2  Co-crystallisation Routes to Paracetamol Form II 
 
In experiments initially targeted at the formation of molecular complexes, it was found 
that co-crystallisation of PA with mono-substituted benzoic acids (BAs) could be used as a 
facile and reliable evaporative route to produce PA II204. After a period of days to weeks, 
depending on the volatility of the solvent used, distinct crystals of both PA II and the pure 
benzoic acid were formed, which could be easily separated and identified by the crystal 
habit and the pink hue characteristic of the PA II crystals. Samples were analysed by PXRD 
(Appendix B4a) to ascertain which PA polymorphs were present. No molecular complex 
was formed, with the BA crystallising concomitantly with PA I or II (or a mixture) in all 
cases. Repeat experiments show consistency in the yields obtained, and recrystallisations 
on the 100 mg scale have been successfully performed to date. Single crystals of form II 
have also been produced, verified by full redetermination of the previously reported 
crystal structure (Appendix A4). Moreover, very large (mm-sized) single crystals of good 
quality have been obtained, representing a significant advance in the production of this 
previously elusive material in large quantities.  
 By systematically tuning the BA co-molecule and solvent used in the co-
crystallisation (Scheme 4-2), 100% yields of PA II can be obtained (Figure 4.2). Table 4.2 
shows a summary of the PA polymorphs obtained from the co-crystallisation 
experiments. Both the solvent and the BA used appear to play a role in controlling the 
crystallisation outcome, possibly through solution-mediated templating processes. The 4-
substituted BAs produce PA II most reliably, with 100% yields obtained reproducibly from 
1:1 crystallisations (Figure 4.2). The three 4-substituted BAs could all be used to produce 
100% form II and resulted in products that, at the least, comprised mixtures of both forms 
from all five solvents used. MeOH and IPA were the most reliable solvents yielding 100% 
PA II using the 4-substituted BAs. Use of the other halo-substituted BAs as co-molecules 
can also give up to 100% form II yields, but less reliably and predictably than in the 4-
substituted cases, with the yield again being solvent dependent. Interestingly, using 
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unsubstituted BA as the structure-directing co-molecule did not lead to the production of 
100% PA II, with a mixture of PA I and II formed when co-crystallised in methanol and only 
PA I formed when co-crystallised in the remaining four solvents used.  
 
 
Scheme 4-2 Methodology for templated selective crystallisation of paracetamol form II 
from multi-component solutions.  
 
 
Figure 4.2 PXRD of the paracetamol co-crystallisation with 4-bromobenzoic acid in 
methanol. All peaks correspond to either paracetamol form II or 4-bromobenzoic acid 
indicating that paracetamol form II is obtained in 100% yield.  
 
The molar ratio of the benzoic acid used in the multi-component crystallisations is also 
important to the yield of PA II obtained. Using the co-crystallisation with 4BRBA in MeOH 
as a model system, the quantity of BA required to produce 100% form II was tested. 100% 
PA II could be produced from a 2:1 molar ratio (PA:4BRBA); using a 4:1 ratio, however, 
resulted in a mixture of PA I and PA II, suggesting that high concentrations of the BA are 
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required to obtain 100% PA II. Similarly, 2:1 co-crystallisations with 4CLBA in MeOH also 
resulted in 100% PA II.  
 
Table 4.2 PXRD quantitative analysis of paracetamol polymorphs from 1:1 co-
crystallisations with various benzoic acid derivatives in various solvents. PXRD patterns 
can be found in Appendices B4a-1 to B4a-10.  






100% Form II 
Mixture 
Mixture 
100% Form II 
100% Form II 
Stable for >1 year  
Some batches 100% II 








Majority Form II 
Mixture 
100% Form II 
Mixture 
100% Form II 
Some batches 100% II 
 
 










100% Form II 
Mixture 
100% Form II 






100% Form I 
100% Form I 
100% Form II 






Converts to I with time 
3ClBA Methanol 
Acetone 
100% Form I 




100% Form I 





100% Form I 







100% Form II 
Mixture 
100% Form I 













100% Form I 
100% Form I 
100% Form I 
100% Form I 
Majority Form I 
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The co-crystallisation route to producing PA II was found to be possible using co-
molecules other than mono-substituted BAs. Tables 4.3 and 4.4 show a summary of other 
co-molecules that could be used to obtain paracetamol form II and the outcomes of the 
quantitative analysis of PA polymorphs from PXRD. The results again show that the 
polymorph obtained is very much dependent on the co-molecule and the solvent used, 
with methanol being the most reliable solvent in most cases.  
 Although very different molecules are used in these co-crystallisation 
experiments, the most common feature is the presence of a carboxylic acid group. As well 
as the mono-substituted BAs, four of the other co-molecules used (Table 4.3) contain 
carboxylic acid groups. This suggested the investigation of a “single component” 
crystallisation using a solvent containing a carboxylic acid group. By using excess 
quantities of acetic acid as a solvent for direct recrystallisation of dissolved PA I (i.e. with 
no co-molecule), large yields of PA II were obtained, although small quantities of PA I 
remained in the samples (Figure 4.3). The sensitivity of these crystallisations to the 
precise conditions is emphasised by the fact that in carrying out these experiments, 
crystallisation from supersaturated solutions of paracetamol in acetic acid - generated by 
heating and with a far lower excess of acetic acid - result instead in the production of 
pure form I, probably due to undissolved paracetamol form I seeding the solution.  
 
Table 4.3 PXRD quantitative analysis of paracetamol polymorphs from 1:1 co-
crystallisations with various co-molecules containing carboxylic acid groups. 
Crystallisations were carried out at room temperature (RT) unless otherwise stated. PXRD 
patterns can be found in Appendices B4a-12 to B4a-15. 
Co-molecule Solvent Form produced Comment 










Small amount of PA I 
Fumaric Acid Methanol 
Ethanol 
Acetone 




Succinic Acid Methanol 
Acetone 
100% Form II 





100% Form II 




Crystallised at 40°C* 
* Other temperatures were used but the products not analysed at the time of writing.  
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Table 4.4 PXRD quantitative analysis of paracetamol polymorphs from 1:1 co-
crystallisations with various co-molecules not containing carboxylic acid groups. 
Crystallisations were carried out at room temperature (RT) unless otherwise stated. PXRD 
patterns can be found in Appendices B4a-16 to B4a-24. In all cases other temperatures 
were studied but the products had not been analysed at the time of writing.  
Co-molecule Solvent Form produced Comment 
Taurine Water 
Water 



















100% Form II 
Form I 
























100% Form II 
Form I 
RT or 40°C 
50° 










100% Form II 
Form I 




Although the use of co-molecules containing carboxylic acid groups in multi-
component crystallisations with paracetamol has been demonstrated as a general route 
to PA II, it was found not to be a universal rule. It has been noted above that it was not 
possible to produce PA II using BA and some 2- and 3- substituted BAs. In addition, co-
crystallisations of PA I with oxalic acid or malonic acid resulted in neither molecular 
complex formation nor generation of PA II. Co-crystallisation with maleic acid resulted in 
a mixture of PA I, maleic acid and a 1:1 PA: maleic acid molecular complex (see Chapter 
8). Similarly, co-crystallisation with citraconic acid also resulted in formation of a 1:1 
molecular complex with PA - isostructural to that formed with maleic acid (also Chapter 
8).  
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As mentioned above, co-molecules that do not contain carboxylic acid groups 
were also used in the PA multi-component crystallisation attempts. Three nitrogen-
heterocycle co-molecules were found to produce PA II in these experiments: pyrazole, 
3,5-dimethylpyrazole and pyrazine (Table 4.4).  
 The use of co-grinding to produce PA II was also investigated. PA I was ground 
with succinic acid, 4-fluorobenzoic acid or 4-bromobenzoic acid both in a solvent-free 
environment and in the presence of a “catalytic” amount of solvent. PXRD analysis of the 
resulting samples indicated that no PA II had been formed and only PA I and the co-
molecule were found to be present.  
 
 
Figure 4.3 PXRD analysis of the recrystallisation of paracetamol from excess acetic acid 
(red). The calculated PXRD pattern for PA II is shown in blue. The yield of PA II is close to 
100% although trace quantities of PA I are present (small peaks indicated by green 
arrows).  A large version of this PXRD pattern can be found in Appendix B4a-11.  
 
Samples in which 100% PA II was formed were found to be stable for periods of greater 
than three years. The critical importance of generating form II at 100% yield is 
emphasised by the fact that the presence of small quantities of form I in the final product 
encourages the conversion of the metastable form II into the more stable form I over a 
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period of weeks to months. This can be seen from PXRD analysis as a significant increase 




Figure 4.4 PXRD analysis of the products from a paracetamol co-crystallisation with 4-
bromobenzoic acid from acetone. Initial analysis (red) shows a mixture of PA I, PA II and 
4BRBA. Analysis of the same sample (same capillary) one month later (blue) shows a 
significant increase in the intensity of the PA I peaks relative to the PA II peaks, reflecting 
the conversion from metastable form II to the more stable form I, which occurs in the 
presence of form I. PA I peaks which have increased significantly in intensity are 
highlighted by green arrows.  
 
 
4.2.3  Paracetamol Form II: Scale up for Continuous Crystallisation in an 
Oscillatory Baffled Crystalliser  
 
Initial attempts were made to scale up the production of PA II into a non-evaporative 
environment within the COBC using the co-crystallisation method presented in this 
chapter. To this end, attempts were made to convert the evaporative co-crystallisation 
method employed in producing PA II to a cooling crystallisation method. 1:1 molar ratio 
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solutions of paracetamol and the co-molecule, at various degrees of supersaturation, 
were therefore generated through heating and the solutions cooled to either 4°C or 
ambient temperature to induce crystallisation. In some cases 2:1 molar ratios were also 
trialled. A summary of the conditions studied is presented in Table 4.5. Cooling 
crystallisations were also carried out using acetic acid as the solvent with no co-molecule 
present.  
 
Table 4.5 Summary of trial conditions for cooling co-crystallisations to produce 







4BRBA 1:1 MeOH 
4CLBA 1:1 MeOH, EtOH 
Succinic Acid 1:1, 2:1  EtOH, IPA, EtOH/Water (50/50, V/V) 
Fumaric Acid 1:1, 2:1 MeOH, EtOH, ACE 
Urea 1:1, 2:1 EtOH, IPA 
N/A N/A Acetic Acid 
 
Under the conditions studied, only PA I could be obtained. Using 4BRBA, 4CLBA or 
succinic acid as the co-molecule resulted mainly in recrystallisation of the co-molecule 
with the PA still in solution due to the large difference in solubility between the two in the 
solvents used. Given that these co-molecules have proven consistent in yielding 100% PA 
II in the evaporation experiments, a more thorough investigation of the conditions may 
be appropriate.  
 
 
4.2.4  Variable Temperature Neutron Diffraction Study of Paracetamol Form II  
 
As stated above, large single crystals (>1 mm3) of PA II were grown using the co-
crystallisation method described. Large crystals, grown by co-crystallising with 4BRBA in 
methanol, were suitable for single crystal neutron diffraction. A variable temperature 
study was carried out in order to investigate the evolution of the hydrogen parameters as 
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a function of temperature. Full refinement details can be found in (Appendix A4, Table A-
4a). 
As unit cell parameters cannot be calculated accurately from Laue diffraction, unit 
cell parameters were fixed to those observed in X-ray structure determinations at the 
corresponding temperatures. Unit cell parameters for the 100K neutron data were taken 
from the 100K single crystal X-ray re-determination carried out as part of this work. Unit 
cell parameters for the 200K and 300K neutron data were taken from X-ray diffraction 
data found in the CSD at the corresponding temperatures205. Structure determination 
using X-rays at 30K has yet to be carried out; the unit cell parameters were therefore 
extrapolated from the difference between 200K and 100K unit cell parameters and may 
not be accurate.  
 Comparison between the parameters obtained from the X-ray and neutron 
diffraction data for the hydrogen bonds found in PA II (Table 4.6) shows good correlation 
between the D···A distances and D-H···A angles at all temperatures, with both sets of data 
showing a gradual increase in D···A distances with increasing temperature. As expected, a 
shortening of the D-H distances (and therefore lengthening of H···A distances) is observed 
from the X-ray data when compared with the neutron values. The X-ray data show very 
little change in D-H and H···A values over the temperature range, however, the neutron 
data shows this to be inaccurate with the H···A distance generally showing a small 
increase with increasing temperature. A slight decrease in the D-H distances is seen 
between 200K and 300K, likely due to the decreased interaction of the hydrogen with the 
acceptor oxygen, which is supported by the increase in H···A distances.  
 The methyl group hydrogen atoms show a significant increase in librational 
motion with increasing temperature (Figure 4.5), similar to that seen in variable 











Table 4.6 Hydrogen bond distances and angles for paracetamol form II from variable 
temperature X-ray and neutron diffraction data. Note that there is currently no X-ray 
diffraction data at 30K for comparison to the neutron data. 
Data / Temp. (K) H-Bond D-H H···A D···A ∠ D-H···A 










































































Figure 4.5 The evolution of the anisotropic displacement parameters of paracetamol form 
II at 30K, 100K, 200K and 300K as determined from single crystal neutron diffraction. A 
significant increase in the libration of the methyl group is observed with increasing 




4.3  Discussion 
 
4.3.1 Paracetamol Form II 
 
A facile and reliable new route to the production of the pharmaceutically relevant PA II 
has been demonstrated using co-crystallisation methodology. By introducing a benign 
second component into the solution environment, PA II can be selectively grown in 100% 
yields. The technique not only offers access to larger quantities of PA II than were 
previously possible (at the 100 mg level to date), but also large single crystals which have 
enabled a neutron diffraction study of PA II to be carried out. The simplicity and flexibility 
of this solution based crystallisation route may have the potential for scale up to a bulk 
process although initial attempts to convert this evaporation crystallisation method to a 
cooling method have to date been unsuccessful.  
 
Co-molecule and Solvent Dependency  
  
The co-crystallisation technique employed has been shown to be co-molecule and solvent 
dependent with regards to the yield of PA II obtained. The substitution position of the BA 
clearly had a significant effect; 4-substituted BAs were the most reliable co-molecules of 
the mono-substituted BAs used, with 100% yields of PA II obtained consistently. 4BRBA 
was found to be particularly reliable in producing 100% PA II with large single crystals.  It 
is unclear why the 2- and 3-substituted BAs were less reliable. It is also interesting that 
non-substituted BA worked poorly with only small amounts of PA II produced when co-
crystallised from methanol.  
 Although much of this study was focused on the use of mono-substituted BAs, a 
number of other structure-directing co-molecules were found. Four others contain a 
carboxylic acid group which in addition to the BAs suggests a relationship may be present 
in terms of the mechanism that leads to the formation of PA II. However, a number of co-
molecules that do not contain carboxylic acid groups were also found to facilitate the 
crystallisation of PA II in 100% yields and it is unclear what relationship, if any, they have 
to the carboxylic acid containing molecules. Three of these molecules - pyrazole, 3,5-
dimethylpyrazole and pyrazine - are NHCs which have also been shown to act as structure 
directing co-molecules for elusive polymorphs of PX (PX III and PX IV – see section 4.5) 
which again may suggest a related mechanism may be responsible. Indazole, another 
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NHC, was also found to direct the formation of a previously unknown phase of PX 
although co-crystallisation experiments of indazole with PA have yet to be carried out. 
 The high selectivity achieved through the use of co-molecules containing 
carboxylic acid groups led to the investigation of acetic acid as a solvent for direct 
recrystallisation of PA I to form PA II. Although close to 100% yields were obtained from a 
solution of excess acetic acid, some PA I remained in the samples. As it has been 
demonstrated that the presence of form I facilitates the PA II→PA I solid-solid conversion, 
100% yields of PA II are vital if the latter is to be stable and optimising of this method is 
therefore required. 
The co-crystallisation experiments indicate methanol is the most reliable solvent 
for production of PA II, with 100% yields possible using all three 4-substituted BAs studied 
(and various other co-molecules). Varying yields of PA II could also be produced from 
methanol solution using co-molecules which otherwise produce only form I (nicotinic acid 
and benzoic acid).   
 
Neutron Diffraction Study of Paracetamol form II 
 
The large single crystals of PA II obtained using the co-crystallisation method enabled the 
first neutron diffraction study of this material to be carried out. The improvement in 
detail of the hydrogen bonds is illustrated by the increasing H···A distances from 200 K to 
300 K which cannot be seen from X-ray diffraction data. The data also shows similar 
libration of the methyl group to that seen in form I. The data may have useful future 
applications in lattice energy calculations of PA II. 
 
4.4 Introduction to Known Piroxicam Crystal Forms 
 
Piroxicam (PX) is a non-steroidal anti-inflammatory drug that has been studied extensively 
in the solid state206-210, but the literature on PX polymorphism is largely conflicting in 
terms of the number and nomenclature of polymorphs. There are currently three known 
polymorphs of piroxicam209, although the crystal structure of form III has yet to be 
determined and has only been characterised by powder XRD and thermal analysis208, 209. 
Forms I and II of PX are easily obtained through simply varying the solvent used or the 
temperature of crystallisation208. Crystallisation of form III has previously involved more 
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complex routes, including cryo-grinding to obtain an amorphous phase followed by 
heating209 or spraying a saturated ethanol solution on dry ice208. Both of these methods 
result in powder products, unsuitable for structure determination using single crystal X-
ray diffraction, and thus, this phase has to date only been characterised by PXRD and DSC. 
In the three known polymorphs of PX, it is present as the non-ionised tautomer only, 
although a zwitterionic tautomer has been observed in the solid state27, 211 (Scheme 4-3). 
A monohydrate of PX is known where PX is in the zwitterionic form211, as well as several 
other multi-component complexes where PX is present as the zwitterionic tautomer27. 
Multi-component complexes where PX is present as the non-ionised tautomer are also 
known27. The tautomer obtained in these complexes can be inferred visually from the 
yellow colour of the zwitterionic complexes and the colourless nature of those that are 
non-ionised. PX is poorly water soluble which affects its bioavailability212; new crystalline 
phases of PX with improved solubility may therefore be desirable.  
 
 
Scheme 4-3 The two known tautomers of piroxicam. 
 
4.5 Multi-Component Crystallisation Routes to Piroxicam Form III, Form IV and a 
Methanol Solvate: Co-Crystallisation with Nitrogen-Heterocycles 
 
4.5.1 Crystallisation Conditions 
 
A series of co-crystallisations of PX were carried out with nitrogen-heterocycles (NHCs) 
using the procedure outlined in Chapter 3. Table 4.7 shows a summary of the co- 
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Table 4.7 Experimental conditions for co-crystallisations of piroxicam with nitrogen-
heterocycles. Co-molecules marked with * resulted in formation of new or elusive phases 
of piroxicam which do not incorporate the co-molecule. Co-molecules marked with # 
resulted in molecular complexes (discussed in Chapter 6). The remaining co-molecules 
resulted in neither a new phase of piroxicam nor a molecular complex. Note: The 
formation of molecular complexes and new phases did not occur under all the conditions 
investigated. 
Co-Molecule Quantity of Co-molecule  Solvent(s) Temp(s) (°C) 
Pyrazole* Excess (2:1 and 4:1 mass 
ratios)  
MeOH, ACN RT, 40, 50 
3,5-dimethylpyrazole* Excess (2:1 mass ratio) MeOH, ACN RT, 40, 50 
Pyrazine*# 1:1 molar, Excess (2:1 molar) ACN RT, 40, 50 
Indazole* 1:1 molar ACN, MeOH, 
MeOH/ACN 
RT, 40, 50 
Imidazole# 1:1 molar MeOH,ACN RT, 40, 50 
2-methylimidazole# 1:1 molar ACN RT, 40, 50 
Benzimidazole# 1:1 molar MeOH/ACN RT, 40, 50 
Benzotriazole# 1:1 molar ACN RT, 40, 50 
1,2,4-triazole# Excess (2:1 mass ratio) ACN RT, 40, 50 
2,2-bipyridine 1:1 molar ACN, MeOH RT, 40, 50 
4,4-bipyridine 1:1 molar MeOH, ACN  RT, 40, 50 
s-triazine Excess (2:1 mass ratio) ACN RT, 30, 40 50 
Quinoxaline Excess (2: 1 mass ratio) MeOH, ACN RT, 40, 50 
1,2,3-triazole (l) Excess (used as solvent) N/A RT, 6 
Pyridazine (l) Excess (used as solvent) N/A RT, 40 
RT = Room Temperature, l = liquid at RT 
 
molecules used in these experiments. Six of the NHC co-molecules used resulted in 
molecular complex formation (marked with # in Table 4.7 and discussed in detail in 
Chapter 6). Four of the co-molecules resulted in the formation of a new or previously 
elusive PX phase not incorporating the co-molecule (Scheme 4-4; marked with * in Table 




Scheme 4-4 The molecular structures of the NHCs which were used to obtain new or 
previously unknown phases of piroxicam.  
 
4.5.2 Co-crystallisation Routes to Piroxicam Form III, Form IV and a Piroxicam Methanol 
Solvate 
 
In initial experiments aimed at molecular complex formation, unit cell screening of the 
resultant crystals found that co-crystallisation of PX with pyrazole from ACN at 50°C 
resulted in the formation of PX form III (PX III). Large (~0.4 mm3) single crystals of PX III 
were formed on the side of the crystallisation vessel, along with significant quantities of 
PX monohydrate and PX II. Full structure determination was carried out (see Section 
4.4.3.1 below) and the calculated PXRD pattern for this structure was then compared to 
the experimental PXRD pattern from previous studies208, 209 to verify that it was indeed 
form III (Figure 4.6). An excess of pyrazole was used in the co-crystallisation experiments 
as pyrazole has a relatively low melting point (69°C) and previous work using 1:1 ratios 
had indicated that pyrazole evaporates from the solution - particularly at high 
temperature. Unit cell screens of repeat co-crystallisations showed that crystallisation of 
form III could be reproduced, albeit still in relatively small quantities. In some cases it was 
also found to crystallise at 40°C although it has not been observed to crystallise at room 
temperature. Subsequently, co-crystallisation experiments were carried out using excess 
3,5-dimethylpyrazole to assess the transferability of the method between similar co-
molecules. Co-crystallisation with excess 3,5-dimethylpyrazole (1:2 mass ratio) using ACN 
or MeOH as the solvent at 50°C resulted in the formation of PX III in similar quantities to 
that in the initial preparation. PX III was not observed to crystallise from MeOH when 
pyrazole was used as the co-molecule.  
In the majority of cases, PXRD was not found to be a useful method of analysis in 
this case as PX III often could not be detected despite being confirmed by unit cell screens 
(Appendices B4b-1 to B4b-3). This may be due to the low quantities of PX III present 
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relative to those of the other components of the phase mixture (PX I and/or II and/or the 
monohydrate) or possibly due to a PX III→PX I phase transformation induced by the 
grinding procedure used in preparation for PXRD analysis. PXRD analysis also showed that 
despite the high concentrations of co-molecule, the majority of both pyrazole and 3,5-
dimethylpyrazole were not present in the final product from the 50°C crystallisations. This 
suggests that these components evaporated from the solution at 50°C although they may 
have been crystallised on the lid of the crystallisation vessel. This was particularly 
unexpected in the case of 3,5-dimethylpyrazole given its melting point is approximately 




Figure 4.6 The calculated PXRD pattern for piroxicam form III (red) and the experimental 
PXRD pattern from a previous study
208
 (bottom).  
 
Co-crystallisation of PX with pyrazine as the benign co-component (2:1 mass ratio, 
pyrazine:PX) resulted in a similar phenomenon: using acetonitrile as the solvent and a 
crystallisation temperature of 50°C (also at 40°C although less reliably), a new form of 
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piroxicam is templated – designated form IV (PX IV). The crystal structure of PX IV is 
unique as it is the only known polymorph where piroxicam molecules are present in both 
the non-ionised and zwitterionic tautomers; furthermore, this has a surprisingly large 
asymmetric unit, with four neutral and one zwitterionic molecule contained within it 
(discussed in detail in section 4.4.3.2). The small needle-shaped crystals of PX IV could be 
distinguished from form I, II and III (all colourless) by the yellow colouring of the crystals – 
which is also seen in molecular complexes of PX containing the zwitterionic tautomer27. 
Relatively high yields of form IV were obtained (Appendix B4b-4), although repeat 
experiments were unpredictable; a previously unknown PX : pyrazine molecular complex 
occasionally formed (see Chapter 6) and/or PX form I, form II or PX monohydrate. This 
indicates the subtle balance that can exist in product formation in these multi-component 
crystallisation experiments. A combination of unit cell screening and visual analysis 
indicated that experiments using 1:1 molar ratios of the co-molecule or crystallisation at 
lower temperatures resulted in formation of PX I or II only (Appendix B4b-5).  
 Crystallisation of PX with indazole was carried out in a 1:1 molar ratio due to 
indazole having a significantly higher melting point than pyrazole and pyrazine (approx. 
148°C), making it unlikely to evaporate during the crystallisation process. When 
crystallised from MeOH at 60°C a new PX : MeOH solvate was formed. As in PX IV, the 
crystal structure was found to contain a mixture of both tautomers, zwitterionic and 
neutral (see section 4.4.3.3). PXRD of the products of the co-crystallisation experiment 
showed that the PX : MeOH solvate was crystallised concomitantly with PX I (PXRD 
Appendix B4b-6). The solvate was not observed to crystallise in experiments carried out 
without the co-molecule under the same conditions (PXRD Appendix B4b-7).  
 
 
4.5.3 Crystal Structures of the New and Elusive Piroxicam Crystalline Phases 
 
The crystal structures of the two new polymorphs of PX and the methanol solvate are 
described below. Crystallographic data and full refinement details can be found in 





4.5.3.1 Piroxicam Form III (PX III) 
 
The crystal structure of PX form III consists of a single molecule in the asymmetric unit 
which forms the same PX dimers that are found in PX form I206. These dimers are formed 
via NH···O hydrogen bonds between the amide NH and the sulfonyl oxygen atoms (Figure 
4.7). The NH···O hydrogen bond length in this dimer is similar to that found in form I, 
although a slightly longer donor-acceptor distance is observed despite the structure being 
determined at lower temperature (100K c.f. 300K for form I) (Table 4.8). The structure of 
form III is also layered in a similar fashion to form I (Figure 4.8a), with the methyl and 
sulfonyl groups bridging between the layers. The differences between form I and form III 
are seen in the extended packing and the weaker hydrogen bonds. PX molecules in form 
III link to PX molecules above, via CH···O hydrogen bonds between the pyridine aromatic 
CH groups and the second sulfonyl oxygen atom (Figure 4.8b). The second sulfonyl oxygen 
in PX I forms hydrogen bonds to the benzene CH group of a PX molecule above (Figure 
4.8c), resulting in very different relative positions of PX molecules in different layers 
(Figure 4.8d).  
 








Table 4.8 Hydrogen bond distances and angles  in the piroxicam dimers in PX form I206 and 
form III (refer to Figure 4.7 for key).  

























A second CH group of the pyridine ring forms CH···O hydrogen bonds with the hydroxyl 
oxygen of a PX molecule below (C···O = 3.384(2) Å) (Figure 4.9). Molecules above and 
below each other are further linked by weak hydrogen bonds between the methyl CH 
groups and the amide carbonyl oxygen (C···O = 3.363(2) Å) as well as well as π···π 
interactions between the amide carbonyl double bonds, with approximately 3.049 Å 
between the centroids of the π bonds (Figure 4.10).  
 
 
Figure 4.8 Crystal packing in piroxicam form III. (a) The layered arrangement of molecules. 
(b) CH···O hydrogen bonds between a pyridine CH and the sulfonyl O of PX molecules 
above and below each other. (c) The similar CH···O hydrogen bonds in PX form I, where the 
sulfonyl oxygen instead forms hydrogen bonds with the benzene CH of the PX molecule 
above. (d) An overlay of the crystal structures of PX I and III, showing the difference in the 




Figure 4.9 CH···O interactions between a pyridine CH group and the hydroxyl oxygen in 
piroxicam form III. 
 
 
Figure 4.10 CH···O and π···π interactions involving the amide oxygen in piroxicam form III. 
 
4.5.3.2 Piroxicam Form IV (PX IV) 
 
As noted above, piroxicam form IV features five molecules in the asymmetric unit and is 
unusual in that four of the molecules are present as the non-ionised tautomer (PXN) and 
the other as the zwitterionic tautomer (PXZ). As before, in addition to the different 
distribution of hydrogen atoms within the tautomers, there is a substantial 
conformational difference between the neutral and zwitterionic forms, offering 
unambiguous conclusion to be drawn regarding the tautomers present from the X-ray 
data. The PXN molecules dimerise with non-equivalent PXN molecules through two 
NH···N hydrogen bonds (Figure 4.11), with two symmetry independent dimers formed in 
this way. The hydrogen bonding in this dimer is unique from that seen in any of the other 
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three polymorphs of PX. The NH···N hydrogen bonds in one dimer are slightly stronger 
than in the other, with the PXN molecules in the weaker dimer possessing stronger 
intramolecular OH···O hydrogen bonds (Table 4.9).  
Equivalent PXZ molecules also dimerise, although the presence of the different 
tautomer results in a completely different type of dimer to that formed by the PXN 
molecules. The dimer is formed by two moderately strong charge-assisted bifurcated 
DHAA N+-H···O hydrogen bonds between the protonated pyridinal nitrogen and the amide 
carbonyl oxygen (also Figure 4.11). This type of dimer is formed by PXZ molecules in all 
previously reported complexes containing PXZ27, 211. 
The PXZ dimers are linked to PXN molecules through a number of weak CH···O 
hydrogen bonds (Figure 4.12). Pyridine CH groups of PXN molecules form charge assisted 
hydrogen bonds to the enolate oxygen of the PXZ molecules (C···O = 3.440 (7)Å) (Figure 
4.12a). Benzene and pyridine CH groups of PXZ molecules also form hydrogen bonds to 
the sulfonyl oxygen atoms of PXN molecules (C···O = 3.445(7) Å and 3.398(9) Å 
respectively) (also Figure 4.12a). Similar hydrogen bonds are formed from the benzene 
and pyridine CH groups of PXN molecules to the sulfonyl oxygen atoms of PXZ molecules 




Figure 4.11 The dimers formed in piroxicam form IV. Non-ionised molecules dimerise 
through NH···N hydrogen bonds (LHS - methyl hydrogen atoms omitted), whilst the 
zwitterionic molecules dimerise via charge-assisted bifurcated DHAA N
+
- H···O hydrogen 





Table 4.9 Hydrogen bond distances and angles in piroxicam form IV (refer to Figure 4.11 
for key). Note that the numbers 1 and 2 refer to the symmetry independent dimers of PXN 
molecules. Hydrogen atoms were placed on calculated positions due to the poor quality of 
the data (see Appendix A4, Table A-4b).  


























































Figure 4.12 Weak CH···O hydrogen bonds linking PXZ dimers to PXN molecules in 
piroxicam form IV. (a) CH···O hydrogen bonds from the PXZ pyridine and benzene ring CH 
groups to the PXN sulfonyl oxygen atoms and from the PXN pyridine ring Ch group to the 
PXZ enolate oxygen. (b) CH···O hydrogen bonds involving the PXZ sulfonyl oxygen atoms.  
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The pairs of PXN molecules in both of the symmetry independent PXN dimers do not lie 
co-planar and these dimers are linked to each other through further moderate to weak 
strength CH···O hydrogen bonds (Figure 4.13) between benzene CH groups and sulfonyl 
oxygen atoms (C···O = 3.079(9) Å, 3.218(9) and 3.112(9) Å). The staggered nature of the 
dimers results in a non-layered structure unlike PX I and PX II. Further CH···O hydrogen 
bonds between PXN molecules are present involving the methyl group and hydroxyl 
oxygen groups (C···O = 3.266(7) Å) and π···π interactions are also present between 
benzene rings, with approximately 3.309 Å between the planes of the rings (Figure 4.14) 
 
Figure 4.13 Weak CH···O hydrogen bonds (red dashed lines) linking PXN dimers in 
piroxicam form III. The diagram also shows the staggered nature of the PXN dimers (one 





Figure 4.14 Further weak interactions between PXN molecules showing the CH···O 
hydrogen bond between the methyl and hydroxyl groups and π···π interactions between 
the benzene rings.  
 
4.5.3.3 Piroxicam : Methanol Solvate (3:1) (PX:MeOH) 
 
Crystals of the piroxicam : methanol solvate were particularly small and of poor quality 
and as a result the data is also poor (Rint = 23.6%). Anisotropic refinement of the heavy 
atoms resulted in implausible thermal parameters for a number of atoms and the 
structure was therefore refined isotropically for the final refinement cycles (see Appendix 
A4 for further details).  
 The PX:MeOH solvate crystallises in a 3:1 molar ratio. The crystal structure is again 
unusual in that piroxicam molecules are again present in mixed tautomeric states - with 
two zwitterionic molecules and one non-ionised molecule in the asymmetric unit. The 
symmetry independent PXZ molecules again dimerise in the same way as is seen in form 
IV, with two moderately strong charge-assisted bifurcated DHAA N+-H···O hydrogen bonds 
formed between them (Figure 4.15). The MeOH molecule lies below the plane of the 
dimer and links to one of the PXZ molecules through a further moderately strong, charge 
assisted OH···O hydrogen bond (also Figure 4.15). Hydrogen bond lengths and angles for 
these interactions are provided in Table 4.10.  
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Figure 4.15 The PXZ dimer in the piroxicam: methanol solvate and the methanol molecule 
hydrogen bonded to the enolate oxygen through an OH···O hydrogen bond. 
 
Table 4.10 Hydrogen bond distances and angles in the PXZ dimer in the piroxicam : 
methanol solvate (refer to Figure 4.15 for key). Values with no errors are due to hydrogen 
atoms being placed on calculated positions.  Note: Due to the poor quality data, heavy 
atoms were refined anisotropically resulting in the poor precision of the D···A values.     





































The PXN molecule links PXZ dimers through weak CH···O hydrogen bonds with the enolate 
oxygen of both PXZ molecules (pyridine C···O = 3.31(4) Å and benzene C···O = 3.48(3) Å) 
(Figure 4.16). The PXN molecule also links to the MeOH molecule through a moderately 
strong NH···O hydrogen bond (N···O = 3.04 (3)Å) with the hydroxyl oxygen acting as 
acceptor (also Figure 4.16). A weak hydrogen bond also occurs between the MeOH 
methyl CH and the pyridine nitrogen (C···N = 3.24(4) Å). The PXZ molecules also link to the 
PXN molecules through CH···O hydrogen bonds between the benzene ring CH groups and 
both the amide oxygen (C···O = 3.38(3) Å) and the sulfonyl oxygen (C···O = 3.22(4) Å) 
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(Figure 4.17). The intramolecular hydrogen bond of the PXN molecule is strong with an 
O···O distance of 2.50(2) Å.  
 
Figure 4.16 The PXN molecule linking PXZ dimers through weak CH···O hydrogen bonds 
involving the enolate oxygen atoms (red dashed lines) in the piroxicam : methanol solvate.  
 
 
Figure 4.17 Weak CH···O hydrogen bonds involving the benzene CH groups of PXZ 
molecules and the amide and sulfonyl oxygen atoms of the PXN molecules in the 
piroxicam : methanol solvate.  
 
The structure is layered (Figure 4.18) with the MeOH molecule linking the PXN molecules 
to PXZ molecules above. Further weak CH···O hydrogen bonds occur between the PXN 
molecules with other PXN molecules and PXZ molecules in the layer above involving the 
sulfonyl oxygen atoms (Figure 4.19a). Similar interactions are also present between PXZ 
molecules - both with adjacent PXZ molecules and PXZ molecules above the plane of the 




Figure 4.18 Layers in the piroxicam : methanol solvate. 
 
 
Figure 4.19 CH···O hydrogen bonds in the piroxicam : methanol solvate involving the 
sulfonyl oxygen atoms between (a) the PXN molecule and the PXN and PXZ molecules 
above and (b) PXZ molecules with other PXZ molecules above and adjacent to them.  
 
 
4.6 Introduction to Gallic Acid Crystal Forms 
 
Gallic acid (3, 4, 5 - trihydroxybenzoic acid, Scheme 4-5) is a naturally occurring substance 
which is known to have pharmaceutical properties213. In the solid state, anhydrous gallic 
acid (GA) is known to have only one crystal form214. However, gallic acid monohydrate 
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(GAM) forms readily and is the only known tetramorphic hydrate for which all four crystal 
structures have been determined215.  
 
Scheme 4-5 Structure of gallic acid 
 
4.7  A Multi-Component Crystallisation Route to a New Porous Form of Gallic Acid 
Monohydrate 
 
4.7.1 Crystallisation Conditions 
 
Co-crystallisations of GA with piracetam (PTM) were carried out according to the 
evaporation procedure outlined in Chapter 3 using a 1:1 molar ratio at room 
temperature. The co-crystallisation screen involved varying the solvent - selected from 
the following: methanol, ethanol, acetone, acetonitrile and ethyl acetate.  
 
4.7.2  A Co-crystallisation Route to a New Porous Form of Gallic Acid Monohydrate  
 
A screen for molecular complexes of GA and PTM resulted in the discovery of a new form 
of GAM (PGAM). This form of GAM is unique from the four published polymorphs in that 
it is porous, with large channels containing disordered solvent molecules running through 
the crystal structure (see Section 4.6.2.1 for structural details). Structure determination 
was carried out from single crystals obtained using methanol as the solvent. Unit cell 
screens showed that PGAM was also formed in crystallisations from ethanol, acetone and 
acetonitrile. On the other hand PXRD of the crystallisation product from methanol (as 
opposed to single crystals isolated from this product) showed no trace of PGAM and did 
not correspond to anhydrous GA or any of the other GAM or PTM polymorphs. Instead, 
the PXRD pattern corresponds to almost 100% of a previously unknown GA : PTM 
molecular complex - later also isolated via co-crystallisation from ethyl acetate (the GA : 
PTM complex is described in detail in Chapter 8) (Appendix B4c-1). This would suggest 
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that PGAM breaks down under mechanical stress during grinding in preparation for PXRD 
analysis. However, PXRD of the product of co-crystallisation from ethanol showed a 
mixture of both PGAM and the GA : PTM molecular complex (Appendix B4c-2). Unit cell 
screening and PXRD analysis of GA recrystallised from methanol without the presence of 
PTM showed that no PGAM was formed with only GAM forms I and II present (Appendix 
B4c-3).  
 
4.7.2.1  Crystal Structure of Porous Gallic Acid Monohydrate (PGAM) 
 
The porous gallic acid monohydrate form has a single GA molecule and a single water 
molecule in the asymmetric unit. The GA molecules dimerise through the typical 
carboxylic acid dimer formed by moderately strong OH···O hydrogen bonds (a in Figure 
4.20). Weaker OH···O hydrogen bonds between the hydroxyl groups (b and c in Figure 
4.20) link the GA molecules into large rings forming the structural frame of the channels. 
The oxygen of the water molecule has large, elongated anisotropic displacement 
parameters (Figure 4.21), suggesting it possibly has a large degree of freedom. As a 
consequence, no water hydrogen atoms could be located (all other hydrogen atoms were 
located using the difference Fourier synthesis). The hydroxyl OH of one GA molecule 
forms a moderately strong OH···O hydrogen bond to the water oxygen (d in Figure 4.20). 
Although hydrogen atoms were not located, the hydrogen bonding of the water molecule 
is inferred from the neighbouring atoms. The water appears to form another moderately 
strong OH···O hydrogen bond to the hydroxyl oxygen of another GA molecule (e in Figure 
4.20). Hydrogen bond distances and angles for these interactions are presented in Table 
4.11.  
 
Table 4.11 Hydrogen bond distances and angles in the porous gallic acid monohydrate 
(refer to Figure 4.20 for key). Note: Hydrogen bond e is a proposed hydrogen bond 
between the GA molecules and the disordered water molecule; water hydrogen atoms 
could not be located. 





























Figure 4.20 Hydrogen bonding forming the pore in the porous gallic acid monohydrate 
crystal structure.  
 
 
Figure 4.21 The elongated anisotropic displacement parameters of the water oxygen 
atom relative to the two GA molecules to which it forms hydrogen bonds. 
 
The hydrogen bonding between the hydroxyl groups (b and c in Figure 4.20) links rings 
parallel to each other to form the channels (Figure 4.22), with each GA molecule forming 
hydrogen bonds to two other GA molecules through these interactions. The channels 
account for a significant proportion of the unit cell volume (Figure 4.23), with 
approximately 5.0% of the unit cell volume (47.60 Å3) accessible to solvent water 
molecules (using a probe with a van der Waals radius of 1.4 Å). The channels contain 
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disordered solvent molecules which could not be resolved. The SQUEEZE procedure216 
was therefore used to remove and estimate the electron density from the channel prior 
to the final refinement cycle. An estimate of 69 electrons per unit cell was given which 
could be accounted for by roughly ten water molecules or 4 methanol molecules although 
a definite conclusion could not be reached.  
 
Figure 4.22 Formation of the channels in the porous form of gallic acid monohydrate 
(PGAM). The hydrogen bonding between hydroxyl groups links the large rings parallel to 
each other to form the channel. The blue GA dimers lie in front of the red dimers, parallel 




Figure 4.23 Relative arrangement of the channels in the porous gallic acid monohydrate.  
 
4.8 Introduction to Piracetam Crystal Forms 
 
The API piracetam (PTM) (Scheme 4-6) has five known polymorphs, the structures of 
which have all been previously determined. Two of the polymorphs can only be isolated 
using high pressure130, 217. Forms II and III are the most stable at ambient temperature 
and are the forms generally produced from evaporation crystallisation experiments218. 
The structure of form I had until recently217 only been determined by PXRD methods217, 
219 as the generation of single crystals is difficult and unpredictable. Forms II and III are 
reported to undergo a solid-solid phase transformation to the metastable form I above 
400K (127°C)217. 
 
Scheme 4-6 Structure of piracetam 
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4.9 A Multi-Component Crystallisation Route to Piracetam form I 
 
4.9.1 Crystallisation Conditions 
Following the results of experiments using pyrazole as a structure-directing co-molecule 
to produce PA form II and PX form III, similar co-crystallisation experiments were carried 
out using PTM and pyrazole. Crystallisation conditions were chosen based on the PX 
experiments to produce PX III, with pyrazole in excess (2:1 mass ratio) using methanol as 
the solvent at 50°C. Control crystallisation experiments were also set up around one 
month after these experiments under the same conditions in the absence of pyrazole.  
 
4.9.2 A Possible Co-Crystallisation Route to Piracetam Form I 
 
Unit cell screening and PXRD (Appendix B4d-1) of the products of the co-crystallisation 
experiments showed that the co-crystallisation had produced a mixture of PTM form I 
and II with repeat experiments showing this to be highly reproducible. PXRD analysis of 
the control experiments in the absence of pyrazole (carried out after the initial co-
crystallisations), however, also showed the same results (Appendix B4d-2). It is unclear 
whether high temperature recrystallisation from methanol is sufficient to produce PTM 
form I or if the initial co-crystallisation experiments have resulted in seeding of the 
laboratory, facilitating the production of PTM I in subsequent experiments in the absence 
of pyrazole.  
 Detection of pyrazole was made difficult as the major peaks in the pyrazole PXRD 
pattern overlap with those of PTM II, although the evidence suggests that at least the 
majority of it is not present in the product. The non-overlapping pyrazole peaks are 
significantly weaker then the major peaks making it difficult to see them even if they were 
there. PXRD of PTM I samples left at room temperature for over a week shows that PTM I 
gradually transforms into the more stable form II as is consistent with previous reports217.  
 
4.10  Discussion 
4.10.1 New and Elusive Phases of Piroxicam 
 
The elusive piroxicam form III and a new polymorph, designated form IV, as well as a new 
PX methanol solvate were crystallised using nitrogen heterocycles as structure-directing 
co-molecules in solution.  
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By crystallising piroxicam in the presence of pyrazole or dimethylpyrazole, piroxicam form 
III has been successfully isolated and its crystal structure determined for the first time. 
Although 100% yields could not be obtained, large crystals suitable for single crystal X-ray 
diffraction were produced for the first time. Similarly, by crystallising PX in the presence 
of pyrazine, a new polymorph of piroxicam has been discovered - form IV. The methanol 
solvate was crystallised using indazole as a co-molecule. Both PX IV and the methanol 
solvate contain a mixture of both the non-ionised and the zwitterionic PX tautomers. All 
other polymorphs of PX contain the PXN tautomer only and only one molecular complex 
of PX was known previously that had a mixture of both tautomers27. This illustrates the 
potential of this co-crystallisation method in accessing crystalline phases possessing 
otherwise unobtainable structural features.  
 
Relative Stability of Piroxicam Polymorphs  
 
As previously stated, the reproducibility of the formation of PX IV was poor using this co-
crystallisation method. The yield of PX III obtained was also low, with PX I or the 
monohydrate crystallising concomitantly in larger quantities. DSC of all polymorphs was 
carried out to determine their relative thermodynamic stability, which could provide a 
rationale behind these observations. The melting points are reported in Table 4.12 along 
with previously reported values for forms I, II and III. The DCS traces for all four forms can 
be found in Appendix C4.  
 
Table 4.12 Melting points (in °C) of the four polymorphs of piroxicam from DSC 
measurements.  
Polymorph I II III IV 
This work 200.4 196.15 197.98 195.7 
Literature 202.6208 199.7208 178.4207* No data 
* In a later publication
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, the same author also reported that form III converts to the 
more stable form II then to form I upon heating - conflicting with their previous data and 
the experimental data obtained in the present study. In the previous reports, form III was 
also prepared from the melt which is not an optimal method as melting of PX is 





Being the dominant form to crystallize under most crystallization conditions, form I is 
unsurprisingly the most stable form. Given the difficulty in crystallizing form III, it may be 
somewhat surprising to see it is the second most stable form according to the DSC 
measurements. This may be explained, however, by the similarity of the crystal structure 
to that of form I, as they both feature the same hydrogen bonding in their piroxicam 
dimers, with the differences lying in the extended packing. The difficulty in obtaining form 
III may therefore arise due to the energetic similarities to form I, with the most stable 
form of the two prevailing under most conditions due to two close lying energy minima. 
Form IV was found to be the least stable form, explaining its late discovery despite the 
extensive previous research into piroxicam polymorphism. The crystallisation of these 
metastable polymorphs is likely to be highly sensitive to perturbations in the 
crystallisation conditions which would explain the difficulty in obtaining consistent yields. 
Examples in the literature report similar issues when using co-crystallisation to produce 
elusive, metastable polymorphs66. It could, however, be possible to optimise yields to 
100% by varying conditions such as the solvent used, the co-molecule used or the 
crystallisation temperature - as has been demonstrated with PA II. 
 
Nitrogen-Heterocycles as Structure Directing Co-molecules: Implications for Polymorph 
Screening 
 
The systematic co-crystallisation experiments of PX with NHCs have led to the discovery 
of two new phases of PX as well as a new route to a previously elusive phase. The 
systematic methodology has been shown to be a critical part of the process, as the initial 
discovery of one of these phases led to further experiments using NHCs as structure 
directing co-molecules - not only with PX, but also with PA and PTM resulting in new 
routes to PA II and PTM I. Polymorph screens of materials generally do not include co-
crystallisation experiments, however, the work presented here indicates there may be a 
case for including co-crystallisation with certain co-molecules as part of systematic 
polymorph screens. 
 
4.10.2 New Form of Gallic Acid Monohydrate 
 
A new porous monohydrate of GA (PGAM) was obtained via co-crystallisation with PTM 
from methanol, ethanol, acetone or acetonitrile. The new form has not been termed 
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“form V” GAM due to the unidentified disordered solvent/water in the pore meaning it 
may not strictly exist as a monohydrate.  
 PXRD of the co-crystallisation from ethanol showed that PGAM may crystallise 
concomitantly with a molecular complex of GA with PTM (see Chapter 8). The PXRD of the 
product of the co-crystallisation from methanol showed only the GA : PTM molecular 
complex. This is despite the fact that unit cell screening of single crystals from the same 
preparation found only PGAM and the structure was subsequently determined from a 
crystal from the same crystallisation batch. It is unclear at present whether the GA : PTM 
complex has formed under the mechanical stress of grinding or if the storage conditions 
have resulted in it forming over time. PXRD analysis of the products of the co-
crystallisation from ethanol showed a mixture of both PGAM and the GA : PTM complex 
suggesting that PGAM does not break down under grinding. Structure determination of 
PGAM has not been carried out from samples recrystallized from solvents other than 
methanol, although it is possible that the disordered solvent/water contained in the pore 
may differ depending on the solvent used, which may affect the stability. Possible 
structure determination of PGAM samples from a range of solvents as well as using other 
analysis methods such as TGA to characterise the disordered solvent in the pores could be 
important steps in understanding the nature of PGAM. The ability to incorporate the 
small solvent molecules into the pores indicates the potential for applications as a 
lightweight organic material for gas storage. 
 
4.10.3 Piracetam Form I: A multi-component crystallisation route or a high temperature 
crystallisation route? 
 
PTM I was initially obtained from co-crystallisation of PTM with pyrazole at 50°C from 
methanol and later obtained from the same conditions in the absence of pyrazole. It is 
unclear if the initial co-crystallisation experiments used to obtain PTM I have resulted in 
seeding of the laboratory environment, thereafter enabling more facile production of this 
metastable form even from single component crystallisations. The possibility remains that 
crystallisation of PTM at 50°C from methanol would have resulted in PTM I regardless of 
this initial co-crystallisation having been carried out. To clarify this, independent 
crystallisations of PTM at 50°C from methanol need to be carried out in another 
laboratory in which PTM I has not previously been obtained.  
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Nevertheless a facile route to obtaining PTM I has been discovered through the 
systematic co-crystallisation methodology employed. The solid-solid phase 
transformations of II and III to form I have been reported to occur above 127°C217, which 
is significantly higher than the temperatures used in the solution method presented here. 
The evaporation method described above also results in good quality single crystals, 
suitable for single crystal X-ray diffraction.  
 
4.10.4 General Comments on Co-crystallisation as a Route to New and Elusive Phases 
 
Potential of Co-crystallisation as a Route to New and Elusive Polymorphs 
 
Co-crystallisation is a relatively unexplored route to obtaining new polymorphs of 
materials and its importance is highlighted in the work presented above. It has been 
shown to offer simple routes to obtaining new and elusive crystal forms of materials with 
otherwise unobtainable characteristics, i.e. larger crystals and yields (PA II and PX III), 
mixed tautomers (PX IV and the PX methanol solvate) and porous structures of 
extensively studied materials (PGAM).  
 Systematic identification of a certain classes of co-molecule which direct the 
formation of metastable forms of a material may have applications in having the same 
effect for other materials. This is seen with the NHCs which have been used to direct the 
formation of both PA II and three new PX crystal forms. It is interesting also to note that 
multicomponent crystallisations using a variety of NHCs have previously been used to 
produce a new zwitterionic polymorph of 2-(p-tolylamino)nicotinic acid66. The systematic 
approach to the crystallisation conditions also resulted in a method of obtaining PTM I, 
although the exact conditions required remain unclear. 
 Challenges in using this method of polymorph selection do however remain, with 
removal of the co-molecule from the final product a problem in some cases. PXRD 
analysis showed that certain co-molecules in this work were not present in the final 
product (e.g. pyrazole, pyrazine); selection of co-molecules such as these may overcome 
this problem. The metastable polymorphs produced can also be difficult to reproduce (PX 
IV) or difficult to obtain in 100% yields (PX III, PGAM). Significant tuning may therefore be 
required to obtain 100% yields; this has however been successfully achieved with PA II.  
 The scale up of this method to an industrial level may also prove problematic. The 
preliminary work carried out with PA II showed that conversion of this evaporation 
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method to a cooling method may not necessarily be straightforward although further 




The mechanism by which certain co-molecules direct the formation of a particular crystal 
form of another material remains unclear. The evidence gathered in this study suggests a 
solution-based mechanism rather than epitaxy, as no intergrowths of crystals with the co-
molecule were observed. Also, when using pyrazole, 3,5-dimethylpyrazole and pyrazine 
as co-molecules, very little or no co-molecule was found in the final product isolated in 
the crystallisation vessel. Further evidence of a solution based mechanism was provided 
by the systematic approach using co-crystallisation of PA with carboxylic acids to produce 
PA II, which led to the use of acetic acid as a solvent to obtain yields of approaching 100% 
PA II in a single component preparation. A solution-based mechanism could also offer a 
partial explanation for the failed attempts at using co-grinding to produce PA II. The 
ability to use NHCs to produce a number of different crystal forms of PX and PA also 
indicates a related mechanism may be involved. The mechanism of nucleation in general 
is not well understood and thus the nature of a possible solution based mechanism is not 
obvious. Possibilities include co-molecule assisted stabilisation of pre-nucleation 
aggregates of the metastable forms or the co-molecule possibly inhibiting nucleation of 
the more stable form. Another interesting point is that high temperature conditions (ca. 
50°C) are a required condition for the crystallisation of all three PX crystal forms reported 
here, for the crystallisation of PTM I, and also play an important part in the crystallisation 
of PA II when using NHC co-molecules. In some cases an excess quantity of the co-
molecule is required to produce the desired polymorph; this may also have implications 
as to the mechanism.  
 The role of impurities in these co-crystallisation experiments also warrants 
investigation. As many of the compounds used as structure directing co-molecules are of 
similar chemical identity and were obtained from the same supplier, it is conceivable that 
the same or similar impurities are present alongside the different compounds. It could 
therefore be the case that these trace impurities are having a structure directing effect 
towards the crystallisation of the metastable forms obtained. The presence of impurities 
may also provide an explanation for the pink hue observed in some of the PA II crystals 
obtained. Another factor worthy of investigation is the role of the crystallisation vessel 
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surface, as the co-molecules may be interacting with the vessel in such a way as to 




In summary, it has been shown that the systematic investigation of co-crystallisation 
conditions can lead to new and potentially useful crystal forms of various APIs as well as 
new routes to metastable forms. The method facilitates access to a range of crystal forms 
with otherwise unobtainable structural features as demonstrated by the ability to 
produce crystal forms of PX containing mixed tautomeric states as well as a porous form 
of GAM. It remains unclear whether PTM I is formed due to the structure directing effect 
of the co-molecule or whether its formation is solely due to the use elevated temperature 
conditions.  
Selected NHCs have the ability to direct the crystallisation of both paracetamol and 
piroxicam towards elusive polymorphs. In the cases of PX III and PA II, these otherwise 
difficult to obtain polymorphs can be crystallised in significant quantities from simple 
evaporation and in the case of PX IV and the PX methanol solvate, previously 
undiscovered forms are crystallised. The crystallisation of PX III and IV is more sensitive to 
the crystallisation environment than that of PA II, possibly due to the increased 
competition incurred by the existence of the more stable forms I and II as well as the 
monohydrate. The fact that the similar co-molecules can induce polymorph formation in 
different materials also indicates a related mechanism may be responsible for the 
formation of these elusive polymorphs. The evidence from these experiments also 
indicates that the mechanism is indeed solution based rather than epitaxial. An 
understanding of this mechanism is, however, still elusive. 
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5. Tautomerism in Multi-Component Complexes of Piroxicam with 
Mono-substituted Benzoic Acids 
 
5.1 Known Molecular Complexes of Piroxicam 
 
Various molecular complexes of piroxicam (PX) are known. In these, PX is found to adopt 
a range of forms, including being present as a salt in which it is in the anionic form220, in 
five molecular complexes in which it is in the non-ionised form27 and in five molecular 
complexes in which it is in the zwitterionic form27,221. Prior to the discovery of PX form IV 
(see Chapter 4), molecular complex formation (taken here to include the known solvate, 
piroxicam monohydrate211) was the only reported route to obtaining the zwitterionic 
tautomer of piroxicam in the solid state. A recent study of the molecular complex 
formation of PX with carboxylic acids27 indicated some interesting behaviour, dependent 
on the carboxylic acid used for co-crystallisation. Whereas co-crystallisation with four of 
the co-molecules (succinic acid, 1-hydroxy-2-napthoic acid, caprylic acid and malonic acid) 
resulted in molecular complexes with the non-ionised tautomer of PX (PXN), use of 
benzoic acid as co-molecule resulted in a complex with the zwitterionic tautomer (PXZ), 
while the use of fumaric acid resulted in a complex containing both PX tautomers in a 1:1 
ratio. Of particular interest was the molecular complex of PX with 4-hydroxybenzoic acid 
(4HBA) which exhibited the rare phenomenon of tautomeric polymorphism. This is the 
only previously reported complex of piroxicam to exhibit this type of polymorphism.  
Further studies of tautomerisation in the solid state have potential value in the 
development of APIs for applications, as the ionisation state can have a profound effect 
on the properties of the target API. Most zwitterionic APIs such as PX have issues with 
solubility in polar and non-polar media and studies have shown this can be improved 
through ion-pairing212. Co-crystallisation could offer a more flexible alternative to this, 
given the number of potential co-formers available. It is also important to establish which 
tautomeric form of an API is the most stable upon co-crystallising with a particular co-
former candidate, to ensure that form can be further developed with minimal risk of 
conversion to another form. The ability to predict which tautomeric form is favoured in a 
given multi-component system is therefore a desirable goal, yet to-date we know of only 
one study investigating this12. Whereas salt formation can be anticipated to a certain 
degree using pKa matching111, this rule does not extend to cases such as PX complexes 
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which involve intra- rather than intermolecular H-transfer. It has been demonstrated that 
in some cases where the tautomerism involves formation of a carboxylate, complexes 
containing the zwitterionic form only can be crystallised preferentially by using weakly 
acidic alcohols and exploiting the preferential formation of the COO-···O-H  
heterosynthon26. Previous studies have also indicated that the predominant form present 
in solution is not always the form seen in the solid state62. 
 In this chapter the molecular complex formation of PX and mono-substituted 
benzoic acids is investigated222. The systematic co-crystallisation of PX with a group of 
closely related carboxylic acids is used to establish if a relationship exists between the 
properties of the benzoic acid co-molecules and the PX tautomer present in the resultant 
molecular complex. Identification of such a relationship will hopefully enable us to predict 
which tautomer is preferred in molecular complex formation with a particular co-
molecule. Systematic identification of the most stable polymorphs in systems exhibiting 
tautomeric polymorphism would also be a further tentative step along the road to 
understanding the preference of tautomeric materials such as piroxicam to co-crystallise 
as one tautomer or another depending on the co-former used.  
 
5.2 Tautomeric Polymorphism in Molecular Complexes of Piroxicam with Mono-
Substituted Benzoic Acids 
 
Of the sixteen co-molecules found to form molecular complexes with piroxicam in this 
study, three were found to exhibit tautomeric polymorphism. Crystallographic data and 
refinement details for all six of these complexes can be found in (Appendix A5). 
 
5.2.1 Crystallisation of Polymorphs 
 
Piroxicam : 2-Fluorobenzoic Acid 
Initial co-crystallisation of the PX:2FBA polymorphic pair was carried out in a 50/50 v/v 
mixture of methanol and acetonitrile by varying the temperature, with the zwitterionic 
polymorph (PXZ:2FBA) crystallising at 40°C and the non-ionised polymorph (PXN:2FBA) 
crystallising at 50°C. Repeat experiments proved unpredictable with recrystallisation of 
the starting materials and/or PX monohydrate often the result.   
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Piroxicam : 3-Fluorobenzoic Acid 
The PX:3FBA polymorphic pair were crystallised from pure acetonitrile with large crystals 
of the non-ionised complex (PXN:3FBA) forming at 40°C and small needle-like crystals of 
the zwitterionic complex (PXZ:3FBA) forming at 50°C. In both cases small quantities of the 
other polymorph were also found in the resulting solid product.  
 
Piroxicam : 4-Fluorobenzoic Acid 
The polymorphic piroxicam : 4-fluorobenzoic acid complexes were also crystallised from 
acetonitrile with the zwitterionic complex (PXZ:4FBA) initially crystallising with 100% yield 
at 50°C and the non-ionised complex (PXN:4FBA) crystallising with 100% yield at 40°C. 
100% yields of each polymorph were verified using PXRD, however, PXRD of repeat 
crystallisations were erratic with mixtures of both forms found at 50°C and 100% yield of 
the zwitterionic form also found at 40°C in some experiments (see Appendix B5).  
 
5.2.2 Crystal Structures of Piroxicam Complexes Exhibiting Tautomeric Polymorphism 
 
5.2.2.1  Piroxicam : 2-Fluorobenzoic Acid (Zwitterionic Piroxicam) (PXZ:2FBA) 
 
The zwitterionic PXZ:2FBA complex crystallises with one PXZ molecule and one 2FBA 
molecule in the asymmetric unit. It features a tetramer-like building block with a BZZB (B 
= benzoic acid, Z = zwitterionic piroxicam) configuration (Figure 5.1) with an inversion 
centre lying in the middle of the PXZ dimer. The dimer is formed by charge-assisted, 
DHAA bifurcated intra- and intermolecular N+-H···O hydrogen bonds between the 
protonated PXZ pyridinal NH and the amide carbonyl oxygen atoms forming an )12(22R  
hydrogen bonded ring (Figure 5.1). The hydrogen bonds are moderately strong with N···O 
distances of 2.611(4) Å and 2.920(3) Å respectively (see Table 5.1).  
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Figure 5.1 Tetramer in the PXZ:2FBA complex with the major positions of the 2FBA 
molecules shown (left). The 2FBA molecules are disordered with the major position (60%) 
shown in red and minor position (40%) in blue (right). 
 
The 2FBA molecule (red box in Figure 5.1) is orientationally disordered over two positions. 
The relative occupancies of these two positions were refined to approximately 60/40, 
with the major component oriented with the fluorine on the same side of the ring as the 
carboxylic acid hydroxyl group. The carboxylic acid OH of the 2FBA molecule forms a 
charge-assisted O-H···O- hydrogen bond (O···O = 2.568(3) Å) to the deprotonated PXZ 
oxygen atom to form the tetramer. A weak hydrogen bond is also formed between the 
2FBA carbonyl O and the aromatic CH of PXZ (C···O = 3.233(4) Å). π-π interactions of the 
pyridine ring of PXZ with the enolate oxygen and benzene ring of the PXZ molecule hold 
tetramers above and below each other such that the molecules lie head to tail (Figure 
5.2). These PXZ molecules further interact via weak bifurcated DDHHA CH···O interactions 
between the aromatic CH groups of the pyridine ring and the sulfonyl oxygen (C···O = 
3.217(3) Å and 3.405(3) Å, ∠DHA = 124.7(2)° and 109.6(2)° respectively) (also shown in 
Figure 5.2).   
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Figure 5.2 Piroxicam molecules in the PXZ:2FBA complex lying head to tail relative to each 
other, held together by π-π interactions (red dashed line) and weak CH···O hydrogen 
bonds (blue dashed line).  
 
There are further interactions of the sulfonyl oxygen with the disordered fluorine atoms 
of the 2FBA in the minor position (O···F = 2.851(6) Å, c.f. sum of vdW radii = 2.99 Å), as 
well as weak methyl CH···F (C···F = 2.948(5) Å) hydrogen bonds when the fluorine is in the 
major position (Fig 5.3). The tetramers are arranged in stacks forming a herringbone 
structure as shown in Figure 5.4, with CH···π interactions between 2FBA molecules 
holding different stacks together.  
 
 
Figure 5.3 Weak methyl CH···F hydrogen bonds when fluorine is in the major position (left) 
and weak interactions of the sulfonyl oxygen with fluorine in the minor position (right) in 
the PXZ:2FBA complex.   
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Figure 5.4 Herringbone structure of the PXZ:2FBA complex and the CH···π interactions 
between 2FBA molecules in different stacks (major component shown only).  
 
 
Table 5.1 Hydrogen bond lengths and angles  in the BZZB tetramer formed in zwitterionic 
piroxicam complexes with fluorobenzoic acids (see Figure 5.1 for key). 
 
Complex H-Bond D-H (Å) H···A (Å) D···A (Å) ∠ D-H···A (°)  































































5.2.2.2  Piroxicam: 3-Fluorobenzoic Acid (Zwitterionic Piroxicam) (PXZ:3FBA) 
 
The zwitterionic PXZ:3FBA complex is isomorphous to the PXZ:2FBA structure; the change 
in substituent position therefore has no significant effect on the crystal packing. The 
complex features the same BZZB tetrameric building block (Figure 5.5), but in this case, 
the 3FBA molecule is not disordered. The F atom lies solely on the hydroxyl side of the 
ring, and forms weaker aromatic CH···F hydrogen bonds (C···F = 3.171(7) Å) with a 
neighbouring PXZ molecule (Figure 5.6). A hydrogen bond with the methyl group is still 
 135
possible but is much weaker with a C···F distance of 3.553(2) Å (also Figure 5.6). The 
different position of the F atom on the ring and different CH···F hydrogen bonds result in 
only very slight changes in the packing (Figure 5.7), hence the hydrogen bond distances in 
the tetramer are very similar (see Table 5.1). Although similar, all the hydrogen bond 
distances are slightly stronger with the exception of the intermolecular OH···O interaction 
between the 3FBA molecule and the PXZ molecule, which is slightly weaker.  
 








Figure 5.7 Overlay showing the slight differences in crystal packing of PXZ:3FBA (red) with 
the major component (top) and minor component (bottom) of PXZ:2FBA (blue). Hydrogen 
atoms are omitted for clarity. 
 
5.2.2.3 Piroxicam: 4-Fluorobenzoic Acid (Zwitterionic) (PXZ:4FBA) 
 
The zwitterionic PXZ: 4FBA complex features the same BZZB tetramer-like building block 
(Figure 5.8), lying on an inversion centre, as the other FBA complexes, but is not 
isomorphous to these. The N+-H···O interactions in the PXZ dimer have slightly different 
N···O distances, with a weaker intramolecular hydrogen bond (2.6348(14) Å) but a 
stronger intermolecular hydrogen bond (2.8518(14) Å).  
 
Figure 5.8 Tetramer in the PXZ:4FBA complex. 
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The tetramer differs from that of the other FBA complexes, with the 4FBA molecules lying 
much further out of plane of the piroxicam molecules (Figure 5.9a). The OH···O hydrogen 
bond between the PXZ molecule and the 4FBA molecule is weaker than in the 2- and 
3FBA complexes and there is a stronger intramolecular NH···O hydrogen bond. Further 
differences are seen in the relative arrangement of molecules above and below each 
other. The PXZ molecules interact via π···π interactions and lie head to tail almost directly 
above each other in the 2FBA and 3FBA complexes, with the pyridine ring forming further 
π-interactions with the BA molecule (Figure 5.9b). In the 4FBA complex, the PXZ 
molecules are more staggered relative to each other with only the benzene rings 
overlapping - forming π···π interactions - and no π···π interactions are formed with 4FBA 
(also Figure 5.9b). The PXZ molecules arrange into planar layers with the out of plane 
4FBA molecules intersecting the layers diagonally (Figure 5.9c). The F atom also forms 
weak hydrogen bonds between layers. These hydrogen bonds are formed with the 
aromatic CH of another 4FBA molecule (C···F = 3.280(2) Å) as well as the methyl CH of a 
PXZ molecule (C···F = 3.464(2) Å) (Figure 5.10). A bifurcated hydrogen bond is also formed 
with the pyridine ring NH and CH groups of another PXZ molecule (N···F = 2.9187(13) Å, 
C···F = 3.049(2) Å) (also Figure 5.10). 
 
Figure 5.9 (a) Top, planar tetramers in PXZ:3FBA complex (identical to PXZ:2FBA, not 
shown) and bottom, non-planar tetramers in PXZ:4FBA. (b) Top, relative arrangement of 
π-stacked molecules in PXZ:3FBA (identical to PXZ:2FBA, not shown) and bottom, 
PXZ:4FBA with H-atoms omitted for clarity. (c) Layered structure of PXZ:4FBA, PXZ in blue, 
4FBA in red. 
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Figure 5.10 Weak hydrogen bonds involving the fluorine atom in the PXZ:4FBA complex. 
 
 
5.2.2.4  Piroxicam: 2-Fluorobenzoic Acid (Non-Ionised Piroxicam) (PXN:2FBA) 
 
The PXN molecules in this complex dimerise but due to the lack of intramolecular H-
transfer and the different conformation adopted by non-ionised PXN molecules, the 
dimer formed is completely different to that seen in the zwitterionic PXZ complexes. The 
dimer (Figure 5.11), is formed via two equivalent moderately strong hydrogen bonds 
between the hydroxyl groups and the sulfonyl oxygen atoms (hydrogen bond lengths in 
Table 5.2), with the two piroxicam molecules lying in different planes related by an 
inversion centre. The hydrogen bond is bifurcated with a shorter intramolecular hydrogen 





Figure 5.11 Piroxicam dimer in the PXN:2FBA complex with intermolecular hydrogen 
bonds shown as blue dashed lines and intramolecular hydrogen bonds shown as red 
dashed lines. Hydrogen atoms not involved in the hydrogen bonds have been omitted for 
clarity. 
 
Table 5.2 Hydrogen bond lengths and angles in the BNNB tetramer found in non-ionised 
piroxicam complexes with 2-fluorobenzoic acid and 3-fluorobenzoic acid (refer to Figure 
5.12 for key). 
Complex H-Bond D-H (Å) H···A (Å) D···A (Å) ∠ D-H···A (°) 










































The 2FBA molecules link to each PXN molecule in the dimer via moderately strong N-H···O 
hydrogen bonds to form a hydrogen bonded ring, which can be described by graph-set 
notation )8(22R  (Figure 5.12a). This again forms a tetramer-like building block with a 
BNNB (B = benzoic acid, N = non-ionised piroxicam) configuration (Figure 5.12b), where 
the PXN-2FBA pair lies relatively coplanar and the inverted pair is staggered relative to 
the first.  
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Figure 5.12 Non-ionised piroxicam complex with 2-fluorobenzoic acid, (a) R22(8) hydrogen 
bonded ring linking the 2FBA molecule to the PXN molecule and (b) the hydrogen bonded 
tetramer formed. 
 
The sulfonyl oxygen involved in the PXN dimer also forms weak CH···O hydrogen bonds 
with aromatic CH groups of the PXN and 2FBA molecules below (Figure 5.13). The CH 
group of PXN forms a weak hydrogen bond with the sulfonyl oxygen (C···O = 3.343(2) Å, 
∠CHO = 155.7(17)°), whereas the 2FBA CH lies closer (C···O = 3.055(3) Å) but the 
hydrogen bond is less linear (∠CHO = 108(1)°). The methyl groups, which lie out of the 
plane of the PXN molecule, also form weak hydrogen bonds to the fluorine (C···F = 
3.098(2) Å) and hydroxyl oxygen atoms (C···O = 3.437(2) Å and 3.419(3) Å) of other 2FBA 
molecules (Figure 5.14). This creates a layered structure, with the methyl groups and 
sulfonyl oxygen atoms acting as bridges between layers (Figure 5.15).  
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Figure 5.13 Weak CH···O hydrogen bonds involving the sulfonyl oxygen lying out of the 
plane in the PXN:2FBA complex. 
 
 





Figure 5.15 Layered arrangement of the molecules in the PXN:2FBA complex with sulfonyl 
oxygen and methyl groups bridging the layers (alternate layers shown in different 
colours).  
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5.2.2.5  Piroxicam: 3-Fluorobenzoic Acid (Non-Ionised) (PXN:3FBA) 
 
As in the case of the zwitterionic complexes, the PXN:3FBA complex is isomorphous to the 
PXN:2FBA complex. The tetramer (Figure 5.16) features a slightly stronger OH···O 
hydrogen bond between PXN molecules (see Table 5.2) and a slightly stronger NH···O 
hydrogen bond between the PXN and 3FBA molecules. The intramolecular hydrogen bond 
in the PXN molecule is slightly weaker, however. The methyl CH···F hydrogen bonds 
between planes in PXN:2FBA are replaced by weaker aromatic CH···F hydrogen bonds 
within the planes (C···F = 3.405(2) Å) due to the different fluorine position (Figure 5.17). 
Consequently, only very slight changes in the packing are seen in the PXN:3FBA complex 
when compared with the PXN:2FBA complex (Figure 5.18).  
 
Figure 5.16 The BNNB tetramer in the PXN:3FBA complex. 
 
 
Figure 5.17 Weak CH···F hydrogen bonds between the co-planar 3FBA and PXN pyridine 




Figure 5.18 Overlay of the crystal packing of PXN:2FBA (blue) and PXN:3FBA (red) showing 
the slightly offset position of the FBA molecules relative to the PXN molecules. 
 
5.2.2.6 Piroxicam: 4-Fluorobenzoic Acid (Non-Ionised) (PXN:4FBA) 
 
Like the zwitterionic structures, the PXN:4FBA complex is not isostructural to the 2- and 
3FBA complexes. Once again, the primary building block is a BNNB tetramer-like 
structure. However, the interactions between PXN molecules are very different (Figure 
5.19a).  
 
Figure 5.19 (a) the BNNB tetramer in the PXN:4FBA complex, (b) the relative planes of the 
PXN molecules in the PXN dimer. 
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Table 5.3 Hydrogen bond lengths and angles in the PXN:4FBA complex (refer to Figures 
5.19a and 5.20 for key). Corresponding hydrogen bond distances for the PXN:2FBA and 
PXN:3FBA complexes are shown where relevant. 
Complex H-Bond D-H (Å) H···A (Å) D···A (Å) ∠ D-H···A (°) 
























































The 4FBA molecules link to the PXN molecules in the same way as the 2- and 3FBA 
complexes by forming the hydrogen bonded )8(22R  ring, but in this case the O-H···O 
interactions between PXN molecules are replaced by weak CH···O interactions between 
aromatic CH groups and the hydroxyl oxygen atoms (hydrogen bond distances in Table 
5.3). The PXN dimers lie diagonal relative to each other (Figure 5.19b) and the CH···O 
hydrogen bonds are considerably weaker (Table 5.3) than the OH···O hydrogen bonds in 
the 2FBA and 3FBA complexes. The )8(22R  ring consists of a stronger NH···O interaction 
and a weaker OH···N interaction than the aforementioned complexes. The intramolecular 
OH···O hydrogen bond in PXN is significantly stronger in the 4FBA complex, presumably 
due to the lack of a second donor pulling the hydrogen atom towards it - which is the case 
in the 2FBA and 3FBA complexes. Dimers are also formed between 4FBA molecules by 
weak CH···F hydrogen bonds (Figure 5.20). PXN molecules above and below each other 
interact via further weak hydrogen bonds to the sulfonyl oxygen atom formed by the 
methyl group (C···O = 3.184(3) Å) and CH group (C···O = 3.308(2) Å) of two other PXN 








Figure 5.21 CH···O interactions between the sulfonyl oxygen and the methyl and aromatic 
CH groups of PXN molecules above in the PXN:4FBA complex. 
 
 
Due to the PXN dimers lying out of plane with each other, the overall structure is built up 
of zigzagging bilayers (Figure 5.22), with the CH···O interactions in Figure 5.21 bridging 
across the interface of the bilayers.  
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Figure 5.22 Bilayers in the PXN:4FBA complex with alternate bilayers shown in different 





5.3 Tautomerism in other Complexes of Piroxicam with Mono-substituted Benzoic 
Acids 
 
Of the twenty molecular complexes crystallised, polymorphism was not observed in the 
remaining fourteen. The tautomer present in each of these complexes varied, however, 
depending on the particular mono-substituted benzoic acid present in the complex.  
  
5.3.1  Crystallisation Conditions 
Crystallisations were carried out according to the procedure outlined in Chapter 3. Table 
5.4 below outlines the solvent and temperature systems under which each molecular 
complex described in this section was observed to crystallise. Crystallographic data and 
full refinement details can be found in (Appendix A5).  
 
Table 5.4 Crystallisation conditions for molecular complexes of piroxicam with mono-
substituted benzoic acids. 
Piroxicam Molecular Complex Solvent Temp (°C) 
2-Chlorobenzoic Acid Acetonitrile RT/40/50 
3-Chlorobenzoic Acid Acetonitrile 40/50 
2-Bromobenzoic Acid Acetonitrile 40/50 
3-Bromobenzoic Acid Acetonitrile 40/50 
2-Hydroxybenzoic Acid Acetonitrile RT/40/50 
3-Hydroxybenzoic Acid Monohydrate Acetonitrile RT 
2-Nitrobenzoic Acid Acetonitrile 50 
3-Nitrobenzoic Acid  Acetonitrile/Methanol 
2:1 V/V 
50 
4-Nitrobenzoic Acid (Hydrate) Acetonitrile 50 
2-Methylbenzoic Acid Acetonitrile 50 
3-Methylbenzoic Acid Acetonitrile 40/50 
3-Methylbenzoic Acid: Acetonitrile Solvate  Acetonitrile RT 
4-Methylbenzoic Acid Acetonitrile 40/50 
2-Aminobenzoic Acid Acetonitrile 40/50 
RT = Room Temperature 
 
5.3.1.1  Piroxicam: 2-Chlorobenzoic Acid (Zwitterionic) (PXZ:2CLBA) 
PX in this complex is present as the zwitterionic tautomer, and the structure is built up 
from the BZZB unit that is present in the PXZ:FBA complexes (Figure 5.23). The structure 
consists of relatively flat layers, with the methyl and sulfonyl groups bridging between 
layers (Figure 5.24). Unlike the previous zwitterionic complexes described, the 
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asymmetric unit consists of two PXZ molecules and two 2CLBA molecules and the BZZB 
tetramer is made up of two independent molecules of both the PXZ and the 2CLBA. 
Hydrogen bond lengths in the tetramer are shown in Table 5.5. One 2CLBA molecule has a 
twisted conformation, with the carboxylic group out of plane with the benzene ring. The 
molecule has a torsion angle of approximately 98° between the carboxylic acid carbonyl 
oxygen, the carbon of the carboxylic acid and the aromatic carbons in the 1- and 4-
positions (c.f. 174° for the symmetry independent 2CLBA molecule). 
 
Figure 5.23 The BZZB tetramer in the PXZ:2CLBA molecular complex. * indicates the 
twisted 2CLBA molecule. 
 
Table 5.5 Hydrogen bond lengths and angles in the PXZ:2CLBA tetramer (refer to Figure 
5.23 for key). 
Complex H-Bond D-H (Å) H···A (Å) D···A (Å) ∠ D-H···A (°) 












































Figure 5.24 Layered structure in the PXZ:2CLBA complex with methyl groups and sulfonyl 
oxygen atoms bridging between layers (alternate layers shown in different colours). 
 
The BZZB units are linked within the layers by weak CH···O=S hydrogen bonds (C···O = 
3.346(3) Å and 3.468(3) Å) on both sides of the tetramer (Figure 5.25). Benzene ring CH 
groups of the PX molecule above form a weak hydrogen bond to the twisted carbonyl O 
(C···O = 3.460(9) Å) as well as a weak CH···π interaction with the aromatic π cloud (approx. 
3.308 Å between the carbon and the plane of the benzene ring (Figure 5.26a). The more 
planar 2CLBA molecule forms π···π interactions with the pyridine rings of PXZ molecules 
above and below it (approx. 3.472 Å (PXZ above) and 3.423 Å (PXZ below) between the 
two closest aromatic C-C bonds, as shown in Figure 5.26b). The bridging methyl groups 
and sulfonyl oxygen atoms interact via weak hydrogen bonds (C···O = 3.186(3) Å) (Figure 
5.27) with the methyl group also forming weak interactions with the chlorine of the 




Figure 5.25 The weak CH···O interactions (red dashed) linking tetramers within the layers 




Figure 5.26 Differing weak interactions formed by symmetry independent 2CLBA 
molecules in the PXZ:2CLBA complex. (a) CH···O hydrogen bond (blue dashed line) and 





Figure 5.27 Weak methyl CH···O hydrogen bonds (blue dashed lines) and methyl CH···Cl 
interactions (red dashed lines) bridging layers in PXZ:2CLBA. 
 
 
5.3.1.2 Piroxicam : 3-Chlorobenzoic Acid (Non-Ionised) (PXN:3CLBA) 
 
In the PXN:3CLBA complex, non-ionised PXN molecules dimerise, forming a new synthon, 
different to any of the non-ionised PXN : fluorobenzoic acid complexes (Figure 5.28). The 
dimers consist of bifurcated DHAA intra- and intermolecular OH···O=C hydrogen bonds 
with an )6(22R  hydrogen bonded ring formed lying on an inversion centre. The 
intramolecular interaction is considerably shorter than the intermolecular interaction (see 
Table 5.6). The 3CLBA molecule is linked to both sides of the dimer via the same )8(22R  
hydrogen bonding seen in the PXN:FBA complexes, forming a new type of BNNB tetramer.  
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Figure 5.28 The BNNB tetramer in the PXN:3CLBA molecular complex. 
 
Table 5.6 Hydrogen bond lengths and angles in the BNNB tetramer for complexes 
featuring the OH···O=C PXN homodimer (refer to Figure 5.28 for key).  
Complex H-Bond D-H (Å) H···A (Å) D···A (Å) ∠ D-H···A (°) 





































































































Once again the structure consists of relatively planar layers (Figure 5.29) with the methyl 
group and sulfonyl oxygen bridging the layers. The methyl group forms a weak hydrogen 
bond to the 3CLBA hydroxyl oxygen atom (C···O = 3.330(2) Å) as well as a very weak 
hydrogen bond to the chlorine atom (C···Cl = 3.857(2) Å) (Figure 5.30a). PXN molecules 
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above and below each other are also linked through weak hydrogen bonds between the 
aromatic CH groups and the sulfonyl oxygen atoms (C···O = 3.222(2) Å and 3.287(2) Å) 
(Figure 5.30b). The tetramer building blocks are held together in the layers via weak 
hydrogen bonds between the aromatic CH groups of the 3CLBA and the co-planar sulfonyl 
oxygen of PXN (C···O = 3.215(2) Å) (Figure 5.31).  
 
 




Figure 5.30 Weak hydrogen bonds in the PXN:3CLBA complex. (a) Weak CH···O and CH···Cl 
hydrogen bonds between layers involving the methyl group, (b) weak aromatic CH···O 




Figure 5.31 Weak CH···O hydrogen bonds linking tetramers within layers involving the 
aromatic CH group of 3CLBA and the co-planar sulfonyl oxygen of PXN in the PXN:3CLBA 
complex.  
 
5.3.1.3  Piroxicam: 2-Bromobenzoic Acid (Zwitterionic) (PXZ:2BRBA) 
 
The zwitterionic PXZ:2BRBA complex again features the BZZB tetramer (Figure 5.32). The 
hydrogen bonds in the tetramer are similar in strength to those in the FBA complexes (see 
Table 5.7). 
 
Figure 5.32 BZZB tetramer in the PXZ:2BRBA complex 
 
The structure is layered (Figure 5.33), with the BZZB units in the layers held together by 
weak bifurcated DDHHA CH···O hydrogen bonds (C···O = 3.252(3) Å and 3.273(3) Å) 
between the aromatic CH groups of the 2BRBA and the sulfonyl O of PXZ similar to the 
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2CLBA complex (Figure 5.34). PXZ molecules above and below each other are staggered, 
with the other sulfonyl bridging between layers, forming weak aromatic CH···O=S 
hydrogen bonds (Figure 5.35a). There are also short contacts between this sulfonyl 
oxygen and the bromine atom of the 2BRBA (O···Br = 2.993(2) Å, c.f. sum of vdW radii = 
3.037 Å). The carboxylic acid group of 2BRBA twists out of the plane of the benzene ring, 
a consequence of the larger bromine atom positioned adjacent to it. The molecule has a 
torsion angle of approximately 120° between the carboxylic acid carbonyl oxygen, the 
carbon of the carboxylic acid and the aromatic carbons in the 1- and 4-positions. The PXZ 
methyl group also bridges between layers, forming a weak CH···O hydrogen bond (C···O = 
3.372(4) Å) to the hydroxyl O of the carboxylic group (Figure 5.35b).  
 
 
Figure 5.33 The layered structure of the PXZ:2BRBA complex. 
 
 
Figure 5.34 Bifurcated CH···O hydrogen bonds between the 2BRBA aromatic CH groups 
and the sulfonyl oxygen atoms of the PXZ molecule in PXZ:2BRBA. 
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Table 5.7 Hydrogen bond lengths and angles in the BZZB tetramer of the molecular 
complexes featuring piroxicam in the zwitterionic form (see Figure 5.23 for key). 
Note: * indicates two independent molecules of each component in asymmetric unit 
Complex H-Bond D-H (Å) H···A (Å) D···A (Å) ∠ D-H···A (°) 














































































































































































































Figure 5.35 Weak hydrogen bonds involving bridging sulfonyl oxygen atoms (a) and 




5.3.1.4  Piroxicam: 3-Bromobenzoic Acid (Non-Ionised) (PXN: 3BRBA) 
 
PX in this complex is in the non-ionised tautomeric form and the structure is isomorphous 
to that of the PXN:3CLBA complex, featuring the same BNNB tetramer with the CH···O=C 
dimer at the centre. The PX dimer has a slightly weaker intermolecular interaction and a 
slightly stronger intramolecular interaction than the isomorphic 3CLBA complex (see 
Table 5.6). The interactions in the )6(22R  ring between PXN molecules and 3BRBA 
molecules are both slightly weaker than in the 3CLBA complex. The difference in these 
interactions is very slight and an overlay of the 3BRBA and 3CLBA structures (Figure 5.37) 
shows them to be almost identical in the relative positions of the molecules.  
 




Figure 5.37 An overlay of the isomorphous PXN:3BRBA (red) and PXN:3CLBA (blue) 
complexes. 
 
5.3.1.5  Piroxicam: 2-Hydroxybenzoic Acid (Zwitterionic) (PXZ:2HBA) 
 
The PXZ:2HBA complex contains zwitterionic PXZ molecules with the BZZB tetramer again 
the structural unit (Figure 5.38a). The interactions in the BZZB tetramer are interesting 
when compared to the others, as the NH···O interactions between PXZ molecules are the 
weakest of all the zwitterionic complexes but the OH···O interactions between the PXZ 
and 2HBA molecules are the strongest (Table 5.7). The OH group of 2HBA does not form 
any intermolecular hydrogen bonds with the only interaction involving this group being a 
moderately strong intramolecular hydrogen bond with the carbonyl O (O···O = 2.624(3) 
Å). The 2HBA molecule is twisted relative to the PXZ molecule (Figure 5.38b) and is 
involved in a number of weak hydrogen bonds.  
 
Figure 5.38 (a) The PXZ:2HBA tetramer, (b) the tetramer rotated 90° showing the twisted 
2HBA molecules relative to the plane of the PXZ molecules . 
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The aromatic CH groups of 2HBA form weak hydrogen bonds to the sulfonyl oxygen 
atoms of two PXZ molecules (C···O = 3.319(3) Å and 3.437(3) Å) as well as the hydroxyl O 
of a neighbouring 2HBA molecule (C···O = 3.503(3) Å) (Figure 5.39a). PXZ molecules above 
and below each other are linked by further weak hydrogen bonds between the pyridinal 
CH groups and the sulfonyl oxygen atoms (C···O = 3.317(3) Å) (Figure 5.39b). This gives the 
PXZ dimers a step-like arrangement relative to each other (Figure 5.40a), with the twisted 
2HBA molecules running diagonal to the plane (Figure 5.40b). 
 
Figure 5.39 (a) Weak CH···O hydrogen bonds involving 2HBA in PXZ:2HBA (b) weak CH···O 
hydrogen bonds between PX molecules in PXZ:2HBA. 
 
 
Figure 5.40 Structure of PXZ:2HBA showing (a) the step-like arrangement of the PXZ 
dimers (alternate dimers shown in different colours) and (b) the 2HBA molecules (red) 
running diagonal to the plane of the PXZ molecules (blue).  
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5.3.1.6 Piroxicam: 3-Hydroxybenzoic Acid Monohydrate (Zwitterionic) (PXZ: 3HBA.H2O) 
 
The PXZ:3HBA.H2O complex features the BZZB tetramer (Figure 5.41) with PXZ in the 
zwitterionic form and similar hydrogen bond lengths to the PXZ:2HBA complex (Table 
5.7). Two water molecules act as linkers between tetramers, forming an )8(44R  hydrogen 
bonded ring with two 3HBA molecules (Figure 5.42a). The water oxygen is acceptor to the 
hydroxyl OH of one 3HBA molecule (O···O = 2.708(4) Å) and donor to the hydroxyl oxygen 
of the other (O···O = 3.033(5) Å, ∠DHA = 126(3)°).   
 
Figure 5.41 The PXZ: 3HBA tetramer in the PXZ:3HBA.H2O complex. 
 
 
Figure 5.42 Intermolecular interactions in PXZ:3HBA.H2O (a) )8(44R  rings, (b) hydrogen 
bonding between layers via water molecules, (c) π···π interactions between PXZ molecules 
(red dashed lines) and weak CH···O hydrogen bonds between the aromatic CH and sulfonyl 
O atoms.  
 
The BZZB tetramers connected by the )8(44R  ring are almost co-planar with one another, 
forming layers (Figure 5.43). The water molecule forms another hydrogen bond to the 
carboxylic carbonyl oxygen (O···O = 2.812(5) Å) of the 3HBA molecule lying above/below 
(Figure 5.42b) which links the layers together. Further interactions between layers occur 
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between PXZ molecules, with weak CH···O hydrogen bonds (C···O = 3.271(1) Å) between 
the aromatic CH and sulfonyl O (Figure 5.42c) as well as π···π interactions between the 
pyridine ring and the delocalised enolate π-bond with a distance of approximately 3.241Å 
between the centre of the two bonds (also Figure 5.42c).  
 
 
Figure 5.43 Layered structure of PXZ:3HBA.H2O. 
 
5.3.1.7  Piroxicam : 2-Nitrobenzoic Acid (Zwitterionic) (PXZ:2NBA) 
 
The PXZ:2NBA complex contains PX as the zwitterionic tautomer within the BZZB 
tetramer building block (Figure 5.44). The tetramer building blocks are linked by weak 
CH···O hydrogen bonds between the aromatic CH of the 2NBA molecule and the PXZ 
sulfonyl O (C···O = 3.201(3) Å), along with further weak hydrogen bonds of the aromatic 
CH of the PXZ pyridine ring with the nitro group O (C···O = 3.248(3) Å) (Figure 5.45a). This 
links the tetramers into layers (Figure 5.45b) with the methyl group and one sulfonyl 




Figure 5.44 Tetramer in the PXZ:2NBA complex. 
 
The nitro- and carboxylic acid group of 2NBA are twisted relative to the benzene ring due 
to steric effects. The twisted carboxylic acid group allows a weak hydrogen bond to be 
formed between the protonated pyridinal NH of the PXZ molecule above with the 
carbonyl oxygen (N···O = 2.962(2) Å)(Figure 5.45c). The twisted nitro group forms a weak 
interaction with the methyl CH of the same PXZ molecule (C···O = 3.320(3) Å). A weak 
CH···O hydrogen bond is also formed between the bridging sulfonyl oxygen of PXZ and the 
aromatic CH of the 2NBA molecule below (C···O = 3.296(3) Å) (also Figure 5.45c).  The 
hydrogen bonds in the BZZB tetramer are of similar strength to the other complexes 




Figure 5.45 Crystal Structure of PXZ:2NBA. (a) Weak interactions within layers, (b) layered 
arrangement of molecules, (c) weak interactions between layers.  
 
5.3.1.8  Piroxicam: 3-Nitrobenzoic Acid (Non-Ionised) (PXN:3NBA) 
PX in this complex is in the non-ionised tautomeric form and is isomorphous to the 
layered PXN:3ClBA complex, again comprising of the BNNB tetramer with a CH···O=C  PXN 
dimer (Figure 5.46). Interactions in the tetramer are largely similar to those in the 
PXN:3CLBA complex (Table 5.6). Slightly weaker interactions occur between PXN 
molecules and slight differences are observed in the )6(22R  ring formed between the PXN 
and 3NBA molecules, with the OH···N hydrogen bond being slightly stronger and the 
NH···O interaction being slightly weaker. The nitro group occupies the corresponding 
space that the chlorine atom occupies in the 3ClBA complex; the weak methyl CH···Cl 
hydrogen bonds between layers are replaced with CH···O hydrogen bonds (C···O = 
3.269(3) Å) (Figure 5.47). The nitro group oxygen also forms weak hydrogen bonds within 
the layers with the aromatic CH groups of the two neighbouring PXN molecules  (C···O = 
3.209(2) Å and 3.535(2) Å) (Figure 5.48).  
 164
 
Figure 5.46 The BZZB tetramer in the PXN:3NBA complex. 
 
 
Figure 5.47 PXN methyl interactions with the nitro group and hydroxyl oxygen in 
PXN:3NBA molecular complex. 
 
 
Figure 5.48 Weak CH···O interactions within layers in PXN:3NBA. 
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5.3.1.9  Piroxicam : 4-Nitrobenzoic Acid Hydrate (Non-Ionised) (PXN:4NBA.H2O)  
 
The complex has two non-ionised PXN molecules and two 4NBA molecules in the 
asymmetric unit. A large peak on the Fourier difference synthesis also indicated the 
presence of a single heavy atom not bonded to any other heavy atom - suggesting that 
the atom was the oxygen of a water molecule. Before assignment of the water molecule, 
the excess electron density was estimated using the SQUEEZE procedure216. This 
estimated that 16 excess electrons were present in the unit cell, representing an average 
of less than half a water molecule per asymmetric unit. The poor quality data (Rint = 
14.40%) makes this estimate unreliable. For the final refinement cycle the SQUEEZED 
structure was not used. Instead, the oxygen was fixed at 30% occupancy to obtain a 
reasonable sized thermal parameter, although this may not be an accurate occupancy 
value. Due to the large void in which the water molecule resides, it is likely that it has a 
significant degree of freedom, with the modelled position being the major position. This is 
further supported by various small satellite peaks observed in the Fourier difference map 
(of height <0.25 eÅ−3) surrounding the oxygen atom (see Appendix A5 for full refinement 
details). The water hydrogen atoms could not be located using Fourier difference 
synthesis.  
 The non-ionised PXN molecules dimerise via the OH···O=C dimer, with the 4NBA 
molecule hydrogen bonded via the )8(22R  ring forming the tetramer that has previously 
been seen in PXN complexes with 3CLBA, 3BRBA and 3NBA, although with non-equivalent 
molecules in the tetramer (Figure 5.49).  Hydrogen bond lengths in the tetramer can be 
found in Table 5.6.  
 
 
Figure 5.49 The BNNB tetramer in the PXN:4NBA.H2O complex. 
 166
The structure consists of wave-like layers (Figure 5.50) with the methyl groups and 
sulfonyl oxygen atoms bridging between layers. Weak CH···O hydrogen bonds between 
the methyl and sulfonyl oxygen atoms (C···O = 3.312(3) Å and 3.306(3) Å) are formed 
between every third layer (Figure 5.51a) with the sulfonyl oxygen also involved in weak 
aromatic CH···O hydrogen bonds with PXN molecules in alternate layers (Figure 5.51b). 
The single hydrogen bonds in Figure 5.51b have a C···O distance of 3.548(3) Å, while the 
bifurcated hydrogen bonds have C···O distances of 3.312(3) Å and 3.306(3) Å. A weak 
bifurcated hydrogen bond (Figure 5.51b) is also present between the aromatic CH groups 
of the pyridine ring and the nitro group oxygen atom (C···O = 3.206(3) Å and 3.224(3) Å). 
Aromatic CH groups of two PXN molecules form weak hydrogen bonds to the water 
molecule oxygen (C···O = 3.254(3) Å and 3.262(3) Å) (Figure 5.52). Possible hydrogen 
bonds from the water OH groups are indicated by the proximity to both a PXN sulfonyl 
oxygen and a 4NBA nitro oxygen (O···O = 3.110(6) Å and 2.821(6) Å) (also shown in Figure 
5.52).  
 





Figure 5.51 Weak interactions in the PXN:4NBA complex (a) methyl CH hydrogen bonds 
with the sulfonyl oxygen atoms (b) aromatic CH hydrogen bonds with the sulfonyl oxygen 




Figure 5.52 The major position of the water oxygen atom and hydrogen bond interactions 
in the PXN:4NBA hydrate complex. The 4NBA molecule and bottom two PXN molecules lie 
in the same plane as the water oxygen with the top PXN molecule in the layer above. 
 168
5.3.1.10  Piroxicam : 2-Methylbenzoic Acid (Non-Ionised) (PXN:2MBA) 
 
The non-ionised PXN molecules dimerise through the S=O···H-O dimer seen in the non-
ionised PXN complexes with 2- and 3FBA (Figure 5.53a). The 2MBA molecules are then 
hydrogen bonded to the PXN molecules through the )8(22R  ring (Figure 5.53b). The 
sulfonyl oxygen atom forms weak hydrogen bonds with the aromatic CH groups of two 
neighbouring PXN molecules with approximate C···O lengths of 3.203(2) Å and 3.485(2) Å 
(Figure 5.54a). The other sulfonyl oxygen atom also forms weak hydrogen bonds with the 
aromatic CH of the adjacent 2MBA molecule, as well as with the methyl group of the 
2MBA molecule that is hydrogen bonded to that PXN molecule via the )8(22R ring 
hydrogen bond motif (approximate C···O = 3.361(3) Å and 3.542(2) Å respectively) (Figure 
5.54b). There are also π···π interactions between these two 2MBA molecules (Figure 
5.54b), with a distance of approximately 3.578 Å between the centroids of the two π 
bonds. The non-planar arrangement of the 2MBA molecules relative to the PXN 
molecules in the tetramer results in layers of approximately planar regions of PXN 
molecules intersected by 2MBA molecules running diagonal to the plane of the PXN 
molecules (Figure 5.54c). 
 
 






Table 5.8 Hydrogen bond lengths and angles in the PXN:2MBA tetramer and the other 
complexes which exhibit this hydrogen bonding synthon (see Figure 5.53 for key).  
Complex H-Bond D-H (Å) H···A (Å) D···A (Å) ∠ D-H···A (°) 
































































Figure 5.54 (a) Crystal structure of PXN:2MBA. (a) Weak CH···O hydrogen bonds between 
sulfonyl O and CH of PXN molecules, (b) weak CH···O hydrogen bonds between sulfonyl O 
and 2MBA molecules (blue dashed lines) and π···π interactions between 2MBA molecules 




5.3.1.11  Piroxicam : 3-Methylbenzoic Acid (Zwitterionic) (PXZ:3MBA) 
 
The structure consists of the zwitterionic PXZ:3MBA BZZB tetramers (Figure 5.55, see 
Table 5.7 for bond lengths). The PXZ molecules are stacked upon each other through π···π 
interactions of the pyridine ring with both the benzene ring and the delocalised π bond of 
the deprotonated oxygen (Figure 5.56a). The same two molecules are further linked by 
weak aromatic CH···O=S (C···O = 3.405(4) Å) hydrogen bonds (also Figure 5.56a). Further 
π···π interactions occur between the pyridine ring of the PXZ molecules and the aromatic 
ring of the 3MBA molecules (Figure 5.56b) resulting in stacks of the tetramers. The stacks 
run alternately in different planes (Figure 5.57a). Interactions between stacks in different 
planes are relatively weak with CH···O hydrogen bonds (C···O = 3.450(4) Å) as well as  
CH···π interactions (Figure 5.57b).  
 
 




Figure 5.56 π···π interactions in the PXZ:3MBA complex between (a) PXZ molecules and (b) 





Figure 5.57 Crystal packing in the PXZ:3MBA complex. (a) Regions of stacks lying in 
different planes with 3MBA in red and PXZ in blue; (b) weak interactions between 
molecules lying in different planes.  
 
 
5.3.1.12  Piroxicam: 3-Methylbenzoic Acid Acetonitrile Solvate (Zwitterionic) 
(PXZ:3MBA.ACN)  
 
The PXZ:3MBA.ACN complex crystallises in a 2:1:1 ratio, with the PX molecules in the 
zwitterionic form. Although the BZZB tetramer is present, the 3MBA and acetonitrile 
(ACN) molecules are disordered over two positions related by an inversion centre (Figure 
5.58).  This results in three possible tetramer configurations (Figure 5.59) on a local-level 
when the disorder is removed. The first is the standard BZZB tetramer with two PXZ 
molecules sandwiched by two 3MBA molecules (BZZB),the second is the PXZ dimer 
flanked by two ACN molecules ((ACN):Z:Z:(ACN)), while the third is a combination of the 
two, an (ACN):Z:Z:B. It is not possible to resolve the combination of these which 
contribute to the average disordered structure from this analysis. Table 5.7 shows that 
the NH···O hydrogen bonds between PXZ molecules and OH···O hydrogen bonds between 
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PXZ and 3MBA molecules in the BZZB tetramer (Figure 5.59a) are of comparable strength 
to those in the other zwitterionic piroxicam complexes, despite the presence of the 
solvent molecule.  
 
Figure 5.58 (a) Disordered positions of 3MBA molecules and ACN molecules in the 
PXZ:3MBA.ACN complex, with the hydrogen atoms omitted for clarity. (b) The hydrogen 
bonding arrangements of PXZ with acetonitrile (left) and 3MBA (right). These occur in 
equal proportions.  
 
 
Figure 5.59 The three possible permutations of the tetramer in the disordered 
PXZ:3MBA.ACN complex (a) BZZB (b) (ACN):Z:Z:B (c) (ACN):Z:Z:(ACN). 
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The ACN molecule is hydrogen bonded to the PXZ molecule via weak CH···O interactions 
between the methyl group and the PX enolate O atom (C···O = 3.191(9) Å) as well as weak 
CH···N interactions between aromatic PXZ CH groups and the ACN N (C···N = 3.443(8) Å) 
(Figure 5.59b and c). The disordered tetramers are once again arranged in layers with the 
methyl group and sulfonyl oxygen pointing outward from the layers (Figure 5.60).  
 
 
Figure 5.60 Layered structure of PXZ:3MBA.ACN with alternate layers in different colours. 
 
The layers are linked by weak hydrogen bonds, mainly involving the sulfonyl oxygen atom. 
CH···O interactions are formed between the aromatic benzene CH groups of the PXZ 
molecules below (C···O = 3.366(3) Å) as well as the 3MBA molecule below (C···O = 
3.398(6) Å) (Figure 5.61). A further weak CH···O hydrogen bond is formed between the 
methyl group of 3MBA and the enolate oxygen (C···O = 3.378(9) Å) (Figure 5.62). The ACN 
molecule is also involved in weak hydrogen bonds between layers with ACN dimers 
formed between layers through CH···N interactions (approximate C···N = 3.534(11) Å) as 
well as CH interactions with the PXZ molecules through the enolate oxygen (C···O = 
3.455(9) Å) (Figure 5.63). The main interaction linking tetramers within the layers is the 
bifurcated CH···O interactions involving the sulfonyl oxygen and the pyridinal CH groups 
of PXZ (C···O = 3.204(3) Å and 3.290(3) Å) (Figure 5.64).    
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Figure 5.61 Weak CH···O interactions between layers involving the sulfonyl oxygen atom in 
the PXZ:3MBA.ACN complex.  
 
Figure 5.62 Weak CH···O hydrogen bonds between the 3MBA methyl group and the 
enolate oxygen of PXZ in the PXZ:3MBA.ACN complex. 
 
 
Figure 5.63 Weak hydrogen bonds between layers involving the acetonitrile molecule in 
the PXZ:3MBA.ACN complex. 
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Figure 5.64 Bifurcated CH···O interactions between neighbouring PXZ molecules in the 
layers in the PXZ:3MBA.ACN complex.  
 
 
5.3.1.13  Piroxicam : 4-Methylbenzoic Acid (Zwitterionic) (PXZ:4MBA) 
 
The PX molecules are in the zwitterionic form with the BZZB tetramer again the hydrogen 
bonded building block (Figure 5.65). The BZZB building block differs from the others with 
the 4MBA molecule forming hydrogen bonds to the same deprotonated hydroxyl oxygen 
atom. However, the CH···O hydrogen bond is formed between the carbonyl and the 
aromatic H atom of the benzene ring (C···O = 3.139(4) Å), instead of the pyridinal CH of 
the PXZ molecule.  The hydrogen bonded dimer between PXZ molecules, however, is the 
same as in the other PXZ complexes, with the remaining hydrogen bonds of similar 




Figure 5.65 The BZZB tetramer in the PXZ:4MBA molecular complex. Hydrogen bonds 
common to all PXZ tetramers are shown as blue dashed lines with the unique CH···O 
interactions shown as red dashed lines.  
 
Weak aromatic CH···O=S hydrogen bonds (C···O = 3.230(4) Å) (Figure 5.66a) link PXZ 
molecules together in layers (Figure 5.66b). The sulfonyl oxygen atoms form further weak 
CH···O hydrogen bonds with the aromatic CH groups of PXZ molecules in the layers above 
(C···O = 3.257(4) Å and 3.484(4) Å) as well as the methyl CH groups of 4MBA molecules in 
the alternate layer (C···O = 3.649(5) Å) (Figure 5.67a). Further weak hydrogen bonds occur 
between the PXZ methyl group and the carbonyl oxygen of 4MBA (C···O = 3.547(4) Å) 
accompanied by π···π interactions between the two molecules (Figure 5.67b). This again 
results in layers where the weak hydrogen bonds involving the non-coplanar methyl 
groups and a sulfonyl oxygen connect the layers.  
 
 
Figure 5.66 (a) Weak hydrogen bonds within layers of the PXZ:4MBA complex; (b) layered 




Figure 5.67 Weak interactions between layers. (a) CH···O hydrogen bonds involving the 
sulfonyl oxygen (b) π···π interaction and CH···O hydrogen bond between PXZ and 4MBA. 
 
 
5.3.1.14  Piroxicam : 2-Aminobenzoic Acid (Zwitterionic) (PXZ:2ABA) 
 
The PXZ molecules are in the zwitterionic form and despite the added competition for 
hydrogen bonding due to the amino group, the structure is isomorphous to PXZ:4FBA 
with the BZZB tetramer (Figure 5.68) remaining the main building block. The PXZ dimer 
has N···O distances of 2.651(3) Å (intramolecular) and 2.843(3) Å (intermolecular), while 
the OH···O hydrogen bond between PXZ and 2ABA has an O···O distance of 2.594(2) Å. 
The 2ABA molecules lie diagonal to the plane of the PXZ dimer as in PXZ:4FBA, with the 
formation of a moderately strong hydrogen bond between the amino NH and the sulfonyl 
oxygen of the PXZ molecule below (N···O = 3.137(3) Å) (Figure 5.69). The other NH of the 
amino group forms an intramolecular hydrogen bond with the carbonyl oxygen (N···O = 









Figure 5.69 Intramolecular and intermolecular hydrogen bonding involving the amino 
group in the PXZ:2ABA complex. 
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5.4  Discussion 
 
5.4.1  Supramolecular Synthons 
 
Twenty molecular complexes of piroxicam with mono-substituted benzoic acids have 
been obtained in this study. Of these molecular complexes, twelve are found to 
incorporate the zwitterionic form of piroxicam and eight the non-ionised form.  This adds 
to the non-ionised molecular complex with 4-hydroxybenzoic acid and the two 
zwitterionic molecular complexes with benzoic acid and 4-hydroxybenzoic acid already 
reported27.  A significant conformational change of the piroxicam molecule accompanies 
the intramolecular hydrogen transfer to form the zwitterion (Figure 5.70) and therefore 
the supramolecular units obtained are quite different between the zwitterionic structures 
and the non-ionised structures. This also provides a clear identification of the tautomeric 
form without having to rely on sometimes inaccurate H atom positions. The tautomeric 
form obtained can also be inferred visually from the yellow colour of the zwitterionic 
complexes and the colourlessness of those that are non-ionised.  Tautomeric polymorphs 
have been obtained for the molecular complexes with the fluoro-substituted benzoic 
acids. There is a strong tendency for a four molecule tetrameric unit to be formed in all 




Figure 5.70 The different conformations adopted by piroxicam molecules in the 
zwitterionic and non-ionised forms.  
 
The hydrogen bonded BZZB tetramer of the zwitterionic complexes is recurrent in all of 
the molecular complexes reported here. The piroxicam dimers are approximately planar 
(with the exception of the methyl and sulfonyl groups) and are held together by two 
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charge-assisted bifurcated DHAA N+-H···O hydrogen bonds between the protonated 
pyridinal nitrogen and the carbonyl oxygen.  An inversion centre is located in the middle 
of the resultant )12(22R  ring. The benzoic acid molecule is then connected to this dimer 
on either side through an O-H···O- charge-assisted hydrogen bond to the deprotonated 
hydroxyl group of the piroxicam molecule.  A second, weaker CH···O hydrogen bond is 
formed between an aromatic CH group of the pyridine ring of the piroxicam and the 
carbonyl oxygen of the carboxylic acid group of the benzoic acid. One exception occurs in 
the complex PXZ:4MBA where the carboxylic acid group is rotated relative to the PXZ 
molecule and the weak hydrogen bond is instead formed between the aromatic CH of the 
benzene ring. In both cases these interactions tend to result in the carboxylic acid group 
and the piroxicam molecules being approximately co-planar with each other. Substituent 
effects cause the carboxylic acid group to deviate from the plane of the benzene ring in 
benzoic acid molecules; this has the effect of the benzene ring lying out of the plane of 
the rings in the PX molecules. This is particularly found in the cases where there is a large 
atom at the 2-position although in the PXZ:4FBA complex a large deviation from the plane 
also occurs despite the fluorine being in the 4-position.  
 Analysis of previously reported zwitterionic PXZ complexes with benzoic acids 
shows that this unit is also present in the PXZ:benzoic acid complex27. The 4-
hydroxybenzoic acid (4HBA) molecular complex27 is an exception, however, and does not 
feature the same tetrameric building block. The piroxicam dimer is identical in terms of 
the types of hydrogen bonds formed, but the 4HBA molecule instead coordinates to it 
through a charge-assisted O-H···O- hydrogen bond from the phenolic hydroxy group 
(Figure 5.71, LHS). The carboxylic acid OH then forms an O-H···O hydrogen bond to the 
sulfonyl oxygen of PXZ, with the carbonyl oxygen accepting a hydrogen bond from the 
pyridinal N+-H of a neighbouring PXZ molecule (Figure 5.71, RHS). As highlighted in the 
original publication27, the expected hydrogen bond interaction, based on the strongest 
donor - strongest acceptor rule, is therefore replaced by weaker hydrogen bonds, 
although the OH···O hydrogen bonds are maintained for both the donor and acceptor. 
This deviation from the expected hydrogen bonding may be partly rationalised by the fact 
that the NH···O interaction formed to the carbonyl O is considerably stronger than the 
CH···O interactions that are typically formed in the BZZB tetramer. The PXZ complexes 
with 2- and 3HBA maintain the BZZB synthon; this is not surprising in the case of 2HBA as 
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the hydroxyl group participates in an intramolecular hydrogen bond and therefore is not 
available to provide a different coordination pathway to the piroxicam dimer.  
 
 
Figure 5.71 The hydrogen bonding in the PXZ:4HBA complex27, showing the different 
tetramer formed by the PXZ molecules and the 4HBA molecules (LHS) and the hydrogen 
bonding involving the 4HBA carboxylic acid group (with one PXZ molecule partially 
omitted for clarity) (RHS).   
 
On consideration of the strongest donor and strongest acceptor, it may be surprising that 
there are no occurrences of the positively charged NH group of PXZ forming a hydrogen 
bond with the negatively charged O atom of another PXZ molecule. This interaction, 
however, is most likely inhibited by crystal packing and steric effects due to the 
conformation adopted by PX when it is in the zwitterionic form preventing sufficiently 
close interaction of these groups. Although the BZZB tetramer is the building block of all 
but one of the structures, the extended packing is very different in the majority of these. 
This is due to the lack of any other strong recurring interactions. The weak CH···O=S 
hydrogen bonds occur frequently with either methyl or aromatic H-donors, although 
these interactions are not robust enough to form a reliable synthon and vary in their 
nature from system to system.  
 The complexes featuring non-ionised PXN molecules are less predictable in terms 
of hydrogen bonding patterns, although BNNB tetramers and three recurring synthons 
are observed (see Figures 5.12 and 5.28). One common synthon found in all non-ionised 
PX complexes reported here is a )8(22R  ring (see Figure 5.12a) comprising an NH···O and 
an O-H···N hydrogen bond between BA and PXN molecules. The non-ionised PXN:4HBA 
complex27 is, once again, the exception to this, with the hydroxyl group interacting with 
the piroxicam pyridinal N and amide NH rather than the carboxylic acid group, breaking 
the )8(22R  ring and instead forming an )6(22R  ring (Figure 5.72). The carboxylic acid 
 183
groups then form homodimers with a second 4HBA molecule. The second and third 
recurring synthons are the PXN dimers held together by O-H···O=S hydrogen bonds 
(Figure 5.12) in complexes with 2FBA, 3FBA and 2MBA ,and O-H···O=C hydrogen bonds 
(Figure 5.28) in complexes with 3CLBA, 3BRBA, 3NBA and 4NBA. The former occur in 
complexes with fluorine in the 2- and 3-position and the methyl in the 2-position. The 
small fluorine groups and the position of the methyl in the 2-position mean they are less 
likely to affect the crystal packing whereas the latter three complexes possess benzoic 
acids with bulky groups in the 3-position or 4-position. 
 
 
Figure 5.72 )6(22R hydrogen bonded ring in the PXN:4HBA complex27 (Only part of the PXN 
molecule is shown for clarity).  
 
The interactions occurring between PXN molecules in the PXN:4FBA complex and the 
previously reported PXN:4HBA complex are unique in this series. The former features 
weaker CH···O hydrogen bonds rather than moderately strong O-H···O hydrogen bonds 
between PXN molecules (Figure 5.19a). As there is an intramolecular O-H···O hydrogen 
bond in both cases, the energetic difference between the O-H···O and the CH···O 
interactions may be relatively small.  In addition to the interactions between PXN 
molecules, the 4FBA molecules form dimers connected by pairs of CH···F weak hydrogen 
bonds (Figure 5.20).  The PXN:4HBA complex also shows only weak CH···O hydrogen 
bonds between PXN molecules (Figure 5.73) but the relative arrangement of these is 
different to that seen in the 4FBA complex.  
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Figure 5.73 The weak CH···O hydrogen bonds in the PXN:4HBA molecular complex27 
 
The OH···O hydrogen bond strengths between PXZ and the benzoic acid in the recurring 
zwitterionic PXZ BZZB synthon vary within a fairly narrow range, between 2.533(3) Å 
(PXZ:2HBA) and 2.5985(13) Å (PXZ:4FBA). The NH···O hydrogen bonds between PXZ 
molecules in the BZZB tetramer vary over a larger range of 2.791(6) Å (PXZ:2CLBA) to 
2.929(3) Å (PXZ:2HBA).  
 Some trends are observed in the recurring synthons of the non-ionised PXN 
complexes. The OH···O hydrogen bonds between PXN molecules are stronger in the 
complexes featuring the OH···O=S PXN dimer (O···O = 2.938(2) Å - 2.961(2) Å) than in the 
complexes featuring the OH···O=C PXN dimer (O···O = 2.9818 (15) - 3.128(2) Å). The CH···O 
hydrogen bond (C···O = 3.207(2) Å) between PXN molecules in PXN:4FBA is weaker than 
the OH···O hydrogen bonds in both the OH···O=S and the OH···O=C dimers as expected. 
Other trends are also present with regards to the hydrogen bonding between the PXN 
and the benzoic acid molecule in the non-ionised PXN complexes. The NH···O interaction 
in the )8(22R  ring (Table 5.9) is strongest in the PXN:4FBA complex featuring the CH···O 
PXN dimer whilst the OH···N interaction in this complex is the weakest. The N-H···O 
interaction is generally stronger in the complexes featuring the OH···O=C dimer than 
those with the OH···O=S dimer with the PXN:4NBA hydrate the only exception. Similarly, 
the OH···N interaction of the )8(22R  ring is also stronger in the complexes featuring the 
OH···O=C dimer than those with the OH···O=S dimer. In the complexes featuring the 
OH···O=S dimer, all interactions in the )8(22R  ring are stronger in the fluorobenzoic acid 
complexes than in the PXN:2MBA complex. In the four complexes featuring the OH···O=C 
dimer, the two nitro complexes feature weaker interactions between PXN molecules than 
the two halo-substituted complexes (Table 5.6).  
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Table 5.9 Hydrogen bond distances and angles in the )8(22R  hydrogen bonded ring 
between PXN and mono-substituted benzoic acids (c = NH···O; d = OH···N).  
Complex PXN Dimer H-Bond D···A (Å) ∠ D-H···A (°) 























































There are several isomorphous complexes although no more than three complexes share 
the same crystal packing. The 3-substituted chloro-, bromo- and nitrobenzoic acid 
complexes with PX in the non-ionised tautomeric form all share the same crystal packing 
which may be expected as they all have groups of a similar physical size in the 3-position. 
These groups are therefore not involved in structure directing interactions. The 
complexes PXZ:2FBA and PXZ:3FBA are isomorphous despite having a different 
substitution position for the fluorine atom.  However, the fluorine atom is able to 
participate in CH···F weak hydrogen bonds to the piroxicam molecule without changing 
the crystal packing. When the fluorine is in the 4-position there is less steric hindrance 
and several weak hydrogen bonds are formed to surrounding CH groups and the pyridinal 
NH (Figure 5.10). The same argument can be made for isomorphous PXN:2FBA and 
PXN:3FBA. The fluorine in PXN:4FBA is again more freely available than in the PXN:2FBA 
and PXN:3FBA complexes, forming CH···F dimers between 4FBA molecules. The 
complexes PXZ:4FBA and PXZ:2ABA are also isomorphous, however, which is unusual 
given that 4FBA has a hydrogen bond acceptor (fluorine) in the 4 position and 2ABA has a 
donor (NH2) in the 2 position.  
 
 186
5.4.2  Disorder 
 
Two of the molecular complexes reported exhibit disorder of the co-component.  In the 
PXZ:2FBA complex, the 2FBA molecules are disordered over two positions.  The volume of 
space required to accommodate such a conformational change is small and the fluorine 
atom forms either weak F···O interactions with the sulfonyl oxygen atom (40% occupancy) 
or weak CH···F hydrogen bonds to the methyl group of the PXZ molecule (60% 
occupancy).  This does not, therefore, disrupt the main interactions comprising the BZZB 
supramolecular unit. 
 The PXZ:3MBA.ACN complex is the only example where, at least some of the time, 
the reliable and predictable BZZB unit is broken, at least on a local scale.  The 2:1:1 
stoichiometry of the complex allows three possible short length scale units to be formed, 
BZZB, (ACN):Z:Z:B and (ACN):Z:Z:(ACN). Consideration of the close positions of the two 
disordered, symmetry related positions for the 3MBA or ACN molecules implies that it is 
not possible to have neighbouring units of BZZB adjacent to one another essentially 
forming BZZB:BZZB units. However, it is possible to form BZZB:(ACN):Z:Z:B or 
BZZB:(ACN):Z:Z:(ACN) units. The formation of this solvated complex is crystallisation 
condition dependent and it is only produced at room temperature, with the 1: 1 complex 
of PXZ:3MBA formed at 40°C or above.    
 
5.4.3  Tautomeric polymorphism 
 
Three of the systems reported exhibit the rare phenomenon of tautomeric 
polymorphism, those of the 2FBA, 3FBA and 4FBA complexes. Thermal analysis of all 
polymorphic samples was carried out to determine the most thermodynamically stable 









Table 5.10 Onset point of melting (in °C) from DSC of tautomeric polymorphs. PXN 
represents the polymorph featuring non-ionised piroxicam and PXZ represents the 
polymorph featuring zwitterionic piroxicam. DSC traces for all six complexes can be found 
in Appendix C5.  
 PX:2FBA PX:3FBA PX:4FBA 
PXN 151.4 158.9 166.6 
PXZ Converts to non-ionised 
form at ~140 
164.5 167.5 
 
The DSC patterns of the PX:2FBA polymorphs show the zwitterionic polymorph to be the 
least stable of an enantiotropic pair, with the small broad endotherm at approximately 
139.9°C indicating a solid-solid transformation before melting at approximately 150-
151°C. This is supported by hot-stage microscopy which showed that a distinct change in 
colour (yellow to colourless) occurs upon heating single crystals of PXZ:2FBA to 140°C and 
holding the sample isothermally for 20 minutes. PXRD analysis of the sample after the 
colour change confirmed conversion to the PXN polymorph was occurring (Appendix B5). 
Analysis using PolySNAP195 indicated an increase in the pattern matching coefficient 
between the sample after heating and the calculated PXRD pattern for PXN:2FBA, as well 
as a decreased pattern matching rank between the post-heating regime sample and the 
calculated PXRD pattern for PXZ:2FBA (Table 5.11).  
 
Table 5.11 PolySNAP pattern matching coefficients between calculated PXRD patterns of 
both tautomeric polymorphs of PX:2FBA and of pure PXZ:2FBA (calculated directly from 
the single crystal structure) before and after undergoing the heating regime. The values 
indicate a solid to solid transformation has occurred after heating as the pattern matching 
rank increases with respect to PXN:2FBA and decreases with respect to PXZ:2FBA.  
PXRD Pattern Calculated PXZ:2FBA  Calculated PXN:2FBA 
PXZ:2FBA prior to heating regime 0.3302 0.1440 
PXZ:2FBA post heating regime 0.0782  0.1807 
Note: The PXRD patterns were of poor quality due to the poor crystallinity of the samples, 




Analysis of the PX:4FBA polymorphs show very similar melting points, with the non-
ionised form being the least stable. As highlighted in the previous section, the PXN:4FBA 
complex has only weak CH···O hydrogen bonds between PXN molecules, which is the 
likely reason it is less stable than its zwitterionic counterpart where charge-assisted 
hydrogen-bonds link the two PXZ molecules.  
DSC of the PXZ:3FBA complex shows a considerably higher melting point than the 
PXZ:2FBA complex despite the two being isomorphous and the similar melting points of 2- 
and 3FBA. This is possibly due to the disorder present in the PXZ:2FBA complex as the 
CH···F hydrogen bonds are broken when the fluorine is in the minor position which has 
significant occupancy (40%). DSC of the sample containing the PXN:3FBA complex 
indicates a major endotherm occurring at 158.9°C and a separate minor endotherm at 
170.6°C. The major endotherm is assumed to be the melting point of the PXN:3FBA 
complex indicating that this complex is also more stable than the isomorphous PXN:2FBA 
complex but less stable than the PXZ:3FBA polymorph. As yet the minor endothermic 
peak has not been assigned as it does not fit with the melting point of any known PX or 
3FBA polymorph or PX monohydrate. This small endotherm may indicate a third 
polymorph is present in very small quantities.  
 In both the PX:3FBA and PX:4FBA systems, the zwitterionic polymorph is the most 
stable as may be expected due to the presence of charge-assisted hydrogen bonds. In the 
PX:2FBA system, however, the opposite is true despite these complexes being 
isomorphous with the PX:3FBA complexes. This, again, may be due to the disorder in the 
PXZ:2FBA complex disrupting the hydrogen bonding of the fluorine causing a loss of 
stability that is not seen in the PXZ:3FBA complex as it is not disordered.   
 
 
5.4.4  Factors Influencing Tautomeric form of Piroxicam 
 
Neither the substitution position or substituent type appears to be the main influence on 
the piroxicam tautomer found in the resultant molecular complex. However, an empirical 
observation can be made when considering the pKa values of the co-formers (Table 5.12). 
The groups of co-formers with the lowest and highest pKa values result in complexes 
where the zwitterionic tautomer is found. The non-ionised tautomer of piroxicam is only 
found in the middle range of pKa values (~3.4-4, blue in Table 5.12). One rationale for the 
presence of different tautomers would be that the acidity of the co-former is influencing 
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the solution environment (eq. 5.1) thus promoting one tautomer over another but this is 
not consistent with an observation reported here with two boundary conditions. Solvent 
and temperature effects were also considered, however, in a number of the co-
crystallisations the same solvent and/or temperature systems were used but produced 
different tautomers in the resultant complexes.  
 
Equation 5.1 The Henderson-Hasselbalch Equation: pH = pKa + log ([A¯] / [HA])  
 
The systems exhibiting tautomeric polymorphism are of course exceptions to the 
empirical observation of the effect of pKa on the PX tautomer. It is as yet unclear whether 
these polymorphic complexes are a result of exceptional cases where the energy 
difference between polymorphs is small or if all the complexes are capable of exhibiting 
this phenomenon given the correct crystallisation conditions. It is interesting to note the 
relative pKa values of the benzoic acids which form tautomeric polymorphs with PX - the 
fluorobenzoic acids all lie close to the boundary regions and 4-hydroxybenzoic acid is at 



















Table 5.12 pKa values of benzoic acids and the tautomer observed in their molecular 
complexes with piroxicam. The region where the non-ionised tautomer is present is 
highlighted in blue. In cases where tautomeric polymorphism occurs, the more stable 
polymorph (if known) is signified by *.    
 
Substituent pKa PXZ PXN 
2-Amino 2.11 X  
2-Nitro 2.19 X  
2-Bromo 2.84 X  
2-Chloro 2.94 X  
2-Hydroxy 2.98 X  
2-Fluoro 3.27 X X* 
4-Nitro 3.44  X 
3-Nitro 3.47  X 
3-Bromo 3.81  X 
3-Chloro 3.82  X 
3-Fluoro 3.86 X* X 
2-Methyl 3.91  X 
3-Hydroxy 4.08 X  
4-Fluoro 4.15 X* X 
No Substituent 4.19 X  
3-Methyl 4.27 X  
4-Methyl 4.36 X  
4-Hydroxy 4.58 X X 
 
 
5.4.5  Summary and Conclusions  
 
Piroxicam readily crystallises with a variety of mono-substituted benzoic acids in both the 
zwitterionic and non-ionised forms. A related series of piroxicam complexes exhibiting 
tautomeric polymorphism has also been obtained. An empirical relationship between the 
pKa of the benzoic acid co-former and the preferred PX tautomer in the resultant 
complex has been identified with a pKa region with two boundaries where the non-
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ionised tautomer is favoured. Although a relationship between the pKa of the co-former 
and the PX tautomer might be expected, it is not clear why benzoic acids with relatively 
high and low pKa values would favour one tautomer whereas the benzoic acids with pKa 
values in a middle region would favour the other. More data is required on this system 
and other similar tautomeric systems to ascertain the reliability and rationale for this 
relationship.  
 DSC analysis of the tautomeric polymorphs shows that the PX tautomer adopted 
in each complex is not always the critical factor in determining the relative stability of the 
polymorphic complexes. This is illustrated by the PX:2FBA system in which the non-
ionised polymorph is the most stable despite the lack of charge-assisted hydrogen bonds. 
It is not yet known whether the tautomeric form results in different physical properties. 
 Analysis of the crystal structures has revealed a predominant hydrogen bonding 
pattern in the zwitterionic PXZ complexes with mono-substituted benzoic acids. In all but 
one of the crystal structures (both reported here and in the literature), the BZZB moiety 
corresponding to Figure 5.1 is found with the only exception being the case of 4-
hydroxybenzoic acid. The PX homo-dimerisation that occurs at the centre of the BZZB 
tetramer is however, found in every known zwitterionic piroxicam complex. The non-
ionised PXN complexes have less predictable interactions between PXN molecules 
although two recurring synthons were found. The )8(22R  hydrogen bonded ring synthon 
between PX and the carboxylic acid group of the benzoic acids appears to be fairly robust 
with only one complex not exhibiting this synthon. The hydrogen bond strengths in this 
motif were found to depend on the type of PXN dimer formed at the centre of the 
tetramer, with the complexes exhibiting the OH···O=C dimer generally possessing 
stronger hydrogen bonds between the BA and the PXN molecules.  
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6. Intermolecular Hydrogen Transfer in Multi-Component Complexes of 
Piroxicam 
 
6.1  Introduction to Intermolecular Hydrogen Transfer in Piroxicam Complexes 
 
In the solid state, piroxicam has previously been known to exist in two ionisation states 
when not in its neutral form. As discussed in Chapters 4 and 5, intramolecular hydrogen-
transfer has been observed in polymorphs and molecular complexes of piroxicam 
resulting in the formation of the zwitterion220. Similarly, intermolecular hydrogen transfer 
has been observed previously in a piroxicam complex, forming a salt with a piroxicam 
anion (PX¯), although only one example of this exists212. The complex is a 1:1 salt with 
ethanolamine in which the piroxicam is deprotonated, with the hydrogen transferred to 
the amine group of ethanolamine (pKa = 9.5). The hydroxyl group of piroxicam has a pKa 
of 5.46 and the pyridine nitrogen has a pKa of 1.86 (conjugate acid). No studies have, 
however, been carried out to determine which functional group (and therefore which pKa 
value) should be considered when using the pKa rule (which states the approximation 
that ∆pKa = pKa[protonated base] – pKa[acid] ≥ 3 for salt formation) in predicting 
intermolecular hydrogen transfer in a potentially zwitterionic material such as piroxicam. 
In the solid state, pure piroxicam exists in the non-ionised form (with the exception of the 
metastable form IV - see Chapter 4). It has, however, been shown that the zwitterionic 
form is present in significant quantities220,223 when piroxicam is dissolved in polar solvents 
such as acetonitrile or methanol. This makes it unclear if the hydrogen that is transferred 
should be considered as coming from the hydroxyl group or from the pyridine nitrogen. In 
the case of ethanolamine, the intermolecular hydrogen transfer is successfully predicted 
by application of the pKa rule for hydrogen transfer, regardless of which pKa value is 
considered. The pKa rule has been shown not always to be transferrable between 
systems118, and in a zwitterionic system such as piroxicam the matter is further 
complicated. The piroxicam anion in the ethanolamine complex is formed despite the 
added competition for the proton, i.e. formation of the piroxicam zwitterion. As discussed 
extensively in Chapter 5, piroxicam is prone to adopting the zwitterionic tautomer when 
co-crystallised with weak acids and this also has to be considered when trying to predict 
hydrogen transfer.  
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In the work presented in this Chapter, a series of nitrogen heterocycles of varying 
basicity (Scheme 6-1) were co-crystallised with piroxicam to investigate the occurrence of 
hydrogen transfer from the piroxicam molecule to the basic nitrogen of the heterocycle 
and determine what effects the competition of intramolecular hydrogen-transfer may 
have. Application of the pKa rule will be investigated with regards to these systems and 
whether it is more suitable to consider the pKa value of the hydroxyl group or the pKa of 
the pyridine nitrogen when attempting to predict hydrogen transfer using the ∆pKa rule. 
The results will also be used to investigate further the occurrence of the zwitterionic 
tautomer of piroxicam and the conditions which give rise to its formation in the solid 
state. In addition to using basic N-heterocycles, piroxicam is also co-crystallised with the 
strong organic acids, chloranilic and bromanilic acid (also Scheme 6-1), to investigate the 
possibility of protonating the pyridine ring to form molecular salts where piroxicam is in a 
cationic form (PX+). Co-crystallisation with the weaker acids used in Chapter 5 resulted in 
zwitterionic piroxicam complexes, so acids of a much lower pKa are required to attempt 
to protonate the piroxicam. Again, application of the ∆pKa rule will be investigated with 
regards to these complexes, as piroxicam in this case will behave as a base and this may 
affect if and how the pKa rule can be applied. All complexes will also be analysed from a 
crystal engineering perspective to ascertain if any robust synthons occur which may be 
utilised for future design of molecular complexes of piroxicam.   
 
Scheme 6-1 The NHCs and organic acids used for co-crystallisation with piroxicam.  
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6.2  Crystallisation Conditions 
 
Crystallisations were carried out according to the procedure outlined in Chapter 3. Table 
6.1 below outlines the solvent and temperature systems under which each molecular 
complex described in this section was observed to crystallise.  The piroxicam : pyrazine 
complex (marked *) did not crystallise from all experiments using the conditions 
described. In addition, it crystallised only in very small amounts, either concomitantly 
with piroxicam form IV, or concomitantly with form I, form II and/or the monohydrate.  
 
Table 6.1 Crystallisation conditions for molecular complexes of piroxicam with nitrogen 
heterocycles.  
Piroxicam Molecular Complex Solvent Temp (°C) 
Imidazole hemihydrate Methanol RT 
Imidazole acetonitrile Solvate (1:1:1) Acetonitrile RT 
Imidazole acetonitrile Solvate (4:4:1) Acetonitrile 50 
2-methylimidazole Acetonitrile RT/40/50 
Benzimidazole Acetonitrile 50 
1, 2, 4 - Triazole Acetonitrile 40/50 
Benzotriazole Acetonitrile RT/40 
Pyrazine* Acetonitrile 50 
Chloranilic acid form I Acetonitrile RT 
Chloranilic acid form II Acetonitrile 40 
Chloranilic acid acetonitrile solvate (2: 1: 2) Acetonitrile 50 
Bromanilic acid Acetonitrile RT/40/50 
RT = Room Temperature   
 
6.3  Crystal Structures of Piroxicam Molecular Complexes with Nitrogen-Heterocycles  
 
Nine molecular complexes of piroxicam with nitrogen-heterocycles were produced in this 
study. Full refinement details for all complexes can be found in (Appendix A6 and Table A-
6a). 
 
6.3.1  Piroxicam : Imidazole Hemihydrate (2(PX¯):2(IM+).H2O) 
 
The asymmetric unit of the piroxicam : imidazole hemihydrate features two symmetry 
independent piroxicam (PX) molecules, two symmetry independent imidazole (IM) 
molecules and a single water molecule. Deprotonation of the hydroxyl group occurs in 
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both PX molecules with the hydrogen transferred to the imidazole nitrogen atoms 
resulting in a salt of the PX enolate anion (PX¯) and the IM imidazolium cation (IM+). PX¯ 
molecules adopt a different conformation from that found in both the neutral and 
zwitterionic forms of piroxicam (Chapter 5), with a moderately strong intramolecular 
NH···O hydrogen bond formed (Figure 6.1, Table 6.2). One symmetry independent IM+ 
molecule (B in Figure 6.2) has C-N bond lengths (between the two nitrogen atoms and the 
carbon in the 2-position) of 1.327(5) Å and 1.337(5) Å), whereas the other (B’ in Figure 
6.2) has C-N distances of 1.331(5)Å and 1.334(5)Å.  
 
Figure 6.1 Conformation of the deprotonated PX molecules (PX¯) in the piroxicam : 
imidazole hemihydrate complex (bottom). The conformations of non-ionised PX (top left) 
and zwitterionic PX (top right) are also shown.  
 
Non-equivalent PX¯ molecules are linked by IM+ molecules forming infinite chains of 
alternating PX¯ and IM+ molecules (Figure 6.2). The chains are arranged so that symmetry 
independent molecules also alternate, i.e. in an ABA’B’ configuration (where A and A‘ 
indicate symmetry independent PX¯ molecules). The symmetry independent IM+ 
molecules link PX¯ molecules via different interactions involving the NH groups. One IM+ 
molecule (B in Figure 6.2) links two PX¯ molecules by forming a moderately strong, 
charge-assisted Nδ+-H···O¯ hydrogen bond to the PX¯ enolate oxygen atom of one (b in 
Figure 6.2) and an Nδ+-H···N hydrogen bond to the pyridinal nitrogen atom of the other (a 
in Figure 6.2). Further weaker hydrogen bonds occur between an IM+ CH group with the 
enolate O¯ (e in Figure 6.2) as well as another IM+ CH group with the pyridinal N atoms 
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which do not hydrogen bond to the NH groups (d in Figure 6.2). The second IM+ molecule 
(B’) links two PX molecules by forming two moderately strong Nδ+-H···O hydrogen bonds 
to the PX¯ carbonyl oxygen atoms (f and f’ in Figure 6.2). Further weak hydrogen bonds 
are formed between the CH groups of IM+ and the sulfonyl oxygen atoms of the PX¯ 
molecules (g and g’ in Figure 6.2). This IM+ molecule also forms hydrogen bonds to the 
water molecule via a weak CH···O hydrogen bond (C···O = 3.214(5) Å) (Figure 6.3). All 
hydrogen bond lengths and angles in the chains can be found in Table 6.2. 
 
Figure 6.2 The hydrogen bonding in the chains of PX¯ and IM+ in the piroxicam : imidazole 
hemihydrate complex (letters marked with ‘ indicate a symmetry independent molecule or 




 molecule forms both NH···N and NH···O hydrogen 
bonds (blue dashed lines from B) and the other forms two NH···O hydrogen bonds (blue 
dashed lines from B’). Weaker hydrogen bonds involving CH donors are shown as red 
dashed lines.  
 
Table 6.2 Hydrogen bond lengths and angles in the piroxicam : imidazole hemihydrate 
complex (refer to Figure 6.2 for key). Values which have no errors are due to hydrogen 
atoms being placed on calculated positions.  






















































Figure 6.3 CH···O hydrogen bond between IM+ and the water molecule in the piroxicam : 
imidazole hemihydrate complex.  
 
The water molecule also links equivalent PX¯ molecules in different chains above and 
below it via moderately strong OH···O hydrogen bonds with the amide carbonyl oxygen 
atoms (O···O = 3.068(4) Å and 2.841(4) Å) (Figure 6.4). The water molecules therefore link 
three chains together (Figure 6.5).  
 
Figure 6.4 Hydrogen bonds involving the water molecule linking three chains together in 
the piroxicam : imidazole hemihydrate complex. OH···O hydrogen bonds between the 




Figure 6.5 The relative arrangement of three chains linked together by the water 
molecules in the piroxicam : imidazole hemihydrate complex. The water molecule in the 
red chain links to the blue chains above and below (via the hydrogen bonding in Figure 
6.4).  
 
Various hydrogen bonds between chains are present involving the sulfonyl oxygen atoms 
of the PX¯ molecules with each symmetry independent PX¯ molecule forming different 
interactions. The sulfonyl oxygen of one PX¯ molecule forms a moderately strong 
bifurcated hydrogen bond with two pyridine CH groups of the PX¯ molecule below (C···O = 
3.073(5) Å and 3.121(5) Å) as well as a CH···O hydrogen bond with the benzene ring CH of 
another PX¯ molecule (C···O = 3.507(5) Å) (Figure 6.6a). The other sulfonyl oxygen of the 
same molecule forms further CH···O hydrogen bonds with the methyl group of the PX¯ 
molecule above (C···O =2.873(5) Å) as well as an IM+ CH group (C···O = 3.333(5) Å) (Figure 
6.6b). One sulfonyl oxygen atom of the symmetry independent PX¯ molecule forms 
similar interactions with an IM+ CH group and a PX¯ methyl group (C···O = 3.360(5) Å and 
3.042(5) Å respectively) (Figure 6.6c), with the other sulfonyl oxygen forming a CH···O 






Figure 6.6 Weak CH···O interactions involving the PX¯ sulfonyl oxygen atoms in the 
piroxicam: imidazole hemihydrate complex.   
 
6.3.2  Piroxicam : Imidazole Acetonitrile Solvate (1:1:1) (PX¯:IM+.ACN) 
 
The PX molecules in the 1:1:1 piroxicam: imidazole acetonitrile solvate are again 
deprotonated to form the enolate oxygen with the hydrogen transferred to the IM 
molecule forming the imidazolium cation. The asymmetric unit for this complex features 
one of all three components with the PX¯ molecule again adopting the conformation seen 
in the hemihydrate. The IM+ molecule has delocalisation of the charge, with C-N 
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distances of 1.332(3) Å and 1.328(3) Å between the carbon in the 2-position and the two 
nitrogen atoms.   
Once again infinite chains with an ABAB configuration are formed featuring two of 
the interactions that are also found in the PX¯:IM+ hemihydrate above. Each IM+ molecule 
forms a moderately strong, charge-assisted NH···O¯ hydrogen bond to the enolate oxygen 
of one PX¯ molecule as well as a slightly weaker NH···O hydrogen bond to the amide 
carbonyl oxygen atom (Figure 6.7). No NH···N hydrogen bonds are present in this case 
involving the IM+ NH and the pyridinal N of PX¯, with weak CH···N interactions occurring 
only (also Figure 6.7). Alternate PX¯ molecules in the chains lie head-to-tail relative to 
each other, unlike the hemihydrate, in which alternate PX molecules lie head-to-head. 
Hydrogen bond lengths and angles in the chains can be found in Table 6.3.  
 The ACN molecule is linked into the chains via weak hydrogen bonds to the 
sulfonyl oxygen of PX¯ via the methyl group (C···O = 3.407(4) Å) and weak CH···N 
hydrogen bonds from the IM+ CH group to the ACN nitrogen (C···N = 3.355(4) Å) (Figure 
6.8a). ACN molecules also dimerise via weak CH···N hydrogen bonds (C···N = 3.439(4) Å) 
(also shown in Figure 6.8a). The methyl group of ACN forms a further weak CH···O 
hydrogen bond to the sulfonyl oxygen of the PX¯ molecule below (C···O = 3.570(4) Å) 
(Figure 6.8b).  
 
Table 6.3 Hydrogen bond lengths and angles in the 1:1:1 piroxicam : imidazole acetonitrile 
solvate complex (refer to Figure 6.7 for key). Values which have no errors are due to 
hydrogen atoms being placed on calculated positions.  
























Figure 6.7 Hydrogen bonding between PX¯ and IM+  in the 1:1:1 piroxicam : imidazole 
acetonitrile complex. NH···O hydrogen bonds are shown as blue dashed lines and the 
CH···N hydrogen bond is shown as a red dashed line.  
 
 
Figure 6.8 Weak hydrogen bonds involving the ACN molecule in the 1:1:1 piroxicam : 
imidazole acetonitrile complex. (a) Weak CH···O and CH···N hydrogen bonds linking ACN 
molecules into the chains and weak CH···N hydrogen bonds resulting in ACN dimers. (b) 
The weak CH···O hydrogen bond between the ACN molecule and the PX molecule in the 
chain below.   
 
As well as forming the weak hydrogen bonds with the ACN molecules, one sulfonyl 
oxygen atom forms further weak CH···O hydrogen bonds with the CH groups of benzene 
rings and pyridine rings of neighbouring PX¯ molecules (C···O = 3.194(3) Å and 3.598(3) Å) 
(Figure 6.9a). A weak hydrogen bond is formed to the other sulfonyl oxygen atom by the 
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CH group of the IM+ molecule above (C···O = 3.297(3) Å) (Figure 6.9b). A moderately 
strong, bifurcated CH···N hydrogen bond is also formed between the methyl group of PX¯ 
and the pyridinal N of the PX¯ molecule below, with C···N = 3.187(3) Å (Figure 6.10).  
 
 
Figure 6.9 CH···O hydrogen bonds in the 1:1:1 piroxicam: imidazole acetonitrile complex. 
(a) Weak CH···O hydrogen bonds involving the sulfonyl oxygen between PX¯ molecules 
adjacent to each other and (b) Weak CH···O hydrogen bonds between the IM
+
 CH and PX¯ 
sulfonyl oxygen below. 
 
 
Figure 6.10 Weak CH···N interactions between the PX¯ methyl group and the pyridinal 
nitrogen in the 1:1:1 piroxicam: imidazole acetonitrile complex.  
 
6.3.3  Piroxicam : Imidazole Acetonitrile Solvate (4:4:1) (4(PX¯):4(IM+).ACN) 
 
The asymmetric unit of the 4:4:1 piroxicam : imidazole acetonitrile solvate has two 
symmetry independent PX¯ molecules and IM+ molecules and a single acetonitrile 
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molecule with 50% occupancy. It was crystallised from the same PX:IM component ratio 
(1:1) and solvent (ACN) as the 1:1:1 solvate but was found to crystallise only at 50°C (the 
1:1:1 solvate crystallised at room temperature). As in the previous two complexes in this 
chapter, the PX¯ hydroxyl is deprotonated with the hydrogen transferring to the IM 
nitrogen; the PX- molecule therefore adopts the same conformation as is found in the 
previous two complexes. The C-N bond lengths between the 2-carbon and the nitrogen 
atoms of IM+ are almost identical, indicating delocalisation of the charge across the two 
nitrogen atoms (C-N = 1.328(4) Å, 1.322(4) Å and 1.330(4) Å, 1.331(4) Å in the two 
independent molecules).  
 One PX¯ molecule is disordered, with two positions of the pyridine ring (Figure 
6.11). The two positions were refined to a 60/40 occupancy ratio. Fixing the two positions 
at 50/50 occupancy resulted in implausible thermal parameters. The disorder of the ring 
is related to the disorder of the ACN molecule which was refined at 50% occupancy across 
an inversion centre. Refinement of the ACN molecule at 100% occupancy resulted in 
abnormally large thermal parameters with the molecule lying unusually close to the 
minor position of the PX¯ pyridine ring, with the central carbon of the ACN molecule lying 
approximately 2.046 Å from the nearest carbon. Refining the ACN molecule at 50% 
occupancy resulted in plausible thermal parameters and can be rationalised by 
consideration of the proximity to the two positions of the pyridine rings. The disordered 
pyridine rings of the PX¯ molecules are arranged above and below the ACN molecules 
(Figure 6.12). In the model proposed, the ACN molecule favours one position across the 
inversion centre depending on which position the pyridine ring occupies. When the ring 
above occupies the major position, the ring below favours the minor position (Figure 
6.12a). With the rings are in this configuration, one ACN molecule lies close to the bottom 
ring, with an implausible C···C distance between the two closest carbon atoms (see Table 
6.4). The other position is therefore favoured in this case, where the C···C values between 
the carbon atoms are more plausible (also Table 6.4). When the pyridine rings occupy the 
reverse positions (minor above, major below), the other position of the ACN molecule is 
occupied (Figure 6.12b). There is a discrepancy, however, between the occupancy values 
of the disorder model, with the positions of the ring refined to a 60/40 occupancy ratio 
and the ACN molecules 50/50 disordered across the inversion centre. This suggests 
another possibility, where in some cases both ACN molecules related by the inversion 
centre are occupied and both of the neighbouring PX pyridine rings point away (i.e. both 
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rings occupy the major position). In other cases the rings would point inwards (i.e. occupy  
the minor position) and neither of the two ACN positions would be occupied.  
 
Figure 6.11 The two positions of the disordered pyridine ring in the PX¯ molecules of the 
4:4:1 piroxicam : imidazole acetonitrile complex. The major position (60% occupancy) is 




Figure 6.12 Proposed disorder model of the 4:4:1 piroxicam : imidazole acetonitrile solvate 
complex. (a) The top pyridine ring is in the major position and the bottom ring in the minor 
position. The red position of the ACN molecule is occupied in this case. (b) The top pyridine 
ring is in the minor position and the bottom ring in the major position. The blue position of 
the ACN molecule is occupied in this case. Parts of the PX molecules are omitted. 
 
Table 6.4 The distances between the closest PX¯ pyridine and ACN carbon atoms in Figure 
6.12a. The values show that the red ACN position is likely to be favoured in this case due 
to the implausible C···C distance with the blue ACN position (indicated with *).  
ACN Position C14A···C37 (Å) C14B···C37 (Å) 
Red ACN (Figure 6.12a) 3.387(8) 3.097(10) 
Blue ACN (Figure 6.12a) 3.794(8) 2.425(10)* 
 
The structure consists of infinite chains similar to those observed in the 1:1:1 PX¯:IM+.ACN 
complex, with the same NH···O hydrogen bonding present between PX¯ and IM+ 
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molecules (Figure 6.13 and Table 6.5). The same weak CH···N hydrogen bond is also 
present between the IM+ CH group and the PX¯ pyridine N and is much stronger in this 
complex than in the 1:1:1 complex, although in general the interactions in this complex 
are slightly weaker. The chains are symmetry independent (i.e. an ABAB and an A’B’A’B’ 
chain), with the IM+ of only one chain interacting with the ACN molecule through a CH···N 
hydrogen bond (Also Figure 6.13). A difference is found when comparing the relative 
position of the ACN molecule, with the molecule lying along a different direction relative 
to the chain and no longer forming a CH···O hydrogen bond with the PX¯ sulfonyl O as in 
the 1:1:1 complex. Hydrogen bond lengths and angles in the chains can be found in Table 
6.5.  
 PX¯ molecules are linked to neighbouring symmetry independent PX¯ molecules in 
different chains by weak CH···O hydrogen bonds between the sulfonyl oxygen atoms and 
the CH groups of the pyridine (C···O = 3.404(6) Å) and benzene (C···O = 3.094(4) Å) rings 
(Figure 6.14a). The sulfonyl oxygen atoms also form further weak hydrogen bonds with 
the molecules below (Figure 6.14b). The sulfonyl oxygen atoms of both PX¯ molecules 
form hydrogen bonds with the CH groups of IM+ molecules below (C···O = 3.197(3) Å and 
3.178(4) Å) with one PX¯ molecule also forming a hydrogen bond with the pyridine CH 
group of the PX¯ molecule below (C···O = 3.291(4) Å).  
 
Table 6.5 Hydrogen bond lengths and angles in the 4:4:1 piroxicam : imidazole acetonitrile 
solvate complex (refer to Figure 6.13 for key). Equivalent values for the 1:1:1 solvate are 
also shown for comparison. Values which have no errors are due to hydrogen atoms being 
placed on calculated positions.  










































































Figure 6.13 Hydrogen bonding in the symmetry independent chains of PX¯ and IM+ 




Figure 6.14 Weak CH···O interactions involving the sulfonyl oxygen atoms with (a) 
neighbouring PX¯ molecules and (b) PX¯ and IM+ molecules below. 
 
 
6.3.4  Piroxicam : 2-methylimidazole (PX¯:2MIM+) 
 
The piroxicam : 2-methylimidazole molecular salt complex crystallises in a 1:1 ratio with 
the hydroxyl hydrogen of PX again having transferred to the 2MIM nitrogen forming a 2-
methylimidazolium cation (2MIM+). The piroxicam anion adopts the conformation found 
in the previous complexes in this chapter. The 2MIM+ molecules show delocalisation of 
the charge, evidenced by the bond lengths between the two nitrogen atoms and the 2-
carbon (C-N = 1.317(3) Å and 1.326(3) Å).  
ABAB chains of PX¯ and 2MIM+ molecules are again formed and the structure 
directing NH···O¯ and NH···O hydrogen bonds within the chains are the same as those 
seen in the PX¯:IM+.ACN complex (Figure 6.15). The NH hydrogen bond to the carbonyl O 
is again the weaker of the two interactions (Table 6.6). The NH···O interactions are 
weaker than those in the 1:1:1 PX¯:IM+.ACN although the NH interaction with the enolate 
oxygen is stronger than that seen in the 4:4:1 ACN solvate with the amide carbonyl 
interaction weaker. A key difference lies in the relative arrangement of alternate PX¯ 
molecules, which are arranged in a head-to-head arrangement as opposed to head-to-tail 
as in the PX¯:IM+.ACN complex. This difference means the weak CH···N hydrogen bond 
between the IM+ and the PX¯ pyridinal N is no longer present, although the absence of 
the solvent ACN molecule means a weak CH···O interaction to the sulfonyl oxygen atom is 
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formed as the PX¯ molecule lies closer to the 2MIM+ molecule (also Figure 6.15). 
Hydrogen bond lengths and angles in the chains can be found in Table 6.6.  
Adjacent chains are linked by moderately strong CH···O hydrogen bonds (C···O = 
3.178(3) Å) between the CH of the pyridine ring and the sulfonyl oxygen which is 
hydrogen bonded to the 2MIM+ molecule (Figure 6.16). This holds the chains together in 
layers which are then stacked upon each other (Figure 6.17). Weak CH···O hydrogen 
bonds between the other sulfonyl oxygen atom and the CH groups of the pyridine and 
benzene rings of the PX molecules above help hold the layers together (C···O = 3.266(3) Å 
and 3.406(3) Å) (Figure 6.18).   
 
 















Table 6.6 Hydrogen bond lengths and angles in the piroxicam : 2-methylimidazole salt 
complex (refer to Figure 6.13 for key). Equivalent interactions in the PX¯:IM+ 1:1:1 and 
4:4:1 acetonitrile solvate complexes are also shown for comparison.  





































































Figure 6.16 The weak CH---O hydrogen bond (red dashed line) between the PX¯ pyridine 
ring and the sulfonyl oxygen holding adjacent chains together in the piroxicam : 2-
methylimidazole molecular salt complex.  
 
 210
Figure 6.17 Layered arrangement of chains in the piroxicam : 2-methylimidazole 
molecular salt complex with alternate chains in different colours.  
 
 
Figure 6.18 CH···O interactions between the sulfonyl oxygen and the CH groups of the 
benzene ring and pyridine ring of the PX¯ molecule above in the piroxicam : 2-
methylimidazole molecular salt complex. 
 
Further weak hydrogen bonds are present between layers involving the methyl groups of 
both PX¯ and 2MIM+. The methyl CH of PX¯ forms very weak hydrogen bonds to the 
amide carbonyl oxygen of the PX¯ molecule above/below (C···O = 3.653(3) Å) (Figure 
6.19). The 2MIM+ methyl CH forms a stronger hydrogen bond to the enolate oxygen of 
the PX¯ molecule above/below (C···O = 3.250(3) Å) (Figure 6.20).   
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Figure 6.19 Weak CH···O hydrogen bonds between the PX¯ methyl group CH and the 
carbonyl oxygen atoms in the piroxicam : 2-methylimidazole molecular salt complex. 
 
 
Figure 6.20 Weak hydrogen bonds between the 2MIM+ methyl CH and the enolate oxygen 
of PX¯ in the piroxicam : 2-methylimidazole molecular salt complex. 
 
6.3.5  Piroxicam : Benzimidazole (PX¯:BZ+) 
 
The piroxicam : benzimidazole molecular salt complex has four molecules (two symmetry 
independent molecules of both PX¯ and BZ+) in the asymmetric unit, with the PX hydroxyl 
hydrogen having transferred to the BZ nitrogen forming the benzimidazolium cation (BZ+). 
PX- molecules adopt the same conformation as the PX- anions in the previously described 
molecular complexes in this chapter. The C···N distances to the carbon in the 2-position in 
the symmetry independent BZ+ molecules are similar. One molecule (B in Figure 6.21) has 
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C-N distances of 1.333(6) Å and 1.317(6) Å and the other (B’) has distances of 1.323(6) Å 
and 1.334(6) Å. 
Once again the structure is primarily made up of chains of alternating PX¯ and BZ+ 
molecules with an ABA’B’ arrangement. The structure directing NH···O¯ and NH···O 
hydrogen bonds are arranged in the same way as in the PX¯:IM+.ACN complex with 
alternate PX¯ molecules lying head-to-tail relative to each other (Figure 6.21). The NH···O 
hydrogen bonds from one BZ+ molecule (B’ in Figure 6.21) are stronger than in any of the 
IM complexes or the 2MIM complex (Table 6.7). The NH···O interactions from the other 
BZ+ molecule (B) are slightly weaker and more comparable with the 4:4:1 solvate 
complex. Weak hydrogen bonds are also present between the BZ+ benzene ring CH 
groups and the sulfonyl oxygen atoms and pyridinal nitrogen atoms of the PX¯ molecules 
(also Figure 6.21).  
 
 
Figure 6.21 Hydrogen bonding in the ABA’B’ chains of the piroxicam : benzimidazole 










Table 6.7 Hydrogen bond lengths and angles in the piroxicam: benzimidazole salt complex 







). ACN are shown for comparison. Values which have no errors are due to 
hydrogen atoms being placed on calculated positions. 
Complex H-Bond D-H (Å) H···A (Å) D···A (Å) ∠ D-H···A (°) 















































































































Weak CH···O hydrogen bonds are formed to the sulfonyl oxygen atoms from CH groups of 
both the BZ+ benzene ring (C···O =  3.556(6) Å) and the PX¯ benzene ring (C···O = 
3.167(7) Å), holding adjacent chains together in layers which stack on top of each other 
(Figure 6.22). Both symmetry independent PX¯ molecules interact with BZ+ molecules in 
the chain below with CH···O hydrogen bonds between the BZ+ CH and the sulfonyl oxygen 
of PX¯ (C···O = 3.207(7) Å and 3.189(7) Å) as well as π-π interactions (Figure 6.23) between 
the PX¯ pyridine rings and the BZ+ benzene rings. The π···π distances are approximately 




Figure 6.22 The structure of the piroxicam : benzimidazole molecular salt complex. (a) 
Arrangement of chains within the layers, with alternate chains in different colours, (b) 
weak CH···O hydrogen bonds to the sulfonyl oxygen atoms formed by the PX¯ and BZ
+
 
aromatic CH groups in neighbouring chains within layers (blue dashed lines). Interactions 
within the chains are shown as red dashed lines, (c) arrangement of layers relative to each 
other, with alternate layers in different colours. Note that neighbouring PX¯ and BZ
+
 
molecules in the layers overlap slightly.  
 
 
Figure 6.23 CH···O hydrogen bonds and π···π interactions between PX¯ and BZ+ molecules 
above and below each other in the piroxicam : benzimidazole molecular salt complex 






6.3.6  Piroxicam : 1, 2, 4 - Triazole (2PXZ:TZ) 
 
The piroxicam : triazole complex crystallises in a 2:1 ratio with no intermolecular 
hydrogen transfer occurring. Intramolecular hydrogen transfer does occur however, with 
PX molecules present in the zwitterionic tautomeric form and adopting the typical 
conformation found in this form (Figure 6.1). The asymmetric unit has two fully occupied 
PXZ molecules and two TZ molecules with 50% occupancy. Both symmetry independent 
TZ molecules are 50/50 disordered across an inversion centre resulting in two possible 
positions of the molecules (Figure 6.24).  
 
 
Figure 6.24 Disorder of the triazole molecules in the piroxicam : triazole complex. The 
black circle indicates the inversion centre which relates two incomplete parts of each 
molecule.  
 
The PXZ molecules dimerise through the )12(22R  ring (Figure 6.25) which is consistent 
with PXZ complexes with mono-substituted benzoic acids (see Chapter 5). Hydrogen bond 
lengths in the dimer can be found in Table 6.8. The TZ molecule links the dimers through 
moderately strong, charge-assisted NH···O¯ interactions with the PXZ enolate oxygen and 
weak CH···N interactions between the TZ N and the CH of the pyridine ring of the next PXZ 
molecule (Figure 6.26). A weak CH···O¯ hydrogen bond to the enolate oxygen of the next 
PX molecule is also formed (Also figure 6.26). When the TZ molecule lies in the second 
disordered position, the same interactions are formed in reverse (Figure 6.26b). The 
infinite chains created by these interactions have an TZZT configuration (where T = 
triazole and Z = zwitterionic piroxicam). Only symmetry equivalent PXZ and TZ molecules 
 216
are present in the same chain, i.e. chains of TZZT and T’Z’Z’T’. Hydrogen bond lengths and 
angles for both chains can be found in Table 6.8. 
 
Figure 6.25 The PXZ dimer in the piroxicam : triazole complex. 
 
 
Table 6.8 Hydrogen bond lengths and angles in the piroxicam : triazole complex (refer to  
Figures 6.25 and 6.26 for key). Values which have no errors are due to hydrogen atoms   
being placed on calculated positions.  
Complex H-Bond D-H (Å) H···A (Å) D···A (Å) ∠ D-H···A (°) 










































































Figure 6.26 (a) The hydrogen bonding between TZ molecules and PXZ molecules in the 
piroxicam : triazole complex with (b) showing the same interactions formed in reverse 
when the TZ molecule is in the second position. 
 
The symmetry independent chains are arranged alternately (Figure 6.27a) and this forms 
layers which are stacked upon each other in a wave-like fashion (Figure 6.27b). PXZ 
molecules in the alternate chains are linked by a moderately strong CH···O hydrogen bond 
between the aromatic CH of the pyridine ring and the sulfonyl oxygen atom which lies in 
the plane of the layer (C···O = 3.183(4) Å) (Figure 6.28a). The other sulfonyl oxygen 
bridges between layers and forms three CH···O hydrogen bonds of moderate to weak 
strength with molecules in the layers above (Figure 6.28b). The interactions are formed 
with the pyridine ring CH group of the PXZ molecule above (C···O = 3.249(4) Å), as well as 
the CH group of a TZ molecule (3.005(9) Å). A weak CH···O hydrogen bond is also formed 
to the methyl group of the PXZ molecule two layers above (3.203(4) Å). The symmetry 
independent PXZ molecule has one sulfonyl molecule in a similar environment, with the 
same three CH···O interactions formed (Figure 6.29a). The hydrogen bonds with the 
pyridine and methyl CH groups are similar to those in the other molecule, with C···O 
distances of 3.376(4) Å and 3.135(3) Å respectively. A large difference is seen in the TZ 
interaction however, which has a C···O distance of 3.461(6) Å in the second molecule. The 
CH···O interaction with PXZ molecules in the alternate chain is no longer present, replaced 
instead by a very weak CH···O hydrogen bond to a PXZ molecule above (C···O = 3.717(4) Å) 




Figure 6.27 Layers in the piroxicam : triazole complex. (a) The arrangement of alternate 
chains in a single layer, with symmetry independent chains shown in different colours. The 
aromatic H and sulfonyl O atoms that form moderately strong hydrogen bonds between 
chains are highlighted in yellow. Only one TZ orientation is shown for clarity. (b) Relative 
arrangement of layers in a wave like fashion with methyl groups and sulfonyl oxygen 
atoms bridging between layers.  
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Figure 6.28 Interactions of sulfonyl oxygen atoms in the piroxicam : triazole complex. (a) 
CH···O interactions between neighbouring chains in the layers. (b) CH···O interactions 
involving the sulfonyl oxygen atom bridging between layers. Only one TZ orientation is 




Figure 6.29 Interactions of the PXZ sulfonyl oxygen atoms (symmetry independent of the 
PXZ molecule in Figure 6.28) in the piroxicam: triazole complex. Only one TZ orientation is 
shown for clarity. (a) CH···O hydrogen bonds to molecules in the layer(s) above. (b) CH···O 
interaction of the second sulfonyl oxygen atom (also to the layer above). 
 
6.3.7  Piroxicam : Benzotriazole (PXZ:BZT) 
 
The piroxicam : benzotriazole 1:1 molecular complex again features PX molecules in the 
zwitterionic form with no intermolecular hydrogen transfer occurring. PXZ molecules 
again adopt the typical conformation of this tautomer. PXZ molecules again dimerise 
forming the )12(22R  ring (Figure 6.30). The hydrogen bonding of the BZT molecule to the 
PXZ molecule is similar to that in the PXZ:TZ complex, with a moderately strong, charge-
assisted NH···O¯ hydrogen bond to the enolate oxygen (also Figure 6.30). This forms a 
tetramer with a BZT:ZZ:BZT configuration, similar to the tetramers seen in the PXZ 
complexes with mono-substituted benzoic acids in Chapter 5. The hydrogen bond lengths 
and angles in the tetramer are presented in Table 6.9 along with the analogous hydrogen 
bonds in the PXZ:TZ complex (where applicable). All analogous bond lengths in the two 
complexes are similar despite the different arrangement of the nitrogen atoms and the 




Figure 6.30 Hydrogen bonding in the PXZ:BZT complex forming an ABBA tetramer. 
 
Table 6.9 Hydrogen bond lengths and angles in the piroxicam : benzotriaozle complex 
(refer to Figure 6.30 for key). Analogous values for the piroxicam : triazole complex are 
also shown for comparison. Values which have no errors are due to hydrogen atoms being 
placed on calculated positions.  
Complex H-Bond D-H (Å) H···A (Å) D···A (Å) ∠ D-H···A (°) 


































































The sulfonyl oxygen atoms again form a series of weak hydrogen bonds to molecules 
above and below (Figure 6.31). One sulfonyl oxygen atom forms three CH···O hydrogen 
bonds, with the pyridine CH of a PXZ molecule below (C···O = 3.440(4) Å), the methyl CH 
of another PXZ molecule (C···O  3.648(5) Å) below and the CH of a BZT molecule below 
(C···O  = 3.489(5) Å). The other sulfonyl oxygen forms only weak hydrogen bonds to the 
methyl group of the PXZ molecule above with an inversion centre relating these two 
molecules so that an equivalent interaction goes both ways with C···O = 3.475(5) Å. PXZ 
molecules are further linked by weak CH···π interactions between the benzene rings with 
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an approximate C···π distance of 3.365 Å (Figure 6.32). The overall crystal packing has PXZ 
molecules arranged in a herringbone pattern (Figure 6.33a). BZT molecules are arranged 
parallel to each other, intersecting the herringbone arrangement of the PXZ molecules 
(Figure 6.33b).  
 










Figure 6.33 Crystal packing in the piroxicam : benzotriazole complex. (a) The herringbone 
arrangement of the PXZ molecules (BZT molecules omitted) (b) the relative arrangement 




6.3.8  Piroxicam : Pyrazine (2PXZ:PZN)  
 
The piroxicam : pyrazine complex crystallises in a 2:1 ratio with no intermolecular 
hydrogen transfer occurring. PX is in the zwitterionic tautomeric form with the typical 
conformation of this tautomer. There are two PXZ molecules in the asymmetric unit and 
two symmetry independent halves of PZN molecules lying on inversion centres. The PXZ 
molecules again form dimers via the typical )12(22R  ring (Figure 6.34). The PZN molecules 
are linked to the PXZ molecules through moderately strong, charge-assisted CH···O¯ 
hydrogen bonds with the enolate oxygen as well as weak CH···N hydrogen bonds from a 
PXZ pyridine CH group to the PZN nitrogen (also Figure 6.34). This forms infinite chains 
with a PZZPZZ configuration (where P = pyrazine and Z = zwitterionic piroxicam). The 
hydrogen bond lengths and angles in the chains are given in Table 6.10.  
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Figure 6.34 Hydrogen bonding in the chains of PXZ and PZN in the piroxicam : pyrazine 
complex (only one symmetry independent chain shown).  
 
Table 6.10 Hydrogen bond lengths and angles in the piroxicam : pyrazine complex (refer 
to Figure 6.34 for key; hydrogen bonds marked a and a‘ indicate identical hydrogen bonds 
in the symmetry independent chains). Values which have no errors are due to hydrogen 
atoms being placed on calculated positions.  
Complex H-Bond D-H (Å) H···A (Å) D···A (Å) ∠ D-H···A (°) 



















































Symmetry independent chains are arranged alternately, linked by a weak to moderately 
strong CH···O hydrogen bond (C···O = 3.252(15) Å) between the PXZ benzene CH groups 
and the PXZ sulfonyl oxygen atoms to form layers (Figure 6.35). The layers are stacked 
upon each other (Figure 6.36a), linked by CH···O hydrogen bonds involving the sulfonyl 
oxygen atoms which bridge between the layers (Figure 6.36b). Both symmetry 
independent bridging sulfonyl oxygen atoms form similar interactions, with weak CH···O 
hydrogen bonds formed with the PXZ pyridine ring (C···O = 3.476(15) Å and 3.544(15) Å) 
and PZN (C···O = 3.575(14) Å and 3.457(15) Å) molecules in the layer below and a 
 225
moderately strong hydrogen bond formed to the methyl group of the PXZ molecules two 
layers away (C···O = 3.021(15) Å and 2.968(17) Å).  
 
 
Figure 6.35 Relative arrangement of symmetry independent chains showing (a) the CH···O 
hydrogen bond between PXZ molecules of neighbouring chains and (b) the relative 
arrangement of these chains which form layers (alternate symmetry independent chains 
linked by the interaction in (a) shown in different colours).  
 
 
Figure 6.36 (a) Relative arrangement of layers in the piroxicam : pyrazine complex. (b) 
CH···O hydrogen bonds involving the bridging sulfonyl oxygen atoms (bottom PXZ 
molecule and hydrogen atoms partially omitted for clarity).  
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6.4 Crystal Structures of Molecular Complexes of Piroxicam with Strong Acids: 
Chloranilic Acid and Bromanilic Acid 
 
To investigate the possibility of protonation of the PX pyridine ring to form a molecular 
salt containing a PX cation, chloranilic and bromanilic acid were chosen as co-molecules 
as they have low pKa values (chloranilic acid pKa1 = 0.76; bromanilic acid pKa1 = 0.22) 
and are known to readily give up at least one hydrogen atom when co-crystallised with 
bases that have pKa values in a similar range to the PX pyridine ring224,225. Four complexes 
were produced using these co-molecules. Full refinement details for all complexes can be 
found in (Appendix A6 and Table A-6b).  
 
6.4.1 Piroxicam : Chloranilic Acid Form I (PX+:CA¯) (Triclinic)  
 
The 1:1 salt complex of piroxicam with chloranilic acid (CA) contains one molecule of each 
component in the asymmetric unit. An OH hydrogen from the CA molecule is transferred 
to the pyridinal nitrogen of PX, forming a positively charged PX ion (PX+) and a CA anion 
(CA¯). This is the first time such an ion of PX has been isolated in the solid state.  It adopts 
the same conformation as is seen in the non-ionised form of PX, with a short strong 
intramolecular OH···O hydrogen bond (Figure 6.37).   
 
 
Figure 6.37 Conformation of the protonated piroxicam molecules (PX+) in the piroxicam : 
chloranilic acid form I complex. The conformation of non-ionised piroxicam is also shown 
for comparison.  
 
CA¯ molecules dimerise through the OH groups and carbonyl groups forming moderately 
strong OH···O hydrogen bonds (d in Figure 6.38). The PX+ molecules are then linked either 
side of the dimer to form relatively co-planar tetramers. They are linked via two 
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asymmetric, charge assisted, bifurcated NH···O hydrogen bonds to the deprotonated CA¯ 
oxygen and the carbonyl oxygen (a, b and c in Figure 6.38). One bifurcated hydrogen bond 
has a DHAA configuration and the second a DDHHA configuration. The amide NH of PX+ 
forms a moderately strong hydrogen bond with the deprotonated oxygen atom (longer C-
O distance), which then forms hydrogen bonds to the pyridine NH through a slightly 
stronger interaction. The pyridine NH also forms another moderately strong - although 
weaker than the others - NH···O hydrogen bond to the carbonyl oxygen atom of CA¯. 
Hydrogen bond lengths and angles can be found in Table 6.11.  
 
Figure 6.38 Hydrogen bonded tetramers in the piroxicam : chloranilic acid 1:1 form I 
complex.  
 
Table 6.11 Hydrogen bond lengths and angles in the piroxicam : chloranilic acid 1:1 form I  
complex (refer to Figure 6.38).  
Complex H-Bond D-H (Å) H···A (Å) D···A (Å) ∠ D-H···A (°) 


























Tetramers are linked by a series of weak hydrogen bonds involving the PX+ aromatic CH 
groups to form layers (Figure 6.39a).  The CH groups form hydrogen bonds with the CA¯ 
hydroxyl oxygen atom (C···O = 3.548(2) Å) as well as the chlorine atom of the 
neighbouring CA¯ (C···Cl = 3.882(2) Å) and the sulfonyl oxygen of the PX+ molecule (C···O = 
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3.255(2) Å). The layers are stacked upon each other with the PX+ methyl and sulfonyl 
oxygen bridging between layers (Figure 6.39b). The methyl group forms a weak hydrogen 
bond with an oxygen atom of the CA¯ molecule below (C···O = 3.548(2) Å), as well as a 
weak hydrogen bond with the chlorine atom (C···Cl = 3.882(2) Å) (Figure 6.40). The 
bridging sulfonyl oxygen atom forms weak hydrogen bonds with the pyridine CH groups 
of two PX+ molecules above (C···O = 2.951(2 )Å and 3.122(2) Å).  
 
 
Figure 6.39 Layers in the piroxicam : chloranilic form I salt complex. (a) The weak 
hydrogen bonds linking tetramers to form layers (different tetramers are coloured red and 
blue; donors and acceptors in the weak hydrogen bonds are coloured by atom). (b) The 




Figure 6.40 Weak interactions between layers involving the methyl and sulfonyl groups in 
the piroxicam : chloranilic acid 1:1 salt complex.  
 
 
6.4.2  Piroxicam : Chloranilic Acid Form II (PX+:CA¯) (Monoclinic) 
  
The Form II polymorph of the piroxicam: chloranilic acid complex also has a single 
molecule of each in the asymmetric unit, with hydrogen transfer from the CA OH to the 
PX pyridinal N. The conformation of PX+ is the same as that seen in form I. It was 
crystallised from a 1:1 ratio of the component materials in ACN at 40°C, whereas form I 
was crystallised from the same conditions at room temperature.  
 The CA- molecules no longer dimerise, however, the main interactions between 
the CA¯ and PX+ molecules are similar to those in form I as they are linked through NH···O 
interactions involving the same groups (Figure 6.41). The chloranilic acid molecule, 
however, is twisted relative to the PX molecule (Figure 6.42), lying almost perpendicular 
to the plane of the pyridine ring as opposed to the co-planar arrangement in form I. The 
angle between the plane of the PX+ pyridine ring and the plane of the CA¯ six-membered 
ring is approximately 81°, whereas in form I the angle is approximately 21°. This changes 
the hydrogen bonding interactions slightly, leading to the formation of two DDHHA type 
bifurcated hydrogen bonds. The carbonyl oxygen atom now lies below the plane of the 
pyridine ring and forms an NH···O interaction with the amide oxygen (d in Figure 6.41), as 
well as a slightly stronger interaction with the pyridine NH - which is also observed in 
form I (see Table 6.12 for hydrogen bond lengths and angles). The two NH···O hydrogen 
bonds involving the deprotonated oxygen with the pyridine NH and the amide NH (a and 
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b in Figure 6.41) are both moderately strong, but with a slightly stronger amide 
interaction and slightly weaker pyridine interaction than in form I (also Table 6.12). The 
carbonyl lying below the plane of the pyridine ring also allows it to form a bifurcated, 
DDHHA, moderately strong CH···O hydrogen bond with the CH groups of the pyridine ring 
of the PX molecule below (C···O = 3.191(3) Å and 3.163(3) Å) (Figure 6.43). The two PX+ 
molecules are also linked via weak CH···O hydrogen bonds of the pyridine CH with the 
sulfonyl oxygen (C···O = 3.318(3) Å).  
 
 
Figure 6.41 Hydrogen bonding between CAˉ and PX+ molecules in the piroxicam : 
chloranilic acid form II salt complex. Hydrogen bonds involving the deprotonated oxygen 










Table 6.12 Hydrogen bond lengths and angles in the piroxicam : chloranilic acid 1:1 form II 
complex (refer to Figure 6.41 for key). Values for the analogous interactions in form I  
are also shown for comparison).  
Complex H-Bond D-H (Å) H···A (Å) D···A (Å) ∠ D-H···A (°) 















































Figure 6.42 Relative arrangements of the PX+ (blue) and CAˉ (red) molecules in piroxicam : 
chloranilic acid (a) form I and (b) form II. Viewed along the plane of the pyridine ring.  
 
 
Figure 6.43 The bifurcated CH···O hydrogen bonds between PX+ and CA¯ molecules and the 
CH···O=S interactions between PX
+
 molecules in the piroxicam : chloranilic acid form II salt 
complex (some H atoms omitted for clarity). 
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Unlike form I, CA¯ molecules do not dimerise through the hydroxyl group, instead forming 
moderately strong OH···O interactions with the sulfonyl oxygen of another PX+ molecule 
(Figure 6.44). The interaction is moderately strong (C···O = 2.799(2) Å, ∠ D-H···A = 
124(2)°), with the hydroxyl oxygen also forming significant lone-pair···π interactions with 
the benzene ring of the PX+ molecule, with a distance of approximately 2.970 Å between 
the oxygen and the centre of the π-bond (also Figure 6.44). Pyridine CH groups of a 
neighbouring PX+ molecule form weak hydrogen bonds to both the hydroxyl oxygen and 
the sulfonyl oxygen (C···O = 3.221(3) Å an 3.318(3) Å). Further hydrogen bonds are 
formed involving the CA¯ carbonyl and two neighbouring PX+ molecules, with a 
moderately strong CH···O hydrogen bond formed with the pyridine CH of one (C···O = 
3.164(3) Å) and a weak CH···O hydrogen bond with the benzene CH of another (C···O = 
3.437(3) Å) (Figure 6.45).  
 
 
Figure 6.44 Interactions of the CA¯ hydroxyl with PX+ molecules in the piroxicam : 






Figure 6.45 Hydrogen bond interactions of the CA¯ carbonyl oxygen with the aromatic CH 
groups of two PX
+
 molecules in the piroxicam : chloranilic acid form II complex.   
 
PX+ molecules all run in the same direction in a relatively layered arrangement, with CA¯ 
molecules running across the layers interlocking the structure (Figure 6.46). The chlorine 
of the CA¯ molecule again interacts with a PX+ molecule through a weak hydrogen bond 
with the methyl group as in form I (C···Cl = 3.340(2) Å). The other Cl atom interacts with 
another PX+ molecule via lone-pair···π interactions with the benzene ring (Figure 6.47). 
PX+ molecules above and below each other interact with π···π interactions between the 
amide carbonyl double bonds with approximately 3.162 Å between the centroid of the 
bonds (Figure 6.48). Neighbouring PX molecules form moderately strong DDHHA 
bifurcated hydrogen bonds between the benzene ring CH groups and the sulfonyl oxygen 




Figure 6.46 Relative arrangement of PX+ and CA¯ molecules in the piroxicam : chloranilic 
acid form II complex. PX molecules (blue) run from bottom left to top right with CA 
molecules (red) interlocking the structure.  
 
 
Figure 6.47 Interactions of the CA¯ chlorine atoms in the piroxicam : chloranilic acid form II 




Figure 6.48 Interactions between PX molecules, showing the π···π interactions between 
amide carbonyls (red dashed lines) as well as the bifurcated CH···O hydrogen bonds 
between the benzene ring and the sulfonyl oxygen (blue dashed) in the piroxicam : 
chloranilic acid form II complex.  
 
 
6.4.3  Piroxicam : Chloranilic Acid Acetonitrile Solvate (2(PX+):CA2¯.2(ACN)) 
 
The piroxicam : chloranilic acid acetonitrile solvate (2:1:2) complex features a single PX+ 
molecule in the asymmetric unit with one half of a doubly deprotonated CA molecule 
(CA2¯) lying on an inversion centre, as well as a single ACN molecule. It was crystallised 
from the same conditions as PX+:CA- forms I and II but at 50°C. The PX+ molecule has the 
same conformation as is found in these two complexes.  
 The complex exhibits the same pattern of three hydrogen bonding interactions 
between co-planar CA2¯ and PX+ molecules (a bifurcated DDHHA arrangement and a 
bifurcated DHAA arrangement) as is found in form I of the 1:1 PX+:CA¯ complex (Figure 
6.49). As the CA molecule is doubly deprotonated, this synthon occurs on both sides of 
the CA2¯ molecule forming trimers. Analysis of C-O bond lengths in the CA2¯ molecule 
indicates that the carbonyl (C=O = 1.239(4) Å) lies in the same position as it does in 
PX+:CA¯, thus forming a single hydrogen bond with the pyridine NH group, with the 
deprotonated oxygen (C-O¯ = 1.268(4) Å) forming bifurcated DDHHA hydrogen bonds 
with both the amide and pyridine NH groups. Table 6.13 shows that the hydrogen 
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bonding in the trimer is generally stronger than the corresponding hydrogen bonds in 
PX+:CA¯ forms I and II with the exception of the pyridine NH interaction with the 
deprotonated oxygen. An overlay of the structure with that of form I (Figure 6.50) shows 
this is due to a difference in the relative position of the CA2¯ and CA¯ molecules relative to 
the PX+ pyridine ring. The PX+ molecule also has a slight difference in conformation, with a 
stronger intramolecular hydrogen bond in the solvated complex (e in Table 6.13). The 
conformation of the PX+ molecule also allows the methyl group to form a weak hydrogen 
bond with the CA2¯ chlorine atom (C···Cl = 3.746(4) Å) (Figure 6.51).  
 
Figure 6.49 Hydrogen bonding between CAˉ and PX+ molecules in the 2:1:2 piroxicam : 











Table 6.13 Hydrogen bond lengths and angles in the 2:1:2 piroxicam : chloranilic acid 
acetonitrile solvate complex (refer to Figure 6.49 for key). Values for the corresponding 
interactions in form I and II are also shown for comparison.  
































































Figure 6.50 Relative positions of the PX pyridine rings to the CA¯ and CA2¯ molecules in the 
piroxicam : chloranilic acid form I (blue) and piroxicam : chloranilic acid acetonitrile 
solvate (red) complexes. Overlay is calculated for the pyridine rings and the neighbouring 
amide nitrogen. 
 
Trimers are linked via further weak hydrogen bonding of the CA2¯ molecule with the 
pyridine ring CH groups of other PX+ molecules (Figure 6.51). The CH groups form weak 
hydrogen bonds to both the chlorine and carbonyl atoms of CA2¯ with a C···Cl distance of 
3.579(4) Å and a C···O distance of 3.418(4) Å. PX molecules are also linked by weak 
hydrogen bonding through the ACN molecules (Figure 6.52).  Two CH groups of the PX 
benzene ring form hydrogen bonds to nitrogen atoms of two ACN molecules forming 
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)10(42R  rings with C···O distances of 3.452(5) Å and 3.517(6) Å. The aforementioned 
interactions hold the molecules together in wave-like layers which are stacked upon each 
other with the methyl groups and sulfonyl oxygen atoms again bridging between layers 
(Figure 6.53) and forming weak CH···O hydrogen bonds (C···O = 3.267(4) Å and 3.469(4) Å) 
(Figure 6.54).  
 
Figure 6.51 Weak hydrogen bonds (red dashed lines) between PX+ and CA2¯ molecules in 
the piroxicam : chloranilic acid acetonitrile solvate complex.  
 
 
Figure 6.52 )10(42R  hydrogen bond ring formed by PX+ and ACN molecules in the 




Figure 6.53 Layered crystal packing in the piroxicam : chloranilic acid acetonitrile solvate 
complex. 
 
Figure 6.54 Weak hydrogen bonds between layers involving the methyl groups and 
sulfonyl oxygen atoms of PX
+
 in the piroxicam : chloranilic acid acetonitrile solvate 
complex. 
 
6.4.4  Piroxicam : Bromanilic Acid (PX+:BRA¯)  
 
The piroxicam : bromanilic acid salt complex is isomorphous to form II of the piroxicam : 
chloranilic acid complex. The structure directing hydrogen bonds in the complex (Figure 
6.55) are similar in strength to those in PX+:CA¯ (II) (see Table 6.14 for hydrogen bond 





Figure 6.55 Hydrogen bonding between BRAˉ and PX+ molecules in the piroxicam : 
chloranilic acid form II salt complex. Hydrogen bonds involving the deprotonated oxygen 
are shown on the left with hydrogen bonds involving the carbonyl on the right.  
 
 
Table 6.14 Hydrogen bond lengths and angles in the piroxicam: bromanilic acid salt 
complex (refer to Figure 6.55 for key). Values for the corresponding interactions in 
piroxicam: chloranilic acid form II are also shown for comparison.  
Complex H-Bond D-H (Å) H···A (Å) D···A (Å) ∠ D-H···A (°) 



















































Table 6.15 Unit cell parameters of the isomorphous PX+:BRA¯ and PX+:CA¯ (II) complexes. 
Complex Spc Grp a (Å) b (Å) c (Å) β (°) V (Å3) 
PX+: BRA¯ P21/c 8.842(2) 13.437(2) 19.242(4) 100.518(11) 2247.8(7) 




6.5  Discussion 
 
6.5.1  Supramolecular Synthons 
 
Piroxicam Complexes with N-heterocycles 
 
Of the eight PX complexes with N-heterocycles (NHCs), transfer of the PX hydroxyl 
hydrogen to the NHC to form PX¯ occurs in five. Of the five complexes, three were 
solvated complexes with imidazole (IM), which all featured protonation of the IM despite 
varying the crystallisation conditions. The other three complexes feature intramolecular 
hydrogen transfer and form PXZ. No complexes crystallised with the non-ionised form of 
piroxicam. The conformation of PX¯ seen in the complexes is distinct from the 
conformations of PXZ and PXN and is the same in all five complexes in which it occurs 
(Figure 6.1). 
All five PX¯ complexes feature chains of alternating PX¯ and NHC, generally with 
an ABAB arrangement although some variations occur depending on the number of 
symmetry independent molecules in the asymmetric unit (i.e. ABA’B’, A’B’A’B’). All also 
exhibit similar hydrogen bonding synthons, although with some noticeable differences 
from complex to complex. Four of the complexes feature NHC molecules sandwiched 
between two PX¯ molecules and linked by NH···O=C hydrogen bonds to the PX¯ amide 
oxygen and NH···O¯ hydrogen bonds to the PX¯ enolate oxygen. These interactions are to 
be expected as this arrangement matches the strongest hydrogen bond acceptors of PX¯ 
with the strongest donors of IM+. The 2(PX¯):2(IM+).H2O complex is the only exception to 
this, as neither of the two symmetry IM+ molecules follow this hydrogen bonding pattern 
despite also having an ABAB arrangement (Figure 6.2). Instead, one chain features 
hydrogen bonds from the IM+ NH groups to the PX¯ pyridine nitrogen and enolate oxygen, 
and the other chain has both NH groups hydrogen bonding to the PX¯ amide oxygen 
atoms. One enolate oxygen atom of PX¯ is therefore not hydrogen bonded to the IM+ NH 
groups and instead forms a hydrogen bond to the IM+ CH in the 4/5 position, thus not 
satisfying the strongest donor/acceptor criterion. Other IM+ CH groups in the 4 and 5 
positions in the structure form hydrogen bonds with either the PX¯ pyridine nitrogen or a 
sulfonyl oxygen atom. These interactions are also seen in the other PX¯ structures, with 
the CH···N interactions occurring in the 1:1:1 and 4:4:1 PX:IM.ACN complexes, as well as 
with the analogous CH groups in the 5/8 positions of BZ+ in the PX¯:BZ+ complex (Figure 
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6.21). The PX¯:2MIM+ complex does not have this interaction due to the alternate PX¯ 
molecules lying head to head rather than head to tail which makes the pyridine nitrogen 
unavailable for hydrogen bonding to the 2MIM+ CH groups (Figure 6.15). The CH···O=S 
interaction does occur in the PX¯:2MIM+ complex as well as the PX¯:BZ+ complex (5/8 
position) but does not occur in either of the PX:IM.ACN solvates. In the 1:1:1 ACN solvate 
it is compensated for by a CH hydrogen bond forming to the ACN nitrogen, with the ACN 
methyl group then forming a CH···O=S hydrogen bond to the PX¯ molecule (Figure 6.8). A 
similar CH···N hydrogen bond to the ACN is formed in the 4:4:1 complex, although no 
CH···O=S interaction is formed between the ACN and PX¯ as the ACN methyl group points 
away from the sulfonyl oxygen (Figure 6.13b).    
It is interesting to note that despite exhibiting similar hydrogen bonding 
arrangements to the 2MIM+ and BZ+ complexes, no 1:1 complex of PX and IM could be 
isolated, with instead two ACN solvates and a hydrate produced from varying the 
conditions. This is likely due to the small size of IM compared with BZ and 2MIM, as both 
have bulky groups attached to the imidazole group. To compensate for the void that 
would be left and to ensure efficient packing in the absence of these groups, a solvent 
molecule is incorporated into the PX¯:IM+ complexes. This is reflected in the relative 
positions of the H2O and ACN molecules in the complexes, as the H2O molecule is 
hydrogen bonded to the CH group in the 2-position and the ACN molecules form 
hydrogen bonds to the CH in the 4/5 position. The solvent molecules therefore occupy 
equivalent positions to the methyl group and benzene ring in 2MIM and BZ respectively.  
In the three complexes featuring PXZ with NHCs, the PXZ molecules dimerise, as is 
consistent with all known PXZ complexes. With the exception of the pyridinium nitrogen 
which is involved in hydrogen bonding to form the PXZ dimer, consistent hydrogen 
bonding is observed between the strongest NHC donors and the strongest free PXZ 
acceptors in all cases. Both the PXZ:TZ and PXZ:BZT complexes form NH···O¯ hydrogen 
bonds between the TZ/BZT NH and the enolate oxygen. The PZN CH also forms hydrogen 
bonds to the enolate O¯. In all complexes a hydrogen bond is also formed from the same 
CH group of the PX¯ pyridine nitrogen to a nitrogen atom of the heterocycle.  
The PXZ:PZN complex is unusual as the only hydrogen bonds between PZN and 
PXZ molecules involve CH donors, as this is the only possible PZN donor and the 
pyridinium nitrogen is unavailable due to dimerisation of PXZ molecules. The fact that no 
conventional hydrogen bonds occur between the molecules may explain why 
crystallisation of this complex occurs so rarely and in such small quantities.  
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As PZN is symmetrical, the same interactions are formed on both sides of the 
molecule and it therefore forms chains with an ABBA configuration, with the PXZ dimers 
sandwiched by two PZN molecules resulting in a 2:1 complex (PXZ:PZN). In the PXZ:TZ 
complex, the disorder of the TZ molecule means it can effectively also form the same 
interactions on both sides and therefore also forms a 2:1 complex of PZZPZZ chains. The 
small size of the molecule allows it to occupy two possible positions without major 
disruption of the crystal packing. The PXZ:BZT complex, however, forms a 1:1 complex 
with tetramers of BZT:PXZ:PXZ:BZT, analogous to the common tetramer found in PXZ 
complexes with benzoic acids (see Chapter 5). Chains are not formed as there is no 
symmetry in the BZT molecule and only one sufficiently strong donor to form hydrogen 
bonds to the enolate O¯.  
 
Piroxicam Complexes with Strong Acids: Chloranilic Acid and Bromanilic Acid  
 
All PX complexes with CA and BRA resulted in intermolecular hydrogen transfer from the 
CA/BRA to the PX pyridine ring forming PX+. The polymorphic PX+:CA¯ forms I and II both 
crystallise in a 1:1 ratio with similar hydrogen bonding patterns between the PX+ and CA¯ 
molecules. Form II has an extra NH···N hydrogen bond, however, due to the change in 
orientation of the CA¯ molecule relative to the PX+ molecule. Interestingly, increasing the 
temperature of crystallisation from RT to 40°C resulted in the formation of this second 
polymorph which has the CA¯ molecule in a different orientation from form I. Increasing 
the crystallisation temperature to 50°C resulted in the ACN solvate complex with double 
deprotonation of the CA molecule. Deprotonation of both OH groups of the CA molecule 
is somewhat expected due to the decrease in pKa associated with increasing 
temperature. Unlike the PX:CA complexes, only a single PX+:BRA¯ phase was produced 
regardless of the temperature at which the crystallisation was carried out. In all 
complexes the strongest donor/strongest acceptor rule is satisfied, with charge-assisted 
hydrogen bonds formed between the protonated pyridine nitrogen of PX+ and the 
deprotonated oxygen of CA¯ (or CA2¯). In the case of the ACN solvate, this results in a 2:1 






6.5.2  Hydrogen Transfer and pKa 
 
In total, five of the PX complexes with NHCs featured hydrogen transfer from the PX 
molecule to the basic nitrogen of the NHC. Table 6.16 shows that hydrogen transfer 
occurs in the complexes with the most basic three co-formers: all three IM complexes, 
the 2MIM complex and the BZ complex. The remaining three co-formers are poorly basic 
and resulted in complexes with the zwitterionic PX tautomer. Analysis of the ΔpKa values 
using the PX OH group or the N+-H group as the acidic group show that the TZ, BZT and 
PZN complexes would not be expected to result in hydrogen transfer in either case, as the 
ΔpKa values are all negative or, in the case of TZ and N+-H, very small.  
Interpretation of the ΔpKa values of the complexes where hydrogen transfer 
occurs is slightly more complicated. Using the OH group as the acid, the ΔpKa values are 
all smaller than would be expected for complexes where hydrogen transfer occurs (all < 
3), although all lie between 0 and 3 where hydrogen transfer may or may not occur. The 
ΔpKa for the 2MIM complex (2.42) is relatively close to the empirically significant value of 
3, meaning hydrogen transfer is more likely to occur. The ΔpKa value for the PX 
complexes with IM is relatively low (1.53), despite hydrogen transfer occurring in all three 
complexes formed under different crystallisation conditions. Using the acid pKa value of 
the N+-H produces far larger ΔpKa values and a clearer distinction of where hydrogen 
transfer will occur. This would also suggest it may be more appropriate, in the conditions 
studied at least, to describe the process as deprotonation of the pyridinium nitrogen 
rather than deprotonation of the hydroxyl, i.e. to consider PX as the zwitterionic form 
rather than the non-ionised form.  
 The ΔpKa values (where PX is a base) for the CA and BRA complexes follow a 
similar pattern to that found in the NHCs, in that the ΔpKa values suggest that it would 
perhaps be more appropriate to consider protonation of the enolate oxygen, rather than 
protonation of the pyridine nitrogen. The ΔpKa values using the N+-H pKa value for the 
base are relatively small, and again smaller than may be expected in complexes where 
hydrogen transfer occurs. The fact they lie between 0 and 3 means hydrogen transfer 
may still occur. On the other hand, the ΔpKa values calculated when using the OH value 
again provide a much clearer distinction as to when hydrogen transfer occurs. Table 6.16 
also includes the strongest acid used in Chapter 5 to form a molecular complex of 
piroxicam. Treating PX as the zwitterion and using the OH pKa value here results in a ΔpKa 
of 3.35 which would suggest intermolecular hydrogen transfer is likely to occur although 
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none is observed in the molecular complex formed. However, as previously stated, the 
ΔpKa rule is more of a guide and not always transferrable between systems and a slightly 
higher ΔpKa value may be required for hydrogen transfer to occur in this system.   
  
Table 6.16 ΔpKa values for the molecular complexes of piroxicam and the piroxicam 
ionisation state in each complex where ∆pKa = pKa[protonated base] – pKa[acid]. ΔpKa 
values using both the hydroxyl group and the N
+
-H group of piroxicam as the acid/base 
are shown. pKa values for the NHC co-formers are quoted for the conjugate acid of the 








OH (pKa = 
5.46) 
ΔpKa  
N+-H (pKa = 
1.86) 
Bases     
Imidazole (3 complexes) 6.99 PX¯ 1.53 5.13 
2-Methylimidazole  7.88 PX¯ 2.42 6.02 
Benzimidazole  5.53 PX¯ 0.07 3.67 
1,2,4-Triazole  2.27 PXZ -3.19 0.41 
Benzotriazole  1.60 PXZ -3.86 -0.26 
Pyrazine  0.65 PXZ -4.48 -1.15 
Acids     
Chloranilic Acid (3 complexes)  0.76 PX+ 4.7 1.1 
Bromanilic Acid  0.22 PX+ 5.24 1.64 
2-Aminobenzoic Acid  2.11 PXZ 3.35 -0.25 
 
 
6.5.4  Summary and Conclusions 
 
6.5.4.1  N-Heterocycles as Co-formers 
 
PX has been shown to form eight molecular complexes with NHCs. The three poorly basic 
NHCs (pKa = 0.65 - 2.27) resulted in complexes with the zwitterionic PXZ form, with no 
intermolecular hydrogen transfer. All exhibited the dimerisation of the PXZ molecules as 
seen in all known complexes featuring PXZ, with the strongest hydrogen bond donor of 
the NHC interacting with the enolate oxygen. In the case of PZN and TZ this forms infinite 
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chains due to the symmetry in PZN and the disorder of TZ which allow the same NH···O¯ 
and CH···O¯ interactions to form both sides of the molecules. In the case of BZT, discrete 
hydrogen bonded tetramers are formed as the NH donor of BZT only lies on one side. The 
BZT:PXZ:PXZ:BZT tetramers are analogous to the BZZB tetramers formed in the 
zwitterionic PXZ complexes with benzoic acids discussed in Chapter 5.   
Tuning of the pKa values of the co-former allows complexes to be formed with the 
PX¯ anion. Five complexes were crystallised featuring PX¯ by using bases with pKa values 
in the range 5.33-6.99. All PX¯ complexes exhibit consistent hydrogen bonding synthons, 
with interactions of the strongest donors and strongest acceptors (NH···O and NH···O¯) 
prevailing in all complexes except the anomalous 2(PX¯):2(IM+).H2O complex. All 
complexes resulted in chains with a general ABAB arrangement of the molecules.  
 Three complexes with PX¯:IM+ were formed, with a hemihydrate as well as 1:1:1 
and 4:4:1 ACN solvates. No 1:1 PX¯:IM+ complex could be formed despite varying the 
crystallisation conditions. Selective crystallisation of the three PX¯:IM+ solvates could be 
controlled by varying the crystallisation temperature.  
 Analysis of the ΔpKa values suggest that it may be more appropriate to consider 
PX as the zwitterionic form, with the N+-H group as the acid, when attempting to predict 
hydrogen transfer using the ΔpKa rule. The resulting ΔpKa values give a clearer indication 
of whether or not hydrogen transfer will occur. Data on more complexes across a greater 
pKa range would be useful in quantifying the minimum ΔpKa at which hydrogen transfer 
should be expected for PX complexes with NHCs. 
 
 
6.5.4.2  Acids as Co-formers 
 
Molecular complexes of CA and BRA with PX resulted in salts where PX is present as a 
cation with both the hydroxyl and pyridine N protonated. This is the first time PX has 
been observed in the PX+ form.  
 Polymorphism of the 1:1 complex can be induced by changing the crystallisation 
temperature. Both forms have the same basic hydrogen bonding motif, with the CA¯ 
molecule in form II twisted relative to its position in form I and forming an extra hydrogen 
bond. A further increase in the crystallisation temperature resulted in the 2:1:2 ACN 
solvate which surprisingly reverts back to the motif seen in form I.  
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 The ΔpKa values again indicate that PX should possibly be considered as the 
zwitterion when applying the ΔpKa rule. ΔpKa values using the OH pKa as the base value 
give a clear indication that hydrogen transfer will occur. The ΔpKa value of the PXZ:2ABA 
complex from Chapter 5 indicates that hydrogen transfer from acids does not necessarily 
occur at ΔpKa > 3, and stronger acids are required. Again, more complexes across a 
greater ΔpKa range are needed to adjust the predicted minimum ΔpKa value for hydrogen 
transfer to occur. 
 
 
6.5.4.3 General Comments on Hydrogen Transfer in Molecular Complexes of Piroxicam 
 
PX forms a range of different types of complexes with both acids and bases and adapts its 
ionisation state according to the co-former. The influence of pKa is apparent in these 
complexes and by tuning the pKa of the co-former, the piroxicam ionisation state can be 
tuned accordingly. Co-crystallisation with strong acids (pKa < 0.77) can be used to obtain 
the cationic PX+ form of piroxicam whereas weaker benzoic acid derivatives can be used 
to obtain either the zwitterionic form or the non-ionised form depending on which side of 
the boundary regions (discussed in Chapter 5) the acids lie. Tautomeric polymorphs are 
also possible with the mono-substituted acids although predicting when they will occur is 
not possible from the data obtained so far. The use of strong bases (pKa > 5.52) can result 
in complexes with PX¯ and weaker bases (pKa < 2.28) have been shown to result in 
complexes with PXZ. 
 The data presented in this chapter and in Chapter 5 however, suggest that more 
work is required with regards predicting which form of PX will be present in a given 
complex. When co-crystallising with the mono-substituted benzoic acids it is not yet clear 
why two boundary regions exist where PXZ and PXN are formed and until this is 
understood it cannot be considered a hard rule. It also does not account for the 
tautomeric polymorphism observed in four of the complexes. Also, it has been suggested 
in this chapter that it may be more appropriate to consider PX as the zwitterionic 
tautomer when calculating ΔpKa values for PX complexes. However, no definite ΔpKa 
value has yet been defined as a boundary at which intermolecular hydrogen transfer is 
expected to occur for either acids or bases.  
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7. Controlling Co-crystallisation Based Molecular Complex Formation of 
Paracetamol and its Derivatives 
 
7.1  Introduction to Molecular Complexes of Paracetamol 
 
As discussed in previous chapters, the solid form adopted by an API is an important 
consideration as it directly affects its physicochemical properties. When co-crystallising a 
particular API it is therefore useful to be able to predict, at least to a certain degree, the 
dominant interactions that will occur in the molecular complex formed, as these play an 
important role in controlling the structure and hence properties of the complex; this is 
tackled through the supramolecular synthon approach discussed in Chapter 1. As 
discussed in Chapter 4, the solid forms of paracetamol (PA) are the subject of much study, 
with much focus on improving physical properties through exploiting the polymorphism 
of the material. Co-crystallisation, however, is also seen as a potential route to optimising 
the properties of PA, via formation of molecular complexes with consequent altered 
physical properties, and it has previously been shown that the compression properties of 
PA can be improved through co-crystallisation17. Despite this, relatively few molecular 
complexes of PA exist, with only eighteen published in the Cambridge Structural Database 
(CSD)65, five of which are hydrates or solvates. The range of co-formers used in these 
complexes show marked variations in nature and a recent study highlighted the variation 
in supramolecular synthons observed in these molecular complexes226. This study also 
highlights the tendency of PA to form molecular complexes with nitrogen heterocycle 
compounds (NHCs). Of the thirteen non-solvate complexes of PA reported in the CSD, five 
of these are with NHCs (excluding compounds with donors/acceptors other than NH/N). 
Of these NHCs, three are co-formers with only nitrogen hydrogen bond acceptors (4,4 - 
bipyridine227, phenazine17 and N, N -dimethylpiperazine227) and two are with piperazine (a 
1:1 complex227 and an ethanol solvate228) which has two NH hydrogen bond donors. An N-
methylmorpholine complex is also known227, which is useful for comparison to the 
complexes with N acceptors only, as the N-methylmorpholine molecule is disordered 
across an inversion centre with the nitrogen and oxygen occupying equivalent positions in 
the two disordered components.  
In this chapter, the co-crystallisation of PA with a number of NHCs (Scheme 7-1) is 
investigated in an attempt to form molecular complexes. The co-formers used in this 
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investigation have been narrowed down to smaller subsets to facilitate a more relevant 
comparison between the supramolecular synthons formed in complexes with particular 
types of co-formers. One subset of co-formers chosen consists of imidazole (IM) and its 
derivatives, namely, 2-methylimidazole (2MIM), 4-methylimidazole (4MIM) and 
benzimidazole (BZ). These complexes will be compared only to each other as no other PA 
complexes with IM derivatives have previously been reported. The second subset consists 
of nitrogen heterocycles with only nitrogen acceptors, namely 2-picoline (2PIC), 3-picoline 
(3PIC), 4-picoline (4PIC). This subset is suitable for comparing to the other PA complexes 
in the CSD with NHCs that have only acceptor nitrogens, i.e. 4,4’-bipyridine (BP)227, 
phenazine (PHEN)17, N, N – dimethylpiperazine227, as well as the N-methylmorpholine227 
complex. 
 
Scheme 7-1 The nitrogen heterocycle co-formers used for co-crystallisation with 
paracetamol and 4-acetamidobenzoic acid.  
 
The co-crystallisation of these NHCs with the related API 4-acetamidobenzoic acid (4ABA), 
which is structurally similar to PA (Scheme 7-2), is also investigated in this chapter. 4ABA 
is a component of immunostimulant antiviral medications, of which no molecular 
complexes have previously been reported and only one polymorph is known229. Its 
molecular structure is similar to that of PA, with the exception of the presence of a 
carboxylic acid group replacing the PA phenolic hydroxyl. The molecular complexes 
produced will be compared to the PA complexes from a crystal engineering perspective to 
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determine if the structural similarity leads to the emergence of comparable, and 
therefore predictable, patterns in the structural motifs and packing in the molecular 
complexes formed with these small subsets of materials. 4ABA and PA have similar 
hydrogen bond donor/acceptor positions and are similar in size which could possibly 
allow them to co-crystallise with similar co-formers and lead to similar hydrogen bonding 
arrangements and crystal packing. The much lower pKa of the 4ABA carboxylic acid OH 
however, means it is a much better hydrogen bond donor and is more likely to be 
deprotonated should a co-former which is a strong enough base be used. The extra 
hydrogen bond acceptor in 4ABA (the carboxylic acid carbonyl) may also result in 
different hydrogen bonding arrangements from those in corresponding PA complexes. It 
is hoped, however, that a pattern might emerge from which the hydrogen bonding in a 
complex of one of the APIs will allow a reasonably accurate prediction of the hydrogen 
bonding present in a complex of the other API with the same co-former. The ultimate aim 
of such studies is eventually to be able to design molecular complexes of a material with 
specific properties based on the properties of molecular complexes of a similar material.  
 
 
Scheme 7-2 The molecular structures of paracetamol (left) and 4-acetamidobenzoic acid 
(right). 
 
7.2 Crystallisation Conditions 
 
Crystallisations were carried out according to the procedure outlined in Chapter 3 unless 
otherwise stated. Table 7.1 below outlines the solvent and temperature systems under 
which each molecular complex described in this section was observed to crystallise. 




Table 7.1 Crystallisation conditions for molecular complexes of paracetamol and 4-
acetamidobenzoic acid with nitrogen-heterocycles.  
Molecular Complex Solvent Temp (°C) 
PA:IM Methanol/Ethanol/Isopropanol RT (All solvents) 
PA:2MIM (1:2) Acetone 40 
PA:4MIM Methanol/Acetone 40 (both solvents) 
4ABA:IM Acetone 40/50 
4ABA:2MIM (2:1) Methanol/Acetone RT/40/50 
4ABA:4MIM Methanol*/Acetone# 6*/6#/40# 
4ABA:BZ Methanol*/Acetone# 6*/RT#/40#/50# 
4ABA:BP Methanol RT/40/50 
RT = Room Temperature 
 
Paracetamol: 2-methylimidazole (1:2)  
This complex crystallised in a 1:2 molar ratio, despite a 1:1 molar ratio of the components 
being used in the co-crystallisation experiments. Unsuccessful attempts were made to 
alter the ratio of the molecular complex formed by co-crystallising in 2:1 molar ratios in 
methanol and acetone using the procedure outlined in Chapter 3.  
 
4-acetamidobenzoic acid: 2-methylimidazole (2:1)  
This complex crystallised in a 2:1 molar ratio, despite a 1:1 molar ratio of the components 
being used in the co-crystallisation experiments. Unsuccessful attempts were made to 
alter the ratio of the molecular complex formed by co-crystallising in 1:2 molar ratios in 
methanol and acetone using the procedure outlined in Chapter 3.  
 
4-acetamidobenzoic acid: 2-picoline (1:1) 
Crystallisation of this molecular complex was achieved by cooling crystallisation. This was 
carried out by dissolving 0.15g 4ABA in minimal 2PIC at 65°C to generate a supersaturated 
solution and allowing the solution to cool to 6°C. Attempts were made to generate a 
molecular complex using the general evaporation procedure outlined in Chapter 3 using 







4-acetamidobenzoic acid: 3-picoline (1:1) 
Crystallisation of this molecular complex was achieved by cooling crystallisation. This was 
carried out by dissolving 0.15g 4ABA in minimal 3PIC at 50°C to generate a supersaturated 
solution and allowing the solution to cool to 6°C. Attempts were made to generate a 
molecular complex using the general evaporation procedure outlined in Chapter 3 using 
molar quantities of 3PIC in various solvents. These resulted in amorphous material being 
formed.  
 
4-acetamidobenzoic acid: 4-picoline (1:1) 
Crystallisation of this molecular complex was achieved by cooling crystallisation. This was 
carried out by 0.15g 4ABA in minimal 4PIC at 70°C to generate a supersaturated solution 
and allowing the solution to cool to 6°C. Attempts were made to generate a molecular 
complex using the general evaporation procedure outlined in Chapter 3, using molar 
quantities of 4PIC in various solvents. These resulted in amorphous material being 
formed. 
 
7.2.1 Co-crystallisation of Paracetamol with Benzimidazole and Picolines 
 
Unsuccessful attempts were made to co-crystallise paracetamol with benzimidazole using 
the procedure outlined in Chapter 3. The solvents used were methanol, ethanol, acetone 
and IPA. The molar ratios of the components were also varied between 1:1, 2:1 and 1:2 in 
attempts to induce molecular complex formation.  
 Unsuccessful attempts to co-crystallise PA with 2-, 3- and 4PIC were also carried 
out using the same procedure used in the co-crystallisations with 4ABA. Further 
unsuccessful attempts to co-crystallise PA with picolines were made by using the 
evaporation procedure outlined in Chapter 3. 1:1 molar ratios of PA and the picolines 
were dissolved in methanol, ethanol and acetone and the solvent evaporated at 6°C, 
ambient temperature, 40°C and 50°C. PA was also dissolved in excess quantities of the 






7.2.2 Paracetamol: Imidazole Molecular Complex: Scale up for Continuous 
Crystallisation in an Oscillatory Baffled Crystalliser 
 
The pharmaceutically acceptable co-former used in the PA:IM complex made it an ideal 
candidate for attempted scale-up to a continuous crystallisation process. Studies have 
also shown that the toxic effect of PA on the liver may be reduced by the presence of IM 
derivatives230,231, meaning the complex also has potential pharmaceutical applications.  
 To facilitate co-crystallisation in a COBC, attempts were made to convert the 
evaporation co-crystallisation method employed in producing the complex to a cooling 
crystallisation method. 1:1 molar ratio solutions of various degrees of supersaturation 
were therefore generated through heating and the solutions crash cooled to either 4°C or 
ambient temperature to induce crystallisation. This, mainly resulted in crystallisation of 
the less soluble PA with the majority of IM remaining in solution and no molecular 
complex being formed. The relative molar ratios were varied to 1:2 (PA:IM) in an attempt 
to promote molecular complex formation. However, this was also unsuccessful. The 
solvents used were ethanol and IPA, chosen for their relatively low toxicity.  
 
7.3  Crystal Structures of Multi-component Complexes of Paracetamol and 
Imidazoles  
 
Three molecular complexes of PA with IM and its derivatives were produced in this study. 
Crystallographic data and full refinement details can be found in (Appendix A7, Table A-
7a). 
 
7.3.1  Paracetamol : Imidazole (PA:IM) 
 
The 1:1 paracetamol : imidazole complex consists of one molecule of each component in 
the asymmetric unit with no hydrogen transfer occurring between the molecules. PA 
molecules form hydrogen bonds to each other through moderately strong interactions 
involving the amide NH of one with the hydroxyl oxygen of another (a in Figure 7.1). The 
hydroxyl group then forms a moderately strong OH···N hydrogen bond to the IM nitrogen 
atom, with the IM acting as a linker between PA molecules and forming further hydrogen 
bonding to another PA molecule through another moderately strong NH···O interaction 
with the amide carbonyl (b and c in Figure 7.1). These interactions form infinite chains, 
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with two chains branching off from each PA molecule. Hydrogen bond distances and 
angles can be found in Table 7.2. The two PA molecules linked by the IM molecules lie 
parallel to each other, while the two PA molecules linked directly to the first two through 
the NH···OH hydrogen bonds run parallel to each other, in intersecting planes with the 
first two, resulting in a staggered arrangement of PA molecules interlocking the structure 
(Figure 7.2). CH···π interactions are also present between the CH group of IM and the 
paracetamol benzene ring, with approximately 3.619 Å between the donor carbon and 
the centroid of the π bond (Figure 7.3). Slightly weaker CH···π interactions are present 
between the aromatic CH of the PA molecule and one of the IM double bonds with a 
distance of approximately 3.709 Å between the donor carbon and the centroid of the π 
bond (also Figure 7.3).  
 
 





Figure 7.2 The crystal packing in the paracetamol : imidazole complex. (a) PA molecules 
(blue) linked by IM molecules (green) lie parallel to each other. PA molecules (red) linked 
directly to the blue PA molecules run parallel to each other in planes intersecting the 











7.3.2  Paracetamol : 2-methylimidazole (1:2) (PA:2MIM)  
 
The 1:2 paracetamol: 2-methylimidazole complex consists of two 2MIM molecules and a 
single PA molecule in the asymmetric unit, forming a neutral complex with no hydrogen 
transfer occurring. 
 The paracetamol molecules are in the same hydrogen bonding environment as 
seen in the PA:IM complex (Figure 7.4). The hydrogen bonds are of similar strength to 
those in the PA:IM complex (Table 7.2), although with a slightly stronger OH···N 
interaction between the PA and 2MIM. The stronger OH···N interaction is reflective of the 
stronger basicity of 2MIM (pKa = 7.88 c.f. 6.99 for IM). A slightly weaker NH···O 
interaction occurs between the 2MIM NH and the PA amide oxygen. One major 
difference occurs in the hydrogen bonding arrangement of PX:2MIM, as the 2MIM 
molecule does not hydrogen bond directly to another PA molecule, instead forming a 
moderately strong NH···N hydrogen bond (N···N = 2.817(2) Å) to a symmetry independent 
2MIM molecule, meaning that PA molecules are linked through two 2MIM molecules 
instead of one (Figure 7.5).   
 
 
Figure 7.4 Hydrogen bonding environment of the PA molecule in the paracetamol : 2-








Table 7.2 Hydrogen bond lengths and angles in the paracetamol : imidazole and 
paracetamol : 2-methylimidazole complexes (refer to Figure 7.4 for key).  

































Figure 7.5 PA molecules linked by two 2MIM molecules in the paracetamol : 2-
methylimidazole complex. 
 
PA molecules again lie along planes running in two directions (Figure 7.6a). Parallel PA 
molecules are linked by a PA molecule lying along the second plane. This PA molecule 
links to another non-parallel PA molecule through the two hydrogen bonded 2MIM 
molecules. The planes of the PA molecules intersect, resulting in a herringbone 
arrangement of PA molecules (Figure 7.6b). Viewing the structure along the c-axis shows 
that the structure consists of domains of PA and 2MIM separated by domains of the 
symmetry independent 2MIM molecule (Figure 7.7). As in the PA:IM complex, there are 
again significant CH···π interactions (Figure 7.8). These involve the methyl CH of the IM 
interacting with the benzene ring of the PA molecule as well as the aromatic CH of the 




Figure 7.6 Crystal packing in the paracetamol : 2MIM complex. (a) The relative planes of 
the paracetamol molecules. The red PA molecules are hydrogen bonded directly to the 
orange PA molecule and lie parallel with the blue PA molecule. The blue PA molecule links 
to the orange PA molecule through the two IM molecules (green). (b) The staggered 




Figure 7.7 View along the c-axis in the paracetamol : imidazole complex, showing domains 
of PA and 2MIM (blue and green, respectively) separated by domains of the symmetry 
independent 2MIM molecule (red). 
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Figure 7.8 CH···π interactions in the paracetamol : 2methylimidazole complex. 
 
 
7.3.3  Paracetamol : 4-methylimidazole (PA:4MIM) 
 
The 1:1 paracetamol : 4-methylimidazole complex features one molecule of each 
component in the asymmetric unit. The PA molecule in the complex is twisted around the 
C-N bond so that the amide carbonyl and the methyl group lie out of plane with the 
benzene ring (Figure 7.9). The twisting is fairly pronounced, with a C5-C8-N3-C1 torsion 




Figure 7.9 Twisting around the C-N bond of the PA molecule in the paracetamol : 4-
methylimidazole complex. H-atoms other than that on the amide nitrogen are omitted for 
clarity.  
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A hydrogen bond is formed from the 4MIM NH to the PA carbonyl oxygen (c in Figure 
7.10), as is also seen in the IM and 2MIM complexes. This interaction is similar in strength 
to that seen in the PA:2MIM complex (hydrogen bond distances and angles in Table 7.3). 
The twisting of the carbonyl oxygen means it is also able to form another moderately 
strong OH···O hydrogen bond with the hydroxyl of another paracetamol molecule as it is 
no longer limited sterically by the benzene ring (a in Figure 7.10). Other than the NH···O 
interaction, the hydrogen bonding in the complex is completely different to the IM and 
2MIM complexes. Moderately strong NH···N interactions are formed between the PA 
amide NH and the 4MIM nitrogen (b in Figure 7.10) instead of the NH···O interactions 
between PA molecules found in the IM and 2MIM complexes.  
 
 
Figure 7.10 Hydrogen bonding environment of the PA molecule in the paracetamol : 4-
methylimidazole complex. 
 
Table 7.3 Hydrogen bond lengths and angles in the paracetamol : 4-methylimidazole 
complex (refer to Figure 7.10 for key). Values for the equivalent NH···O interactions in the 
PA:IM and PA:2MIM complexes are also shown for comparison. 
















PA:IM c 0.96(2) 1.91 (2) 2.7618(14) 160(2) 
PA:2MIM c 0.92(2) 1.93(2) 2.820(2) 163(2) 
 
The PA forms hydrogen bonds with 4MIM (b and c in Figure 7.10), creating infinite chains 
of alternating PA and 4MIM (Figure 7.11a). The chains are then linked to adjacent chains 
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by the OH···O hydrogen bonds between PA molecules forming infinite PA chains in that 
direction. The PA molecules are arranged in a herringbone pattern and separated from 
the PA molecules below by the 4MIM molecules (Figure 7.11b). PA molecules are further 
linked to other PA molecules by weak CH···O hydrogen bonds (C···O = 3.5013(13) Å) 
between an aromatic CH and the hydroxyl oxygen (Figure 7.12). Weak CH···π interactions 
are also present between the 4MIM CH groups and the benzene rings of PA molecules, as 
well as between an aromatic CH group of the PA molecule and the aromatic 4MIM ring 
(Figure 7.13).   
 
Figure 7.11 Crystal packing in the paracetamol : 4-methylimidazole complex. (a) Infinite 
chains of alternating PA (red) and 4MIM (blue) linked by NH···O and NH···N interactions. 
(b) The herringbone arrangement of the PA molecules linked by OH···O hydrogen bonds, 
with 4MIM molecules separating PA molecules above and below each other.  
 
 
Figure 7.12 Weak CH···O hydrogen between PA molecules in the paracetamol : 4-




Figure 7.13 CH···π interactions between the 4MIM CH groups and the PA benzene ring 
(red-dashed line, LHS) and between the PA CH group and the 4MIM ring (RHS). 
 
 
7.4 Crystal Structures of Multi-component Complexes of 4-Acetamidobenzoic Acid 
and Nitrogen-Heterocycles 
 
Eight molecular complexes of 4ABA with NHCs were produced in this study. 
Crystallographic data and full refinement details can be found in (Appendix A7, Table A-
7b). 
 
7.4.1   4-Acetamidobenzoic acid : Imidazole (4ABA¯:IM+)  
 
The 1:1 4-acetamidobenzoic acid : imidazole complex features two symmetry 
independent molecules of each component in the asymmetric unit with the acidic 
hydrogen of both 4ABA molecules transferred to the basic nitrogen of the IM molecule 
forming a 4-acetamidobenzoate (4ABA¯) : imidazolium IM+ salt. The C-N distances in the 
two IM+ molecules between the carbon in the 2-position and the two nitrogen atoms 
suggest the charge is delocalised (C-N = 1.320(3) Å, 1.329(2) Å and 1.321(2) Å, 1.327(2) Å). 
4ABA¯, however, has a clear displacement of the negative charge onto one oxygen of the 
carboxylate group, evidenced in the C···O distances (1.237(2) Å, 1.290(2) Å and 1.244(2) Å, 
1.277(2)Å). Lengthening of the C=O bond and shortening of the C-O bond does, however, 
still occur.  
 The hydrogen bonding of both symmetry independent 4ABA¯ molecules is similar, 
although small differences do exist between them (Figure 7.14). Both the 4ABA¯ 
molecules are linked to symmetry equivalent 4ABA¯ molecules through NH···O hydrogen 
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bonding of the amide NH with a carboxylate oxygen in both cases, although in one case 
the hydrogen bond is charge assisted with the deprotonated oxygen (more δ¯) acting as 
acceptor (d in Figure 7.14, left), while in the other the carbonyl (less δ¯) is the acceptor (d’ 
in Figure 7.14, right). Three IM+ molecules are directly hydrogen bonded to each 4ABA¯ 
molecule. The NH of one IM+ forms a similar bifurcated DHAA hydrogen bond with the 
carboxylate oxygen atoms in each case, forming a stronger, charge assisted hydrogen 
bond with the deprotonated oxygen, as would be expected. One 4ABA¯ molecule is linked 
to an IM+ molecule through hydrogen bonds to its carboxylate carbonyl oxygen by the CH 
group in the 2-position (e in Figure 7.14) and to another IM+ molecule through hydrogen 
bonds to its amide carbonyl through an NH···O interaction (c in Figure 7.14). The other 
4ABA¯ molecule (RHS in Figure 7.14) has IM+ molecules forming hydrogen bonds to the 
same positions, but through different interactions: NH···O interactions with the 
deprotonated carboxylate oxygen (b in Figure 7.14), and CH···O interactions with the 
amide carbonyl oxygen (g in Figure 7.14). Hydrogen bond lengths and angles can be found 
in Table 7.4. 
  
 
Figure 7.14 Hydrogen bonding of the two symmetry independent 4ABA¯ molecules in the 








Table 7.4 Hydrogen bond lengths and angles in the 4-acetamidobenzoic acid : imidazole 
salt complex (refer to Figure 7.14 for key). 
Complex H-Bond D-H (Å) H···A (Å) D···A (Å) ∠D-H···A (°) 



















































Symmetry equivalent 4ABA¯ molecules link to each other in infinite staggered chains 
(Figure 7.15a) through the NH···O interactions (d and d’ in Figure 7.14), with IM+ 
molecules linking each 4ABA¯ molecule in the chain to another 4ABA¯ chain (Figure 
7.15b). Significant π···π interactions are also present between IM+ and 4ABA¯ molecules 
with distances of approximately 3.325 Å and 3.281 Å between the centroids of the closest 
π systems (Figure 7.16).  
 
Figure 7.15 (a) Chains of 4ABA¯ in the 4ABA¯:IM+ complex (b) The IM+ molecules linking 





Figure 7.16 π···π interactions between 4ABA¯ and IM+ molecules in the 4-
acetamidobenzoic acid : imidazole salt complex. 
 
7.4.2   4-Acetamidobenzoic acid : 2-methylimidazole (2:1) (4ABA:4ABA¯:2MIM+) 
 
The 2:1 4-acetamidobenzoic acid : 2-methylimidazole complex crystallises in a 2: 1 ratio, 
with the acidic hydrogen atom of one 4ABA molecule transferring to the 2MIM nitrogen, 
meaning the asymmetric unit consists of one neutral 4-acetamidobenzoic acid molecule 
(4ABA), one 4-acetamidobenzoate molecule (4ABA¯) and a 2-methylimidazolium molecule 
(2MIM+). The 4ABA¯ molecule has the delocalised charge displaced onto one oxygen of 
the carboxylate group, although with lengthening of the C=O bond and shortening of the 
C-O bond (C-O = 1.274(2) Å and 1.242(2) Å). The 2MIM+ molecule has a more delocalised 
charge with C-N lengths of 1.336(3) Å and 1.324(3) Å (carbon in the 2-position).    
 Chains of the neutral 4ABA molecules are formed through moderately strong 
NH···O hydrogen bonds involving the amide groups (d in Figure 7.17, Table 7.5 for 
hydrogen bond distances and angles). The 4ABA¯ molecules form similar chains through 
the same type of interaction, with a slightly stronger NH···O interaction formed (d’ in 
Figure 7.17). The chains are linked through a short, strong OH···O hydrogen bond 
between the carboxylic acid hydroxyl of 4ABA and the more δ¯ oxygen (longer C-O bond) 
of the 4ABA¯ carboxylate (c in Figure 7.17). The O-H distance in this hydrogen bond is 
significantly lengthened, suggesting the hydrogen is partially shared (Table 7.5). The 
chains are further linked through the 2MIM+ molecules, with NH···O hydrogen bonds 
formed between one 2MIM+ NH group and the carbonyl oxygen of 4ABA, with the other 
NH group forming an NH···O hydrogen bond with the other carboxylate oxygen of 4ABA¯ 
(b and a in Figure 7.17 respectively). Both of these hydrogen bonds have long D-H 
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distances (Table 7.5) suggesting partial sharing of the hydrogen atom. Chains linked 
together in this way form layers that are stacked upon each other (Figure 7.18).  
 
Figure 7.17 Hydrogen bonding in the 4-acetamidobenzoic : 2-methylimidazole complex. 
 
 
Table 7.5 Hydrogen bond lengths and angles in the 4-acetamidobenzoic acid : 2-
methylimidazole complex (refer to Figure 7.17 for key). 






























Figure 7.18 Relative arrangement of the layers in the 2:1 4-acetamidobenzoic acid : 2-
methylimidazole complex.  
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Few significant interactions occur between layers, with only weak hydrogen bonds 
occurring (Figure 7.19). An aromatic CH group of the 2MIM+ forms hydrogen bonds to the 
carboxylic acid carbonyl oxygen (C···O = 3.216(3) Å) of the 4ABA below and the methyl 
group of 2MIM+ hydrogen bonds to the carboxylic acid hydroxyl oxygen of the 4ABA 
molecule above (C···O = 3.305(3) Å, ∠DHA = 123.2(1)°) (Figure 7.19a). CH···π hydrogen 
bonds also occur between 4ABA¯ and 4ABA molecules with approximately 3.655 Å 
between the carbon and the centroid of the C=C bond (Figure 7.19b).  
 
 
Figure 7.19 Interactions between layers in the 2:1 4-acetamidobenzoic acid : 2-
methylimidazole complex. (a) CH···O hydrogen bonds between the 2MIM
+
 molecule and 
the 4ABA molecules. (b) CH···π hydrogen bonds between 4ABA¯ and 4ABA molecules. 
 
 
7.4.3   4-Acetamidobenzoic acid : 4-methylimidazole (4ABA:4MIM) 
 
The 1:1 4-acetamidobenzoic acid: 4-methylimidazole complex crystallises in a 1:1 ratio 
with the acidic hydrogen of the 4ABA transferring to the 4MIM molecule. Delocalisation 
of the positive charge in the 4MIM+ molecule is evidenced by the N-C distances to the 
carbon in the 2-position (C-N = 1.324(2) Å and 1.326(2) Å). The C-O distances in the 4ABA¯ 
indicate that the delocalised negative charge is displaced towards one oxygen (C-O = 
1.245(2) Å and 1.284(2) Å), with the C=O again lengthened and the C-O shortened.  
 Interactions between 4ABA¯ molecules are similar to those seen in the 
4ABA:4ABA¯:2MIM+ complex, with chains of 4ABA¯ formed through moderately strong 
NH···O hydrogen bonds involving the amide groups (d in Figure 7.20). These NH···O 
hydrogen bonds in this complex are, however, considerably weaker than those in the 
4ABA:4ABA¯:2MIM+ complex (Table 7.6). The 4ABA¯ chains in this complex are linked in a 
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different way to those in the 4ABA¯:2MIM+ complex, as no neutral 4ABA molecules are 
present. The chains are therefore linked solely through the two NH groups of 4MIM+ 
molecules forming NH···O hydrogen bonds with the carboxylate oxygen atoms of 4ABA¯ 
molecules (a and b in Figure 7.20). The N-H bonds in these interactions are again 
relatively long (Table 7.6) The CH group in the 5-position of the 4MIM+ molecule also 
forms a weak hydrogen bond to the carboxylate oxygen of 4ABA¯ which is slightly less δ¯ 
in nature (e in Figure 7.20). These interactions again link the molecules into layers, 
although these layers are flatter than those in the 4ABA-:2MIM+ complex (Figure 7.21). 
The NH···O hydrogen bonds between the 4MIM+ and 4ABA¯ in this complex (a and 
b in Figure 7.20) are both similar to the NH interaction with the carboxylic acid carbonyl 
oxygen in the 4ABA:4ABA¯:2MIM+ complex (b in Figure 7.17) - this despite both being 
charge assisted. The NH···O hydrogen bonds are, however, considerably weaker than the 
NH interaction with the carboxylate oxygen in the 4ABA:4ABA¯:2MIM+ complex (a in 
Figure 7.17). 
 
   
 
Figure 7.20 Hydrogen bonded chains of 4ABA¯ linked by 4MIM+ molecules in the 4-






Table 7.6 Hydrogen bond lengths and angles in the 4-acetamidobenzoic acid: 4-
methylimidazole salt complex (refer to Figure 7.20 for key). Corresponding values for the 
4-acetamidobenzoic acid: 2-methylimidazole complex are also shown for comparison.  
Complex H-Bond D-H (Å) H···A (Å) D···A (Å) ∠D-H···A (°) 










































Note: a and b in the 4ABA¯: 4MIM
+
 complex are both NH···O¯ interactions with the 
deprotonated oxygen, whereas a in the 4ABA:4ABA¯:2MIM
+
 complex is an NH···O 
interaction with a carboxylate oxygen which is more of a carbonyl in nature and b is an 
NH···O interaction with a carboxylic acid carbonyl oxygen.  
 
The layers are again held together by weak interactions (Figure 7.22). The methyl groups 
of both the 4MIM+ and 4ABA¯ molecules form weak hydrogen bonds with the amide 
oxygen of the 4ABA¯ molecule below (C···O = 3.518(2) Å and 3.531(2) Å, respectively). 
Significant π···π interactions are also present between the 4ABA¯ and 4MIM+ molecules, 
with approximately 3.267 Å and 3.425 Å between the two sets of closest C=C bonds (also 
Figure 7.22).  
 
 




Figure 7.22 The weak CH···O hydrogen bonds (blue dashed lines) and π···π interactions 
(red dashed lines) between layers in the 4-acetamidobenzoic acid : 4-methylimidazole 
complex.  
 
7.4.4   4-Acetamidobenzoic Acid : Benzimidazole Monohydrate (ABA¯:BZ+.H2O) 
 
The 1:1 4-acetamidobenzoic acid : benzimidazole monohydrate complex features one 
molecule of each component in the asymmetric unit. The acidic hydrogen of 4ABA has 
transferred to the BZ nitrogen forming a benzimidazolium ion and a 4-acetamidobenzoate 
ion. The charge in both molecules is delocalised with the bond lengths indicating only 
slight displacement of the charge in both cases. The C-N bonds in BZ+ between the 
nitrogen atoms and the 2-carbon have C-N distances of 1.321(3) Å and 1.334(3) Å. C-O 
distances in the carboxylate group of 4ABA¯ are 1.262(3) Å and 1.278(3) Å. 
The crystal structure consists of infinite ABAB chains of 4ABA¯ and BZ+ molecules 
linked by strong NH···O interactions (Figure 7.23). The slightly more δ+ NH in the BZ+ 
molecule forms hydrogen bonds to the slightly more δ¯ carboxylate oxygen (a in Figure 
7.23). The hydrogen in this interaction appears not to occupy fully the modelled position 
on the nitrogen. The Fourier difference synthesis shows the electron density to be 
significantly elongated in the direction of the acceptor oxygen atom (Figure 7.24). This 
suggests that the current model (with the hydrogen placed on the electron density 
maximum and bonded to BZ) may not be an accurate reflection of the true position. The 
N-H bond is also very long suggesting sharing of the hydrogen atom (Table 7.7). The bond 
lengths in 4ABA¯ and BZ+ suggest, however, that the charge is delocalised in both 
molecules, and therefore that BZ is protonated and 4ABA is deprotonated. No 
improvement upon the current model is possible without neutron diffraction data and 
therefore definite conclusions cannot be drawn. Hydrogen bond lengths and angles (a in 
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Table 7.7) are calculated for the hydrogen in the modelled position and may not be truly 
representative of the detailed, possibly disordered, location of this hydrogen atom. The 
second NH group of BZ forms a moderately strong hydrogen bond to the amide carbonyl 





Figure 7.23 Hydrogen bonding in the 4-acetamidobenzoic acid : benzimidazole 
monohydrate complex showing the infinite chains formed by NH···O hydrogen bonds (top) 
and the interactions of the water molecules (bottom). 
 
Table 7.7 Hydrogen bond lengths and angles in the 4-acetamidobenzoic acid : 
benzimidazole monohydrate complex (refer to Figure 7.23 for key).  




































Figure 7.24 Fourier difference map showing the electron density close to the modelled 
position of the hydrogen atom (H7) in the short, strong NH···O hydrogen bond between 
4ABA¯ and BZ+ in the 4-acetamidobenzoic acid : benzimidazole monohydrate complex. The 
map is calculated with the H atom (H7) removed from the model. The electron density is 
smeared out in the direction of the acceptor oxygen atom (not shown) suggesting the 
model is not a true reflection of the hydrogen position.  
 
Neighbouring chains are linked into bilayers through the water molecules, with the 4ABA¯ 
amide NH group forming a moderately strong hydrogen bond to the water oxygen (c in 
Figure 7.23). The methyl group of 4ABA¯ also forms a weak hydrogen bond to the water 
oxygen (f in Figure 7.23). The water OH then forms a moderately strong hydrogen bond to 
the 4ABA¯ molecule in the next chain via the carboxylate oxygen which is not hydrogen 
bonded to BZ+ (d in Figure 7.23). The second water OH group forms another moderately 
strong hydrogen bond to the same carboxylate oxygen of a 4ABA¯ molecule above (e in 
Figure 7.23) resulting in the bilayers stacking upon each other (Figure 7.25). Significant 
π···π stacking between BZ+ molecules is also present between the stacked bilayers with 
approximately 3.432 Å between the centroids of the two π bonds (Figure 7.26). Weak 
hydrogen bonds (Figure 7.27a) hold neighbouring bilayers together resulting in a 
herringbone arrangement of the bilayers. One is a weak, bifurcated, DDHHA hydrogen 
bond, formed between the CH groups of the BZ+ benzene ring and the carboxylate oxygen 
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of a 4ABA¯ molecule (C···O =  3.439(4) Å and 3.446(4) Å). Another weak hydrogen bond is 
formed between an aromatic 4ABA¯ CH group and the BZ+ benzene ring (distance from C 
to centre of π bond = approximately 3.800 Å).   
 
 
Figure 7.25 Crystal packing in the 4-acetamidobenzoic acid : benzimidazole monohydrate 
complex. The view along the a-axis (LHS) shows the chains of 4ABA¯ and BZ
+ 
are linked 
into bilayers by water molecules (green).  The view along the ac diagonal (RHS) shows 
how the bilayers are stacked upon each other (Separate chains within the bilayers shown 
in red and blue). 
 
 





Figure 7.27 Relative arrangement of bilayers in the 4-acetamidobenzoic acid : 
benzimidazole monohydrate complex. (a) Weak interactions between neighbouring 
bilayers. (b) Herringbone arrangement of the bilayers.  
 
 
7.4.5   4-Acetamidobenzoic acid : 4,4’-bipyridine (2:1) (ABA:BP)  
 
The asymmetric unit of the 4-acetamidobenzoic acid : 4,4-bipyridine complex features 
one 4ABA molecule and half of a BP molecule, with the BP molecule lying on an inversion 
centre. No hydrogen transfer occurs in the complex. The crystal structure comprises 
chains of 4ABA molecules, linked through moderately strong NH···O hydrogen bonds 
between the amide groups (a in Figure 7.28, see Table 7.8 for hydrogen bond distances 
and angles). The chains are linked through moderately strong OH···N hydrogen bonds 
between the carboxylic OH group of 4ABA and the BP nitrogen (b in Figure 7.28). The O-H 
distance in this hydrogen bond is again relatively long. These interactions result in infinite 
hydrogen bonded units, with large gaps between the BP molecules in the units (Figure 
7.29a). 4ABA molecules linked through the amide groups do not lie co-planar (Figure 
7.29b), with the molecules running alternately in different planes, resulting in a zigzagging 
arrangement of the hydrogen bonded units (Figure 7.29c).  
 275
 
Figure 7.28 The hydrogen bonded 4ABA chains linked by BP molecules in the 4-





Figure 7.29 Crystal packing in the 4-acetamidobenzoic acid : 4, 4’ - bipyridine complex. (a) 
Infinite hydrogen bonded units formed by the interactions shown in Figure 7.28 (red = BP, 
blue = 4ABA). (b)  The non co-planar arrangement of hydrogen bonded 4ABA molecules in 
the chains. (c) Rotation of (a) by 90° showing the zigzagging arrangement of the units. 
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Table 7.8 Hydrogen bond lengths and angles in the 4-acetamidobenzoic acid : 4,4’-
bipyridine complex (refer to Figure 7.28 for key).   
Complex H-Bond D-H (Å) H···A (Å) D···A (Å) ∠D-H···A (°) 












The 4ABA and BP molecules of other units pass through the gaps in the units, interlocking 
the structure (Figure 7.30). The 4ABA molecules passing through the gaps interact with 
the 4ABA molecules in the units via weak aromatic CH···O hydrogen bonds with the 
hydroxyl oxygen (C···O = 3.1878(14) Å) (Figure 7.31a). Further weak CH···O hydrogen 
bonds are formed by the aromatic CH groups of the BP molecules with the amide oxygen 
(C···O = 3.5338(15) Å) (also Figure 7.31a). BP molecules also interact with 4ABA molecules 
via a bifurcated DDHHA hydrogen bond to the carboxylic acid carbonyl oxygen (C···O = 
3.4079(14) Å and 3.2651(14) Å) (Figure 7.31b). π···π stacking is also present between 













Figure 7.30 Interpenetration of the primary hydrogen bonded units in the 4-
acetamidobenzoic acid : 4,4-bipyridine complex. Two interpenetrating units with the 
different units coloured red and blue (top) and BP (blue) and 4ABA (red) molecules passing 





Figure 7.31 Weak hydrogen bonding in the 4-acetamidobenzoic acid : 4,4-bipyridine 
complex. (a) Weak CH···O hydrogen bonds of 4ABA with other 4ABA molecules and BP 




Figure 7.32 π···π stacking between 4ABA and BP molecules in the 4-acetamidobenzoic acid 
: 4,4-bipyridine complex.  
 
 
7.4.6  4-Acetamidobenzoic acid : 2-picoline (4ABA:2PIC) 
 
The 1:1 4-acetamidobenzoic acid : 2-picoline complex features one 4ABA and one 2PIC 
molecule in the asymmetric unit with no hydrogen transfer occurring. Chains of 4ABA are 
formed through moderately strong NH···O hydrogen bonds of the amide NH with the 
carbonyl oxygen atoms (a in Figure 7.33, see Table 7.9 for hydrogen bond lengths and 
angles). Stronger OH···N hydrogen bonds are then formed between the 4ABA carboxylic 
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OH and the 2PIC nitrogen (b in Figure 7.33). The O···N distance in this hydrogen bond is 
short and the O-H bond is lengthened significantly (Table 7.9). The 4ABA molecules in the 
chains are not co-planar (Figure 7.34a), instead lying alternately along two sets of parallel 
planes resulting in an interlocked structure (7.34b) with weak hydrogen bonds linking the 
chains.  
 
Figure 7.33 Hydrogen bonding in the 4-acetamidobenzoic acid : 2-picoline complex 
showing moderately strong NH···O hydrogen bonds forming chains of 4ABA and the 
OH···N hydrogen bonds linking 2PIC molecules to the 4ABA molecules.  
 
Table 7.9 Hydrogen bond lengths and angles in the 4-acetamidobenzoic acid : 2-picoline 
complex (refer to Figure 7.33 for key). 
Complex H-Bond D-H (Å) H···A (Å) D···A (Å) ∠D-H···A (°) 













Figure 7.34 Crystal packing in the 4-acetamidobenzoic acid : 2-picoline complex. (a) The 
relative arrangement of the 4ABA molecules (and the hydrogen bonded 2PIC molecules) in 
the chains showing the molecules running alternately in different directions. (b) The 
interlocked structure (molecules running in parallel planes are coloured accordingly). 
 
 
The 2PIC molecules link chains together through weak aromatic CH···O hydrogen bonds 
(C···O = 3.484(4) Å) to the 4ABA hydroxyl oxygen (Figure 7.35a) as well as weak CH···O 
hydrogen bonds (C···O = 3.518(4) Å and 3.510(5) Å) from the methyl CH to two 4ABA 
amide oxygen atoms (Figure 7.35b). A 4ABA methyl CH also forms a weak CH···π hydrogen 
bond (Figure 7.35c) with the aromatic ring of another 4ABA molecule (distance from 




Figure 7.35 Weak hydrogen bonds in the 4-acetamidobenzoic acid : 2-picoline complex 
(red dashed lines). (a) CH···O hydrogen between the 2PIC aromatic CH group and 4ABA 
hydroxyl oxygen. (b) CH···O hydrogen bonds between the 2PIC methyl CH groups and the 
4ABA amide oxygen atoms. (c) Methyl CH···π hydrogen bonds between 4ABA molecules.   
 
 
7.4.7   4-Acetamidobenzoic acid : 3-picoline (4ABA:3PIC) 
 
The 4-acetamidobenzoic acid : 3-picoline complex features one 4ABA and one 3PIC 
molecule in the asymmetric unit with no hydrogen transfer occurring. As in the 4ABA: 
2PIC complex, the 3PIC molecule forms hydrogen bonds to the 4ABA carboxylic acid 
hydroxyl via an OH···N bond (Figure 7.36a). Chains of 4ABA are formed through 
moderately strong NH···O hydrogen bonds involving the NH and carbonyl of the amide 
groups (Figure 7.36a). The hydrogen bonding in these chains is slightly stronger than that 
seen in the NH···O hydrogen bonds between the amide NH and the carboxylic acid 
carbonyl in the 4ABA:2PIC complex (Table 7.10). The 4ABA molecules in the chains do not 




Figure 7.36 The hydrogen bonded chains in the 4-acetamidobenzoic acid : 3-picoline 
complex. (a) Hydrogen bonding in the chains. (b) 90° rotation of (a) showing the slightly 
staggered arrangement of the 4ABA molecules relative to each other. 
 
Neighbouring chains are linked by weak CH···O hydrogen bonds between the aromatic CH 
groups of 3PIC with the 4ABA carboxylic acid hydroxyl oxygen (C···O = 3.190(2) Å, ∠DHA = 
100.5(12) Å) as well as between the 3PIC methyl CH and the 4ABA carboxylic acid 
carbonyl oxygen (C···O = 3.527(3) Å) (Figure 7.37a). This creates non co-planar layers 
which are arranged in a wave-like fashion (Figure 7.37b). The interactions between these 
layers are weak with two types of methyl CH···O hydrogen bonding occurring between 
4ABA molecules (Figure 7.38a). The first weak hydrogen bond occurs between the methyl 
group and the carboxylic acid hydroxyl oxygen with a C···O distance of 3.412(2) Å. The 
second hydrogen bond is slightly weaker with a C···O distance of 3.516(2) Å and involves 
the carboxylic acid carbonyl oxygen as the acceptor. Significant π···π interactions are also 
present between the aromatic rings of 4ABA and 3PIC molecules in different layers with 
distances of approximately 3.360 Å and 3.415 Å between the two sets of closest π bonds 
(Figure 7.38b).  
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Figure 7.37 The non-coplanar layers in the 4-acetamidobenzoic acid : 3-picoline complex. 
(a) The weak CH···O interactions (red dashed lines) holding chains together in layers. (b) 




Figure 7.38 The weak interactions between layers in the 4-acetamidobenzoic acid : 3-
picoline complex. (a) The weak methyl CH hydrogen bonds with the carboxylic acid oxygen 
atoms. (b) π···π interactions between 4ABA and 3PIC molecules (H-atoms omitted for 
clarity).  
 
7.4.8   4-Acetamidobenzoic Acid : 4-picoline (4ABA:4PIC) 
 
The 1:1 4-acetamidobenzoic acid : 4-picoline complex features one 4ABA and one 4PIC 
molecule in the asymmetric unit with no hydrogen transfer occurring. The structure-
 284
directing hydrogen bonds in the complex are similar to those in the 4ABA:3PIC complex 
with NH···O interactions of the amide groups linking the 4ABA molecules into infinite 
chains and the carboxylic acid OH forming hydrogen bonds to the 4PIC nitrogen atom 
(Figure 7.39). Once again the O-H distance in this hydrogen bond is lengthened (Table 
7.10). Both the hydrogen bonds in this complex, however, are slightly stronger than those 
in the 3PIC complex (Table 7.10). The relative orientation of alternate 4ABA molecules in 
the chains is significantly different from that found in the ABA:3PIC complex (Figure 7.40), 
with the planes of the benzene rings almost at right angles (approximately 87.40°) to each 
other, whereas the planes of alternate 4ABA molecules in the 4ABA:3PIC complex lie 
much closer to parallel (approximately 10.31° between the planes of the benzene rings). 
 
 






Figure 7.40 Relative arrangement of 4ABA chains in the molecular complexes with 4-
picoline (left) and 3-picoline (right) as viewed along the plane of the benzene ring.  
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Table 7.10 Hydrogen bond lengths and angles in the 4-acetamidobenzoic acid complexes 
with 3- and 4-picoline (refer to Figure 7.36 and Figure 7.39 for key). The corresponding 
values for the 4ABA:2PIC and 4ABA:BP complexes are also shown for comparison.  
Complex H-Bond D-H (Å) H···A (Å) D···A (Å) ∠D-H···A (°) 








































Note: NH···O hydrogen bonds in the 4ABA:2PIC complex (marked a*) involve the carboxylic 
carbonyl of 4ABA; values for hydrogen bond a in the other complexes refer to NH···O 
interactions with the amide carbonyl.  
 
The aromatic CH groups of 4ABA form hydrogen bonds to both the carbonyl oxygen of the 
amide group (C···O = 3.533(2) Å) and the carbonyl oxygen of the carboxylic acid group 
(C···O = 3.270(2) Å) (Figure 7.41). The CH forms hydrogen bonds with the carboxylic acid 
carbonyl oxygen, linking the 4ABA molecules in a herringbone arrangement (Figure 7.42), 
while the NH···O chains (in Figure 7.39) link these herringbone units into layers. The 4PIC 
molecules then intersect these layers (also Figure 7.42).  
 
 
Figure 7.41 Weak hydrogen bonds (red dashed lines) between 4ABA molecules in the 4-




Figure 7.42 Crystal packing in the 4-acetamidobenzoic acid : 4-picoline complex showing 
the herringbone arrangement of 4ABA molecules (blue, left) and the relative positions of 
the 4PIC molecules (red, right).  
 
Further weak interactions are present involving the 4PIC molecules (Figure 7.43). Weak 
CH···π hydrogen bonds are formed between an aromatic CH group of 4PIC and the 4ABA 
benzene ring (distance from C to centroid of π bond = approximately 3.542 Å). Another 
aromatic CH group forms a weak hydrogen bond to the carboxylic acid carbonyl oxygen of 
another 4ABA molecule (C···O = 3.226(2) Å). A 4ABA methyl group also forms another 
CH···π hydrogen bond to the 4PIC benzene ring (distance from C to centroid of π bond = 
approximately 3.588 Å).   
 
Figure 7.43 Weak CH···π and CH···O hydrogen bonds involving the 4PIC molecule in the 4-




In total three molecular complexes of paracetamol (PA) were synthesised in the co-
crystallisation experiments. The co-formers used (imidazole (IM), 2-methylimidazole 
(2MIM) and 4-methylimidazole (4MIM)) were also successfully co-crystallised with 4-
acetamidobenzoic acid (4ABA). 4ABA was also successfully co-crystallised with 4,4-
bipyridine, for which a molecular complex with PA can be found in the CSD227. In addition, 
four other molecular complexes of 4ABA were synthesised; the co-formers used 
(benzimidazole (BZ), 2-picoline (2PIC), 3-picoline (3PIC) and 4-picoline (4PIC)) could not, 
however, be co-crystallised with PA under the conditions studied.  
 
7.5.1 Supramolecular Synthons 
 
Molecular Complexes of Paracetamol with Imidazole and Derivatives 
 
Of the three complexes of PA with IMs, two exhibited very similar hydrogen bonding 
synthons. These were the PA:IM complex and the PA:2MIM complex (see Figure 7.4). 
Both complexes exhibit the same hydrogen bonding between PA molecules with the 
amide NH forming a hydrogen bond to the hydroxyl oxygen. The PA molecules also form 
hydrogen bonds to the IM and 2MIM molecules via the same interactions, with NH···O 
hydrogen bonds from the IM/2MIM to the PA amide carbonyl and OH···N hydrogen bonds 
from the PA OH to the IM/2MIM nitrogen. The major difference in the 2MIM complex is 
the presence of two 2MIM molecules separating the PA molecules, linked to each other 
through an NH···N hydrogen bond, resulting in the 1:2 (PA:2MIM) ratio of the complex. 
The PA:2MIM complex is unable to adopt an isostructural structure to that of PA:IM, as 
the IM CH in the 2-position forms significant CH···π interactions with a PA benzene ring 
(Figure 7.3) which is not possible with the bulkier methyl group in the 2-position. 
Rearrangement of the weak interactions alone is not sufficient to stabilise an equivalent 
structure in the 2MIM complex, as the hydrogen bonding involving PA molecules either 
side of the methyl group in the 2-position would presumably also be unfavourable in that 
case. The PA:IM complex has very little space either side of the 2-position of IM and could 
not accommodate a methyl group in this position (Figure 7.44). The 2MIM molecules in 
the PA:2MIM complex lie head to tail allowing sufficient space for the methyl groups (also 
Figure 7.44). The different arrangement results in the NH of one IM molecule forming a 
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hydrogen bond to the nitrogen of the second IM molecule, a weaker acceptor than the 
amide oxygen.  
 The PA:4MIM complex shares little in common with the other two complexes in 
terms of hydrogen bonding although it is the only complex to exhibit hydrogen bonding 
between the strongest donor and strongest acceptor, the OH···O hydrogen bond from the 
PA hydroxyl to a PA amide carbonyl oxygen. The only hydrogen bond to feature in all 
three complexes is the NH···O hydrogen bond from the IM NH to the same amide 
carbonyl oxygen (Figure 7.10). The amide group of PA in the PA:4MIM complex is twisted 
out of the plane of the benzene ring (Figure 7.9), which allows two hydrogen bonds to be 
formed to the carbonyl oxygen. No such twisting occurs in the other two complexes, 
preventing a second hydrogen bond being formed as the benzene ring sterically limits 
access to the position. Significant CH···π interactions also occur in all three complexes 
although they vary in nature from system to system.  
 
 
Figure 7.44 Spacefill diagram showing the relative positions of the IM and 2MIM 
molecules in the (a) PA:IM and (b) PA:2MIM complexes. The 2-position of IM is too 
crowded to accommodate a bulky methyl group whereas the packing in the PA:2MIM 






Molecular Complexes of 4-Acetamidobenzoic Acid with Imidazole and Derivatives 
 
All four complexes of 4ABA with imidazole and its derivatives resulted in complexes with 
intermolecular hydrogen transfer between the carboxylic acid group of 4ABA and the 
basic nitrogen of the IM ring. The 4ABA:4ABA¯:2MIM+ complex is a partial exception to 
this, having one 4ABA molecule neutral and the other deprotonated. In all cases a charge 
assisted hydrogen bond is formed between the NH of the imidazolium ring and a 
carboxylate oxygen. In the 4ABA¯:IM+ complex this occurs between both symmetry 
independent pairs of 4ABA¯ and IM+ molecules, while one IM+ molecule also forms a 
second NH···O interaction of this kind through the other NH group. Two of these 
interactions are also formed in the 4ABA¯:4MIM+ complex. The 4ABA¯:BZ+.H2O complex 
possesses the strongest of these hydrogen bonds (Table 7.11), as may be expected given 
BZ is the least basic co-former and therefore produces the strongest conjugate acid (pKa = 
5.53). The Fourier difference map showing elongation of the hydrogen position in the 
hydrogen bond (Figure 7.24), as well as the long N-H bond which suggests sharing of the 
hydrogen atom, is also explained by the weak basicity of BZ. The next strongest of these 
hydrogen bonds occurs in the 4ABA¯:IM+ complex; this is also expected as IM is the 
second weakest of the bases (pKa = 6.99). Both hydrogen bonds in the 4MIM complex are 
weaker than the hydrogen bond in the 2MIM complex, which is unexpected as 4MIM has 
a lower pKa than 2MIM (4MIM pKa = 7.5 c.f. 7.88 in 2MIM).  
 
Table 7.11 Hydrogen bond lengths and angles between the NH groups of the imidazolium 
rings and 4ABA carboxylate oxygen in the 4ABA complexes with IM, 2MIM, 4MIM and BZ.  




















1.02(3) 1.61(3) 2.630(2) 169(3) 












 a 1.21(4) 1.34(4) 2.544(3) 178(4) 
 
In cases where the second NH group of the imidazolium ring does not also form a 
hydrogen bond to the carboxylate oxygen, hydrogen bonds are formed to carbonyl 
oxygen atoms of 4ABA/4ABA¯. In the 4ABA¯:IM+ complex the second IM+ molecule forms 
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a hydrogen bond with the amide carbonyl oxygen which is also the case in the 
4ABA¯:BZ+.H2O complex. In the 4ABA:4ABA¯:2MIM
+ complex, on the other hand, the 
second NH···O hydrogen bond is with the carboxylic acid carbonyl oxygen of the neutral 
4ABA molecule.   
 The 2MIM+ and 4MIM+ complexes share the same hydrogen bonding between 
4ABA¯ molecules (Figures 7.17 and 7.20), with chains of 4ABA¯ formed in both complexes 
through NH···O hydrogen bonding of the amide groups. The neutral 4ABA molecules in 
the 2MIM complex also form chains through this synthon. This synthon does not occur in 
the complexes with IM+ or BZ+. The amide NH of 4ABA¯ molecules in the 4ABA¯:IM+  
complex is hydrogen bonded to the carboxylate oxygen atom to form a similar type of 
chain. In the 4ABA¯:BZ+.H2O complex, the amide NH is hydrogen bonded to the water 
molecule which then in turn is hydrogen bonded to the carboxylate oxygen through an 
OH···O interaction.   
 The 4ABA:4ABA¯:2MIM+ complex is the only complex that does not crystallise in a 
1:1 ratio, forming a complex with a 2:1 ratio with both neutral and deprotonated 4ABA 
molecules in the asymmetric unit (for completeness, this could also be termed a 1:1:1 
complex if the neutral and deprotonated ABA molecules are regarded as distinct species). 
This ratio of components in the product complex is found despite being crystallised from 
a 1:1 molar ratio of the components. The presence of the neutral 4ABA molecule 
increases competition for hydrogen bonding to the carboxylate site of the deprotonated 
4ABA¯. With the OH···O hydrogen bond formed between 4ABA and 4ABA¯ molecules, 
only one 2MIM+ molecule can form a hydrogen bond to the site resulting in the 2:1 ratio 
(Figure 7.17). In the 4ABA¯:4MIM complex, which shares the same amide NH···O 
hydrogen bonding between 4ABA¯ molecules, two 4MIM+ molecules form hydrogen 
bonds to the carboxylate site, resulting in a 1:1 ratio of components in the product 
complex (Figure 7.20). The different position of the methyl in the 2MIM+ complex would 
prevent the formation of the same hydrogen bonding arrangement as found in the 
4MIM+ complex.  
 
 
Molecular Complexes of 4-Acetamidobenzoic Acid with Aprotic N-Heterocycles 
 
Four complexes of 4ABA with aprotic nitrogen heterocycles (aNHCs) were synthesised, 
and no hydrogen transfer was found to occur in any of the complexes formed. In all four 
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complexes a common synthon is formed between the 4ABA and the aNHC, with the 
carboxylic acid OH forming a hydrogen bond to the nitrogen atom in all cases. In the case 
of the 4ABA:BP complex, this results in a 2:1 molar ratio as there are two acceptor 
nitrogen atoms present.  
 Three of the four complexes feature the same 4ABA chains seen in the 4ABA¯ 
complexes with 2MIM+ and 4MIM+, formed through NH···O hydrogen bonds between the 
amide groups. The exception to this is the 4ABA:2PIC complex, where similar chains are 
formed but with the NH···O=C interaction involving the carboxylic acid carbonyl as the 
acceptor. This carbonyl oxygen forms only weak CH···O hydrogen bonds in the other three 
complexes. 
 
Comparison of Molecular Complexes of Paracetamol and 4-Acetamidobenzoic acid with 
Imidazole and Derivatives 
 
Comparing the synthons present in these structures is complicated by the fact that 
hydrogen transfer occurs in the 4ABA complexes which alters the hierarchy of the 
hydrogen bonding strengths of the donors and acceptors available. In spite of this, 
patterns do emerge. A common synthon is the NH···O hydrogen bond between the 
imidazole/imidazolium NH and the amide carbonyl of PA/4ABA. This occurs in all three PA 
complexes as well as the 4ABA¯ complexes with IM+ and BZ+. The interactions of the 
4ABA¯ carboxylate and the PA carboxylic acid can also be considered interchangeable to a 
certain degree. With the exception of the PA:4MIM complex, the OH···N interaction 
between PA and the imidazole nitrogen is interchangeable with the charge assisted 
NH···O interaction between the imidazolium NH and the 4ABA carboxylate oxygen. The 
combination of these interactions results in a 1:1 complex in four of the five cases in 
which it occurs; the PA:2MIM complex is the exception, due to the steric affect of the 
methyl in the 2-position. The amide chains occurring in the 4ABA complexes with 2MIM+ 
and 4MIM+ are not seen in any of these PA complexes.   
 
 
Comparison of Molecular Complexes of Paracetamol and 4-Acetamidobenzoic acid with 
Aprotic Nitrogen Heterocycles 
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Of the aNHCs successfully co-crystallised with 4ABA, only BP has also been co-crystallised 
with PA227. Three other complexes of PA with aNHCs can be found in the CSD, however, 
which are suitable for comparison to the 4ABA complexes reported here. These are the 
complexes with phenazine17, N,N-dimethylpiperazine227 and N-methylmorpholine227. The 
N-methylmorpholine molecule in the PA : N-methylmorpholine complex is disordered 
across an inversion centre, with the effective equivalence of the nitrogen and oxygen 
atom resulting in it being isostructural with the PA : N,N-dimethylpiperazine complex. The 
lack of hydrogen transfer in the 4ABA complexes here makes the comparison more 
relevant than in the complexes with imidazole and its derivatives.  
 As discussed above, the four complexes of 4ABA exhibit persistent patterns of 
hydrogen bonding with only one (4ABA:2PIC) showing slight variation. Analysis of the PA : 
N,N-dimethylpiperazine complex and the isostructural PA : N-methylmorpholine complex 
shows that these two complexes share comparable hydrogen bonding synthons to those 
found in the 4ABA complexes with BP, 3PIC and 4PIC (Figure 7.45). All feature chains of 
4ABA or PA formed through NH···O hydrogen bonds of the amide groups. NH···O 
hydrogen bonds are also formed in both between the aNHC and either the carboxylic acid 
or hydroxyl OH group. As in the 4ABA complex with BP, the presence of two nitrogen 
atoms in the aNHC results in 2:1 PA:aNHC complexes being formed in both of these 
complexes.   
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Figure 7.45 Hydrogen bonding in (a) the PA : N,N-dimethylpiperazine complex227, (b) the 
PA:BP complex
227
 and (c) the 4ABA:4PIC complex. The PA : N,N-dimethylpiperazine 




Comparison of the 4ABA and PA complexes with BP shows very different hydrogen 
bonding arrangements (Figure 7.46). The PA complex features chains of PA formed 
through OH···O hydrogen bonds between the hydroxyl and the amide carbonyl, whereas 
the 4ABA complex features 4ABA chains formed through NH···O hydrogen bonding of the 
amide groups. BP molecules are hydrogen bonded to each PA molecule through NH···N 
interactions of the amide NH with the second BP nitrogen, forming only weak hydrogen 
bonds with the aromatic CH groups of PA. This results in a 1:1 ratio of the components in 
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the molecular complex as opposed to the 2:1 ratio found in the 4ABA complex due to the 
two OH···N interactions formed. 
 
Figure 7.46 The hydrogen bonding arrangement in the 1:1 PA:BP complex (top) and the 
2:1 4ABA:BP complex (bottom). The conventional hydrogen bonds are shown as blue 
dashed lines with the CH···N hydrogen bonds between PA and BP shown as red dashed 
lines.  
 
The PA complex with phenazine (PHEN)17 again shows a different hydrogen bonding 
arrangement to any of the 4ABA complexes or other PA complexes (Figure 7.47). The 
complex crystallises in a 1:2 ratio (PA:PHEN) with PA molecules forming both OH···N and 
NH···N hydrogen bonds to the PHEN nitrogen atoms, with further weak aromatic CH···N 
hydrogen bonds also present, along with aromatic CH···O hydrogen bonds to the amide 
oxygen of other PA molecules.  
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 Figure 7.47 Hydrogen bonding in the PA:PHEN complex17. Conventional OH···O and NH···N 
hydrogen bonds are shown as blues dashed lines, whilst weak CH···N and CH···O hydrogen 
bonds are shown as red dashed lines. 
 
 
7.5.2 Hydrogen Transfer and ∆pKa 
 
No hydrogen transfer occurs in any of the PA complexes and this can be rationalised by 
consideration of the ∆pKa values for these complexes (Table 7.12). The hydroxyl group of 
PA is weakly acidic (pKa = 9.5) and as a result all ∆pKa values for the complexes are 
negative.  
 Hydrogen transfer behaviour in the majority of the 4ABA complexes can similarly 
be rationalised by application of the ∆pKa rule (also Table 7.12). Use of the co-formers 
with the highest ∆pKa values (IM, 2MIM and 4MIM) results in complexes exhibiting 
hydrogen transfer, whereas in the majority of complexes with weaker bases (2PIC, 3-PIC, 
4PIC and BP) no hydrogen transfer occurs. The 4ABA¯:BZ+.H2O complex is anomalous as 
the ∆pKa value is below that of the PIC complexes yet hydrogen transfer appears to 
occur, as indicated by the bond distances in both the component 4ABA¯ and BZ+ 
molecules; as discussed above, however, the hydrogen position determined from the 
single crystal X-ray diffraction data is poorly defined. This highlights the difficulty in 
predicting hydrogen transfer when the ∆pKa lies between 1 and 3. 
 The 4ABA:4ABA¯:2MIM+ complex may also be classed as an anomaly due to the 
presence of both neutral and deprotonated 4ABA molecules. In this case the ∆pKa is 
greater than 3 and so hydrogen transfer is expected. Complexes such as these highlight 
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one of the flaws in attempting to predict hydrogen transfer via the pKa rule, in this case 
the fact that it does not account for the 2:1 molar ratio in the complex.  
 The inability to obtain molecular complexes through the co-crystallisation of PA 
with BZ, 2PIC, 3PIC or 4PIC can also be partly rationalised by inspection of the ∆pKa 
values. The majority of co-formers for which large negative ∆pKa values are obtained 
using the PA acidity value (∆pKa ≤  −3.50 - red in Table 7.12) could not be co-crystallised 
to form molecular complexes under the conditions studied. The PA : BP complex is the 
exception to this, with the poor basicity of BP and poor acidity of PA reflected in the ∆pKa 
value. This explains the lack of OH···N hydrogen bonds, with the low affinity causing the 
OH group to favour the much stronger amide acceptor of another PA molecule in this 
complex.  In contrast, for 4ABA, all co-formers used yield ∆pKa values ≥ −1 and hence 
molecular complexes are formed successfully in these cases.   
 
Table 7.12 ΔpKa values for the molecular complexes of 4ABA and PA with NHCs, where 
∆pKa = pKa[base] – pKa[acid]. pKa values for the NHC co-formers are quoted for the 
conjugate acid of the basic nitrogen. Complexes where hydrogen transfer occurs are 
highlighted in blue. Boxes highlighted in red indicate co-formers which did not co-
crystallise with PA to form molecular complexes. 
 
Co-Former, pKa1  
ΔpKa  
PA (pKa = 9.50) 
ΔpKa  
4ABA (pKa = 4.27) 
2-Methylimidazole, 7.88 -1.62 3.61* 
4-Methylimidazole, 7.55 -1.95 3.28 
Imidazole, 6.99 -2.51 2.27 
2-Picoline, 6.00 -3.50 1.73 
4-Picoline, 5.99 -3.51 1.72 
3-Picoline, 5.70 -3.80 1.43 
Benzimidazole, 5.53 -3.97 1.26 
4, 4 - Bipyridine, 3.27 -6.23 -1.00 
* The 2:1 4-acetamidobenzoic acid : 2-methylimidazole complex features one 
deprotonated 4ABA¯ and one neutral 4ABA.  
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7.5.3 Scale Up of the Paracetamol : Imidazole Co-crystallisation for Continuous 
Crystallisation in an OBC 
 
The inability to convert the evaporative process used for the co-crystallisation of this 
complex to a cooling crystallisation process meant that scale up for trials in the batch OBC 
was not possible. The different solubilities of the two components resulted in the PA 
crystallising out of solution with the majority of IM remaining in solution and not 
crystallising. This highlights the need to carry out extensive investigations of the solvent 
system and relative concentrations required to convert an evaporative process to a 
cooling process, as the conditions used in each process are not necessarily 
interchangeable. PXRD analysis (Appendix B7a) shows that the co-crystallisation from 
evaporation produced a mixture of the molecular complex and the two starting 
components. The difference in solubility between components of a molecular complex 
has also, of course, wider reaching implications when considering the potential use of 
even molecular complexes with favourable properties in industries such as 
pharmaceuticals; the inability to scale up efficiently in non-evaporative continuous 
crystallisation environments would make such materials non-viable. Following on from 
the preliminary investigations reported here, further studies are ongoing in this area 
within a larger collaborative project as part of the EPSRC National Centre in Continuous 
Crystallisation and Manufacturing232; these include the examination of other important 
variables such as the cooling rate, which was not controlled in the trials carried out, 
and/or seeding of the supersaturated solution.  
 
7.5.4  Summary and Conclusions 
 
All co-formers which formed molecular complexes with PA also formed molecular 
complexes with 4ABA although the reverse was not true as BZ, 2PIC, 3PIC or 4PIC could 
not be co-crystallised with PA to form molecular complexes under the conditions studied, 
yet all co-crystallised readily with 4ABA. The increased flexibility of 4ABA to form 
molecular complexes readily with weak bases such as BZ, 2PIC, 3PIC and 4PIC is likely due 
to the stronger hydrogen bond donating carboxylic acid present in 4ABA, as illustrated by 
the relatively large negative ∆pKa values between PA and these co-formers compared 
with the ∆pKa values for 4ABA and the same co-formers.  
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 No hydrogen transfer occurred in any of the PA complexes, which is to be 
expected given the negative ∆pKa values for these complexes. The hydrogen transfer 
observed in the 4ABA complexes is relatively predictable based on ∆pKa values, with the 
exception of the 4ABA¯:BZ+.H2O complex.  
 The formation of PA complexes with IM and 2MIM resulted in structures with 
similar supramolecular synthons, despite a 1: 1 component ratio being formed in the 
complex with IM and a 1:2 (PA:2MIM) complex being formed in the complex with 2MIM. 
The PA:4MIM complex, on the other hand, resulted in a very different hydrogen bonding 
arrangement due to twisting of the PA molecule allowing two hydrogen bonds to be 
formed to the amide oxygen. The NH···O interaction of the imidazole ring with the amide 
oxygen is the only common synthon to be found in all three complexes. This synthon is 
also found in the 4ABA¯ complexes with BZ+ and IM+ (in the latter case the synthon 
formation involves one symmetry independent IM+ only). The synthon is not as persistent 
in the 4ABA complexes with imidazoles however, as the carboxylate group provides extra 
competition for hydrogen bond acceptors. NH···O hydrogen bonds to the carboxylate 
oxygens are found in all 4ABA complexes with imidazole derivatives, with both 
imidazolium NH groups forming hydrogen bonds to the carboxylate in some cases.  
 The 4ABA complexes with aNHCs, where no hydrogen transfer occurs, show 
reproducible supramolecular synthons in three of the four complexes produced; these 
comprise OH···N hydrogen bonds between the carboxylic acid OH and the aNHC nitrogen 
as well as chains of 4ABA formed through NH···O hydrogen bonding between amide 
groups. Analogous synthons are seen in the PA complexes with N,N-dimethylpiperazine227 
and N-methylmorpholine227. The presence of these synthons allows prediction of the 
relative ratio of the components based on the number of acceptors in the aNHC, as 2:1 
PA/4ABA:aNHC complexes are formed when there are two acceptors sites for the OH···N 
hydrogen bond. These synthons are formed less reliably in the PA complexes, with 
completely different interactions formed between PA molecules and the aNHCs in the 
complexes with phenazine17 and BP227. Although the 4ABA:2PIC complex deviates from 
the hydrogen bonding seen in the other three 4ABA:aNHC complexes, the OH···N 
hydrogen bond still persists and the only change is the acceptor group in the NH···O=C 
hydrogen bonds between 4ABA molecules. In this case the carboxylic acid carbonyl 
replaces the amide carbonyl as the hydrogen bond acceptor.   
 For the small subsets of materials studied, the ability to predict the hydrogen 
bonding arrangement in complexes of PA from analysis of complexes of 4ABA (or vice 
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versa) is found not to be reliable in complexes where hydrogen transfer occurs from the 
4ABA to the imidazole co-former. Complexes of 4ABA where no hydrogen transfer occurs 
show more promise for comparison to PA complexes. There is possible potential to 
predict the ratio of components based on the number of acceptors in the aNHC. The 
completely different hydrogen bonding in the PA and 4ABA complexes with BP shows that 
prediction of both hydrogen bonding and molar ratios is still relatively unreliable.  
The ability to predict which co-formers will readily co-crystallise to form molecular 
complexes with PA, based on those which co-crystallise with 4ABA, is also unreliable, 
although in the experiments carried out all co-formers that formed complexes with PA 
could also be co-crystallised with 4ABA, indicating that 4ABA is more predisposed to 
molecular complex formation with the small subsets of materials studied.   
To investigate the potential for scaling up the co-crystallisation of paracetamol 
with imidazole into a continuous crystallisation environment, a thorough exploration of 
possible conditions is required to achieve a non-evaporative process in which the 
molecular complex is produced. Investigation of variables such as solvent, relative molar 
ratios of the components, cooling rates and seeding may lead to a viable process. Studies 
such as this may give clues to the potential of molecular complexes with favourable 




8. Additional Molecular Complexes of APIs 
 
The co-crystallisation screening of APIs carried out in this study resulted in a number of 
other molecular complexes being synthesised. The molecular complexes of paracetamol 
(PA) with maleic acid (MA) and citraconic acid (CCA) were produced as part of the PA co-
crystallisation screen with carboxylic acid containing co-molecules described in Chapter 4. 
The molecular complex of piracetam (PTM) with gallic acid (GA) is also discussed here. 
This complex is also mentioned in Chapter 4, as it often crystallised concomitantly with 
the porous phase of gallic acid monohydrate. Three other molecular complexes of PTM 
are also discussed. The discussion will focus mainly on the primary hydrogen bonding 
synthons observed in the complexes and comparison made to complexes with similar co-
formers in the Cambridge Structural Database (CSD)65.  
 
8.1 Molecular Complexes of Paracetamol with Co-Formers Containing Multiple 
Carboxylic Acid groups  
 
As discussed in Chapter 7, there is a marked variation in the types of co-formers found to 
co-crystallise with paracetamol in terms of the functional groups present and the 
synthons formed. Only two complexes of paracetamol (PA) with carboxylic acids are 
known, one of which is with the dicarboxylic acid, oxalic acid17 and the other with the 
tricarboxylic acid, citric acid233 (Scheme 8-1). No molecular complexes of paracetamol 
with monocarboxylic acids are known. As discussed in Chapter 4, monocarboxylic acids 
tend not to form molecular complexes with paracetamol and instead have been found 
often to direct the formation of paracetamol form II in co-crystallisation experiments. The 
preparation and crystal structures of two further molecular complexes of PA with 
dicarboxylic acids, maleic acid and citraconic acid (also Scheme 8-1), are described below. 
Full refinement details for all structures can be found in (Appendix A-8).  
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Scheme 8-1 The structures of the co-molecules with multiple carboxylic acid groups that 
form molecular complexes with paracetamol. (a) oxalic acid; (b) citric acid; (c) maleic acid; 
(d) citraconic acid. 
 
 
8.2 Crystallisation Conditions 
 
8.2.1 Paracetamol : Maleic Acid 
 
The paracetamol maleic acid molecular complex could be crystallised using the general 
co-crystallisation procedure outlined in Chapter 3, from methanol, ethanol, isopropanol 
or acetonitrile at room temperature.  
 
8.2.1.1  Paracetamol : Maleic Acid Molecular Complex: Scale up for Continuous 
Crystallisation in an Oscillatory Baffled Crystalliser 
 
The PA : MA molecular complex was considered a good candidate for scale up to cooling 
crystallisation in the COBC as MA is a pharmaceutically acceptable co-former and maleate 
salts are commonly used in the pharmaceutical industry234.  
 To facilitate co-crystallisation in a COBC, a similar screen of cooling conditions to 
that carried out for the PA:IM complex was used (see Chapter 7). Attempts were made to 
convert the evaporation co-crystallisation method employed in producing the complex to 
a cooling crystallisation method. 1:1 molar ratio solutions of various degrees of 
supersaturation were therefore generated through heating and the solutions cooled to 
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either 4°C or ambient temperature to induce crystallisation. The samples were left to cool 
to the relevant temperature with no control exercised over the cooling rate. This mainly 
resulted in crystallisation of the less soluble PA, with the majority of MA remaining in 
solution and no molecular complex being formed. The relative molar ratios were varied to 
1:2 (PA:MA) in an attempt to promote molecular complex formation. However, this was 
also unsuccessful. The solvents originally used were ethanol, IPA and acetone, chosen for 
their relatively low toxicity. Due to the failure to yield the molecular complex from cooling 
co-crystallisation, anti-solvent addition was also investigated using IPA as the solvent and 
one of hexane, diisopropyl ether or ethyl acetate as the anti-solvent. This, however, also 
failed to yield the PA:MA molecular complex.  
 
 
8.2.3  Paracetamol : Citraconic Acid 
 
The paracetamol : citraconic acid molecular complex was crystallised from methanol at 
room temperature, using the general co-crystallisation procedure outlined in Chapter 3.  
 
 
8.3 Crystal Structures of Multi-Component Complexes of Paracetamol and 
Dicarboxylic Acids 
 
8.3.1 Paracetamol : Maleic Acid (PA:MA) 
 
The asymmetric unit of the PA:MA complex consists of two PA molecules and two MA 
molecules. The structure comprises infinite chains of alternating PA and MA molecules 
held together by OH···O hydrogen bonds (Figure 8.1). The moderately strong OH···O 
hydrogen bonds are formed between the PA hydroxyl and an MA carbonyl (a and a’ in 
Figure 8.1) and a stronger OH···O hydrogen bond is formed between an MA hydroxyl and 
the PA carbonyl (b and b’ in Figure 8.1). A short, strong intramolecular OH···O hydrogen 
bond is also formed in the MA molecule (d and d’ in Figure 8.1). Neighbouring symmetry 
independent chains are linked into two-chain ribbons via NH···O hydrogen bonds 
between the PA and the oxygen atom of the maleic acid hydroxyl which is involved in the 
intramolecular hydrogen bond (c and c’ in Figure 8.1). Hydrogen bond distances and 
angles are shown in Table 8.1. The methyl groups of the PA molecules also form weak 
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hydrogen bonds to neighbouring MA oxygen atoms in the same chain (C···O = 
3.1759(14) Å, and 3.1743(14) Å) as well as significantly weaker hydrogen bonds to MA 
oxygen atoms in the neighbouring chain (C···O = 3.496(2) Å and 3.501(2) Å) (red dashed 
lines in Figure 8.1). 
 
 
Figure 8.1 Hydrogen bonded chains in the paracetamol : maleic acid molecular complex. 
Conventional hydrogen bonds are shown as blue dashed lines whereas weak CH···O 
hydrogen bonds involving the PA methyl group are shown as red dashed lines.  
 
 
Table 8.1 Hydrogen bond lengths and angles in the paracetamol : maleic acid and 
paracetamol : citraconic acid complexes (refer to Figure 8.1 for key). 






























































The hydrogen bonded ribbons are linked into sheets by weak bifurcated CH···O hydrogen 
bonds (C···O = 3.2011(15) Å and 3.2138(15) Å) involving the CH groups of one of the MA 
molecules and the PA hydroxyl oxygen atom (Figure 8.2). The hydroxyl oxygen of this MA 
molecule is also linked to the neighbouring ribbon through a weaker CH···O hydrogen 
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bond with the CH group of the symmetry independent MA molecule (C···O = 
3.4710(14) Å).  
 
Figure 8.2 The weak CH···O hydrogen bonds between ribbons (red-dashed lines) in the 
PA:MA complex (top) and the sheets formed by these ribbons (bottom, alternate ribbons 
coloured red and blue).  
 
The sheets are stacked upon each other to form a layered structure (Figure 8.3a). Layers 
are linked by π···π interactions between the PA aromatic rings and the MA double bonds 
with approximately 3.375 Å and 3.430 Å between the planes of the aromatic rings and the 
centroids of the MA double bonds (Figure 8.3b). The layers are further linked via weak 
hydrogen bonds between the methyl groups of PA with the carboxylic acid oxygen atoms 
of MA (C···O = 3.4684(14) Å and 3.7561(14) Å), as well as with the nitrogen atom of 




Figure 8.3 Packing in the PA:MA complex. (a) The layered arrangement of the sheets; (b) 
π···π interactions between layers; (c) weak hydrogen bonds between layers involving the 
methyl groups.  
 
 
8.3.2 Paracetamol : Citraconic Acid (PA:CCA) 
 
The PA:CCA complex features the same hydrogen bonded ribbons as the PA:MA complex 
(Figure 8.4), with similar hydrogen bond strengths (Table 8.1). The asymmetric unit in 
PA:CCA contains only one occurrence of each molecule as opposed to two formula units 
in the PA:MA complex. The ribbons are again arranged into sheets, although neighbouring 
ribbons are displaced relative to each other due to the presence of the methyl group; 
interactions between ribbons are therefore significantly different (Figure 8.4b). The 
bifurcated CH···O hydrogen bonds between the MA CH groups and the PA hydroxyl 
oxygen are no longer present. Instead, an aromatic CH group of another PA molecule 
forms a hydrogen bond to this PA hydroxyl oxygen (C···O = (3.414(4) Å) (Figure 8.4b). The 
CCA CH group then forms hydrogen bonds to the hydroxyl oxygen of another MA 
molecule (C···O = 3.567(3) Å).   
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Figure 8.4 (a) The two-chain hydrogen bonded ribbons in the PA:CCA complex; (b) the 
weak CH···O hydrogen bonds linking ribbons.   
 
 
The sheets have a layered arrangement (Figure 8.5a), with π···π interactions linking layers 
between the PA aromatic ring and the carbonyl double bonds of the MA molecules 
(Figure 8.5b). The π···π interactions have distances of approximately 3.413 Å and 3.446 Å 
between the centroid of the carbonyl and the closest bond in the aromatic ring.  
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Figure 8.5 Crystal packing in the PA:CCA complex. (a) The layered arrangement of the 




8.4 Discussion of Paracetamol Molecular Complexes 
 
8.4.1 Supramolecular Synthons in Paracetamol Molecular Complexes with Co-formers 
Comprising Multiple Carboxylic Acid Groups 
 
The molecular complexes of PA with MA and CCA have identical primary hydrogen 
bonding motifs. Both form infinite hydrogen bonded chains of alternating PA and 
MA/CCA molecules linked by OH···O hydrogen bonds and NH···O hydrogen bonds linking 
two layers into ribbons. The structures differ in the extended packing due to the presence 
of the methyl group in the CCA complex preventing the formation of the bifurcated CH···O 
hydrogen bonds between the MA CH groups and the PA hydroxyl. Both complexes 
feature a layered packing arrangement.  
 The hydrogen bonding in the PA complexes with MA and CCA is difficult to 
compare to that in the oxalic acid17 and citric acid233 complexes, as the intramolecular 
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hydrogen bond in MA/CCA makes one hydroxyl hydrogen unavailable for hydrogen 
bonding. The citric acid (CTA) complex forms a 2:1 (PA:CTA) complex and two of the CTA 
carboxylic acid groups dimerise while the other forms an OH···O hydrogen bond to the 
hydroxyl oxygen of another CTA molecule (Figure 8.6a). This means the only strong 
interactions between PA and CTA are OH···O hydrogen bonds involving the PA hydroxyl 
with a carboxylic acid carbonyl on the CTA and the CTA hydroxyl with the PA hydroxyl 
oxygen (Figure 8.6b). The remaining hydrogen bonding sites in PA form hydrogen bonds 
with other PA molecules. The PA hydroxyl OH interaction with the CTA carboxylic acid 
carbonyl is present in the MA/CCA complexes (shown in Figure 8.6d) but other than this 
the structures have very different hydrogen bonding due to homomeric interactions 
dominating in the PA:CTA complex.   
 The PA : oxalic acid (OA) complex shares more similarities with the MA/CCA 
complexes. Just as in the MA/CCA complexes, the PA hydroxyl forms hydrogen bonds to 
the OA carboxylic acid carbonyl and the OA hydroxyl forms hydrogen bonds to the PA 
carbonyl oxygen (Figure 8.6c). The PA NH also forms hydrogen bonds to a carboxylic acid 
carbonyl in all three complexes. The lack of an intramolecular hydrogen bond in OA 
results in some differences however, as the hydroxyl hydrogen is free to form a hydrogen 
bond to the PA hydroxyl oxygen. This replaces the weak CH···O hydrogen bonding 
involving the PA hydroxyl oxygen that occurs in the MA/CCA complexes. Nevertheless all 
three structures consist of infinite chains of alternating PA and MA/CCA/OA molecules 





Figure 8.6 Hydrogen bonding in the paracetamol molecular complexes with carboxylic 
acids. (a) Carboxylic acid dimers in the PA : citric acid complex233; (b) hydrogen bonding 
between PA molecules and the citric acid molecule in the PA : citric acid complex; 
(c) hydrogen bonding between PA and oxalic acid molecules in the PA : oxalic acid 
complex
17
; (d) hydrogen bonding in the PA:CCA complex. 
 
8.4.2  Scale up of the Paracetamol : Maleic Acid Molecular Complex 
 
The failure to convert the PA:MA co-crystallisation from an evaporation process to a 
cooling process once again shows the difficulty in transferring these systems and suggests 
a more careful consideration of the solvent used and component solubilities is required. 
The PA:MA complex represents an ideal candidate for scale up due to the 
pharmaceutically acceptable co-former used. The crystal structure of this complex is also 
layered with possible slip layers, which suggests investigation of its compaction properties 
for tabletting. As discussed in Chapter 4, this is seen as one of the main advantages that 
would be provided by using PA II instead of PA I as the marketed form and the use of a 
pharmaceutically acceptable molecular complex such as that reported here may provide a 
viable alternative without the stability issues of PA II. Tests on the physical properties of 







In total, four molecular complexes of paracetamol with co-formers containing multiple 
carboxylic acid groups have been synthesised; two were produced as part of this study 
and two were previously known17, 233. One complex was formed with the tricarboxylic 
acid, citric acid, and three with dicarboxylic acids: maleic acid, citraconic acid and oxalic 
acid. Formation of complexes with the three dicarboxylic acids all resulted in similar 
hydrogen bonding motifs. The MA and CCA complexes show identical arrangement of the 
primary hydrogen bonds with the added methyl group of CCA causing differences in the 
extended packing. The PA:OA complex features one major difference in its hydrogen 
bonding arrangement, which is the OH···O hydrogen bond formed to the PA hydroxyl, 
made possible as neither hydroxyl of OA is involved in an intramolecular hydrogen bond 
as is the case in the MA/CCA complexes. The extra carboxylic acid group and hydroxyl 
group of citric acid contributes to a very different hydrogen bonding arrangement as well 
as a 2:1 stoichiometric ratio.  
 There are no known molecular complexes of PA with monocarboxylic acids and 
this study suggests potential for further PA molecular complexes with co-formers 
containing multiple carboxylic acid groups. This work also suggests that dicarboxylic acids 
in particular may be of interest due to the relatively consistent hydrogen bonding motifs 
observed. The layered arrangement of all three PA : dicarboxylic acid complexes also 
suggests there may be scope for investigating the compaction properties of these 
complexes - the pharmaceutically acceptable complex with maleic acid being of particular 
interest in this respect. Attempts to convert the evaporation crystallisation process 
employed in the synthesis of the latter complex to a cooling or anti-solvent process viable 
for scale-up have so far been unsuccessful. Further work is required to find a suitable 
solvent system and greater consideration of solubility is required, possibly by utilising 
ternary phase diagrams. 
 
 
8.5 Molecular Complexes of Piracetam  
 
As discussed in Chapter 4, the co-crystallisation of the nootropic API piracetam (PTM) 
with gallic acid (GA) resulted in the crystallisation of a porous form of gallic acid 
monohydrate (PGAM), mostly concomitantly with a molecular complex of PTM:GA. 
 311
Analysis of the CSD shows that PTM has only been found to form molecular complexes 
with five different co-formers40, 92, all of which contain carboxylic acid groups. This section 
will discuss the primary hydrogen bonding synthons in the PTM:GA complex, with 
comparison to the known molecular complexes of PTM and another new molecular 
complex, formed with the dicarboxylic acid citraconic acid (CCA). In particular, the 
occurrence of the amide-carboxylic acid R22(8) heterodimer is investigated in the 
PTM : carboxylic acid complexes. A previous study92 found this synthon to be unreliable in 
predicting the hydrogen bond motifs in PTM complexes. Two other new PTM complexes 
with chloranilic acid (CA) and bromanilic acid (BRA) are also described and discussed in 
terms of the primary hydrogen bonding motifs observed. The occurrence of an R22(9) 
heterodimer with chloranilic/bromanilic acid (Scheme 8-2) is investigated, as this is 
analogous to the amide-carboxylic acid heterodimer in terms of hydrogen bond 
donors/acceptors. Full refinement details for all structures presented in this section can 
be found in (Appendix A-8).  
 
Scheme 8-2 The piracetam-carboxylic acid R22(8) dimer (LHS) and the analogous R
2
2(9) 
dimer formed by piracetam with chloranilic or bromanilic acid (RHS, X = Br or Cl).  
 
 
8.6 Crystallisation Conditions 
 
Piracetam : Gallic Acid 
 
As described in Chapter 7, the PTM: GA molecular complex was obtained in powder form 
from evaporation crystallisation experiments using methanol or ethanol (concomitant 
with PGAM) and single crystals could be obtained from ethyl acetate with a single drop of 





Table 8.2 below summarises the crystallisation conditions under which single crystals of 
the remaining three complexes discussed in this section were isolated. All co-
crystallisations were carried out at room temperature following the general evaporation 
procedure outlined in Chapter 3.  
 
Table 8.2 Crystallisation conditions for the synthesis of molecular complexes of PTM with 
citraconic acid, chloranilic acid and bromanilic acid.  
Complex  Molar Ratio (in solution) Solvent 
PTM:CCA  1:1 Acetone 
PTM:CA  1:1 Acetonitrile 
PTM:BRA  1:1 Acetone 
 
 
8.7 Crystal Structures of Multi-Component Complexes of Piracetam 
 
8.7.1 Piracetam : Gallic Acid (PTM:GA) 
 
The PTM:GA complex contains one molecule of each component in the asymmetric unit. 
The PTM and GA molecules dimerise, although the dimer is not of the amide-carboxylic 
acid type as might have been expected. Instead, the dimer is formed through the amide 
group forming hydrogen bonds with the neighbouring hydroxyl groups in the 3- and 4-
positions, with one OH group acting as a hydrogen bond donor to the amide carbonyl and 
the oxygen of the other as an acceptor for the amide NH group. This forms a hydrogen 
bonded R22(9) ring (a and b in Figure 8.7). Both hydrogen bonds in the dimer are 
moderately strong (see Table 8.3). The second amide NH also forms a moderately strong 
NH···O hydrogen bond with the GA hydroxyl in the 5-position (c in Figure 8.7). This 
hydroxyl group also forms an OH···O hydrogen bond to the carboxylic acid carbonyl of 
another GA molecule (e in Figure 8.7). The GA molecules form two moderately strong 
OH···O hydrogen bonds to the pyrrolidone carbonyl of PTM through the hydroxyl in the 3-
position and the carboxylic acid hydroxyl (d and f in Figure 8.7).  
Molecules in the structure are stacked in two directions (Figure 8.8a), with weak 
interactions holding the stacks together (Figure 8.8b). The molecules are stacked in pairs 
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of PTM molecules followed by pairs of GA molecules. PTM molecules in the stacks are 
linked by weak CH···O hydrogen bonds between the CH groups in the pyrrolidone rings 
and the amide oxygen atoms (C···O = 3.224(4) Å).  An acetamide CH group of PTM forms 
CH···π interactions with the aromatic ring of GA (approx. 3.345 Å between the carbon and 
the plane of the ring). The aromatic rings of GA molecules are then stacked upon each 
other via π···π interactions (approx. 3.386 Å between the plane of the rings).  
 
Figure 8.7 The heterodimer formed by PTM and GA molecules in the PTM:GA complex 
(top) and the remaining NH···O and OH···O hydrogen bonds that occur between PTM and 




Table 8.3 Hydrogen bond lengths and angles in the piracetam : gallic acid complex (refer 
to Figure 8.7 for key). 


































Figure 8.8 Crystal packing in the PTM:GA complex. (a) The molecules arranged in stacks 
running in two directions (the different parallel stacks are coloured red and blue); (b) the 
interactions between stacked molecules. 
 
 
8.7.2 Piracetam : Citraconic Acid (PTM:CCA) 
 
The PTM:CCA complex features one occurrence of each molecule in the asymmetric unit. 
PTM molecules in the complex form homodimers through the amide groups and CCA 
molecules also form carboxylic acid homodimers (a and b in Figure 8.9). Both the NH···O 
hydrogen bonds in the amide dimers and the OH···O hydrogen bonds in the carboxylic 
acids group are moderately strong (Table 8.4). Another moderately strong NH···O 
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hydrogen bond links the PTM amide group to the GA carboxylic acid carbonyl (c in Figure 
8.9). The dimers are further linked by a moderately strong OH···O hydrogen bond 
involving the second carboxylic acid hydroxyl of CCA and the pyrrolidone carbonyl oxygen 
(d in Figure 8.9). This links the molecules into infinite hydrogen bonded chains of 
alternating homodimers.  
 
 
Figure 8.9 The homodimers in the PTM:CCA complex, linked into chains by OH···O and 
NH···O hydrogen bonds between PTM and CCA molecules.  
 
 
Table 8.4 Hydrogen bond lengths and angles in the piracetam : citraconic acid complex 
(refer to Figure 8.9 for key). 
























The PTM molecules and the CCA molecules are arranged in linear three molecule units, 
with the PTM amide groups pointing outwards (Figure 8.10a). The PTM amide groups 
interrupt these three molecule units, forming the homodimers described above (also 
Figure 8.10a). This forms a layered structure, with the amide groups bridging between 
layers (Figure 8.10b). The CCA carboxylic acid dimers lie along the plane of these layers. 
The pyrrolidone CH groups form weak hydrogen bonds between layers to both the 
carboxylic acid carbonyl oxygen of CCA (C···O = 3.3542(14) Å) and the pyrrolidone 
carbonyl of another PTM molecule (C···O = 3.5276(14) Å) (Figure 8.11a). The layers are 
further linked by weak hydrogen bonds involving the CCA CH groups. The methyl CH 
group of CCA forms a weak CH···O hydrogen bond to the carboxylic acid hydroxyl oxygen 
of the CCA molecule in the next layer (C···O = 3.3406(15) Å) (Figure 8.11b). The CH group 
of CCA also forms a weak CH···O hydrogen bond to the bridging amide carbonyl (C···O = 
3.3826(13) Å) (also Figure 8.11b).  
 
 
Figure 8.10 Crystal packing in the PTM:CCA complex. (a) Arrangement of the CCA 
molecules and PTM pyrrolidone rings along the plane with the PTM amide group pointing 
outwards and forming the amide homodimer; (b) the resultant layered arrangement of 
the structure with amide groups bridging between layers.  
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Figure 8.11 Weak CH···O hydrogen bonds (red dashed lines) in the PTM:CCA complex. 
(a) Weak CH···O hydrogen bonds involving the pyrrolidone CH groups; (b) weak CH···O 
hydrogen bonds involving the CCA CH groups.   
 
 
8.7.3 Piracetam : Chloranilic Acid (PTM:CA) 
 
The PTM:CA complex crystallises in a 1:1 ratio. The asymmetric unit features a single PTM 
molecule with two unconnected halves of CA molecules. The two half CA molecules lie on 
inversion centres and thus two symmetry independent CA molecules are present in the 
complex. One CA molecule is linked to the pyrrolidone oxygen of PTM through a 
moderately strong OH···O hydrogen bond, with another PTM molecule linked to the 
carbonyl of the CA molecule through an amide NH···O hydrogen bond (Figure 8.12a). This 
results in chains being formed with CA molecules linked by two PTM molecules (also 
Figure 8.12a). The PTM molecules are linked to the second symmetry independent CA 
molecule through moderately strong NH···O and OH···O hydrogen bonds involving the 
amide group to form an R22(9) ring (Figure 8.12b) This forms PTM:CA:PTM trimers which 
link the chains forming a 2D network (Figure 8.12c). Hydrogen bond distances and angles 
are shown in Table 8.5.  
 The pyrrolidone rings of PTM molecules in neighbouring chains lie in the gaps of 
the 2D network, forming weak hydrogen bonds that link the networks in the third 
dimension (Figure 8.13). Weak CH···O hydrogen bonds are formed to the molecules in the 
chains between the pyrrolidone CH groups and the amide carbonyl of PTM (C···O = 
3.373(4) Å), as well as the hydroxyl oxygen of CA (C···O = 3.519(5) Å) (e and f, respectively 
in Figure 8.13). A further weak hydrogen bond is present between a pyrrolidone CH group 
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Figure 8.12 Hydrogen bonding in the PTM:CA complex. (a) The chains formed by OH···O 
and NH···O hydrogen bonds between PTM and CA molecules; (b) the trimers formed by the 
CA molecule with two PTM molecules through the R
2
2(9) ring formed with the amide 
group; (c) the hydrogen bonded chains in (a) linked by the hydrogen bonding motif in (b).  
 
 
Table 8.5 Hydrogen bond lengths and angles in the piracetam : chloranilic acid complex 
(refer to Figure 8.12 for key). 


























Figure 8.13 The two PTM molecules lying in the gaps of the 2D hydrogen bonded network 
of PTM:CA (shown in Figure 8.12c) and the weak hydrogen bonds between them and the 
surrounding molecules (red dashed lines).  
 
 
8.7.4 Piracetam : Bromanilic Acid (PTM:BRA) 
 
The PTM:BRA complex crystallises in a 1:1 ratio; unlike the PTM:CA complex, it features 
one full BRA molecule in the asymmetric unit with a single PTM molecule. The complex 
displays the same two primary hydrogen bonding motifs as the PTM:CA complex (Figure 
8.14). As all BRA molecules are symmetry equivalent, however, each is therefore linked to 
PTM molecules by both the R22(9) ring seen in the PTM:CA:PTM trimers (c and d in Figure 
8.14) and by the NH···O and OH···O hydrogen bonds in the PTM:CA chains (a and b in 
Figure 8.14). In the PTM:CA complex, CA is linked to two PTM molecules in the trimers 
and four PTM molecules in the chains. As the hydrogen bonding of BRA in the PTM:BRA 
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complex is a combination of both hydrogen bonded units, it is therefore linked to three 
PTM molecules (the average of the two CA molecules). The hydrogen bond strengths are 
generally similar in both complexes (Table 8.6).   
 
Figure 8.14 The primary hydrogen bonding motifs between PTM molecules and BRA 
molecules in the PTM:BRA complex.  
 
Table 8.6 Hydrogen bond lengths and angles in the piracetam : bromanilic acid complex 
(refer to Figure 8.14 for key). Equivalent values for the PTM:CA complex are provided for 
comparison. 
 Note: The single BRA molecule in the PTM:BRA complex forms hydrogen bonds a-d to 
PTM molecules, while in the PTM:CA complex one CA molecule forms two sets of hydrogen 
bonds a and b only, while a symmetry independent molecule forms two sets of c and d 
only. 











































The structure is made of regions of zigzagging PTM molecules separated by regions of 
zigzagging BRA molecules (Figure 8.15). The neighbouring PTM molecules are linked via 
weak CH···O hydrogen bonds between the acetamide CH and the pyrrolidone oxygen 
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(C···O = 3.311(3) Å) (highlighted in Figure 8.15). Weak hydrogen bonds are also present 
between the PTM NH and the BRA bromine (C···Br = 3.430(2) Å) (also highlighted in Figure 
8.15).  
 
Figure 8.15 The crystal packing of the PTM:BRA complex showing the zigzagging regions 
of PTM (blue) separated by zigzagging regions of BRA molecules (red) (top). A weak CH···O 
hydrogen bond between PTM molecules is highlighted (bottom left), as is a region where 
the NH···Br hydrogen bond occurs, with the relative positions of the R
2
2(9) ring and NH···O 
hydrogen bonds also shown (bottom right).  
 
 
8.8 Discussion of Piracetam Molecular Complexes 
 
8.8.1 Supramolecular Synthons in Piracetam Molecular Complexes 
 
Four new 1:1 molecular complexes of PTM have been produced in this study, with the co-
formers gallic acid (GA), citraconic acid (CCA), chloranilic acid (CA) and bromanilic acid 
(BRA). The PTM:CCA complex did not result in the formation of the amide-carboxylic acid 
heterodimer despite the presence of two carboxylic acid groups, with amide-amide and 
carboxylic acid-carboxylic acid homodimers formed instead. The PTM:GA complex also 
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failed to yield the amide-carboxylic acid dimer, although a heterodimer was formed 
through an R22(9) ring involving the PTM amide group and two GA hydroxyl groups. This 
dimer is analogous to the R22(9) ring found in the PTM complexes with CA and BRA, with 
the hydroxyl oxygen of GA acting as an acceptor instead of the CA/BRA carbonyl oxygen.  
 The inability to obtain the amide-carboxylic acid dimer is consistent with the 
known complexes of PTM. There are currently seven PTM : carboxylic acid molecular 
complexes in the CSD, utilising five different co-formers (complexes with both racemic 
mandelic acid and L-mandelic acid are known92, although both are treated as a single co-
former for the purpose of this discussion due to the identical functional groups present).  
In these seven complexes, the amide-carboxylic acid dimer is observed in only three; the 
co-formers used were 2,5-dicarboxylic acid40, 4-hydroxybenzoic acid40 and citric acid (3:2 
complex)92. In addition only one of the three symmetry independent PTM molecules in 
the 3:2 citric acid complex forms the heterodimer, with another PTM molecule forming 
amide-amide homodimers and the other forming neither dimer. The amide-amide 
homodimer also occurs in both mandelic acid complexes as well as in the PTM:CCA 
complex presented above, therefore occurring in four of nine complexes in total. Analysis 
of the interactions of the carboxylic acid in all nine PTM complexes (both those described 
here and those found in the CSD) shows that the carboxylic acid has a far greater 
tendency to form an OH···O hydrogen bond to the pyrrolidone carbonyl oxygen; this 
interaction is found in seven of the nine PTM complexes, including the GA and CCA 
complexes described above (see Figures 8.7 and 8.9).   
 The PTM complexes with BRA and CA both exhibit two identical primary hydrogen 
bonding synthons. One synthon is the expected R22(9) ring which is analogous to the 
amide-carboxylic acid heterodimer. The second is made up of both the amide NH···O 
interaction with the CA/BRA carbonyl and the CA/BRA hydroxyl OH···O interaction with 
the PTM pyrrolidone carbonyl. Interestingly, in the CA complex each symmetry 
independent CA molecule participates in only one type of synthon while in the PTM:BRA 





Although carboxylic acids appear to be useful co-formers for co-crystallisation with PTM, 
the evidence of these structures suggests that the amide-carboxylic acid dimer is not a 
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suitable supramolecular synthon target for these systems and the competition from other 
interactions needs to be considered. The amide-carboxylic acid dimer was found to occur 
in only three of nine PTM : carboxylic acid complexes in total. The carboxylic acid group 
appears to be far more likely to form OH···O hydrogen bonds to the pyrrolidone carbonyl 
oxygen with this occurring in seven of the nine complexes. The amide-amide homodimer 
was also found to occur more frequently than the amide carboxylic acid-heterodimer - 
although only slightly, with four complexes exhibiting this synthon. When co-crystallising 
PTM with carboxylic acids, it may therefore be appropriate to anticipate the formation of 
the carboxylic acid-pyrrolidone OH···O hydrogen bond, rather than a carboxylic acid-
amide heterodimer.  
 The occurrence of the OH···O hydrogen bonds involving the pyrrolidone carbonyl 
in the PTM complexes with CA and BRA, again suggests it may be appropriate to 
anticipate that the strongest hydrogen bond donor of the co-former will interact with the 
pyrrolidone carbonyl oxygen. In these complexes, however, the occurrence of the R22(9) 
hydrogen bonded ring is equally prevalent. A similar R22(9) heterodimer is seen in the 
PTM:GA complex (Figure 8.7). It may be of interest to investigate the occurrence of this 
R22(9) heterodimer, by selection of suitable co-formers, to determine if it is more 
prevalent than the amide-carboxylic acid heterodimer. If so, it may be useful in the crystal 
engineering of PTM molecular complexes.  
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9. Conclusions and Forward Look 
 
9.1 Multi-Component Crystallisation as a Route to New and Elusive Polymorphs 
 
9.1.1 Paracetamol Form II 
 
Co-crystallisation methodology has been demonstrated as a method of producing new 
and elusive polymorphs (and solvates) of a variety of materials with pharmaceutical 
properties. The metastable and pharmaceutically relevant paracetamol form II (PA II) 
could be produced from simple evaporation co-crystallisation with a variety of mono-
substituted benzoic acids and the yield obtained has been shown to be dependent on the 
substituent and substitution position as well as the solvent used for crystallisation. It was 
shown to be possible to obtain 100% yields of PA II and the use of 4-substitued benzoic 
acids as co-former was found to be particularly consistent in obtaining this. Other co-
formers containing carboxylic acid groups could also be used, namely, nicotinic acid, 
fumaric acid, succinic acid and creatine. This led to the investigation of a carboxylic acid as 
a solvent, with recrystallisation of PA from excess acetic acid found to be a route to 
producing PA II with yields close to 100%. Several other co-molecules not containing 
carboxylic acid groups were also found to encourage the crystallisation of PA II under 
certain conditions, including the three nitrogen heterocycles (NHCs), pyrazole, 3,5-
dimethylpyrazole and pyrazine.  
 The co-crystallisation method of producing PA II consistently resulted in large 
(> 1 mm3) crystals being produced. This enabled the first variable temperature single 
crystal neutron diffraction study of PA II to be carried out. A comparison of the hydrogen 
bond parameters was made between the neutron and X-ray data. Good agreement was 
found between the donor and acceptor atom distances at corresponding temperatures, 
as expected. The neutron data, however, showed a general increase in H···A distances 
with temperature as well as a decrease in D-H distances between 200 K and 300 K; this 
evolution of the hydrogen parameters was not observed in the X-ray data. The neutron 
data also showed that there is a significant increase in librational motion of the methyl 
hydrogen atoms with temperature - similar to that seen in neutron diffraction studies of 
PA I.   
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The simplicity of the co-crystallisation method to produce PA II, as well as the flexibility in 
terms of the co-molecules and solvents that can be used, made it a good candidate for 
scaled-up crystallisation in the OBC. Problems were encountered, however, in converting 
the evaporation co-crystallisation process to a cooling co-crystallisation process - with no 
PA II produced under the conditions investigated. Problems were encountered with some 
of the more reliable co-molecules (in the evaporation experiments) due to the poor 
solubility of the co-molecules used (4-chlorobenozic acid, 4-bromobenzoic acid, succinic 
acid), as they mainly crashed out preferentially from the solution, leaving the PA 
remaining in solution. Using more soluble co-molecules resulted in only PA I crystallising. 
A more thorough investigation of the cooling crystallisation parameters is therefore 
required to assess the viability of using this co-crystallisation method to produce PA II on 
a large scale in non-evaporative environments. This should involve trying different co-
molecules from those that have been investigated here, as well as different solvents. 
More careful control over the cooling rate may be required and the effect of altering the 
cooling rate should also be investigated. 
 
9.1.2 New Crystal Forms of Piroxicam 
 
Co-crystallisation was used to obtain a new polymorph of PX - PX form IV - as well as a 
new PX : methanol solvate. Both of these new phases featured a mixture of both the 
zwitterionic and non-ionised PX tautomers. A simple evaporative co-crystallisation route 
to the known PX III polymorph was also discovered, which enabled the first full crystal 
structure determination to be carried out on this polymorph. All three phases were 
obtained using NHCs as the structure-directing co-molecules at elevated temperatures. 
PX III was produced by co-crystallisation with an excess quantity of pyrazole or 3,5-
dimethylpyrazole at 40°C/50°C; PX IV could be obtained from co-crystallisation with 
excess pyrazine at 40°C/50°C and the PX : methanol solvate was produced by co-
crystallisation with indazole at 60°C. 
 Problems were encountered in obtaining 100% yields of PX III, while the 
reproducibility of PX IV was poor. DSC measurements of all polymorphs were carried out 
to rationalise this. The stability of the polymorphs was found to be I>III>II>IV. The 
crystallisation of PX IV is likely to be highly sensitive to perturbations of the crystallisation 
environment due to its poor stability relative to the other three polymorphs. The poor 
yield of PX III, despite being the second most stable form, is possibly due to this 
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polymorph lying in an energy minimum close to that of PX I, which may mitigate against 
its formation. This is supported by the fact that both feature the same primary hydrogen 
bonding motifs between PX molecules.  
 Future work should involve optimisation of the co-crystallisation process to obtain 
consistent 100% yields of PX III and IV. This may involve experimenting with different 
crystallisation temperatures between 40°C and 60°C in smaller increments to find the 
optimal temperature for producing each form. The effect of different solvents should also 
be investigated as well as the ratio of PX to co-molecule that is used. Obtaining large 
yields of these polymorphs would facilitate a thorough investigation of the properties of 
each form to assess what advantages they may have over the more stable forms. In 
particular, it may be of interest to investigate the properties of PX IV and the methanol 
solvate to investigate what effects the mixed tautomers present in these phases may 
have.  
 
9.1.3 A New Porous Form of Gallic Acid Monohydrate 
 
A new porous form of gallic acid monohydrate (PGAM) was obtained from co-
crystallisation with piracetam (PTM). PXRD of the co-crystallisation products from 
methanol or ethanol solution indicated that a gallic acid (GA) : PTM molecular complex 
may crystallise concomitantly with PGAM, although it was not observed in unit cell 
screens of single crystals of the sample. This suggests the molecular complex may have 
formed during the grinding of the sample in preparation for PXRD. This could be resolved 
by repeating the co-crystallisation experiments and using PXRD analysis without grinding 
the sample.  
 The disordered solvent in the pores of PGAM could not be resolved from the 
single crystal X-ray diffraction data collected. Analysis using TGA may give clues as to the 
nature of the solvent in the pores. It remains to be seen whether the solvent can be 
removed from the pores with the structure remaining intact and TGA may also be used to 
determine if this is possible. If the solvent can be removed, PGAM may have potential for 
use as an organic lightweight gas storage material. 
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9.1.4 Piracetam Form I 
 
The elusive metastable form I of PTM was initially crystallised from a co-crystallisation 
experiment with pyrazole at 50°C using methanol as the solvent. Subsequent experiments 
under the same conditions without pyrazole also resulted in the formation of PTM I. It 
remains unclear whether the initial co-crystallisation experiment that resulted in 
crystallisation of PTM I has resulted in subsequent seeding of the laboratory with this 
form. To clarify this it must be independently verified in another laboratory - first by 
crystallisation of PTM in methanol at 50°C to observe which polymorph is obtained. If 
PTM I is not obtained this should be followed by a repeat of the initial co-crystallisation 
experiment outlined here.  
 
9.1.5 Understanding the Mechanism 
 
The mechanism by which the co-molecules used direct the formation of metastable 
phases remains unclear. The evidence from the investigations presented here suggests 
that the mechanism is solution-based rather than epitaxial in nature. The fact that NHCs 
can be used to direct the formation of three different forms of PX is possibly indicative of 
a related mechanism, as is the fact that three of these NHCs have also been observed to 
direct the formation of PA II.  
 Future work to investigate this mechanism should involve co-crystallising the co-
formers which have been observed to direct the formation of metastable forms with a 
variety of other materials to observe what effect they have on the polymorph obtained 
(assuming a molecular complex is not formed). Any structural or property relationships 
between the target molecules of which metastable forms are obtained could give clues 
about the nature of the mechanism. Similarly, structural or property relationships 
between the co-molecules which are found to direct the formation of a metastable form 
of a material may also provide clues as to the mechanism.  
 
 
9.1.6 The Utility of Co-Crystallisation for Polymorph Screening  
 
Co-crystallisation as a route to polymorph screening has been shown to be useful in 
accessing crystal forms which are otherwise difficult to obtain, such as PA II and PX III. It 
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has also been shown to be useful in obtaining forms with otherwise unobtainable 
structural features such as PX IV, the PX : methanol solvate and PGAM. This highlights the 
potential importance of co-crystallisation as a route to polymorph selection. Its viability as 
a common method of polymorph screening, however, remains questionable. Some co-
molecules direct polymorph formation in some materials and not others and there is thus 
an almost infinite number of possible co-molecules that could be screened. The range 
could be narrowed down by using only a select few co-molecules or a select class of co-
molecules which are known to direct polymorph formation in a number of materials 
(possibly materials such as the NHCs used in this work). Issues would remain, however, as 
there are an infinite number of conditions under which these co-crystallisations could be 
carried out. Elevated temperatures may or may not be required and the co-molecule may 
also need to be used in excess, as in the case of the co-crystallisation experiments that 
resulted in the formation PX III and PX IV. Ultimately, a better understanding of the 
mechanism involved could allow prediction of the type of co-molecule required and the 
conditions that may give rise to the formation of a certain polymorph.  
 
 
9.2 Tautomerisation and Polymorphism in Molecular Complexes of Piroxicam with 
Mono-Substituted Benzoic Acids  
 
PX was found to readily form molecular complexes with monosubtituted benzoic acids 
(BAs). Twenty complexes in total were synthesised in this study - twelve incorporating the 
zwitterionic form of PX (PXZ) and eight incorporating the non-ionised form (PXN). This 
adds to the known complexes of PXZ with 4-hydroxybenzoic acid (4HBA) and benzoic acid 
as well as the known complex of PXN with 4HBA27. All PX complexes with fluorobenzoic 
acids were found to exhibit the rare phenomenon of tautomeric polymorphism. Both the 
PXZ and PXN complexes were found to have a tendency to form four-molecule hydrogen 
bonded supramolecular units. These units were comprised of a PX dimer flanked by two 
BA molecules. This BZZB tetramer unit in the PXZ complexes was found to be highly 
robust, with all twenty complexes synthesised exhibiting the same type of hydrogen 
bonding, as well as the known complex with benzoic acid. The PXN complexes were less 
predictable with two recurring PXN dimer synthons observed as well as two complexes 
exhibiting unique hydrogen bonding between PXN molecules (PXN:4FBA and 
PXN:4HBA27).  The hydrogen bonding motif between the PXN molecules and the BA 
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molecules was found to be much more robust with the same )8(22R ring found in all PXN 
structures with the exception of the PXN:4HBA complex27.  
 DSC analysis of the tautomeric polymorphs showed that their relative stability was 
not dependent on the tautomer present in the complex. One might expect the PXZ 
polymorphs to be more stable due to the presence of charge-assisted hydrogen bonds, 
however, the PXN:2FBA complex was found to be more stable than the PXZ:2FBA 
complex. Studies of these tautomeric polymorphs may offer insight into other physical 
properties that may be inferred by the presence of different PX tautomers. 
 An empirical relationship was found between the PX tautomer present in the 
molecular complexes and the pKa of the BA co-formers in the complexes. The data 
gathered suggests a region of co-former pKa values is present within which the non-
ionised PXN tautomer is favoured in molecular complex formation. Co-formers with pKa 
values above or below the boundaries of this region favour the formation of complexes 
incorporating the zwitterionic PXZ tautomer. Using this as a guide allows a reasonable 
prediction to be made regarding which tautomer will be present in a PX complex with 
BAs, which in turn means a reasonable prediction of the hydrogen bonding motifs can 
also be made based on the supramolecular synthons observed in this work. It is unclear, 
however, why BA co-formers with relatively high and relatively low pKa values would 
favour molecular complex formation with PXZ while a middle region would favour 
molecular complex formation with PXN. Further investigation of this is required by 
expanding the number of BA co-formers in this series. It would also be of interest to 
investigate other tautomeric materials via similar systematic co-crystallisation studies to 
determine if such an empirical observation can be made. This may lead to a rationale as 
to why such a boundary region exists. Ultimately, through empirical deduction, this could 
lead to guidelines for predicting intramolecular hydrogen transfer in molecular complexes 
- similar to the pKa rule that is already in use for predicting intermolecular hydrogen 
transfer in molecular complexes.  
  
 
9.3 Intermolecular Hydrogen Transfer in Multi-Component Complexes of Piroxicam 
 
Eight molecular complexes of PX with NHCs were synthesised. Three of the complexes 
were solvated complexes with imidazole (IM). Hydrogen transfer occurred from the PX 
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molecule to the basic nitrogen in all three IM complexes as well as in the 2-
methylimidazole (2MIM) and benzimidazole (BZ) complexes. No intermolecular hydrogen 
transfer occurred in the PX complexes with triazole (TZ), benzotriazole (BZT) or pyrazine 
(PZN). In these three complexes, PX was found to exist in the zwitterionic tautomer.  
 All five of the PX−:NHC complexes feature infinite chains of alternating PX− and 
NHC in an ABABA configuration. Four of the complexes feature the same primary 
hydrogen bonding motifs between the PX− molecule and the NHC molecule. These involve 
the NHC molecule forming two NH···O hydrogen bonds to the PX molecule; one is formed 
to the amide carbonyl oxygen and the second to the PX enolate oxygen. The only PX−:NHC 
complex not to exhibit this hydrogen bonding pattern is the PX:IM hemihydrate. The 
hydrogen bonding in this complex is unusual as it features a CH···O hydrogen bond to the 
PX− enolate oxygen whereas the other four complexes satisfy the strongest donor-
strongest acceptor hydrogen bonding arrangement. No 1:1 PX−:IM+ complex was found, 
despite the two PX−:IM+ acetonitrile solvates exhibiting the same hydrogen bonding 
pattern as the 2MIM and BZ complexes. This was rationalised by the fact that 2MIM and 
BZ have large bulky groups attached to the imidazole ring. In the absence of the solvent 
molecules a large void would be left if it were to form this hydrogen bonding pattern. 
Other than this one exception it would appear that the hydrogen bonding in PX 
complexes with co-molecules possessing the imidazole ring is reasonably predictable.  
 The three PXZ:NHC complexes featured the PXZ dimer that is found in all PXZ 
complexes. The PXZ:TZ and PXZ:BZT complexes both featured the TZ/BZT molecules being 
hydrogen bonded to both PXZ molecules in the dimer through NH···O hydrogen bonds to 
the enolate oxygen atoms. In the case of the PXZ:TZ complex, this results in infinite 
chains, whereas in the PXZ:BZT complex discrete tetramers are formed. The PXZ:PZN 
complex was found to feature only weak CH···O and CH···N hydrogen bonds between PXZ 
and PXN molecules which explains why it crystallised rarely and in small quantities.  
 Co-crystallisation of PX with the strong acids, chloranilic acid (CA) and bromanilic 
acid (BRA), resulted in hydrogen transfer occurring from the acid to the PX molecule in all 
four complexes. Form I and form II of the PX+:CA− complex feature similar hydrogen 
bonding involving the same groups, with form II possessing an extra NH···O hydrogen 
bond due to the a different orientation of the CA- molecule. The PX+:CA2−.ACN 2:1:2 
solvate possesses the same hydrogen bonding motif as is seen in PX+:CA−  form I, which 
results in a 2:1 ratio as the CA is doubly deprotonated. Only one form of the PX+:BRA− 
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complex was found, which was isomorphous to form II of the PX+:CA− complex. This form 
was produced even when PX and BRA were co-crystallised under the same conditions as 
those that resulted in form I of the PX+:CA− complex and the 2:1:2 PX+:CA2−.ACN solvate.  
 The ΔpKa values for the complexes formed in this study suggest that, at least 
under certain conditions, it may be more appropriate to consider PX as the zwitterionic 
form when predicting intermolecular hydrogen transfer using the pKa rule. By considering 
the N+-H group as the acidic group and the enolate O− as the basic group, a clear 
indication is given of which complexes will result in hydrogen transfer.  This is further 
supported by the study which has shown that a significant proportion of PX is in the 
zwitterionic form in polar solvents223. Within this analysis, none of the complexes which 
do not undergo intermolecular hydrogen transfer have a ΔpKa greater than (or even close 
to) the empirically significant value of 3. The study presented here is relatively small and 
more molecular complexes using co-formers with a range of pKa values is required to 
assess how useful the pKa rule is in predicting hydrogen transfer in molecular complexes 
of PX. This would assist in determining whether the pKa values used in the pKa rule 
equation should be derived from the zwitterionic tautomer or the non-ionised tautomer 
of PX.  
 
9.4 General Comments on Hydrogen Transfer in Molecular Complexes of Piroxicam 
 
It has been shown that piroxicam forms molecular complexes with a range of different 
acids and bases. The pKa of these co-formers has been shown to have a major influence 
on the ionisation state of PX in the resultant complex. The work presented here has 
provided a tentative route to predicting which PX form will be present in a particular 
molecular complex based on the pKa of the co-former used – with the non-ionised form, 
the zwitterionic form, the anionic form and the cationic form all obtainable. Challenges 
remain in rationalising the presence of a pKa boundary region in which the non-ionised 
form of PX is found to crystallise with BAs; this boundary region also does not account for 
the existence of the tautomeric polymorphism observed in the PX complexes with 
fluorobenzoic acids. The use of the pKa rule also requires further investigation as to which 
pKa values are most appropriate for use in the pKa equation. Similar systematic studies 
using other tautomeric materials would also be useful to determine to what extent, if 
any, the empirical observations made in this study can be applied to other materials.  
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9.5 Molecular Complexes of Paracetamol and 4-Acetamidobenzoic Acid 
 
PA was found to co-crystallise with imidazole (IM), 2-methylimidazole (2MIM) and 4-
methylimidazole (4MIM) to form molecular complexes. Attempts to form a molecular 
complex with benzimidazole (BZ) were unsuccessful. The PA:IM and PA:2MIM complexes 
exhibited similar primary hydrogen bonding patterns. Steric effects, caused by the 
presence of the methyl group in 2MIM, meant slight differences were observed and this 
resulted in a 1:2 PA:2MIM complex forming as opposed to the 1:1 ratio found in PA:IM. 
The 4MIM complex crystallised in a 1:1 ratio but exhibited a completely different 
hydrogen bonding pattern from that found in the IM and 2MIM complexes. This was 
found to be due to a pronounced twisting of the PA molecule which resulted in the amide 
group lying out of the plane of the aromatic ring; the PA molecule in the PA:IM and 
PA:2MIM complexes was relatively planar. The only common synthon to all three 
complexes was the NH···O hydrogen bond between the IM NH group and the PA carbonyl.  
 4ABA was found to form molecular complexes with IM, 2MIM, 4MIM and BZ (co-
crystallisation with BZ formed a 1:1:1 hydrated complex). The carboxylate hydrogen 
transfers to the basic nitrogen of the imidazole ring in all four complexes. The 
4ABA:2MIM complex was a partial exception to this as it possessed one neutral 4ABA and 
one deprotonated 4ABA−. The presence of a neutral 4ABA molecule increased 
competition for hydrogen bonding to the carboxylate of 4ABA−, meaning that only one 
2MIM molecule could form hydrogen bonding links to it. This resulted in a 2:1 (4ABA: 
2MIM) ratio (which could also be classed as a 1:1:1 4ABA:4ABA−:2MIM+ ratio). The IM, 
4MIM and BZ complexes all featured two IM+/4MIM+/BZ+ molecules forming hydrogen 
bonds to the carboxylate group of 4ABA−, resulting in the different ratio to that found in 
the 4ABA−:2MIM+ complex.  
 Comparison of the PA and 4ABA complexes formed with imidazole derivatives was 
made difficult due to hydrogen transfer occurring in the 4ABA complexes but not in the 
PA complexes. This altered the hierarchy of the hydrogen bond acceptor strengths in the 
4ABA molecule. The lack of robust transferrable synthons in either series of complexes 
also made it difficult to compare them. The NH···O hydrogen bond between the imidazole 
ring NH and the amide carbonyl oxygen was found to occur in all three PA complexes but 
only in two of the 4ABA complexes (4ABA:IM and 4ABA:BZ.H2O). In summary, no robust 
hydrogen bonded synthons are present in either series that would facilitate the 
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prediction of the hydrogen bonding that will occur in molecular complexes with other 
imidazole derivatives. The hydrogen transfer that occurs in the 4ABA complexes also 
precludes prediction of the hydrogen bond interactions of one based on those formed by 
the other with the same imidazole co-former.  
 Four molecular complexes of 4ABA were synthesised with aprotic nitrogen 
heterocycles (aNHCs), 2-picoline (2PIC), 3-picoline (3PIC), 4-picoline (4PIC) and 4,4-
bipyridine (BP). No hydrogen transfer occurred in any of these complexes. All four 
complexes showed consistent OH···N hydrogen bonding between the carboxylic acid 
group and the nitrogen of the aNHC. The 4ABA molecules in three of the complexes also 
featured chains of 4ABA molecules formed by NH···O hydrogen bonds between the amide 
groups. The exception was the 4ABA:2PIC complex which had a slight variation, instead 
forming 4ABA chains through hydrogen bonds between the amide NH and the carboxylic 
acid carbonyl oxygen. The consistent hydrogen bonding seen suggests that the relative 
ratio of components can be predicted based on the number of nitrogen acceptor atoms in 
the aNHC, as illustrated by the 4ABA:BP complex where a 2:1 ratio is found. It should be 
noted, however, that this conclusion is based on a relatively small subset of co-formers 
and considerably more work is required to determine how valid is this conclusion.  
 A complex of PA with BP was previously known227, however PA was not found to 
form molecular complexes with 2-, 3- or 4-picoline under the conditions investigated. The 
4ABA complexes with aNHCs were therefore compared to the four known structures17, 227 
of PA with aNHCs. The phenolic OH···N hydrogen bond to the aNHC nitrogen was found to 
be less persistent than the corresponding OH···N interaction in the 4ABA complexes and 
only found in two of the four complexes. This can be rationalised by the fact that the 
phenolic hydroxyl group is a weaker donor than the carboxylic acid hydroxyl and so 
synthons involving this group are more susceptible to competition from other donors.  
Again, however, this is based on a relatively small subset of co-formers and expanding the 
number of molecular complexes of 4ABA and PA with aNHCs is desirable, to allow more 
definite conclusions to be drawn on how predictable, and comparable, the interactions 
are in both series of complexes.  
 Using the ∆pKa values to predict hydrogen transfer was investigated for all 4ABA 
and PA complexes with imidazole derivatives and aNHCs. For PA, no hydrogen transfer 
occurred as expected, as all ∆pKa values were negative. The 4ABA complexes with IM, 
2MIM and 4MIM all resulted in hydrogen transfer as may be expected given the co-
formers were the most basic of those used. No hydrogen transfer occurred in the 
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4ABA:BP complex, which was also to be expected as it has a negative ∆pKa value. The 
4ABA:BZ complex was anomalous; hydrogen transfer occurred in this complex despite no 
hydrogen transfer occurring in the 4ABA complexes with 2-, 3- and 4PIC - all of which had 
higher ∆pKa values than the aforementioned complex. These results highlight the 
difficulty in using pKa values to predict hydrogen transfer in molecular complexes - 
especially when the ∆pKa value lies between 0 and 3.  
 
 
9.6 Molecular Complexes of Paracetamol with Co-Formers with Multiple Carboxylic 
Acid Groups 
 
Two new molecular complexes of PA were synthesised and characterised, using maleic 
acid (MA) and citraconic acid (CCA) as co-formers. This adds to the known molecular 
complexes of PA with citric acid (CTA)233 and oxalic acid (OA)17 which also contain multiple 
carboxylic acid groups (three and two carboxylic acid groups respectively). The PA 
complexes with MA and CCA feature identical arrangements of the primary hydrogen 
bonding motifs, with differences in the extended packing caused by the presence of the 
methyl group in CCA. The lack of intramolecular hydrogen bonding of the carboxylic acid 
groups in the PA complexes with CTA and OA meant that it was difficult to compare the 
primary hydrogen bonding motifs to those in the MA/CCA complexes. CTA molecules in 
the PA:CTA complex were found to prefer forming hydrogen bonds to other CTA 
molecules. The PA:OA complex was found to share more similarities to the MA/CCA 
complexes in terms of the hydrogen bonding motifs. All three complexes were found to 
form chains of alternating PA and OA/MA/CCA and all form layered structures. This work 
suggests that co-formers with multiple carboxylic acid groups may be useful in 
synthesising molecular complexes of PA.  
 
9.7 General Comments on the Scale-Up Crystallisation of Paracetamol Molecular 
Complexes for Crystallisation in a COBC 
 
Attempts were made in this study to scale up the co-crystallisation of molecular 
complexes of PA with IM and MA for continuous crystallisation in an OBC. None of the 
experiments progressed past the initial stage of converting the evaporation crystallisation 
method, employed in the initial synthesis of the molecular complex, to a cooling 
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crystallisation process. In both cases, the co-former was often found to crash out 
preferentially from solution upon cooling, leaving the PA in solution. This work has 
highlighted the need to investigate extensively the solvent used and the relative solubility 
of the components, as well as the relative concentrations required to convert an 
evaporative process to a cooling process, as the conditions used in each process are not 
necessarily interchangeable. If molecular complexes, such as those presented in this 
work, are to be used on an industrial scale, then ability to scale up crystallisation 
efficiently in a non-evaporative environment is crucial. Future work should involve 
crystallising with a controlled cooling rate as opposed to the crash-cooled crystallisation 
carried out as part of this work. A more in-depth investigation of other parameters such 
as the effect of cooling rate and seeding of the solution should also be carried out. 
Following on from the preliminary investigations reported here, further studies are 
ongoing in this area within a larger collaborative project as part of the EPSRC National 
Centre in Continuous Crystallisation and Manufacturing232. 
 
9.8 Molecular Complexes of Piracetam  
 
Four new molecular complexes of piracetam (PTM) were synthesised in this work, with 
the co-formers gallic acid (GA), citraconic acid (CCA), chloranilic acid (CA) and bromanilic 
acid (BRA). The two PTM complexes with carboxylic acids (GA and CCA) failed to yield the 
amide-carboxylic acid R22(9) heterosynthon. This was found to be consistent with known 
complexes of PTM and this synthon was only found to occur in three of the nine known 
complexes (both in this work and in structures reported in the CSD) of PTM. It was found 
that the carboxylic acid was far more likely to form an OH···O hydrogen bond to the 
pyrrolidone carbonyl oxygen, with this occurring in seven of the nine complexes. In the 
molecular complexes of PTM with CA and BRA, the hydroxyl group of CA/BRA was also 
found to form a hydrogen bond to the pyrrolidone oxygen. The evidence of these 
structures suggests that when co-crystallising PTM, it may be appropriate to anticipate 
the strongest hydrogen bond donor interacting with pyrrolidone oxygen. The PTM 
complexes with CA and BRA also exhibit an R22(9) ring involving the CA/BRA hydroxyl and 
carbonyl groups forming hydrogen bonds to the PTM amide group. This hydrogen 
bonding motif is analogous to the R22(9) ring found in the PTM:GA complex involving two 
of the GA hydroxyl groups, with one hydroxyl acting as a hydrogen bond donor (to the 
CA/BRA carbonyl oxygen) and one an acceptor (to the CA/BRA hydroxyl). It may be of 
 336
interest to investigate the occurrence of this synthon, by suitable selection of co-formers, 
to determine if it is useful in the crystal engineering of molecular complexes of PTM. 
 
9.9 Concluding Remarks 
 
Although predicting the crystal structure of a material from a defined set of conditions 
remains a huge challenge in crystal engineering, insight is provided by empirical 
observations of related materials crystallised under related conditions. In this work, such 
insight has enabled the production and sometimes selective crystallisation of new and 
elusive crystalline phases of materials. It has also facilitated reasonable prediction of 
which ionisation state a material will adopt when co-crystallised with another material to 
form a molecular complex. Challenges remain, however, in rationalising such predictions 
and determining how and when empirically derived “rules” can be applied. This is 
especially relevant with regards to crystal engineering, as it has been shown in this work 
(as well as elsewhere) that hydrogen bonding does not always follow the expected 




APPENDIX A: Crystallographic Data and Refinement Details 
 
For all structures reported, hydrogen atoms were located using a Fourier difference 
synthesis unless stated otherwise. In cases where hydrogen atoms were placed on 
calculated positions, methyl and hydroxyl hydrogen atoms were located initially using a 
Fourier difference synthesis and the bond distances and angles constrained to take 
standard values unless otherwise stated.   
 
APPENDIX A4. Chapter 4 - Multi-Component Crystallisation Routes to New and Elusive 
Polymorphs 
 
Refinement details for all structures can be found in Table A-4.  
 
Paracetamol Form II (X-ray Diffraction Data) 
Single crystal X-ray diffraction data were collected on a Bruker-Nonius Kappa CCD 
diffractometer at 100K.   
 
Paracetamol (Neutron Diffraction Data) 
Single crystal neutron diffraction data were collected using the VIVALDI instrument at the 
Institute Laue Langevin (ILL).  
 The data were processed in the standard space group, Pbca, as opposed to Pcab 
as the software used does not allow processing in non-standard settings. As unit cell 
parameters cannot be calculated accurately using Laue diffraction, unit cell parameters 
were taken from X-ray structure determinations at the corresponding temperatures. Unit 
cell parameters for the 100K neutron data were taken from the 100K single crystal X-ray 
re-determination carried out as part of this work. Unit cell parameters for the 200K and 
300K neutron data were taken from X-ray diffraction data found in the CSD at the 
corresponding temperatures205. Structure determination using X-rays at 30K has yet to be 
carried out; the unit cell parameters were therefore extrapolated from the difference 
between 200K and 100K unit cell parameters and may not be accurate.   
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Piroxicam form III 
Single crystal X-ray diffraction data for this complex were collected on a Bruker AXS Apex 
II CCD diffractometer at 100K. 
 
Piroxicam Form IV  
Single crystal X-ray diffraction data were collected on a Rigaku R-AXIS RAPID Image Plate 
diffractometer at 100K. Single crystals were small and of poor quality and did not diffract 
well. Several attempts at data collection were carried out, including data collection at the 
I19 beamline at Diamond; the data presented is the best which could be obtained from 
the poor quality crystals.   
Anisotropic refinement caused the thermal parameters of one carbon atom (C75) 
to become abnormally elongated along one axis; its thermal parameters were therefore 
fixed to be equal to those of C72 to obtain a plausible approximation. Data were weak 
and of poor resolution with a high Rint (0.106), meaning H-atoms could not be accurately 
located using the Fourier difference synthesis. All hydrogen atoms were therefore placed 
on calculated positions and refined as riding on the atoms to which they were bonded. 
The piroxicam tautomer present was inferred by the conformation of the molecules and 
the hydrogen bonding interactions. The yellow colour of the crystals further evidenced 
the presence of the zwitterionic tautomer.   
 
Piroxicam: Methanol Solvate  
Single crystal X-ray diffraction data were collected on a Rigaku R-AXIS RAPID Image Plate 
diffractometer at 100K. Single crystals were small and of extremely poor quality and did 
not diffract well. Several attempts at data collection were carried out, including data 
collection at the I19 beamline at Diamond; the data presented is the best which could be 
obtained from the poor quality crystals.   
 Anisotropic refinement of the heavy atoms resulted in implausible thermal 
parameters of a number of atoms. Heavy atoms were therefore refined isotropically in 
the final refinement cycles. To locate the hydroxyl hydrogen (H44) of the methanol 
molecule, anisotropic refinement of the heavy atoms was first carried out. H44 was then 
located and the O-H distance constrained to 0.9Å and the thermal parameter refined as 
riding on the oxygen to which it is bonded. All other hydrogen atoms were then placed on 
calculated positions and refined as riding on the atoms to which they were bonded. The 
piroxicam tautomer present was inferred by the conformation of the molecules and the 
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hydrogen bonding interactions. The yellow colour of the crystals further evidenced the 
presence of the zwitterionic tautomer.  
 
Gallic Acid Monohydrate (Porous Form) 
Single crystal X-ray diffraction data for this complex were collected on a Bruker AXS Apex 
II CCD diffractometer at 100K. The crystals were thin needles and diffracted poorly 
resulting in weak data. 
 The water oxygen (O6) has elongated thermal parameters suggesting it may be 
disordered across two or more positions although this disorder could not be modelled 
from the available data. The water hydrogen atoms could not be located - likely a result 
of the disorder of the molecule.  
 All H-atoms were identified from the Fourier difference synthesis. The positions of 
the hydrogen atoms were allowed to freely refine but the size of the thermal parameters 
were constrained to be proportional to the atom to which they were bonded. 
 An excess of electron density was present in the channels, indicating the presence 
of disordered solvent molecules. The disordered solvent molecules could not be resolved 
and the electron density was therefore removed from the final refinement cycle using the 
SQUEEZE procedure216 and the number of electrons estimated. The estimate of 69 
electrons in the unit cell could correspond to approximately ten water molecules or four 
methanol molecules although a definite conclusion has not been reached.  
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Table A-4a Crystallographic data for paracetamol form II from both X-ray and neutron diffraction.  
Radiation Source X-ray Neutron Neutron Neutron Neutron 
Formula C8 H9 N1 O2 C8 H9 N1 O2 C8 H9 N1 O2 C8 H9 N1 O2 C8 H9 N1 O2 
M/g mol-1 151.17 151.17 151.17 151.17 151.17 
T/K 100 30 100 200 300 
Space Group Pcab Pbca* Pbca* Pbca* Pbca* 
a/Å 7.2028(2) 17.167 17.168 17.169 17.162 
b/Å 11.7764(3) 11.756 11.776 11.806 11.837 
c/Å 17.1677(5) 7.143 7.203 7.293 7.406 
Α 90 90 90 90 90 
Β 90 90 90 90 90 
Γ 90 90 90 90 90 
V/Å3 1456.22(7) 1441.57 1456.23 1478.27 1504.50 
Z 8 8 8 8 8 
ρcal/ g cm
-3 1.379 1.391 1.377 1.357 1.333 
μ/mm-1 0.100 N/A N/A N/A N/A 
θ Range/° 2.37 - 27.50 N/A N/A N/A N/A 
Ref (meas. / ind.) 96660 / 1660 17996 / 2298 28761 / 2097 14274 / 1649 14083 / 1116 
Observed>2σ 1363 1900 1727 1255 842 
Rint 0.0667 N/A N/A N/A N/A 
Completeness % 99.6 N/A N/A N/A N/A 
Parameters 136 182 182 182 182 
GooF 1.206 1.294 1.279 1.156 1.202 
R1 (obs) 0.0471 0.0402 0.0376 0.0397 0.0324 
R1 (all) 0.0593 0.0603 0.0600 0.0689 0.0580 
wR2 (all) 0.1394 0.0705 0.0665 0.0671 0.0641 
ρmax,min/e Å
-3/fm A-3 0.422, -0.480 0.074, -0.076 0.056, -0.064 0.042, -0.084 0.035, -0.038 
*Neutron data were solved in the standard space group setting (Pbca) as the software used for processing the data does not allow for non-standard 
settings to be used. Unit cell parameters for neutron data were also fixed to the X-ray values at the corresponding temperature (see above).  
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Table A-4b Crystallographic data for new and elusive phases of piroxicam and gallic acid monohydrate produced by co-crystallisation methods. 
 PX III PX IV PX : MeOH  PGAM 
Formula C15 H13 N3 O4 S1 C15 H13 N3 O4 S1 3(C15 H13 N3 O4 S1), 
(C1 H4 O1) 
(C7 H6 O5), (H2O) 
M/g mol-1 331.35 331.35 1026.09 188.13 
T/K 100 100 100 100 
Space Group P-1 P-1 P-1 P21/n 
a/Å 7.8557(3) 12.6899(9) 7.037(2) 3.6803(3) 
b/Å 10.1043(4) 14.6928(9) 12.917(4) 27.724(2) 
c/Å 10.4713(5) 20.5097(16) 25.467(8) 9.3579(7) 
α 80.602(2) 84.866(2) 84.077(7) 90 
β 68.952(2) 74.669(3) 89.174(7) 94.397(3) 
γ 69.742(2) 84.683(2) 83.327(6) 90 
V/Å3 727.01(5) 3663.7(4) 2287.0(12) 952.00(12) 
Z 2 10 2 4 
ρcal/ g cm
-3 1.514 1.502 1.443 1.299 
μ/mm-1 0.248 0.246 0.236 0.117 
θ Range/° 2.09 - 30.52 3.04 - 24.71 3.02 - 20.82 1.47 - 28.09 
Ref (meas. / ind.) 16541 / 4375 40126 / 11817 14992 / 4731 12141 / 2115 
Observed>2σ 3102 6294 2059 929 
Rint 0.0746 0.1060 0.2357 0.0676 
Completeness % 98.6 94.7 99.4 91.8 
Parameters 260 1039 292 136 
GooF 0.968 1.011 1.440 0.907 
R1 (obs) 0.0407 0.0803 0.2271 0.0568 
R1 (all) 0.0678 0.1562 0.3371 0.1327 
wR2 (all) 0.1011 0.2812 0.5325 0.1636 
ρmax,min/e Å
-3 0.536, -0.468 1.161, -0.790 1.498, -1.383 0.323, -0.205 
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APPENDIX A5. Chapter 5 - Multi-Component Complexes of Piroxicam with Mono-
substituted Benzoic Acids 
 
Refinement details for all structures can be found in Table A-5. 
 
Piroxicam: 2-Fluorobenzoic Acid (PXZ: 2FBA and PXN: 2FBA) 
Single crystal X-ray diffraction data for the PXN: 2FBA complex were collected on a Bruker 
AXS Apex II CCD diffractometer. 
 Single crystal X-ray diffraction data for the PXZ: 2FBA complex were collected on a 
Bruker-Nonius Kappa CCD diffractometer. The disordered benzene ring of the 2-
fluorobenzoic acid molecule has two possible positions which could be identified from the 
Fourier difference map. The two positions are too close to each other to allow a well-
behaved anisotropic refinement. The isotropic thermal parameters of the corresponding 
carbon atoms of each benzene carbon were therefore constrained to be equal and the 
two sites allowed to refine freely against each other to an approximate 60: 40 occupancy. 
Attempts to model two positions of the carboxylic acid group on the 2-fluorobenzoic acid 
resulted in an increased R-factor when compared to the reported model and so a single 
site was retained for this group. This was further supported by the plausible thermal 
parameters of the carboxylic group. Hydrogen atoms not involved in hydrogen bonds 
were placed on calculated positions and refined as riding on the atoms to which they 
were bonded. The H-atoms involved in hydrogen bonds were then identified using Fourier 
difference synthesis. 
  
Piroxicam: 3-Fluorobenzoic Acid (PXZ: 3FBA and PXN: 3FBA) 
Single crystal X-ray diffraction data for the PXN: 3FBA complex were collected on a Bruker 
AXS Apex II CCD diffractometer. 
 Crystals of PXZ: 3FBA were particularly small and of poor quality and data were 
therefore collected using beamline I19 (EH1) at Diamond Light Source. Hydrogen atoms 
not involved in hydrogen bonds were placed on calculated positions and refined as riding 
on the atoms to which they were bonded. The H-atoms involved in hydrogen bonds were 
then identified using Fourier difference synthesis and allowed to freely refine but with the 




Piroxicam: 4-Fluorobenzoic Acid (PXZ: 4FBA and PXN: 4FBA) 
Single crystal X-ray diffraction data for PXN: 4FBA were collected on a Bruker-Nonius 
Kappa CCD diffractometer and data for the PXZ: 4FBA complex collected on a Bruker AXS 
Apex II CCD diffractometer.   
 
Piroxicam: 2-Chlorobenzoic Acid (Zwitterionic) (PXZ: 2CLBA) 
Crystals of PXZ: 2CLBA were particularly small and of poor quality and data were 
therefore collected using beamline I19 (EH1) at Diamond Light Source.  
Hydrogen atoms not involved in hydrogen bonds were placed on calculated 
positions and refined as riding on the atoms to which they were bonded. The H-atoms 
involved in hydrogen bonds were then identified using the Fourier synthesis. 
 
Piroxicam: 3-Chlorobenzoic Acid (Non-Ionised) (PXN: 3CLBA) 
Single crystal X-ray diffraction data for PXN: 3CLBA were collected on a Bruker AXS Apex II 
CCD diffractometer.  
  
Piroxicam: 2-Bromobenzoic Acid (Zwitterionic) (PXZ: 2BRBA) 
Single crystal X-ray diffraction data for PXN: 2BRBA were collected on a Bruker AXS Apex II 
CCD diffractometer.  
Hydrogen atoms not involved in hydrogen bonds were placed on calculated 
positions and refined as riding on the atoms to which they were bonded. The H-atoms 
involved in hydrogen bonds were then identified using the Fourier difference synthesis. 
 
Piroxicam: 3-Bromobenzoic Acid (Non-Ionised) (PXN: 3BRBA) 
Single crystal X-ray diffraction data for PXN: 3BRBA were collected on a Bruker AXS Apex II 
CCD diffractometer.  
 
Piroxicam: 2-Hydroxybenzoic Acid (Zwitterionic) (PXZ: 2HBA) 
Single crystal X-ray diffraction data for PXZ: 2HBA were collected on a Bruker-Nonius 
Kappa CCD diffractometer.  
 
Piroxicam: 3-Hydroxybenzoic Acid Monohydrate (Zwitterionic) (PXZ: 3HBA.H2O) 
Single crystal X-ray diffraction data for PXZ: 3HBA.H2O were collected on a Bruker AXS 
Apex II CCD diffractometer.  
 344
Hydrogen atoms not involved in hydrogen bonds were placed on calculated 
positions and refined as riding on the atoms to which they were bonded. The H-atoms 
involved in hydrogen bonds were then identified using the Fourier synthesis. 
The positions of H21 and H22 (water hydrogen atoms) were allowed to freely refine but 
the size of the thermal parameter was constrained to be proportional to the atom to 
which it was bonded.   
 
Piroxicam: 2- Nitrobenzoic Acid (PXZ: 2NBA) 
Single crystal X-ray diffraction data for PXZ: 2NBA were collected on a Bruker AXS Apex II 
CCD diffractometer. 
 
Piroxicam: 3-Nitrobenzoic Acid (Non-Ionised) (PXN: 3NBA) 
Single crystal X-ray diffraction data for PXZ: 3NBA were collected on a Bruker AXS Apex II 
CCD diffractometer.  
 
Piroxicam: 4-Nitrobenzoic Acid Hydrate (Non-Ionised) (PXN: 4NBA.H2O)  
Single crystal X-ray diffraction data for PXZ:4NBA.H2O were collected on a Bruker-Nonius 
Kappa CCD diffractometer. 
Aromatic hydrogen atoms were placed on calculated positions and refined as 
riding on the atoms to which they were bonded. All other hydrogen atoms were located 
using the Fourier difference map and allowed to refine freely. The water molecule resides 
in a void with a large degree of freedom which makes modelling of it difficult. Estimation 
of the electron density (before assignment of the water oxygen atom) using the SQUEEZE 
procedure indicated 16 electrons were present in the unit cell (representing less than half 
a water molecule per asymmetric unit). The oxygen atom was refined at 30% to obtain 
plausible anisotropic thermal parameters. This position is likely to be the major position 
occupied by the water molecule. The water hydrogen atoms could not be located using 
Fourier difference synthesis.  
 
Piroxicam: 2-Methylbenzoic Acid (Non-Ionised) (PXN: 2MBA) 
Single crystal X-ray diffraction data for PXZ: 2MBA were collected on a Bruker AXS Apex II 




Piroxicam: 3-Methylbenzoic Acid (Zwitterionic) (PXZ: 3MBA) 
Single crystal X-ray diffraction data for PXZ: 3MBA were collected on a Bruker-Nonius 
Kappa CCD diffractometer. 
The methyl hydrogen atoms of the methylbenzoic acid molecule were placed in 
calculated positions and refined as riding on the carbon atom to which they were bonded 
to obtain plausible thermal parameters.  
 
Piroxicam: 3-Methylbenzoic Acid Acetonitrile Solvate (Zwitterionic) (PXZ: 3MBA.ACN) 
Single crystal X-ray diffraction data for PXZ: 3MBA.ACN were collected on a Bruker-Nonius 
Kappa CCD diffractometer. 
Disordered complex PXZ: 3MBA.ACN was refined with 50: 50 occupancy of the two 
positions for the 3-methylbenzoic acid and acetonitrile molecules across an inversion 
centre. Due to overlapping regions of electron density, the thermal parameters of similar 
atoms were constrained to be equal to ensure a well-behaved refinement. This allowed 
anisotropic refinement of all non-hydrogen atoms.  
 H-atoms were identified using Fourier synthesis for the non-disordered PX 
molecule and the remaining disordered H-atoms placed in calculated positions with the 
exception of the carboxylic acid H24 which was found using Fourier difference synthesis 
and allowed to freely refine at 50% occupancy.  
 
Piroxicam: 4-Methylbenzoic Acid (Zwitterionic) (PXZ: 4MBA) 
Single crystal X-ray diffraction data for PXZ: 4MBA were collected using a Rigaku R-
axis/RAPID image plate diffractometer. 
The methyl hydrogen atoms of the methylbenzoic acid molecule were located 
initially using the Fourier difference synthesis and the bond distances and angles 
constrained to take standard values. The thermal parameters of the methyl hydrogen 
atoms were then refined as riding on the carbon atom to which they are bonded. 
 
Piroxicam: 2-Aminobenzoic Acid (Zwitterionic) (PXZ: 2ABA) 
Single crystal X-ray diffraction data for PXZ: 2ABA were collected on a Bruker-Nonius 
Kappa CCD diffractometer. 
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Table A-5 Crystallographic data for molecular complexes of piroxicam with mono-substituted benzoic acids 
 PXZ:2FBA PXZ:3FBA PXZ:4FBA PXN:2FBA PXN:3FBA PXN:4FBA PXZ:2CLBA PXN:3CLBA 
Formula (C15 H13 N3 
O4 S), 
(C7 H5 F O2) 
(C15 H13 N3 
O4 S), 
(C7 H5 F O2) 
(C15 H13 N3 
O4 S), 
(C7 H5 F O2) 
(C15 H13 N3 
O4 S), 
(C7 H5 F O2) 
(C15 H13 N3 
O4 S), 
(C7 H5 F O2) 
(C15 H13 N3 
O4 S), 
(C7 H5 F O2) 
(C15 H13 N3 
O4 S), 
(C7 H5 Cl O2) 
(C15 H13 N3 
O4 S), 
(C7 H5 Cl O2) 
M/g mol-1 471.46 471.46 471.46 471.46 471.46 471.46 487.90 487.90 
T/K 100 100 100 100 100 100 100 100 
Space Group P21/c P21/c P-1 P-1 P-1 P42/n P21/c P-1 
a/Å 10.8016(3) 10.415(11) 6.7753(3) 8.4319(13) 8.4670(6) 24.4459(3) 19.768(17) 8.2160(5) 
b/Å 20.9659(6) 21.17(2) 11.4738(4) 11.4199(18) 11.1895(9) 24.4459(3) 6.917(6) 10.9570(7) 
c/Å 9.2105(2) 9.557(10) 13.7702(6) 12.3466(19) 12.2950(9) 6.9701(1) 31.56(3) 13.7261(9) 
Α 90 90 80.079(2) 115.410(6) 114.729(4) 90 90 67.227(4) 
Β 95.787(2) 100.053(13) 81.802(2) 95.966(7) 96.555(4) 90 100.693(12) 74.686(4) 
Γ 90 90 76.925(2) 100.016(7) 98.491(4) 90 90 68.598(4) 
V/Å3 2075.23(9) 2075(4) 1021.12(7) 1036.0(3) 1026.17(13) 4165.4(4) 4240(7) 1049.85(12) 
Z 4 4 2 2 2 8 8 2 
ρcal/ g cm
-3 1.509 1.509 1.533 1.511 1.526 1.504 1.529 1.543 
μ/mm-1 0.212 0.212 0.216 0.213 0.215 0.212 0.251 0.329 
θ Range/° 1.89- 25.36 1.90- 26.7 1.51-29.4 1.86-28.66 1.86-29.50 1.67-27.49 1.77-26.68 1.63-35.98 
Ref. (meas. / ind.) 26715 / 3776 18646 / 4796 33567 / 5628 29514 / 5252 27127 / 5635 37056 / 4762 36761 / 9709 27036 /9418 
Observed>2σ 2649 2932 4357 3808 2967 2886 5087 5619 
Rint 0.0959 0.0934 0.068 0.1120 0.0883 0.1405 0.1402 0.0786 
Completeness % 99.5 99.7 99.9 98.5 98.5 99.9 98.8% 94.8 
Parameters 286 308 370 370 370 370 613 370 
GooF 1.067 1.044 0.989 0.9610 0.947 0.956 1.094 0.8710 
R1 (obs) 0.0568 0.0952 0.0358 0.0441 0.0417 0.0440 0.1103 0.0454 
R1 (all) 0.0927 0.1437 0.0498 0.0683 0.0682 0.0998 0.1874 0.0851 
wR2 (all) 0.1325 0.2938 0.0985 0.1062 0.1025 0.1058 0.2803 0.1014 
ρmax,min/e Å
-3 0.575, -0.486 1.224, -0.811 0.486, -0.367 0.473, -0.474 0.624, -0.461 0.250, -0.367 0.758, -0.688 0.694, -0.441 
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Table A-5 Crystallographic data for molecular complexes of piroxicam with mono-substituted benzoic acids continued. 
 PXZ:2BRBA PXN:3BRBA PXZ:2HBA PXZ:3HBA.H20 PXZ:2NBA PXN:3NBA PXN:4NBA.xH2O 
Formula (C15 H13 N3 
O4 S), 
(C7 H5 Br O2) 
(C15 H13 N3 
O4 S), 
(C7 H5 Br O2) 
(C15 H13 N3 
O4 S), 
(C7 H6 O3) 
(C15 H13 N3 O4 
S), (C7 H6 O3), 
(H2O) 
(C15 H13 N3 
O4 S), 
(C7 H5 N O4) 
(C15 H13 N3 
O4 S), 
(C7 H5 N O4) 
2(C15 H13 N3 O4 
S), 2(C7 H5 N O4), 
0.3(H2O) 
M/g mol-1 532.36 532.36 469.47 487.49 498.46 498.46 503.86 
T/K 100 100 100 100 100 100 100 
Space Group P-1 P-1 P21/n P-1 P-1 P-1 P21/n 
a/Å 8.8280(5) 8.2526(8) 11.5454(5) 9.1121(11) 8.0433(7) 8.2304(4) 6.9031(2) 
b/Å 10.9297(6) 11.0759(10) 9.2118(4) 9.9763(13) 11.0546(8) 10.8476(6) 36.7155(10) 
c/Å 12.2953(11) 13.7895(18) 19.8419(9) 11.9501(16) 13.8361(11) 13.7358(7) 17.2917(5) 
α 105.494(4) 101.575(5) 90 78.512(5) 99.646(4) 68.267(3) 90 
β 98.381(4) 105.505(6) 102.438(2) 86.201(4) 106.649(4) 75.086(3) 100.571(1) 
γ 105.396(3) 111.738(4) 90 88.375(5) 107.631(4) 69.107(3) 90 
V/Å3 1071.81(13) 1063.1(2) 2060.73(16) 1062.1(2) 1078.84(15) 1053.11(9) 4308.21 
Z 2 2 4 2 2 2 4 
ρcal/ g cm
-3 1.650 1.663 1.513 1.524 1.534 1.572 1.429 
μ/mm-1 2.062 2.079 0.210 0.210 0.210 0.215 0.107 
θ Range/° 1.77-28.29 1.63-26.32 1.88-27.82 1.74-24.54 1.60-29.51 1.61-27.67 1.32-27.57 
Ref (meas. / ind.) 26796 / 5269 26239 / 4328 20087 / 4853 19534 / 3477 25857 / 5764 27710 / 4908 58925 / 9869 
Observed>2σ 4373 3370 2639 2050 4101 3448 5322 
Rint 0.1107 0.0958 0.1531 0.1149 0.0895 0.0850 0.1440 
Completeness % 98.8 99.9 99.1 97.9 95.9 99.6 99.3 
Parameters 322 370 374 337 388 388 688 
GooF 1.028 0.959 0.956 0.908 1.020 0.875 0.908 
R1 (obs) 0.0369 0.0305 0.0506 0.0471 0.0519 0.0380 0.460 
R1 (all) 0.0481 0.0470 0.1301 0.1032 0.0834 0.0620 0.1177 
wR2 (all) 0.0969 0.0666 0.1044 0.1070 0.1251 0.0928 0.1005 
ρmax,min/e Å
-3 1.196, -0.577 0.625, -0.418 0.286, -0.399 0.351, -0.456 0.560, -0.416 0.490, -0.375 0.310, -0.440 
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Table A-5 Crystallographic data for molecular complexes of piroxicam with mono-substituted benzoic acids continued. 
 PXN:2MBA PXZ:3MBA PXZ:3MBA.MeCN PXZ:4MBA PXZ:2ABA 
Formula (C15 H13 N3 O4 S), 
(C8 H8 O2) 
(C15 H13 N3 O4 S), 
(C8 H8 O2) 
2(C15 H13 N3 O4 S), 
(C8, H8, O2), 
(C2, H3, N) 
(C15 H13 N3 O4 S), 
(C8 H8 O2) 
(C15 H13 N3 O4 S), 
(C7 H7 N O2) 
 
M/g mol-1 467.5 467.5 839.91 467.5 468.48 
T/K 100 100 100 100 100 
Space Group P-1 P21/c P-1 P-1 P-1 
a/Å 8.512(3) 9.4317(2) 8.4985(2) 9.5744(12) 6.8637(6) 
b/Å 9.602(3) 11.3940(3) 9.8813(2) 10.4949(16) 11.6363(11) 
c/Å 14.260(5) 20.4344(4) 12.5408(3) 12.5497(16) 13.8047(12) 
α 82.134(23) 90 93.6020(10) 66.362(5) 83.313(4) 
β 75.238(22) 99.9790(10) 104.0920(10) 73.077(4) 79.158(5) 
γ 73.081(22) 90 112.1530(10) 75.292(5) 73.738(5) 
V/Å3  1075.7(6) 2162.76(8) 931.91(4) 1091.6(3) 1037.17(16) 
Z 2 4 1 2 2 
ρcal/ g cm
-3 1.443 1.436 1.497 1.422 1.500 
μ/mm-1 0.198 0.197 0.216 0.195 0.207 
θ Range/° 1.48-28.22 2.02-25.35 1.00-27.10 3.18-27.48 1.83-26.03 
Ref (meas. / ind.) 27724 / 5281 33953 / 3961 19882 / 4108 11677 / 4676 17744 / 4095 
Observed>2σ 3924 2830 2874 2837 3035 
Rint 0.0790 0.1275 0.1337 0.0829 0.0825 
Completeness % 99.2 100 99.7 93.3 99.7 
Parameters 382 371 341 371 378 
GooF 1.032 0.994 1.071 1.033 1.051 
R1 (obs) 0.0410 0.0520 0.0929 0.1177 0.0770 
R1 (all) 0.0651 0.0881 0.0562 0.0651 0.0476 
wR2 (all) 0.1010 0.1255 0.1493 0.1605 0.1137 
ρmax,min/e Å
-3 0.424, -0406 0.305, -0.428 0.535, -0.397 0.362, -0.600 0.216, -0.435 
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APPENDIX A6. Chapter 6 - Intermolecular Hydrogen Transfer in Multi-Component 
Complexes of Piroxicam 
 
Refinement details for all structures can be found in Table A-6.  
 
Piroxicam: Imidazole Hemihydrate (2(PX¯): 2(IM+).H2O) 
Single crystal X-ray diffraction data for this complex were collected on a Bruker AXS Apex 
II CCD diffractometer at 100K.  
 Hydrogen atoms not involved in conventional hydrogen bonds were placed on 
calculated positions and refined as riding on the atoms to which they were bonded. The 
hydrogen atoms involved in hydrogen bonds were then identified using the Fourier 
difference synthesis. 
 The positions of H33 and H34 (water hydrogen atoms) were allowed to freely 
refine but the size of the thermal parameter was constrained to be proportional to the 
atom to which it was bonded. Imidazole (B’) NH hydrogen atoms (H35 and H36) were also 
treated in this way.  
 
Piroxicam: Imidazole Acetonitrile Solvate (1:1:1) (PX¯: IM+.ACN) 
Single crystal X-ray diffraction data for this complex were collected on a Bruker AXS Apex 
II CCD diffractometer at 100K. 
 All hydrogen atoms were placed on calculated positions and refined as riding on 
the atoms to which they were bonded, with the exception of the hydrogen atoms on the 
IM+ nitrogens (H13 and H16), the PX¯ amide nitrogen (H5), and the ACN methyl hydrogen 
atoms (H18, H19 and H20), which were located using the Fourier difference map and 
allowed to freely refine.  
 
Piroxicam: Imidazole Acetonitrile Solvate (4:4:1) (4(PX¯): 4(IM+).ACN) 
Single crystal X-ray diffraction data for this complex were collected on a Bruker-Nonius 
Kappa CCD diffractometer at 100K.  
 Two positions of the disordered pyridine ring were modelled and refined against 
each other, with the thermal parameters of equivalent atoms constrained to be equal. 
The two positions refined to a 60: 40 occupancy ratio. Carbons C12A and C12B could not 
be modelled anisotropically as their relative positions are too close.  
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 The ACN molecule was refined at 50% occupancy, and assumed to be disordered 
across the inversion centre with its position at least partially dependent on that of the PX¯ 
pyridine ring (see Chapter 6: 6.2.3 for further details).  The Fourier difference synthesis 
when reducing the occupancy of the ACN molecule did not indicate a second position 
within the asymmetric unit.  
 Hydrogen atoms not involved in conventional hydrogen bonds were placed on 
calculated positions and refined as riding on the atoms to which they were bonded. The 
hydrogen atoms involved in hydrogen bonds were then identified using the Fourier 
difference synthesis.   
 
Piroxicam: 2-methylimidazole (PX¯: 2MIM+) 
Single crystal X-ray diffraction data for this complex were collected on a Bruker AXS Apex 
II CCD diffractometer at 100K. 
 The 2MIM+ methyl group hydrogen atoms (H5A, H5B and H5C) were located 
initially using the Fourier difference synthesis and the bond distances and angles 
constrained to take standard values.  
 
Piroxicam: Benzimidazole (PX¯: BZ+) 
Single crystal X-ray diffraction data for this complex complex were collected on a Bruker 
AXS Apex II CCD diffractometer at 100K. 
 Hydrogen atoms not involved in conventional hydrogen bonds were placed on 
calculated positions and refined as riding on the atoms to which they were bonded. The 
hydrogen atoms involved in conventional hydrogen bonds were then identified using a 
Fourier difference synthesis. Hydrogen atoms on the PX¯ amide nitrogen atoms (H24 and 
H5) were allowed to freely refine but the size of the thermal parameter was constrained 
to be proportional to the atom to which it was bonded.  
 
Piroxicam: 1, 2, 4 - Triazole (2PXZ: TZ) 
Single crystal X-ray diffraction data for this complex were collected on a Bruker AXS Apex 
II CCD diffractometer at 100K. 
 The disordered TZ molecules were modelled with 50% occupancy across the 
inversion centre. The positions of the nitrogen atoms in the TZ molecules (N8 and N9, N11 
and N12) lie too close to each other to allow a meaningful anisotropic refinement.  
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 All hydrogen atoms on the TZ molecules were placed on calculated positions and 
refined as riding on the atoms to which they were bonded. Hydrogen atoms on the PXZ 
molecules that are not involved in conventional hydrogen bonds were placed on 
calculated positions and refined as riding on the atoms to which they were bonded. The 
hydrogen atoms involved in conventional hydrogen bonds were then identified using the 
Fourier difference synthesis. 
 
Piroxicam: Benzotriazole (PXZ: BZT) 
Single crystal X-ray diffraction data for this complex were collected on a Bruker-Nonius 
Kappa CCD diffractometer at 100K.  
 
Piroxicam: Pyrazine (2PXZ: PZN) 
Crystals of 2PXZ: PZN were particularly small and of poor quality and data were therefore 
collected using beamline I19 (EH1) at Diamond Light Source at 100K. Despite being 
collected using the synchrotron, the data was still weak and of poor quality. Significant 
data were missing along the z-axis, resulting in slight elongation of the thermal ellipsoids 
along this direction.  
 The tautomer of PX was inferred from the conformation of the molecule and the 
hydrogen bonding within the structure. The thermal parameters of pyrazine carbons C33 
and C34 were constrained to be equal to allow a well behaved anisotropic refinement as 
the elongation was particularly pronounced in this molecule. All hydrogen atoms were 
placed on calculated positions and refined as riding on the atoms to which they were 
bonded.  
 
Piroxicam: Chloranilic Acid Form I (PX+: CA¯) (Triclinic) 
Single crystal X-ray diffraction data for the PXN: 2FBA complex were collected on a Bruker 
AXS Apex II CCD diffractometer at 100K. 
 
Piroxicam: Chloranilic Acid Form II (PX+: CA¯) (monoclinic) 
Single crystal X-ray diffraction data for the PXN: 2FBA complex were collected on a Bruker 





Piroxicam: Chloranilic Acid Acetonitrile Solvate (2(PX+): CA2¯.2(ACN)) 
Single crystal X-ray diffraction data for the PXN: 2FBA complex were collected on a Bruker 
AXS Apex II CCD diffractometer at 100K. 
 All hydrogen atoms were located using the Fourier difference synthesis with the 
exception of the methyl group hydrogen atoms of PX+ and ACN which were located 
initially using the Fourier difference synthesis and the bond distances and angles 
constrained to take standard values.   
 
Piroxicam: Bromanilic Acid (PX+: BRA¯) 
Single crystal X-ray diffraction data for the PXN: 2FBA complex were collected on a Bruker 
AXS Apex II CCD diffractometer at 100K. 
 The hydrogen of the BRA hydroxyl was located initially using the Fourier difference 
synthesis and the O-H bond distance constrained to take a standard value. The bond 
angle was constrained to be equal to that of the equivalent O-H bond in the isomorphous 
PX+:CA- II complex. All other hydrogen atoms were located using the Fourier difference 
map. The thermal parameters of the PX+ aromatic hydrogen atoms were refined as riding 
on the atoms to which they were bonded. 
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Table A-6a Crystallographic data for molecular complexes of piroxicam with N-heterocycles.  
 2(PX¯):2(IM+).H2O PX¯:IM+.ACN 4(PX¯):4(IM+).ACN PX¯:2MIM+ 
Formula 2(C15 H12 N3 O4 S), 
2(C3 H5 N2), H2O 
(C15 H12 N3 O4 S), 
(C3 H5 N2), (C2 H3 N) 
4(C15 H12 N3 O4 S),  
4(C3 H5 N2), (C2 H3 N) 
(C15 H12 N3 O4 S), 
(C4 H7 N2) 
M/g mol-1 816.89 440.48 1638.78 413.46 
T/K 100 100 100 100 
Space Group P-1 P21/c P21/n P21/n 
a/Å 6.8019(4) 8.1510(5) 6.9103(1) 10.9928(8) 
b/Å 14.4384 (8) 26.5997(17) 22.1444(5) 15.3135(15) 
c/Å 19.8727(12) 10.1579(7) 25.1813(5) 12.551(1) 
α 90.460(2) 90 90 90 
β 99.276(2) 113.394(3) 97.068(1) 112.039(4) 
γ 101.460(2) 90 90 90 
V/Å3 1886.1(2) 2021.3(2) 3824.07(13) 1958.4(3) 
Z 2 4 2 4 
ρcal/ g cm
-3 1.438 1.447 1.423 1.402 
μ/mm-1 0.211 0.202 0.207 0.202 
θ Range/° 1.44 - 23.51 1.53 - 29.61 1.63 - 27.08 2.11 - 28.31 
Ref. (meas. / ind.) 39268/ 5468 31622/ 5639 56462/ 8406 22807/ 4828 
Observed>2σ 2890 4387 4565 3085 
Rint 0.1704 0.1084 0.1572 0.1100 
Completeness % 97.6 99.0 99.9 99.1 
Parameters 544 305 592 327 
GooF 0.950 1.127 0.978 0.985 
R1 (obs) 0.0565 0.0601 0.0572 0.0567 
R1 (all) 0.1541 0.0797 0.1322 0.1021 
wR2 (all) 0.0989 0.1699 0.1456 0.1309 
ρmax,min/e Å
-3 0.337, -0.323 0.594, -0.597 0.327, -0.389 0.519, -0.373 
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Table A-6a Crystallographic data for molecular complexes of piroxicam with N-heterocycles continued. 
 PX¯: BZ+ 2PXZ: TZ PXZ: BZT 2PXZ: PZN 
Formula (C15 H12 N3 O4 S), 
(C7 H7 N2) 
2(C15 H13 N3 O4 S), 
(C2 H3 N3) 
(C15 H13 N3 O4 S), 
(C6 H5 N3) 
2(C15 H13 N3 O4 S), 
(C4 H4 N2) 
M/g mol-1 449.48 731.76 450.47 742.80 
T/K 100 100 100 100 
Space Group P-1 P-1 P21/c P-1 
a/Å 12.005(3) 6.9267(2) 11.6101(6) 6.792(11) 
b/Å 13.789(3) 8.3356(3) 26.2908(15) 8.646(15) 
c/Å 13.810(4) 28.8177(10) 6.7710(3) 29.66(5) 
α 72.186(7) 86.485(2) 90 94.159(11) 
β 68.682(7) 84.209(2) 103.480(3) 90.51(2) 
γ 80.962(7) 76.271(1) 90 104.78(4) 
V/Å3 2024.8(8) 1606.89(9) 2009.8(2) 1679(5) 
Z 4 2 4 2 
ρcal/ g cm
-3 1.474 1.512 1.489 1.469 
μ/mm-1 0.202 0.235 0.205 0.225 
θ Range/° 1.55 - 23.90 0.71 - 28.26 1.96 - 25.35 2.00 - 25.93 
Ref. (meas. / ind.) 23716/ 6114 35311/ 7358 22167/ 2942 17445/ 6529 
Observed>2σ 2700 5437 2320 2898 
Rint 0.1716 0.0857 0.0444 0.2110 
Completeness % 97.2 92.6 80.2 90.8 
Parameters 598 503 361 387 
GooF 0.882 1.096 1.085 1.246 
R1 (obs) 0.0617 0.0616 0.0542 0.1767 
R1 (all) 0.1856 0.0916 0.0716 0.2680 
wR2 (all) 0.1045 0.1457 0.1512 0.4928 
ρmax,min/e Å
-3 0.328, -0.342 0.544, -0.457 0.852, -0.373 0.956, -0.723 
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Table A-6b Crystallographic data for molecular complexes of piroxicam with strong acids. 
 PX+: CA¯ (I) PX+: CA¯ (II) 2(PX+): CA2¯.2(ACN) PX+: BRA¯ 
Formula (C15 H14 N3 O4 S), 
(C6 H Cl2 O4) 
(C15 H14 N3 O4 S), 
(C6 H Cl2 O4) 
2(C15 H14 N3 O4 S), 
(C6 Cl2 O4), 2(C2 H3 N) 
(C15 H14 N3 O4 S), 
(C6 H Br2 O4) 
M/g mol-1 540.32 540.32 476.89 629.24 
T/K 100 100 100 100 
Space Group P-1 P21/c P-1 P21/c  
a/Å 9.1504(4) 8.5627(5) 7.0616(8) 8.842(2) 
b/Å 10.9678(4) 13.3395(7) 11.6031(13) 13.437(2) 
c/Å 11.7747(5) 19.3963(12) 13.2994(17) 19.242(4) 
α 89.228(2) 90 71.351(5) 90 
β 75.765(2) 100.925(3) 84.932(5) 100.518(11) 
γ 70.977(2) 90 78.919(5) 90 
V/Å3 1080.00(8) 2175.3(2) 1012.8(2) 2247.8(7) 
Z 2 4 1 4 
ρcal/ g cm
-3 1.662 1.650 1.564 1.859 
μ/mm-1 0.455 0.452 0.340 3.755 
θ Range/° 1.79 - 30.56 1.86 - 27.72 1.62 - 24.95 1.86 - 27.83 
Ref (meas. / ind.) 30881/ 6607 39751/ 5083 14653/ 2948 64513/ 5309 
Observed>2σ 4819 3284 1959 3938 
Rint 0.0665 0.0920 0.1007 0.0952 
Completeness % 99.8 99.4 82.9 99.4 
Parameters 376 376 335 366 
GooF 0.945 0.922 0.981 0.917 
R1 (obs) 0.0376 0.0397 0.0447 0.0320 
R1 (all) 0.0586 0.0797 0.0895 0.0492 
wR2 (all) 0.0909 0.0762 0.1058 0.0793 
ρmax,min/e Å
-3 0.524, -0.320 0.474, -0.458 0.400, -0.366 1.092, -0.556 
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APPENDIX A7. Chapter 7 - Controlling Molecular Complex Formation of Paracetamol 
and its Derivatives  
 
Refinement details for all structures can be found in Table A-7. 
 
Paracetamol: Imidazole (PA: IM) 
Single crystal X-ray diffraction data for this complex were collected on a Bruker AXS Apex 
II CCD diffractometer at 100K. 
  
Paracetamol: 2-methylimidazole (1:2) (PA: 2MIM) 
Single crystal X-ray diffraction data for this complex were collected on a Bruker AXS Apex 
II CCD diffractometer at 100K. 
 All H-atoms were identified using a Fourier difference synthesis with the exception 
of the methyl group hydrogen atoms on the 2MIM molecules (H4, H5, H6 and H10, H11, 
H12) which were located initially using a Fourier difference synthesis and the bond 
distances and angles constrained to take standard values. 
 
Piroxicam: 4-methylImidazole (PA: 4MIM) 
Single crystal X-ray diffraction data for this complex were collected on a Bruker AXS Apex 
II CCD diffractometer at 100K. 
 
4-acetamidobenzoic acid: Imidazole (4ABA¯: IM+)  
Single crystal X-ray diffraction data for this complex were collected on a Rigaku R-AXIS 
RAPID Image Plate diffractometer at 100K. 
 The absolute structure was not determined in the analysis as it was not required 
for the purpose of this work.   
 
4-acetamidobenzoic acid: 2-methylimidazole (2:1) (4ABA¯: 2MIM+) 
Single crystal X-ray diffraction data for this complex were collected on a Bruker-Nonius 
Kappa CCD diffractometer at 100K.  
All H-atoms were identified from a Fourier difference synthesis with the exception of the 
methyl group hydrogen atoms on the 2MIM+ molecule (H1, H2 and H3) and the 4ABA¯ 
molecule (H20, H21 and H22) which were located initially using the Fourier difference 
synthesis and the bond distances and angles constrained to take standard values.  
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4-acetamidobenzoic acid: 4-methylimidazole (4ABA¯: 4MIM+) 
Single crystal X-ray diffraction data for this complex were collected on a Bruker-Nonius 
Kappa CCD diffractometer at 100K.  
  
4-acetamidobenzoic acid: benzimidazole monohydrate (4ABA¯: BZ+. H2O) 
Single crystal X-ray diffraction data for this complex were collected on a Bruker AXS Apex 
II CCD diffractometer at 100K.  
 One hydrogen atom of the BZ+ molecule (H7) shows significant elongation of its 
electron density towards the acceptor oxygen atom to which it is hydrogen bonded. The 
hydrogen has been placed on the electron density maximum bonded to the BZ molecule. 
Analysis of the bond lengths in both molecules indicate that the BZ molecule is indeed 
protonated and the 4ABA molecule is deprotonated suggesting this is the most accurate 
model possible with X-ray data. This is discussed further in Chapter 7.   
 
4-acetamidobenzoic acid: 4, 4 - bipyridine (2:1) (4ABA: BP)  
Single crystal X-ray diffraction data for this complex were collected on a Bruker-Nonius 
Kappa CCD diffractometer at 100K.  
  
 
4-acetamidobenzoic acid: 2-picoline (4ABA: 2PIC) 
Single crystal X-ray diffraction data for this complex were collected on a Bruker AXS Apex 
II CCD diffractometer at 100K.  
 
4-acetamidobenzoic acid: 3-picoline (4ABA: 3PIC) 
Single crystal X-ray diffraction data for this complex were collected on a Bruker-Nonius 
Kappa CCD diffractometer at 100K.  
 
4-acetamidobenzoic acid: 4-picoline (4ABA: 4PIC) 
Single crystal X-ray diffraction data for this complex were collected on a Bruker AXS Apex 
II CCD diffractometer at 100K. 
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Table A-7a Crystallographic data for molecular complexes of paracetamol with N-heterocycles. 
 
 PA: IM PA: 2MIM (1:2) PA: 4MIM 
Formula (C8 H9 N O2), (C3 H4 N2) (C8 H9 N O2), 2(C4 H6 N2) (C8 H9 N O2), (C4 H6 N2) 
M/g mol-1 219.24 315.38 233.27 
T/K 100 100 100 
Space Group P21/c C2/c Pbca 
a/Å 9.770(2) 30.940(2) 9.9578(6) 
b/Å 8.661(2) 7.7357(6) 13.7235(7) 
c/Å 13.545(3) 13.9295(9) 18.1220(10) 
α 90 90 90 
β 108.331(11) 91.046(4) 90 
γ 90 90 90 
V/Å3 1088.1(4) 3333.3(4) 2476.5(2) 
Z 4 8 8 
ρcal/ g cm
-3 1.338 1.257 1.251 
μ/mm-1 0.095 0.086 0.088 
θ Range/° 2.20 - 31.10 1.32 - 26.79 2.25 - 33.38 
Ref. (meas. / ind.) 31131 / 3485 26420 / 3536 47349 / 4802 
Observed>2σ 2803 2007 3257 
Rint 0.0446 0.1157 0.1278 
Completeness % 99.6 99.2 99.9 
Parameters 197 270 214 
GooF 1.032 0.900 0.959 
R1 (obs) 0.0421 0.0465 0.0477 
R1 (all) 0.0549 0.1053 0.0768 
wR2 (all) 0.1173 0.0977 0.1349 
ρmax,min/e Å
-3 0.498, -0.189 0.249, -0.193 0.488, -0.224 
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Table A-7b Crystallographic data for molecular complexes of 4-acetamidobenzoic acid with N-heterocycles. 
 4ABA¯: IM+ 4ABA: 4ABA¯: 2MIM+ 4ABA¯: 4MIM+ 4ABA¯: BZ+. H2O 
Formula (C9 H8 N O3), (C3 H5 N2) (C9 H9 N1 O3), (C9 H8 N1 
O3), (C4 H7 N2) 
(C9 H8 N O3), (C4 H7 N2) (C9 H8 N O3), (C7 H7 N2), 
(H2O) 
M/g mol-1 247.25 440.45 261.28 315.33 
T/K 100 100 100 100 
Space Group P 21 21 21 P21/n P21/c P21/c 
a/Å 6.90430(10) 7.35450(10) 13.4181(7) 4.0287(3) 
b/Å 8.7161(2) 9.6675(2) 10.0408(6) 32.217(2) 
c/Å 39.8192(7) 31.1406(5) 9.4283(6) 11.7052(9) 
Α 90 90 90 90 
Β 90 96.0140(10) 107.342(3) 92.541(4) 
Γ 90 90 90 90 
V/Å3 2396.26(8) 2201.90(6) 1212.52(12) 1517.8(2) 
Z 8 4 4 4 
ρcal/ g cm
-3 1.371 1.329 1.431 1.380 
μ/mm-1 0.101 0.098 0.104 0.101 
θ Range/° 3.07 - 27.47 2.21 - 27.88 1.59 - 27.48 1.26 - 25.260 
Ref (meas. / ind.) 10048 / 5411 41495 / 5229 94055 / 2759 17870 / 2742 
Observed>2σ 5083 4183 1814 1748 
Rint 0.0145 0.0811 0.0903 0.1093 
Completeness % 99.0 99.7 99.4 99.8 
Parameters 429 363 232 276 
GooF 1.150 1.129 1.022 0.989 
R1 (obs) 0.0293 0.0543 0.0440 0.0513 
R1 (all) 0.0339 0.0709 0.0864 0.1002 
Wr2 (all) 0.0978 0.1433 0.1034 0.1197 
ρmax,min/e Å
-3 0.289, -0.231 0.478, -0.323 0.254, -0.209 0.275, -0.214 
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Table A-7b Crystallographic data for molecular complexes of 4-acetamidobenzoic acid with N-heterocycles continued. 
 
 4ABA: Bipy (2:1) 4ABA: 2PIC 4ABA: 3PIC 4ABA: 4PIC 
Formula (C9 H9 N O3), 0.5(C10 H8 N2) (C9 H9 N O3), (C6 H7 N1) (C9 H9 N O3), (C6 H7 N) (C9 H9 N O3), (C6 H7 N) 
M/g mol-1 257.26 272.30 272.30 272.30 
T/K 100 100 100 100 
Space Group P21/c P21/c P21/c P21/n 
a/Å 12.8097(11) 11.392(2) 7.6215(2) 12.3881(16) 
b/Å 9.7699(7) 8.7690(13) 18.7544(7) 8.9244(14) 
c/Å 10.1260(8) 14.476(3) 9.8712(3) 13.780 (2) 
Α 90 90 90 90 
Β 98.212(5) 108.381(8) 97.363(2) 114.754(7) 
Γ 90 90 90 90 
V/Å3 1254.3(2) 1372.3(4) 1399.32(8) 1383.5(3) 
Z 4 4 4 4 
ρcal/ g cm
-3 1.362 1.318 1.293 1.307 
μ/mm-1 0.10 0.093 0.091 0.092 
θ Range/° 1.61 - 31.580 1.88 - 22.67 2.17 - 27.13 1.86 - 27.43 
Ref (meas. / ind.) 37929 / 4201 14193 / 1839 19804 / 3079 19020 / 3145 
Observed>2σ 2873 1190 2355 2339 
Rint 0.0848 0.1292 0.0483 0.0928 
Completeness % 99.9 99.9 99.7 99.6 
Parameters 224 245 245 245 
GooF 0.952 1.073 1.058 0.941 
R1 (obs) 0.0440 0.0498 0.0428 0.0383 
R1 (all) 0.0710 0.0972 0.0648 0.0529 
wR2 (all) 0.1178 0.0972 0.1019 0.0973 
ρmax,min/e Å
-3 0.449, -0.190 0.202, -0.191 0.204, -0.195 0.267, -0.203 
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APPENDIX A8. Chapter 8 - Additional Molecular Complexes of APIs 
 
Refinement details for all structures can be found in Table A-8. 
 
Paracetamol : Maleic Acid (PA:MA) 
Single crystal X-ray diffraction data for this complex were collected on a Bruker-Nonius 
Kappa CCD diffractometer at 100K. 
 
Paracetamol : Citraconic Acid (PA:CCA) 
Single crystal X-ray diffraction data for this complex were collected on a Bruker AXS Apex 
II CCD diffractometer at 100K.  
 
Piracetam : Gallic Acid (PTM:GA) 
Single crystal X-ray diffraction data for this complex were collected on a Rigaku R-AXIS 
RAPID Image Plate diffractometer at 100K. 
 
Piracetam : Citraconic Acid (PTM:CCA) 
Single crystal X-ray diffraction data for this complex were collected on a Bruker AXS Apex 
II CCD diffractometer at 100K.  
 
Piracetam : Chloranilic Acid (PTM:CA) 
Single crystal X-ray diffraction data for this complex were collected on a Bruker AXS Apex 
II CCD diffractometer at 100K.  
 
Piracetam : Bromanilic Acid (PTM:BRA) 
Single crystal X-ray diffraction data for this complex were collected on a Bruker AXS Apex 
II CCD diffractometer at 100K.    
 Four large electron density peaks were remaining on the Fourier difference map 
after full assignment of the structure, of size 1.39 - 1.65 e-/Å3. The proximity of these 
peaks to the Br atoms suggests they are not missing atoms (all peaks lie approximately 
0.85Å from Br atoms).
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Table A-8a Crystallographic data for molecular complexes of paracetamol with maleic acid and citraconic acid. 
 PA:MA PA:CCA 
Formula C8 H9 N O2, C4 H4 O4 C8 H9 N O2, C5 H6 O4 
M/g mol-1 267.13 281.26 
T/K 100 100 
Space Group P-1 P21/c 
a/Å 7.24700(10) 7.061(1) 
b/Å 11.13330(10) 23.607(3) 
c/Å 15.7616(2) 7.677(1) 
α 71.6440(6) 90 
β 84.0490(7) 92.930(8) 
γ 80.4430(6) 90 
V/Å3 1188.44(2) 1278.1(4) 
Z 4 4 
ρcal/ g cm
-3 1.493 1.462 
μ/mm-1 0.121 0.117 
θ Range/° 1.36 - 27.49 1.73 - 26.36 
Ref. (meas. / ind.) 45715 /  5436 16355 / 2614 
Observed>2σ 4695 1318 
Rint 0.0328 0.1304 
Completeness % 99.5 99.7 
Parameters 447 241 
GooF 1.036 0.917 
R1 (obs) 0.0314 0.0450 
R1 (all) 0.0390 0.1322 
wR2 (all) 0.0829 0.0822 
ρmax,min/e Å
-3 0.305, -0.229 0.233, -0.218 
 
 363
Table A-8b Crystallographic data for molecular complexes of piracetam with gallic acid, citraconic acid, chloranilic acid and bromanilic acid. 
 PTM:GA PTM:CCA PTM:CA PTM:BRA 
Formula C6 H10 N2 O2, C7 H6 O5 C6 H10 N2 O2, C5 H6 O4 C6 H10 N2 O2, C6 H2 O4 Cl2 C6 H10 N2 O2, C6 H2 O4 Br2 
M/g mol-1 312.28 272.26 351.14 440.04 
T/K 100 100 100 100 
Space Group P21/c P-1 P-1 P21/n 
a/Å 12.554(2) 7.2737(4) 5.3052(4) 5.2279(2) 
b/Å 8.8499(15) 8.9268(5) 11.2111(9) 25.1285(11) 
c/Å 12.6253(17) 10.6101(6) 12.3555(12) 11.3404(5) 
Α 90 95.793(3) 100.689(4) 90 
Β 103.988(5) 105.310(3) 91.025(4) 103.168(2) 
Γ 90 100.116(3) 96.568(4) 90 
V/Å3 1361.1(4) 646.22(6) 716.80(11) 1450.61(11) 
Z 4 2 2 4 
ρcal/ g cm
-3 1.524 1.399 1.627 2.015 
μ/mm-1 0.125 0.115 0.484 5.620 
θ Range/° 3.08 - 27.48 2.01 - 31.95 1.68 - 25.90 1.62 - 30.03 
Ref (meas. / ind.) 10236 / 3044 22460 / 4071 11710 / 2789 34033 / 4231 
Observed>2σ 1684 2905 1762 3565 
Rint 0.0958 0.0550 0.1113 0.0989 
Completeness % 97.5 100 99.7 99.8 
Parameters 263 236 247 247 
GooF 1.056 0.930 0.928 1.001 
R1 (obs) 0.0562 0.0374 0.0457 0.0317 
R1 (all) 0.1209 0.0576 0.0910 0.0397 
wR2 (all) 0.1633 0.0898 0.1020 0.0790 
ρmax,min/e Å
-3 0.355, -0.427 0.460, -0.205 0.395, -0.345 1.646, -0.640 
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APPENDIX B: Powder X-ray Diffraction 
 
Appendix B4a - Powder X-ray Diffraction of Paracetamol Form II from Multi-Component Crystallisations (Section 4.2) 
 
 
Appendix B4a-1 PXRD analysis of the co-crystallisation of paracetamol and 4-bromobenzoic acid in methanol (red) overlaid with the calculated PXRD 
pattern of paracetamol form II (blue). The pattern shows unambiguously the presence of paracetamol form II in approximately 100% quantities. 
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Appendix B4a-1 PXRD analysis of the co-crystallisation of paracetamol and 4-bromobenzoic acid in methanol (red) overlaid with the experimental PXRD 
pattern of 4-bromobenzoic acid (blue). The pattern shows that all peaks not corresponding to paracetamol form II correspond to 4-bromobenzoic acid.  
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Appendix B4a-1 PXRD analysis of the co-crystallisation of paracetamol and 4-bromobenzoic acid in methanol (red) overlaid with the experimental PXRD 


















Appendix B4a-5 PXRD of the co-crystallisation of paracetamol with 3-chlorobenzoic acid in methanol. The pattern shows a mixture of 3ClBA and PA I in 
100% yield. No PA II was found to be present in the co-crystallisation with 3ClBA that were analysed.  
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Appendix B4a-6 PXRD of the co-crystallisation of paracetamol with 3-fluorobenzoic acid in isopropanol. The pattern shows a mixture of 3FBA and PA II 













Appendix B4a-9 PXRD of the co-crystallisation of paracetamol with 2-fluorobenzoic acid in ethanol. The pattern shows a mixture of 2FBA with both PA I 
and PA II. 100% PA II was not achieved under the conditions studied using 2FBA as the co-molecule. 
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Appendix B4a-10 PXRD of the co-crystallisation of paracetamol with benzoic acid in methanol. The pattern shows a mixture of BA with both PA I and PA 
II. 100% PA II was not achieved under the conditions studied using BA as the co-molecule.  
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Appendix B4a-11 PXRD of the recrystallisation of paracetamol from excess acetic acid. The pattern shows almost 100% PA II. Small peaks 




Appendix B4a-12 PXRD of the co-crystallisation of paracetamol with nicotinic acid in ethanol. The pattern shows a mixture of nicotinic acid with both 
PA I and PA II (PA II in the majority).  
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Appendix B4a-14 PXRD of the co-crystallisation of paracetamol with succinic acid in methanol. The pattern shows a mixture of succinic acid (alpha and 
beta forms) with PA II in 100% yield.  
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Appendix B4a-15 PXRD of the co-crystallisation of paracetamol with creatine in methanol. The pattern shows a mixture of creatine monohydrate with 
PA II in 100% yield.  
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Appendix B4a-17 PXRD of the co-crystallisation of paracetamol with creatinine in a methanol/acetonitrile 50/50 (V/V) mixture at 30°C. The pattern 
shows a mixture of creatinine with PA II in 100% yield.  
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Appendix B4a-18 PXRD of the co-crystallisation of paracetamol with erythritol in a methanol/acetonitrile 50/50 (V/V) mixture at 30°C. The pattern 
shows a mixture of erythritol with PA II in 100% yield.  
 384
 
Appendix B4a-19 PXRD of the co-crystallisation of paracetamol with resorcinol in acetonitrile. The pattern shows a mixture of resorcinol with both PA I 
and PA II (PA I in the majority).  
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Appendix B4a-20 PXRD of the co-crystallisation of paracetamol with urea in methanol. The pattern shows a mixture of urea with both PA I and PA II.  
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Appendix B4a-22 PXRD of the co-crystallisation of paracetamol with pyrazole in methanol at 50°C (top, red). The pattern shows PA II in 100% yield 
(calculate PA II shown below in blue). The pattern indicates no pyrazole is present.  
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Appendix B4a-23 PXRD of the co-crystallisation of paracetamol with 3,5-dimethylpyrazole in methanol at 50°C. The pattern shows a mixture of PA I and 
PA II with only small quantities of 3,5-dimethylpyrazole detected.  
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Appendix B4a-24 PXRD of the co-crystallisation of paracetamol with pyrazine in methanol at 50°C. The pattern shows PA II in 100% yield. The majority 
of the pyrazine appears to have sublimed during the evaporation process. 
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Appendix B4b - Powder X-ray Diffraction of New and Elusive Polymorphs of Piroxicam from Multi-Component Crystallisations (Section 4.4) 
 
Appendix B4b-1 PXRD of the co-crystallisation of piroxicam with pyrazole (1:2 mass ratio) in acetonitrile at 40°C (red). The pattern shows a poor match 
with the calculated PX III pattern (blue) despite its presence being confirmed by unit cell screening of single crystals. The peaks instead correspond to a 
mixture of PX II and PX monohydrate.  
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Appendix B4b-2 PXRD of the co-crystallisation of piroxicam with pyrazole (1:2 mass ratio) in acetonitrile at 50°C (red). The pattern shows a poor match 
with the calculated PX III pattern (blue) despite its presence being confirmed by unit cell screening of single crystals. The peaks instead correspond to 
PX I.  
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Appendix B4b-3 PXRD of the co-crystallisation of piroxicam with 3,5-dimethylpyrazole (1:2 mass ratio) in acetonitrile at 50°C (red). The pattern shows 
the presence of PX III (blue) although the majority is PX I.  
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Appendix B4b-4 PXRD of the co-crystallisation of piroxicam with pyrazine (1:2 mass ratio) in acetonitrile at 40°C (red). The pattern shows a high yield of 
PX IV (blue) with PX II also present. The PX IV pattern is calculated from 100K data while the experimental PXRD was carried out at room temperature; a 
slight x-shift may therefore be required for some of the peaks. 
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Appendix B4b-5 PXRD of the co-crystallisation of piroxicam with pyrazine (1:1 mass ratio) in acetonitrile at 50°C (red). The pattern shows a poor match 
with PX IV (blue) and shows approximately 100% PX II.  
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Appendix B4b-6 PXRD of the co-crystallisation of piroxicam with indazole in methanol at 60°C (red). The pattern shows a significant quantity of the PX : 
methanol solvate (blue) with PX I also present. The PXRD pattern for the PX : methanol solvate was calculated from 100K data while the experimental 
PXRD was carried out at room temperature; an x-shift is therefore required to match the peaks.  
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Appendix B4b-7 PXRD of the recrystallisation of piroxicam from methanol at 60°C (red). The pattern shows 100% form I (blue) with no PX : methanol 
solvate present.  
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Appendix B4c - Powder X-ray Diffraction of the Porous Gallic Acid Monohydrate from Multi-Component Crystallisations (Section 4.6) 
 
Appendix B4c-1 PXRD of the co-crystallisation of gallic acid with piracetam from methanol (red, room temperature). The patterns shows 100% of the 
gallic acid : piracetam molecular complex (blue, calculated at 100K) and none of the porous gallic acid monohydrate, despite its presence being 




Appendix B4c-2 PXRD of the co-crystallisation of gallic acid with piracetam from ethanol (red). The pattern shows the presence of the porous gallic acid 
monohydrate (blue). The other peaks correspond to the GA : PTM molecular complex as well as PTM III and GAM I.  
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Appendix B4c-3 PXRD of the recrystallisation of gallic acid from methanol with no co-molecule (red). The pattern shows only GAM I and GAM II (blue 
and black).  
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Appendix B4d - Powder X-ray Diffraction of the Piracetam Form I from Multi-Component Crystallisations (Section 4.8) 
 
Appendix B4d-1 PXRD of the co-crystallisation of piracetam with pyrazole (1:2 mass ratio) in methanol at 50°C (red). The patterns shows a mixture of 
piracetam from I (blue) and form II (remaining peaks). 
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Appendix B4d-2 PXRD of the recrystallisation of piracetam in methanol at 50°C (red). The pattern shows a mixture of piracetam from I (blue) and form 
II (remaining peaks). 
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Appendix B - Powder X-Ray Diffraction for Molecular Complexes of Piroxicam with Mono-Substituted Benzoic Acids 
 
 
Figure B5-1 PXRD of the PXZ : 2FBA complex from co-crystallisation experiment (red) (prior to heating regime) shows an almost perfect match with 
PXRD calculated directly from the crystal structure of PXZ : 2FBA (Blue).   
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Figure B5-2 PXRD of the PXZ : 2FBA complex from crystallisation experiment (red) (prior to heating regime) shows a poor match with PXRD calculated 
directly from the crystal structure of PXN : 2FBA (Blue). 
 404
 
Figure B5-3 PXRD of PXZ : 2FBA sample, after annealing at 140°C for twenty minutes (red), shows a distinct change in the crystal structure when 
compared with the PXRD of the PXZ : 2FBA complex before heating (blue).   
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Figure B5-4 PXRD of PXZ : 2FBA sample post annealing (red) shows a closer match with the calculated PXRD from the PXN : 2FBA crystal structure 
(blue). Note: complete solid - solid phase transition is not achieved resulting in some remaining PXZ : 2FBA. 
 406
 
Figure B5-5 PXRD of PXZ : 2FBA sample post annealing (red) is no longer a match with the calculated PXRD of the PXZ : 2FBA complex (blue). 
 407
 
Figure B5-6 PXRD profile of initial crystallisation of PXZ: 4FBA from acetonitrile at 50°C showing 100% yield was obtained (Calculated profile for both 
tautomeric polymorphs shown for comparison).  
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Figure B5-7 PXRD profile of repeat crystallisation of PX and 4FBA from acetonitrile at 50°C showing a mixture of PXZ: 4FBA and PXN: 4FBA was obtained 
(majority PXZ: 4FBA). 
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Figure B5-8 PXRD profile of initial crystallisation of PXN: 4FBA from acetonitrile at 40°C showing 100% yield was obtained. 
 410
 
Figure B5-9 PXRD profile of repeat crystallisation of PX and 4FBA from acetonitrile at 40°C showing 100% yield of PXZ: 4FBA was obtained. 
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Appendix B7 - Powder X-ray Diffraction of the Molecular Complex of Paracetamol with Imidazole 
 
 
Figure B-7a Powder X-ray diffraction pattern of the paracetamol: imidazole co-crystallisation (black). The pattern shows a mixture of paracetamol (red), 
imidazole (blue) and the co-crystal (major unique peaks highlighted with a green arrow).  
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APPENDIX C: Thermal Analysis 
 
Appendix C4 - DSC Analysis of Piroxicam Polymorphs 
 
 














Figure C4-4 DSC of piroxicam form IV. 
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Appendix C5 - Thermal Analysis of Piroxicam Molecular Complexes with Mono-Substituted Benzoic Acids 
 
 
















Figure C5-5 DSC trace of PXN: 3FBA. 
 421
 
Figure C5-6 Overlay of PXZ: 3FBA and PXN: 3FBA DSC traces. 
 422
 
Figure C5-7 DSC trace of PXZ: 4FBA. 
 423
 
Figure C5-8 DSC trace of PXN: 4FBA. 
 424
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